<SEC-DOCUMENT>0001628280-21-010387.txt : 20210514
<SEC-HEADER>0001628280-21-010387.hdr.sgml : 20210514
<ACCEPTANCE-DATETIME>20210514171440
ACCESSION NUMBER:		0001628280-21-010387
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		53
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210514
DATE AS OF CHANGE:		20210514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		21925968

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cpix-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:04e28feb-0224-48c2-9aed-5419303ac6e2,g:7c5adb88-3a13-4fc9-bea7-995fc46bc2d7,d:bed5a8c73c54452487f262c52ff9017c--><html xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:cpix="http://www.cumberlandpharma.com/20210331" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180L2ZyYWc6OWExZjA3ZTllZmI2NGNjMmFiZmZhOGRjYzI5ZDY0NWUvdGFibGU6ZjEwOGY4YTQyYWM2NGRhNTlhMjA2ZGM2MjdlZGY1YTgvdGFibGVyYW5nZTpmMTA4ZjhhNDJhYzY0ZGE1OWEyMDZkYzYyN2VkZjVhOF81LTEtMS0xLTA_f7862fdf-139e-453e-89ed-7e9448a68bc0">2021</ix:nonNumeric><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180L2ZyYWc6OWExZjA3ZTllZmI2NGNjMmFiZmZhOGRjYzI5ZDY0NWUvdGFibGU6ZjEwOGY4YTQyYWM2NGRhNTlhMjA2ZGM2MjdlZGY1YTgvdGFibGVyYW5nZTpmMTA4ZjhhNDJhYzY0ZGE1OWEyMDZkYzYyN2VkZjVhOF82LTEtMS0xLTA_99926dee-1365-47f0-9335-eb40651dec7c">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180L2ZyYWc6OWExZjA3ZTllZmI2NGNjMmFiZmZhOGRjYzI5ZDY0NWUvdGFibGU6ZjEwOGY4YTQyYWM2NGRhNTlhMjA2ZGM2MjdlZGY1YTgvdGFibGVyYW5nZTpmMTA4ZjhhNDJhYzY0ZGE1OWEyMDZkYzYyN2VkZjVhOF83LTEtMS0xLTA_f3e2e0b2-fba2-4a22-95a1-e02a4f858100">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180L2ZyYWc6OWExZjA3ZTllZmI2NGNjMmFiZmZhOGRjYzI5ZDY0NWUvdGV4dHJlZ2lvbjo5YTFmMDdlOWVmYjY0Y2MyYWJmZmE4ZGNjMjlkNjQ1ZV83OQ_be221f3d-a6d1-4c5d-8e19-bd1577ef422d">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180L2ZyYWc6OWExZjA3ZTllZmI2NGNjMmFiZmZhOGRjYzI5ZDY0NWUvdGV4dHJlZ2lvbjo5YTFmMDdlOWVmYjY0Y2MyYWJmZmE4ZGNjMjlkNjQ1ZV84MA_63b724cd-9e1a-45c1-9d96-d7eb5d3f0dbf">0001087294</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i38218dfd921040d7b3b26c174a646322_I20210510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32068be194474f9cb55326666a7fbec0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida5da6da6f1940a89e2ca94214d39333_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie233d42748ec407f95f541fbd71d46ac_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2ffeb106dc64405a2176740c3911624_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib06687c2aa5440aa9603d320be455732_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic61089dc435b40fba685b7b8a3119d6a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if890c44461b6436496221a526f27e535_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadc27382cf1543aeab148380997ffd49_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i932d3a3642fe4eea9f64a3315bad0bf3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic03d7f9f76264ef5b4cb398729aed58c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42ffa52e2ca34a65970a04537b3b4818_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cbedf5761f7490b8032ca938d802c9f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2641b7e1d4f4e36a6431338fd938d84_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32683bdb8c0e4ba1bd2ad06feb02693a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02023e16463a45f891a3eca1a68aa423_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b204f4dda214716a8d2597171f9411e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6a93a5acaec4b8598b2aebbfadd4119_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i832ffbf2902c4a768fc2b9b3becc3924_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd6f054d04374954ad9f0a6ad2ea298c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i745ba0295e724b4bbd4b33a5ee76d597_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icce24f39974b4ed98da8bfbe93943fbf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cpix:Segment</xbrli:measure></xbrli:unit><xbrli:context id="i529667d136134653822f8cd1f52ea7d0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c72789317264e7cac1350e71f0ab560_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cea9b0a3e2640afb98e17b1e3a6f819_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i590eaf4520974d29b6b01a687d2d13fc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id94b2cb8e46b43f8ba1807feeb2a3fe7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i586cba84dc4847daab9569a2b1c1b879_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib469a00b1c1e41ebaf007975ede59684_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcc02cc49f4b429aa9f1c74f9bc16e6b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f27ae48034942de95317f99306eea46_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i645b158fe75341daa01ca68e5cf1c2b6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i613693e28d6e4692be7579f7e5ab1d49_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i823406d319024699bfab22321dde04e3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39d646b80ea44ec583582f1c79953d87_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0edefe7ed797492eae26ff926abd627a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i763bd43cce884a5780a96bbcfb7e0253_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i541a71eb9df04c92806ebdb9f1ae4771_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e10e772bb294442900e5d9b697e71e3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4068d158ecb7413b92d283e5bce21c80_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3f04630c9f547b5be864f1c66564cb8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b759ac132064b2787c2b5a4ad1e70f7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd43aeaa2b4b4955aef55acce99cd31d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a40e1cbac204fb18cf00c3b1f6c81c6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i61c481ad9f504703a94e6b9be6f518e2_I20100513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2010-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26d732474c194cee89c889d4f8a693f2_I20160131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08b1da814e684be58d651fa09524635d_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2eda2a4dac14ec3b727863dc09461ee_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i176b3b536b2f4266bb9351936fafc0a5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id97ac84efc164cb38bbe53650262439c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8efd5212c2ea4438a3c6b998c82af06a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:IncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ddf705ec76d45ce90dcfd34b198b915_I20201007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:FourthAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49d1ed31c7894e6b987d5f1b88ea735e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida4acda1a0824ddd98ba37f7456c0970_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic626a31ddbca438a89b05457be379d25_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic599c92ccd35431db3b06f4238341683_D20200814-20200814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib53bd71fe3994d2da24c5195efd6412c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ccab55d30cd4f3595d41c3c3554b52a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i830bb87cb40044cd957e698b46665fd6_D20200420-20200420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-20</xbrli:startDate><xbrli:endDate>2020-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59247f7dd59d4f28aee9f37d45d509aa_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd3a639d6f35423aa3c2f6243856ec35_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c5f356638654bbdaf6b452874ae5eaf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4690540184b48fa90ef75b783a03efb_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied6025b276df445997781e0a3e02560b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3416c55598e64e2b95051149db842304_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0ecdd80f5234983a18050bf8ecf1cda_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0a8b608c7614df795f5ef973e97f9d9_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7582538d23084840b14af98041033df1_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8d1afac2fe04daeb9be14e2c01cb3cf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0eada6a93ec412dbdce374da1fb4f0c_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id745598dd60b4f4088bc62c2d5c607b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a68ec61d27040248d7dd487e14454d4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78e7ac2dbdbe4730beeb4a8d45f46205_D20191001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a4c618331f148a9b3e193bc04d8c16e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6874375315de4805a4b9a90949e9e0a9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d4b97906e974844a32b25017974062a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ibed5a8c73c54452487f262c52ff9017c_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18yMDEy_ff6a6f6e-cd70-42a3-895e-0e87f75ada01">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6NjY1NDZlYmI3MDMwNGU4MDk1YjJhMTE2ZTM4MjczZjEvdGFibGVyYW5nZTo2NjU0NmViYjcwMzA0ZTgwOTViMmExMTZlMzgyNzNmMV8wLTAtMS0xLTA_c8d05ffd-1b67-4738-9809-64849bd7369d">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18xMzE_94939131-3d30-4b7c-af17-f8aee63cb279">March 31, 2021</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6OGYyNDQwMDE3YTQyNDcyYThiNGU2NDIwM2UyNDIzNmYvdGFibGVyYW5nZTo4ZjI0NDAwMTdhNDI0NzJhOGI0ZTY0MjAzZTI0MjM2Zl8wLTAtMS0xLTA_512a1272-0084-4db8-8e66-1d3ce05a3c33">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18yMDE1_d022d4d1-cf98-4200-8d49-a48db962c4c1">001-33637</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18yMDA2_161a0e35-e34c-4fad-b523-410ca98b0eda">Cumberland Pharmaceuticals Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified In Its Charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:48.532%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6MjgwMDMwZDg3OGY5NDY3YTkwNWI2NTQ0NGU5MjdhZDkvdGFibGVyYW5nZToyODAwMzBkODc4Zjk0NjdhOTA1YjY1NDQ0ZTkyN2FkOV8wLTAtMS0xLTA_daed7df7-6f34-4678-b61b-ec6b1132301d">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6MjgwMDMwZDg3OGY5NDY3YTkwNWI2NTQ0NGU5MjdhZDkvdGFibGVyYW5nZToyODAwMzBkODc4Zjk0NjdhOTA1YjY1NDQ0ZTkyN2FkOV8wLTItMS0xLTA_53e0ff7c-59f8-4ed7-9e6d-6fa381e3355c">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporation or Organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6MjgwMDMwZDg3OGY5NDY3YTkwNWI2NTQ0NGU5MjdhZDkvdGFibGVyYW5nZToyODAwMzBkODc4Zjk0NjdhOTA1YjY1NDQ0ZTkyN2FkOV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphMTYzZDg4Njk1ZWU0NGYwOTM1ZTM5YTc5MTU5YTExYV81_b1f8d365-90e2-4bbe-9446-a6f598fa05a1">2525 West End Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6MjgwMDMwZDg3OGY5NDY3YTkwNWI2NTQ0NGU5MjdhZDkvdGFibGVyYW5nZToyODAwMzBkODc4Zjk0NjdhOTA1YjY1NDQ0ZTkyN2FkOV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphMTYzZDg4Njk1ZWU0NGYwOTM1ZTM5YTc5MTU5YTExYV85_d1475538-1afe-4550-89c3-0d3632cb5ab9">Suite 950</ix:nonNumeric>,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6MjgwMDMwZDg3OGY5NDY3YTkwNWI2NTQ0NGU5MjdhZDkvdGFibGVyYW5nZToyODAwMzBkODc4Zjk0NjdhOTA1YjY1NDQ0ZTkyN2FkOV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphMTYzZDg4Njk1ZWU0NGYwOTM1ZTM5YTc5MTU5YTExYV8xMw_52ecac74-0e07-4427-ba66-6774e76cc534">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6MjgwMDMwZDg3OGY5NDY3YTkwNWI2NTQ0NGU5MjdhZDkvdGFibGVyYW5nZToyODAwMzBkODc4Zjk0NjdhOTA1YjY1NDQ0ZTkyN2FkOV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphMTYzZDg4Njk1ZWU0NGYwOTM1ZTM5YTc5MTU5YTExYV8xNw_62e87303-23c6-48a1-a4bc-cdb89fa43c68">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6MjgwMDMwZDg3OGY5NDY3YTkwNWI2NTQ0NGU5MjdhZDkvdGFibGVyYW5nZToyODAwMzBkODc4Zjk0NjdhOTA1YjY1NDQ0ZTkyN2FkOV8zLTItMS0xLTA_14cc438b-5116-465f-ad5b-ed0b49cec3e4">37203</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18yMDA4_ab3907ed-78d9-4a51-86cb-a193fef27409">615</ix:nonNumeric>) <ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18yMDA5_af818f16-f07f-44d6-8878-ea09edadd910">255-0068</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18yMDEw_5116375a-427b-4674-8faf-554a0a44b9d1">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18yMDA3_3ced5073-0912-4fec-9507-b46c1b5be0f9">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6M2JlMmEwMTJiMTU2NDNhMDk4ZDc1N2E2NjQ3OWVkYmYvdGFibGVyYW5nZTozYmUyYTAxMmIxNTY0M2EwOThkNzU3YTY2NDc5ZWRiZl8xLTAtMS0xLTA_aff32518-15c4-4dee-88b8-653ae0b8cd4b">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" format="ixt:booleantrue" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6M2JlMmEwMTJiMTU2NDNhMDk4ZDc1N2E2NjQ3OWVkYmYvdGFibGVyYW5nZTozYmUyYTAxMmIxNTY0M2EwOThkNzU3YTY2NDc5ZWRiZl8xLTUtMS0xLTA_785b8669-8ce9-4a55-bdad-0b3069a38dd9">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Emerging growth company</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6M2JlMmEwMTJiMTU2NDNhMDk4ZDc1N2E2NjQ3OWVkYmYvdGFibGVyYW5nZTozYmUyYTAxMmIxNTY0M2EwOThkNzU3YTY2NDc5ZWRiZl8yLTItMS0xLTA_1dd6ff34-5101-4af8-b191-cfb9bcb4a5d9">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to&#160;Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18yMDEx_b5b1e754-a11d-41d7-b7fa-cd74961acc65">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date: <ix:nonFraction unitRef="shares" contextRef="i38218dfd921040d7b3b26c174a646322_I20210510" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18xMDk5NTExNjI5ODMy_c0023b3f-7fd0-4603-9374-b60e4d21c7c6">15,050,025</ix:nonFraction> shares of common stock as of May&#160;10, 2021.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"></td><td style="width:31.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6NGMxM2Y5NWJiMTNlNDU4MWI2ZTY5NmRlODJkZTZhNTQvdGFibGVyYW5nZTo0YzEzZjk1YmIxM2U0NTgxYjZlNjk2ZGU4MmRlNmE1NF8xLTAtMS0xLTA_4db93bd3-51c6-45b0-972e-e254e18891fb">Common stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6NGMxM2Y5NWJiMTNlNDU4MWI2ZTY5NmRlODJkZTZhNTQvdGFibGVyYW5nZTo0YzEzZjk1YmIxM2U0NTgxYjZlNjk2ZGU4MmRlNmE1NF8xLTItMS0xLTA_a128c659-e87a-410b-af00-a5b9159cb3cc">CPIX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6NGMxM2Y5NWJiMTNlNDU4MWI2ZTY5NmRlODJkZTZhNTQvdGFibGVyYW5nZTo0YzEzZjk1YmIxM2U0NTgxYjZlNjk2ZGU4MmRlNmE1NF8xLTQtMS0xLTA_47eb58ae-5f24-4352-bb46-5e3f06fdbae0">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:9pt"><span><br/></span></div><div id="ibed5a8c73c54452487f262c52ff9017c_7"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.331%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.469%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_10">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_10">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;padding-right:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_13">Item&#160;1. Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_13">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_16">1</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_19">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_19">2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_22">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_22">3</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_25">Condensed Consolidated Statements of Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_25">4</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_28">Notes to the Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_28">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_61">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_61">14</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_82">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_82">24</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_85">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_85">24</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_88">PART II &#8211; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_88">25</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_91">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_91">25</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_94">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_94">25</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_97">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_97">25</a></span></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_100">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_100">26</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_103">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibed5a8c73c54452487f262c52ff9017c_103">27</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ibed5a8c73c54452487f262c52ff9017c_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#8211; FINANCIAL INFORMATION</span></div><div id="ibed5a8c73c54452487f262c52ff9017c_13"></div><div style="-sec-extract:summary;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Financial Statements (Unaudited)</span></div><div id="ibed5a8c73c54452487f262c52ff9017c_16"></div><div style="-sec-extract:summary;margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMy0xLTEtMS0w_d33521a3-b4cd-427a-9856-711dee5fa502">24,922,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMy0zLTEtMS0w_fe1c004c-6244-43f1-966b-fede490650b0">24,753,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfNS0xLTEtMS0w_29839a91-62fe-4f02-9134-dd58203d5088">12,549,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfNS0zLTEtMS0w_af242aa1-5d35-4891-8938-a663a877b5e6">12,377,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfNi0xLTEtMS0w_0292b84e-9564-4c3f-8b67-25ee9943f2e1">10,010,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfNi0zLTEtMS0w_5fab1f31-8dc6-4297-87a6-0c817a17b06c">10,638,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfOC0xLTEtMS0w_8f658f14-e20e-499f-8703-c94d9170b88b">1,900,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfOC0zLTEtMS0w_d1e36c81-23d5-451a-89ec-eae869ac31ba">2,199,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfOS0xLTEtMS0w_aac82d83-eda7-4ae8-8aee-94483a8b5ca9">49,383,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfOS0zLTEtMS0w_ef682c62-abff-4c73-94cf-efac23a8b68f">49,969,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTAtMS0xLTEtMA_e08e8a0f-31a3-4e29-bcc1-1aa0069caa8d">10,415,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTAtMy0xLTEtMA_f042b44a-8008-40ae-a3a4-fb073beacd91">11,656,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTEtMS0xLTEtMA_aa83e25e-73fb-4582-b096-50a09db6256b">534,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTEtMy0xLTEtMA_cd08681a-f8dd-4b18-8742-cca21acdf631">574,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTItMS0xLTEtMA_76fb9a83-5ec1-40ed-90cb-3df39a883608">27,024,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTItMy0xLTEtMA_ab8903a5-dc52-414c-9c5c-7ed1074ade11">28,118,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTMtMS0xLTEtMA_54a0ac28-45c0-4f0b-8993-8e8be71432d8">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTMtMy0xLTEtMA_841d9fe2-690e-4354-8902-1191a2f2def4">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTUtMS0xLTEtMA_e6f68ee6-031b-45cd-af89-12fb7eb56130">1,784,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTUtMy0xLTEtMA_8a2d7a39-c421-4f89-9abd-0202e1a6c662">2,028,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTYtMS0xLTEtMA_52a1e1ed-af2b-49cb-a05d-22f8ce38d44b">3,323,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTYtMy0xLTEtMA_24e0c4d7-96dd-4ed5-8572-839c3ffa7555">3,234,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTctMS0xLTEtMA_06cd07a6-20fd-4a57-9661-41fd0c2bcd36">93,348,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTctMy0xLTEtMA_cc4803e7-bf6e-4fc1-b0a0-8062958465dc">96,463,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjAtMS0xLTEtMA_89c424ee-fe3d-43ce-bfcc-80ed383caee7">10,466,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjAtMy0xLTEtMA_116515bb-9e93-43f2-8d3b-9d5b84435c19">13,396,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjItMS0xLTEtMA_7796e2c6-0558-49f6-995c-98d965dcdafe">1,042,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjItMy0xLTEtMA_dc94fbbf-3c81-49db-abe0-1fb72ccc9b00">1,016,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjQtMS0xLTEtMA_9e0f663f-4808-477e-bad1-b51ac216d73d">11,339,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjQtMy0xLTEtMA_324c97e6-4ca2-413a-b8ed-4e7beae9bf31">11,254,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjUtMS0xLTEtMA_744eacf5-00f8-49ed-91f2-8886148f46ce">22,847,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjUtMy0xLTEtMA_6c20335d-5c80-4416-955d-9fcaea94d70e">25,667,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjYtMS0xLTEtMA_e72ee778-5567-4e11-8863-440f6384af43">15,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjYtMy0xLTEtMA_80787f93-52ed-462f-a02a-96c1c18f6620">15,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjctMS0xLTEtMA_cb40b9a6-bb5e-42c8-86cd-e07142a6e99b">789,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjctMy0xLTEtMA_c9d0c727-a838-40f7-a4f0-60c637a599de">1,059,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjgtMS0xLTEtMA_3cf53b17-f013-4d4e-85be-d2e06e81f63a">7,833,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjgtMy0xLTEtMA_f4a58ad9-68f9-4efc-a306-9b2e02ad46fb">7,862,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjktMS0xLTEtMA_6cd25af9-6d1d-44dc-8726-56d5c69922d8">46,470,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjktMy0xLTEtMA_82f00a52-f8eb-48d1-85d6-8478c42f5f84">49,589,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzAtMS0xLTEtMA_24861e21-64a8-4f6d-b12e-a2340c5fc4c4"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzAtMy0xLTEtMA_6081c930-102a-4cea-9a2e-4f6e408d842f"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#8212;<ix:nonFraction unitRef="usdPerShare" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI5MDU4Mzk1MDE1ZTRiNWM4ZGU1MTcwNGMyMjFhYWQzXzE3_4a90d0a5-e8b6-46d3-a393-81809ef3b4d3"><ix:nonFraction unitRef="usdPerShare" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI5MDU4Mzk1MDE1ZTRiNWM4ZGU1MTcwNGMyMjFhYWQzXzE3_b618b274-8d48-4d53-8410-cecdd2764c56">no</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI5MDU4Mzk1MDE1ZTRiNWM4ZGU1MTcwNGMyMjFhYWQzXzMx_3a1b34fb-db9f-491e-8035-5d383a1baee8"><ix:nonFraction unitRef="shares" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI5MDU4Mzk1MDE1ZTRiNWM4ZGU1MTcwNGMyMjFhYWQzXzMx_f12e2eeb-1599-4ceb-b23f-9cad955f0321">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI5MDU4Mzk1MDE1ZTRiNWM4ZGU1MTcwNGMyMjFhYWQzXzUz_15a76be6-cdb6-4ad8-99b9-713e4836e965"><ix:nonFraction unitRef="shares" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI5MDU4Mzk1MDE1ZTRiNWM4ZGU1MTcwNGMyMjFhYWQzXzUz_eeadc2e3-1b8a-43a6-84a4-a159d7563a5f">15,084,464</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI5MDU4Mzk1MDE1ZTRiNWM4ZGU1MTcwNGMyMjFhYWQzXzYw_55264ba8-416e-4543-a917-95f9a693f62a"><ix:nonFraction unitRef="shares" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI5MDU4Mzk1MDE1ZTRiNWM4ZGU1MTcwNGMyMjFhYWQzXzYw_8bfc0231-3bf1-4c57-9e45-8c33713e6eb6">14,988,429</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMS0xLTEtMA_281bc740-d703-41f5-8e51-613064f94b53">48,981,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMy0xLTEtMA_64c2bfd4-79bc-4017-b20b-b5817e8b7a49">49,121,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (deficit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzQtMS0xLTEtMA_a4771095-bb7f-4edb-8ccb-67c4e0af2513">1,964,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzQtMy0xLTEtMA_5ae1f4d7-7dc9-4ead-83fe-f3a8f0dd34cd">2,131,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzUtMS0xLTEtMA_e60561c1-d8bf-470f-b636-d978833b2129">47,017,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzUtMy0xLTEtMA_ba3c2eeb-23c4-492c-9fe1-ad5b64ecabaf">46,990,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzYtMS0xLTEtMA_69db001e-5651-40d9-bd6f-86e60d54e48c">139,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzYtMy0xLTEtMA_8b2402a7-3810-48df-9ba3-1e5ad24917a0">117,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzctMS0xLTEtMA_3a4d177b-a63d-4aac-be48-9b064b18e104">46,877,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzctMy0xLTEtMA_85ab35a6-eac1-4551-a28e-cf483a79f0bd">46,873,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzgtMS0xLTEtMA_acc8603e-6fb6-490d-9a4c-75cb818295d1">93,348,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzgtMy0xLTEtMA_6852c40a-30a2-4a4f-86d0-26f691f6dc09">96,463,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ibed5a8c73c54452487f262c52ff9017c_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.399%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMi0xLTEtMS0w_e841fe40-cca9-43f6-a292-bcf416010925">10,537,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMi0zLTEtMS0w_9f7d72ad-210a-414d-85a5-9116d33da034">8,330,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfNC0xLTEtMS0w_90586fae-1ad3-454e-99ac-c9ee6840d334">2,417,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfNC0zLTEtMS0w_a092a26e-ab23-4fb5-b101-1a51232f719e">1,634,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfNS0xLTEtMS0w_301c2017-453d-4354-879a-61bfde8f7c7d">3,787,340</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfNS0zLTEtMS0w_a92df567-9d5d-433e-aa73-f20d64eda4f6">3,707,676</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfNi0xLTEtMS0w_55c50c9f-7e61-46cd-9146-abf97a1b4017">1,257,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfNi0zLTEtMS0w_b2f2c74b-3697-4402-8ae4-b8480d4da8d3">1,722,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfNy0xLTEtMS0w_1e9a1dd4-4281-4b74-a6ef-58514ee9ca56">2,230,509</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfNy0zLTEtMS0w_0ca2a97d-9aea-40d9-a2ad-45c543d2f2e3">2,036,284</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfOC0xLTEtMS0w_6ec40728-295d-409c-b5f2-1882e606c562">1,168,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfOC0zLTEtMS0w_b734b62b-6a84-4c19-b8bf-76b62bfa1b3d">1,076,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfOS0xLTEtMS0w_e350de00-52ca-4f1b-a66c-4752e6ab21c5">10,861,459</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfOS0zLTEtMS0w_3cbdb0b4-1419-4370-80c3-a8dbc9e22f53">10,176,735</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTAtMS0xLTEtMA_8b8d139a-a7fd-4b99-bb49-14f59b07ed77">324,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTAtMy0xLTEtMA_046da1cd-ce3e-40be-b04b-6b006041f03e">1,846,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTEtMS0xLTEtMA_1e4443db-9cc9-442d-bf8b-49d0b503656a">5,426</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTEtMy0xLTEtMA_2fc3870a-a699-4faa-ac63-67d082111d5f">29,888</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTItMS0xLTEtMA_a4c7379f-5d83-4d33-92fe-bb34760c705a">24,417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTItMy0xLTEtMA_4b36212d-72b3-452b-a931-ad19a62178a1">33,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTMtMS0xLTEtMA_4d5dc03d-f595-4682-b525-cdf2cb3e0777">343,291</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTMtMy0xLTEtMA_e114a97d-92dc-4115-9234-f7ebd2bf7cf8">1,849,178</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTQtMS0xLTEtMA_dab3f8a4-d725-4a99-a76f-2b0028570f95">7,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTQtMy0xLTEtMA_cc770ad9-0e65-4eea-8e70-488e02beb7ba">34,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTUtMS0xLTEtMA_f70f9fd6-6381-435a-8bf4-30043e54eac3">350,749</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTUtMy0xLTEtMA_f5f0e4ac-d631-4ca7-9f9b-aa2516b5b4a1">1,883,418</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTYtMS0xLTEtMA_5baed91d-594a-4426-a50b-c6ba3234eb82">495,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTYtMy0xLTEtMA_1049c477-057b-4f74-b478-8dc4cc4f75de">818,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTctMS0xLTEtMA_704e1c94-abc0-40d6-af33-754c88910bc0">144,661</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTctMy0xLTEtMA_8ca5ee37-e8e2-4271-8f31-0b410c3b892b">1,065,145</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTgtMS0xLTEtMA_c953f20e-2dcc-426e-902a-9cbb34db97e5">22,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTgtMy0xLTEtMA_38c11bb2-890c-477f-b418-e8268b19696b">9,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTktMS0xLTEtMA_6d3d5965-f6be-4ce1-89a9-20450e17c16e">166,828</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTktMy0xLTEtMA_640be224-2250-4e6a-9bfa-cd9636bc3f3b">1,055,620</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Continuing operations - basic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjEtMS0xLTEtMA_2fe4bed7-d61f-4bf2-913a-75bdc25930fd">0.02</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjEtMy0xLTEtMA_06f1ac42-42ce-4159-9f55-8f44256a0795">0.12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Discontinued operations - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjItMS0xLTEtMA_23719c4b-c48e-4431-9de0-e1b6c2b77eca">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjItMy0xLTEtMA_c55102c0-8d74-4721-9c9b-525a70dd7c94">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjMtMS0xLTEtMA_5fc32c6c-0243-4383-98ac-1575270faefd">0.01</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjMtMy0xLTEtMA_92083032-3aa3-4990-9890-b4d152c4eb62">0.07</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Continuing operations - diluted</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjUtMS0xLTEtMA_b5120b41-4b96-497c-88ca-c74461e1a32b">0.02</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjUtMy0xLTEtMA_e05168eb-ff78-487c-81b7-e5f69876af5d">0.12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Discontinued operations - diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjYtMS0xLTEtMA_82c87cc6-7636-4e3c-8eef-2ee18ea5c0d9">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjYtMy0xLTEtMA_5e954a03-4809-402e-afaa-152c5874e8a8">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjctMS0xLTEtMA_471b74cc-5f1f-4bb9-8103-dfd541b64264">0.01</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjctMy0xLTEtMA_3b38c04c-5940-4926-8e81-c570de37e4fa">0.07</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjktMS0xLTEtMA_3f443b5e-ab6e-4d21-ba42-06ae5407afc6">14,974,663</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjktMy0xLTEtMA_e275d1b9-295a-472e-8e87-c97786815ebd">15,240,614</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMzAtMS0xLTEtMA_ee53aef5-becf-4d4f-b0c3-f2e6dadf5002">15,244,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMzAtMy0xLTEtMA_5fe8f37d-1e79-4a11-8666-533b5b9701a8">15,578,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ibed5a8c73c54452487f262c52ff9017c_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMy0xLTEtMS0w_a8098da5-5a8b-4dd3-807c-b612652d4f37">144,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMy0zLTEtMS0w_d1b89506-f4e5-457f-ae24-a9a5960f1c94">1,065,145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNC0xLTEtMS0w_977daff6-1329-4239-bb5e-f539f3d4f188">495,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNC0zLTEtMS0w_4db65a1e-d7a5-4b53-8765-d86405af3fde">818,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNS0xLTEtMS0w_d852595b-fd5d-414a-a7d5-8f7ffe220d1d">350,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNS0zLTEtMS0w_087bc6a1-13f3-4749-aed3-2b515571f115">1,883,418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNy0xLTEtMS0w_97b27229-dc34-44f0-990a-9fde269d614b">1,227,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNy0zLTEtMS0w_391cfd0c-283e-4058-a501-ab62d8461e60">1,152,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfOS0xLTEtMS0w_f3c296d5-de0b-48ee-adb6-de0a31f68f55">162,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfOS0zLTEtMS0w_019c0741-d45f-4f37-ab7a-9d1bfa22ba44">264,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in non-cash contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTAtMS0xLTEtMA_33996a0e-72ba-4d8e-bced-935031d31b2b">280,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTAtMy0xLTEtMA_73de50ff-2b0d-4f2e-8dfb-b0d408963182">543,006</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in cash surrender value of life insurance policies over premiums paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTAtMS0xLTEtMTE1Nw_ca90fe73-4bef-4d7b-801e-44d072ba9e91">76,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTAtMy0xLTEtMTE1Nw_be55e431-09c7-48f0-8a3e-c9ec60684514">548,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTEtMS0xLTEtMA_8c22a6e7-7e3f-4e98-97d3-72af3a52d79b">13,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTEtMy0xLTEtMA_505260f2-1ba7-472c-8d81-72e54b6c2c91">11,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in assets and liabilities affecting operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTQtMS0xLTEtMA_e56b51c4-83cf-43eb-88c3-d5682d328adb">171,584</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTQtMy0xLTEtMA_9a41cd78-e787-4eab-85fd-b769df65fd6f">2,014,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTUtMS0xLTEtMA_bd1d62c9-734d-4d62-8784-93b42d68d454">1,868,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTUtMy0xLTEtMA_0b7de498-367f-4ce8-a3d5-416ad68a3426">706,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTYtMS0xLTEtMA_7c26d9bf-2154-421d-85db-197be2dcfce4">507,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTYtMy0xLTEtMA_2b059168-d0de-4039-b93a-c0b031ed4c06">545,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTctMS0xLTEtMA_ecfdf822-336a-4c6f-819a-1696fab9393f">1,311,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTctMy0xLTEtMA_fa9dccda-9af6-4124-b451-d054872905e9">2,394,824</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTgtMS0xLTEtMA_65a323e3-b9f3-4e7a-a8a4-0a028e780d62">299,937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTgtMy0xLTEtMA_4b3f3c82-40aa-4842-b6f8-42e402fc53b4">865,109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTktMS0xLTEtMA_4d6de2aa-9386-40a4-b002-486a94df09ee">1,290,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTktMy0xLTEtMA_87d788fc-1b74-4e1d-ae43-f2a3b1e0e67b">444,331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjAtMS0xLTEtMA_75af0df2-9df4-4ce1-8a8b-aa7196652d28">495,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjAtMy0xLTEtMA_6053790d-0916-4080-a7eb-73081e6ecdb0">1,332,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjEtMS0xLTEtMA_45bfa7fa-b178-4a58-8d62-7379cc600294">1,785,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjEtMy0xLTEtMA_b7b3203a-30a0-43c9-ba47-3178eea1df35">888,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjMtMS0xLTEtMA_2f9d4eca-757b-40ac-adf5-cbb8831eb342">19,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjMtMy0xLTEtMA_7f29ea41-f4de-4048-8cc9-dae1ce8722c4">22,726</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note receivable investment funding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLifeInsurancePolicies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjYtMS0xLTEtMA_6f527164-737f-4121-b025-934d52839698">200,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromLifeInsurancePolicies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjYtMy0xLTEtMA_2c31d0fe-a568-4ef2-b400-7a0b14ed26e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjgtMS0xLTEtMA_2449fc14-77a6-4a08-9faa-0a4d19677d39">98,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjgtMy0xLTEtMA_115b6b43-4970-4ed6-943a-c8bff538159e">548,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjktMS0xLTEtMA_ef396d20-fc0b-45db-b129-8bddacf33292">318,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjktMy0xLTEtMA_2d5e23fd-29a3-48a4-9be1-6e8133033355">571,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzItMS0xLTEtMA_d49c8c49-8a89-4573-a9ad-ee26bf311e73">15,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzItMy0xLTEtMA_1fc9bd9f-a5a8-4c8d-9006-4f132ceea3a5">18,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments on line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzMtMS0xLTEtMA_d5a77f4c-dd25-4dff-93af-acd36b01b58d">15,000,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzMtMy0xLTEtMA_8360529b-da6b-4a23-9ba5-37239fc10dbf">18,500,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzUtMS0xLTEtMA_ad7de5a4-9ad3-4d6c-92cf-a984bc0e286f">995,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzUtMy0xLTEtMA_3325443d-b2b0-47fb-815d-2db6ca25daf6">260,735</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of subsidiary shares from noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzAtMS0xLTEtNDI4_d2784439-047b-4a41-97cc-72c01005e7a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzAtMy0xLTEtNDI4_b65a482b-b337-4ce9-a79e-6cfd3a7b9cf7">800,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzctMS0xLTEtMA_492cefbb-24a6-4530-9af7-5c21e7d7d20f">302,802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzctMy0xLTEtMA_ee9ac09d-6d48-448f-8d2f-10846d231047">442,544</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzgtMS0xLTEtMA_0cbc351f-cab8-4292-a436-206fc5c9ed91">1,298,079</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzgtMy0xLTEtMA_2bdbd0fb-0663-42ed-b25f-362a9042cde0">1,503,279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzktMS0xLTEtMA_0f91d6dd-e8ae-4395-b654-13511ab3c7b8">169,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzktMy0xLTEtMA_8c0a8c15-29a3-4a02-935d-268274bf1cc7">1,185,901</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNDAtMS0xLTEtMA_dc60aede-ca52-4038-bba2-e0f400ee2984">24,753,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5da6da6f1940a89e2ca94214d39333_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNDAtMy0xLTEtMA_e29111e4-76fd-4711-b164-40fa5c0233ce">28,212,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNDEtMS0xLTEtMA_d342e7b7-4740-4d09-8907-d8595c7f4a81">24,922,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie233d42748ec407f95f541fbd71d46ac_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNDEtMy0xLTEtMA_63888486-fa78-4fb8-b684-108203907049">27,026,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ibed5a8c73c54452487f262c52ff9017c_25"></div><hr style="page-break-after:always"/><div style="min-height:33.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2ffeb106dc64405a2176740c3911624_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfMi0xLTEtMS0w_1e14be1d-c13a-46ae-9024-7e193a17b6eb">15,263,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ffeb106dc64405a2176740c3911624_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfMi0zLTEtMS0w_067a296a-9382-40d4-b110-3074cb793c43">49,914,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib06687c2aa5440aa9603d320be455732_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfMi01LTEtMS0w_0d54dc08-2851-498c-9b15-63472af9d41c">1,208,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic61089dc435b40fba685b7b8a3119d6a_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfMi03LTEtMS0w_a6cfc10c-3e13-4e6a-8ed0-beb71221a747">37,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5da6da6f1940a89e2ca94214d39333_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfMi05LTEtMS0w_84a4de80-407c-4120-99ba-141ac6392bc4">51,085,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if890c44461b6436496221a526f27e535_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfMy0xLTEtMS0w_8e4f8de7-9a16-4c11-ae33-33e1094fd07b">219,850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if890c44461b6436496221a526f27e535_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfMy0zLTEtMS0w_85479f12-6052-4d8c-99be-7f24225e0fb4">264,574</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfMy05LTEtMS0w_e321a44f-8ff7-4068-8359-f306243dec02">264,574</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if890c44461b6436496221a526f27e535_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNC0xLTEtMS0w_5797046c-5cd1-451b-94de-b83ace6c718a">164,866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if890c44461b6436496221a526f27e535_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNC0zLTEtMS0w_e771120b-1e43-459e-9b15-d9a1d0d1fe62">441,624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNC05LTEtMS0w_1e931085-b9e5-4db2-a392-7bd14f47e0a0">441,624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadc27382cf1543aeab148380997ffd49_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNS01LTEtMS0w_a93f83f8-1249-4d94-864f-055d9fa8febd">1,055,620</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i932d3a3642fe4eea9f64a3315bad0bf3_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNS03LTEtMS0w_ed0a48b3-0c5b-433e-a1f0-14c69b4de50c">9,525</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNS05LTEtMS0w_8432aa26-13cd-4e66-9a60-5c51388eb506">1,065,145</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic03d7f9f76264ef5b4cb398729aed58c_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNi0xLTEtMS0w_9446a4c1-ddfe-472e-b436-07fd773dae46">15,318,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic03d7f9f76264ef5b4cb398729aed58c_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNi0zLTEtMS0w_98a75a51-942e-4fc9-8a94-c2bd9dcbcb8e">49,737,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42ffa52e2ca34a65970a04537b3b4818_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNi01LTEtMS0w_77aa352c-b109-4a8c-a66e-bd875c1bc715">152,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cbedf5761f7490b8032ca938d802c9f_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNi03LTEtMS0w_ba9d34e1-58d0-4279-ab67-4c4efb2813d1">47,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie233d42748ec407f95f541fbd71d46ac_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNi05LTEtMS0w_a06b689d-d2d7-4ab6-88b4-ca48035b8122">49,843,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retained earnings (deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2641b7e1d4f4e36a6431338fd938d84_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfMi0xLTEtMS0w_f41b8b47-179b-49f7-a763-2f3e05117a16">14,988,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2641b7e1d4f4e36a6431338fd938d84_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfMi0zLTEtMS0w_73507129-8916-4bd0-9f18-58f13f2194f3">49,121,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32683bdb8c0e4ba1bd2ad06feb02693a_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfMi01LTEtMS0w_5e3a7a69-114c-4648-85a5-a2160e2d76e8">2,131,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02023e16463a45f891a3eca1a68aa423_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfMi03LTEtMS0w_e3b7dd69-7318-40ee-aca6-946e87104aed">117,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfMi05LTEtMS0w_f28d4529-4a6a-42b7-b4e7-48f1e4c4b113">46,873,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b204f4dda214716a8d2597171f9411e_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfMy0xLTEtMS0w_d59869e4-115a-42ca-bba0-447f0ea2f11d">187,759</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b204f4dda214716a8d2597171f9411e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfMy0zLTEtMS0w_93ad612f-61d1-489b-b6bb-f42aa26cb1c0">162,960</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfMy05LTEtMS0w_5d44cbd0-1232-4325-bc15-684074fa8385">162,960</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0b204f4dda214716a8d2597171f9411e_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNC0xLTEtMS0w_18d86210-d815-4678-aa61-228b90347dcc">91,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b204f4dda214716a8d2597171f9411e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNC0zLTEtMS0w_861478ef-82fe-487f-a81e-3a462ce85c5b">303,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNC05LTEtMS0w_fb4a3c68-fa18-4928-90ca-d3385ab8eee5">303,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6a93a5acaec4b8598b2aebbfadd4119_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNS01LTEtMS0w_602a2215-b12b-48eb-8072-18ba969e181f">166,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i832ffbf2902c4a768fc2b9b3becc3924_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNS03LTEtMS0w_52594f89-da13-4557-8ce8-514296b4b2bd">22,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNS05LTEtMS0w_292430f1-5c38-46c7-9105-7e77e9c518fc">144,661</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd6f054d04374954ad9f0a6ad2ea298c_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNi0xLTEtMS0w_5eb96418-6f3f-40a7-b038-94859a3c2777">15,084,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd6f054d04374954ad9f0a6ad2ea298c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNi0zLTEtMS0w_f5de3545-fd84-441e-8ce5-24ee4ee39998">48,981,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i745ba0295e724b4bbd4b33a5ee76d597_I20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNi01LTEtMS0w_dfbe3db3-c7a7-42c0-8b82-f3e338e4c73e">1,964,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icce24f39974b4ed98da8bfbe93943fbf_I20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNi03LTEtMS0w_9519dd5c-22b9-463e-a315-e30181a0e2dc">139,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNi05LTEtMS0w_643fa925-65de-4a20-bbfd-c8a764c34a3d">46,877,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:31.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ibed5a8c73c54452487f262c52ff9017c_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="ibed5a8c73c54452487f262c52ff9017c_31"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1) <ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zMS9mcmFnOjg2MzQzNjEwY2Y1ZDQ0Njk5OGQ2MWU2ZTE1NjE2ODQyL3RleHRyZWdpb246ODYzNDM2MTBjZjVkNDQ2OTk4ZDYxZTZlMTU2MTY4NDJfMTEzNTU_4aef16a5-4f1b-4cfc-8c19-38e0e5ea8a9e" continuedAt="ie34d74932c824c0b9c63e71aed53c269" escape="true">ORGANIZATION AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="ie34d74932c824c0b9c63e71aed53c269" continuedAt="i1a5a9b3836a443259d90b567eb08b10f"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital and field sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2020, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2020 (the &#8220;2020 Annual Report on Form 10-K&#8221;). The results of operations for the three months ended March 31, 2021, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in Note 9, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Totect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been presented in the financial statements and footnotes to reflect the discontinued status of Ethyol and Totect. Refer to Note 9, for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revision of prior period condensed consolidated statement of cash flows presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has made a revision to prior period amounts to conform to the current year presentation of the cash surrender value of life insurance policies over premiums paid on the condensed consolidated statement of cash flows.  The revised amounts were previously included as net changes in assets affecting operating activities.  These revisions have no net effect on the reported net cash provided by operating activities nor any impact on the reported operating results or balance sheet for the 2020 period presented.  </span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect its employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="i1a5a9b3836a443259d90b567eb08b10f" continuedAt="idb006e22874b41bd9a6676addd73ca3e"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, Cumberland has faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue.  Our business and our clinical studies were impacted as less patients sought elective surgeries and our access to medical facilities was substantially limited.  During 2020, we carefully monitored our supply chain during the pandemic including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain its employees&#8217; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.</span></div><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zMS9mcmFnOjg2MzQzNjEwY2Y1ZDQ0Njk5OGQ2MWU2ZTE1NjE2ODQyL3RleHRyZWdpb246ODYzNDM2MTBjZjVkNDQ2OTk4ZDYxZTZlMTU2MTY4NDJfMTEzNDg_3cf21652-02d0-452b-8c45-2289d712c660" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies:</span></div><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zMS9mcmFnOjg2MzQzNjEwY2Y1ZDQ0Njk5OGQ2MWU2ZTE1NjE2ODQyL3RleHRyZWdpb246ODYzNDM2MTBjZjVkNDQ2OTk4ZDYxZTZlMTU2MTY4NDJfMTEzNTE_42405416-9360-45bd-a543-4ffa367ff585" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of a contingent consideration liability associated with a business combination.</span></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zMS9mcmFnOjg2MzQzNjEwY2Y1ZDQ0Njk5OGQ2MWU2ZTE1NjE2ODQyL3RleHRyZWdpb246ODYzNDM2MTBjZjVkNDQ2OTk4ZDYxZTZlMTU2MTY4NDJfMTEzNTI_328123b6-d2ac-4c53-86de-adb7f799b7ff" continuedAt="i8aafa526b4f44aff923b60e2b2332bae" escape="true">Operating Segments</ix:nonNumeric></span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idb006e22874b41bd9a6676addd73ca3e"><ix:continuation id="i8aafa526b4f44aff923b60e2b2332bae">The Company has <ix:nonFraction unitRef="segment" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zMS9mcmFnOjg2MzQzNjEwY2Y1ZDQ0Njk5OGQ2MWU2ZTE1NjE2ODQyL3RleHRyZWdpb246ODYzNDM2MTBjZjVkNDQ2OTk4ZDYxZTZlMTU2MTY4NDJfMTA1NDU_4ef1d08c-4f08-4e7e-bf66-026ab176416a">one</ix:nonFraction> operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</ix:continuation></ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ibed5a8c73c54452487f262c52ff9017c_37"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2) <ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RleHRyZWdpb246ODYyMGYxYTc2NzdjNDgwMDlmMjUxNTFkMWQ2Yjc3ZjdfNDI5_e7cd8ff3-1c8d-47d3-9416-45033d87912b" continuedAt="i56259a4091e645d99c269ff1ae564bd2" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i56259a4091e645d99c269ff1ae564bd2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RleHRyZWdpb246ODYyMGYxYTc2NzdjNDgwMDlmMjUxNTFkMWQ2Yjc3ZjdfNDMx_721c8e87-f8f7-478e-ba64-cf67a9484b64" continuedAt="i90a184d6e0914496a490ea35cdd97bdd" escape="true">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2021 and 2020:</ix:nonNumeric></span></div><div style="text-align:justify"><ix:continuation id="i90a184d6e0914496a490ea35cdd97bdd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfMy0xLTEtMS0w_f70f9fd6-6381-435a-8bf4-30043e54eac3">350,749</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfMy0zLTEtMS0w_f5f0e4ac-d631-4ca7-9f9b-aa2516b5b4a1">1,883,418</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfNC0xLTEtMS0w_5baed91d-594a-4426-a50b-c6ba3234eb82">495,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfNC0zLTEtMS0w_1049c477-057b-4f74-b478-8dc4cc4f75de">818,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfNS0xLTEtMS0xOTUx_66e368ca-3de1-41f8-90c4-8d0aa6c44aff">144,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfNS0zLTEtMS0xOTUx_be41b949-3f19-496e-a724-046fd0e1dc11">1,065,145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfNS0xLTEtMS0w_c953f20e-2dcc-426e-902a-9cbb34db97e5">22,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfNS0zLTEtMS0w_38c11bb2-890c-477f-b418-e8268b19696b">9,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfNi0xLTEtMS0w_6d3d5965-f6be-4ce1-89a9-20450e17c16e">166,828</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfNi0zLTEtMS0w_640be224-2250-4e6a-9bfa-cd9636bc3f3b">1,055,620</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfOC0xLTEtMS0w_3f443b5e-ab6e-4d21-ba42-06ae5407afc6">14,974,663</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfOC0zLTEtMS0w_e275d1b9-295a-472e-8e87-c97786815ebd">15,240,614</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfMTAtMS0xLTEtMTk1MQ_dbf829bb-3f65-40c2-844d-8bd917f46e6d">269,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfMTAtMy0xLTEtMTk1MQ_5eeb6546-82ba-4fa2-833b-7f078a666e53">337,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfMTAtMS0xLTEtMA_ee53aef5-becf-4d4f-b0c3-f2e6dadf5002">15,244,146</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfMTAtMy0xLTEtMA_5fe8f37d-1e79-4a11-8666-533b5b9701a8">15,578,309</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.518%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and 2020, restricted stock awards and options to purchase <ix:nonFraction unitRef="shares" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RleHRyZWdpb246ODYyMGYxYTc2NzdjNDgwMDlmMjUxNTFkMWQ2Yjc3ZjdfMjUz_a1cdeaba-2962-430a-ad61-f1939d53453e">215,600</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RleHRyZWdpb246ODYyMGYxYTc2NzdjNDgwMDlmMjUxNTFkMWQ2Yjc3ZjdfMjYw_c1e43dbb-afc7-4a27-8c78-d341f227f30c">431,226</ix:nonFraction> shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div></ix:continuation><div id="ibed5a8c73c54452487f262c52ff9017c_40"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3) <ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RleHRyZWdpb246MzViZjAyYzAxYWQ4NDI0ZTlmMTg5MDE1ZjIxMDcxNTJfMjMxNQ_531ca765-c12f-44d3-bfee-cf0433401b85" continuedAt="id286e48684e6444bbb6afc9abb4f1fc3" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="id286e48684e6444bbb6afc9abb4f1fc3" continuedAt="i537d6dd2ac314699b69a1005b249b19b"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. </span></div><div style="margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RleHRyZWdpb246MzViZjAyYzAxYWQ4NDI0ZTlmMTg5MDE1ZjIxMDcxNTJfMjMxOQ_ddb24f23-153b-43b8-a79b-ec2b14985092" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three months ended March 31, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.082%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i529667d136134653822f8cd1f52ea7d0_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfMy0xLTEtMS0w_4f9e22d7-7790-4d72-9f92-891910ea1689">2,994,378</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c72789317264e7cac1350e71f0ab560_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfMy0zLTEtMS0w_283aca1c-4bcb-46b7-b233-62ad1f976f4d">3,311,696</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cea9b0a3e2640afb98e17b1e3a6f819_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfNC0xLTEtMS0w_2a06980c-11e7-4c25-807e-a646ec4f5147">5,052,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590eaf4520974d29b6b01a687d2d13fc_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfNC0zLTEtMS0w_137b905e-a31b-4a8c-aaff-b7a36394894b">2,425,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id94b2cb8e46b43f8ba1807feeb2a3fe7_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfNS0xLTEtMS0w_1489e0bc-c1fa-4596-a8b4-5aa45f48c15a">1,539,496</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586cba84dc4847daab9569a2b1c1b879_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfNS0zLTEtMS0w_09bec910-2884-48df-9dee-1f102fd6b281">1,096,291</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib469a00b1c1e41ebaf007975ede59684_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfNi0xLTEtMS0w_1ccfc71b-01a0-4958-b5be-e5e156816a90">117,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcc02cc49f4b429aa9f1c74f9bc16e6b_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfNi0zLTEtMS0w_14260d12-2681-4842-be7a-1a43afaaa7ec">713,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f27ae48034942de95317f99306eea46_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfNy0xLTEtMS0w_35643522-0185-40e4-ac23-6c555f801d22">450,263</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i645b158fe75341daa01ca68e5cf1c2b6_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfNy0zLTEtMS0w_ad546a39-1120-45ba-b9b3-c900e540ef08">114,770</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i613693e28d6e4692be7579f7e5ab1d49_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfOC0xLTEtMS0w_f38768bf-9429-40a0-9399-ef544dc186ec">1,134,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i823406d319024699bfab22321dde04e3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfOC0zLTEtMS0w_d1d9d1a0-b0ad-401d-b9c2-71860744fd22">208,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39d646b80ea44ec583582f1c79953d87_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfOS0xLTEtMS0yMzc_1c43feba-d345-4931-a1d5-434e09a8a3ad">32,252</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0edefe7ed797492eae26ff926abd627a_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfOS0zLTEtMS0yNDM_33c0349e-4d77-496f-a9e7-611ef03ab763">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i763bd43cce884a5780a96bbcfb7e0253_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfOS0xLTEtMS0w_196d93e6-6483-4403-a4dd-021e5d240a85">182,102</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541a71eb9df04c92806ebdb9f1ae4771_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfOS0zLTEtMS0w_053464f4-6eb1-4135-9a95-1c6bb0a88011">459,560</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfMTAtMS0xLTEtMA_2587ed58-584c-4341-b840-199867a6916b">10,537,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfMTAtMy0xLTEtMA_f0ccd5ce-bf17-434a-a19d-12819b3f6ff1">8,330,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Omeclamox-Pak revenue for the first quarter of 2021 was the result of Cumberland currently being out of commercial inventory of this product. The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19, and their operations are currently suspended. The Company is awaiting resumption of their operations.  Net revenue for the first quarter of 2021 was also negatively impacted by product returns during the period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i537d6dd2ac314699b69a1005b249b19b" continuedAt="ie5eaae72195847ada0bb3574bf07c3b3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie5eaae72195847ada0bb3574bf07c3b3">Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i2e10e772bb294442900e5d9b697e71e3_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RleHRyZWdpb246MzViZjAyYzAxYWQ4NDI0ZTlmMTg5MDE1ZjIxMDcxNTJfMjIxNw_67c261ae-5b53-46b4-a4c4-e43c765d611f">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4068d158ecb7413b92d283e5bce21c80_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RleHRyZWdpb246MzViZjAyYzAxYWQ4NDI0ZTlmMTg5MDE1ZjIxMDcxNTJfMjIyNA_32b4c045-ee2d-4d33-a29c-bfe494928edb">0.2</ix:nonFraction> million for the three months ended March 31, 2021 and 2020</ix:continuation>, respectively.</span></div><div id="ibed5a8c73c54452487f262c52ff9017c_43"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4) <ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMjA2NA_06691972-4218-449e-ab8d-ed0ba94754fb" continuedAt="i4f3528f1e1e347e9aaa749cc7500eff0" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="i4f3528f1e1e347e9aaa749cc7500eff0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#8217;s warehouses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At March 31, 2021 and December 31, 2020, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $<ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMTA5OTUxMTYzMDQxMA_677e2d5e-685b-44d5-bb32-96ab30e48ee2">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMTA5OTUxMTYzMDM3OA_40930b6c-f808-4dad-a527-f76159c587d2">0.2</ix:nonFraction> million, respectively.  </span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory at March 31, 2021 and December 31, 2020.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consigned inventory represents Authorized Generic inventory stored with Perrigo until shipment.   </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $<ix:nonFraction unitRef="usd" contextRef="ic3f04630c9f547b5be864f1c66564cb8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMTA5OTUxMTYzMTU2Mw_2c09cb6a-00ca-4ba7-9de6-3b7464ac7b2a">15.6</ix:nonFraction> million that were all initially classified as non-current inventories at the date of acquisition.  At March 31, 2021 and December 31, 2020, total non-current inventory, including Vibativ and ifetroban, was $<ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMTgwOQ_51231c4e-0217-4478-b1b0-13e464c1647f">10.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMTgxNg_8821c5f4-f4b2-4164-9e50-de84bd0c461d">11.7</ix:nonFraction>&#160;million, respectively. The Company had $<ix:nonFraction unitRef="usd" contextRef="i7b759ac132064b2787c2b5a4ad1e70f7_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMTg1MA_4c89d1af-2180-4cd7-a0b5-a7199a4c702e">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic3f04630c9f547b5be864f1c66564cb8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMTA5OTUxMTYzMTkzMA_c6e0d23d-8fa6-4cb9-b87f-38ea70df9426">2.1</ix:nonFraction> million of Vibativ finished goods included in non-current inventory at March 31, 2021 and December 31, 2020.  The Company also has obtained $<ix:nonFraction unitRef="usd" contextRef="idd43aeaa2b4b4955aef55acce99cd31d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMTA5OTUxMTYzMTY5OA_1ec454d7-ff27-4c45-9b9d-88bf4954c256"><ix:nonFraction unitRef="usd" contextRef="i2a40e1cbac204fb18cf00c3b1f6c81c6_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMTA5OTUxMTYzMTY5OA_c9e8c95f-6bd4-4d75-aecd-5df002058046">0.4</ix:nonFraction></ix:nonFraction>&#160;million of finished goods in non-current inventory for API related to its ifetroban clinical initiatives at March 31, 2021 and December 31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2021 and December 31, 2020 t<ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMjA2NQ_ee443190-2ea3-49fe-bdc0-d7b4f92036d3" continuedAt="iafd9a6ce4b1f4cceb2f7b1aca3bda73b" escape="true">he Company's net inventories consisted of the following:</ix:nonNumeric></span><ix:continuation id="iafd9a6ce4b1f4cceb2f7b1aca3bda73b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:57.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfMi0yLTEtMS0w_bc1d9888-067d-4a18-b25a-9ea028ac4252">14,763,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfMi00LTEtMS0w_85c4d800-7f65-43a1-80d0-b934b6c57493"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfMi00LTEtMS0w_a87595c0-4f9a-49b2-84b8-a42980a4c8ca">16,223,162</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfMy0yLTEtMS0w_23a307a0-e150-4c44-ba23-ebeb0e64b9d7">166,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfMy00LTEtMS0w_8aa43aca-d9fb-47cc-8b59-cccbe7b389a1"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfMy00LTEtMS0w_967e84c7-bb22-469d-bab6-b11559378ac2">128,005</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfNC0yLTEtMS0w_939c49d1-5b92-4fa0-9119-9bf3907d85be">5,497,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfNC00LTEtMS0w_a59fe63e-109a-404f-9734-a219d4f801f6"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfNC00LTEtMS0w_f7fc6513-7e0d-4e6c-8152-1d7516c5491b">5,943,732</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfNS0yLTEtMS0w_ccee4921-d5da-4291-b27a-e888e092b07c">20,426,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfNS00LTEtMS0w_fad0ec44-7b44-4599-ab6c-6d5be1a9770c">22,294,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfNi0yLTEtMS0w_2095f614-e0d1-452d-94dd-bbb7754a376c">10,415,786</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfNi00LTEtMS0w_f72e202e-8091-4656-8800-9e954337d43b">11,656,742</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfNy0yLTEtMS0w_df926762-746d-40ec-8d89-12ac3fe76efa">10,010,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfNy00LTEtMS0w_c83b058d-6dd9-4816-8fe4-d48e1034fc06">10,638,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="ibed5a8c73c54452487f262c52ff9017c_46"></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5) <ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RleHRyZWdpb246ODQ1MWFmZTA3ZWE0NDVlNzkyYmU4YWI3MDkwNTVmMThfMTc5NQ_d09f9ed8-1806-4483-9564-99742d56c4dd" continuedAt="i5bfdfeeff1cc4540aa4083771d5fa3ae" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i5bfdfeeff1cc4540aa4083771d5fa3ae"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is <ix:nonFraction unitRef="number" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RleHRyZWdpb246ODQ1MWFmZTA3ZWE0NDVlNzkyYmU4YWI3MDkwNTVmMThfMTYzNw_e915ab4e-5f32-4f5a-ac40-e9345a21d4bc">7.42</ix:nonFraction>%. The weighted-average remaining lease term at March 31, 2021 is <ix:nonNumeric contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RleHRyZWdpb246ODQ1MWFmZTA3ZWE0NDVlNzkyYmU4YWI3MDkwNTVmMThfMTY5Mg_d672bae0-b99e-4670-acdc-005803a5c8e9">1.7</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="cpix:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RleHRyZWdpb246ODQ1MWFmZTA3ZWE0NDVlNzkyYmU4YWI3MDkwNTVmMThfMTc5Mw_dc9c2930-f229-45ee-9a8e-f97744a63ee0" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2021 and December 31, 2020 , the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjZmNDBiYTgwYTEzYzQ2YzU4NWIwNzI0NjE1YzhhYjkwL3RhYmxlcmFuZ2U6NmY0MGJhODBhMTNjNDZjNTg1YjA3MjQ2MTVjOGFiOTBfMS0yLTEtMS0w_e6f68ee6-031b-45cd-af89-12fb7eb56130">1,784,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjZmNDBiYTgwYTEzYzQ2YzU4NWIwNzI0NjE1YzhhYjkwL3RhYmxlcmFuZ2U6NmY0MGJhODBhMTNjNDZjNTg1YjA3MjQ2MTVjOGFiOTBfMS00LTEtMS0w_346306d0-56b8-4495-8348-fea13322983d">2,028,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjVhN2YyOTEyZjYxNTRiMTE4NzhhYzc2ZjcyMTc4YzZhL3RhYmxlcmFuZ2U6NWE3ZjI5MTJmNjE1NGIxMTg3OGFjNzZmNzIxNzhjNmFfMS0yLTEtMS0w_7796e2c6-0558-49f6-995c-98d965dcdafe">1,042,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjVhN2YyOTEyZjYxNTRiMTE4NzhhYzc2ZjcyMTc4YzZhL3RhYmxlcmFuZ2U6NWE3ZjI5MTJmNjE1NGIxMTg3OGFjNzZmNzIxNzhjNmFfMS00LTEtMS0w_e6e03b8c-00a9-465e-a8cc-7636f7c1e225">1,016,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjVhN2YyOTEyZjYxNTRiMTE4NzhhYzc2ZjcyMTc4YzZhL3RhYmxlcmFuZ2U6NWE3ZjI5MTJmNjE1NGIxMTg3OGFjNzZmNzIxNzhjNmFfMy0yLTEtMS0w_cb40b9a6-bb5e-42c8-86cd-e07142a6e99b">789,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjVhN2YyOTEyZjYxNTRiMTE4NzhhYzc2ZjcyMTc4YzZhL3RhYmxlcmFuZ2U6NWE3ZjI5MTJmNjE1NGIxMTg3OGFjNzZmNzIxNzhjNmFfMy00LTEtMS0w_d873dae5-ad4b-4d11-81a2-3767e5c9cf95">1,059,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="cpix:LeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjVhN2YyOTEyZjYxNTRiMTE4NzhhYzc2ZjcyMTc4YzZhL3RhYmxlcmFuZ2U6NWE3ZjI5MTJmNjE1NGIxMTg3OGFjNzZmNzIxNzhjNmFfNC0yLTEtMS0w_1e794a74-5be4-455d-b3ea-234d806b10a5">1,831,274</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32068be194474f9cb55326666a7fbec0_I20201231" decimals="0" format="ixt:numdotdecimal" name="cpix:LeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjVhN2YyOTEyZjYxNTRiMTE4NzhhYzc2ZjcyMTc4YzZhL3RhYmxlcmFuZ2U6NWE3ZjI5MTJmNjE1NGIxMTg3OGFjNzZmNzIxNzhjNmFfNC00LTEtMS0w_a0526f03-1e5d-4f95-b195-eb343d99d1bc">2,076,472</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $<ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RleHRyZWdpb246ODQ1MWFmZTA3ZWE0NDVlNzkyYmU4YWI3MDkwNTVmMThfMTA5OTUxMTYzMzc1MQ_bf4a69fe-adc0-472d-a99b-d1346935014e">0.3</ix:nonFraction> million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div></ix:nonNumeric><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RleHRyZWdpb246ODQ1MWFmZTA3ZWE0NDVlNzkyYmU4YWI3MDkwNTVmMThfMTc5NA_a3a9443f-2902-467d-bf1f-15cbaba4cbff" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at March 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOmJkNGM5ZTRkZTJmMzQyNmU4NzBhYmIxZjEzMjhkZWU0L3RhYmxlcmFuZ2U6YmQ0YzllNGRlMmYzNDI2ZTg3MGFiYjFmMTMyOGRlZTRfMi0yLTEtMS0w_6112cac3-5152-4b8b-971d-963e6487e264">862,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOmJkNGM5ZTRkZTJmMzQyNmU4NzBhYmIxZjEzMjhkZWU0L3RhYmxlcmFuZ2U6YmQ0YzllNGRlMmYzNDI2ZTg3MGFiYjFmMTMyOGRlZTRfMy0yLTEtMS0w_654fe661-2ba2-4bcb-ae13-5183fba137a2">1,019,313</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOmJkNGM5ZTRkZTJmMzQyNmU4NzBhYmIxZjEzMjhkZWU0L3RhYmxlcmFuZ2U6YmQ0YzllNGRlMmYzNDI2ZTg3MGFiYjFmMTMyOGRlZTRfNC0yLTEtMS0w_6067b3e2-5871-4f1d-b4e5-6c48f93033b7">92,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:zerodash" name="cpix:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOmJkNGM5ZTRkZTJmMzQyNmU4NzBhYmIxZjEzMjhkZWU0L3RhYmxlcmFuZ2U6YmQ0YzllNGRlMmYzNDI2ZTg3MGFiYjFmMTMyOGRlZTRfNS0yLTEtMS0w_e8a7d313-5647-4c30-a90e-4e72978e42df">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOmJkNGM5ZTRkZTJmMzQyNmU4NzBhYmIxZjEzMjhkZWU0L3RhYmxlcmFuZ2U6YmQ0YzllNGRlMmYzNDI2ZTg3MGFiYjFmMTMyOGRlZTRfNi0yLTEtMS0w_609590d1-760c-4d8a-b40d-f4c977538481">1,974,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOmJkNGM5ZTRkZTJmMzQyNmU4NzBhYmIxZjEzMjhkZWU0L3RhYmxlcmFuZ2U6YmQ0YzllNGRlMmYzNDI2ZTg3MGFiYjFmMTMyOGRlZTRfNy0yLTEtMS0w_7ca8c2c4-c39a-4615-86bb-3d5efc421387">143,199</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOmJkNGM5ZTRkZTJmMzQyNmU4NzBhYmIxZjEzMjhkZWU0L3RhYmxlcmFuZ2U6YmQ0YzllNGRlMmYzNDI2ZTg3MGFiYjFmMTMyOGRlZTRfOC0yLTEtMS0w_e0b22d5e-f84b-4b28-ad82-2e1fd117f288">1,831,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. <ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RleHRyZWdpb246ODQ1MWFmZTA3ZWE0NDVlNzkyYmU4YWI3MDkwNTVmMThfMjE5OTAyMzI2MzI5Ng_ad879b04-7d11-4bba-8c5b-912b5061015a" continuedAt="i4d76a6b26422464882e1fe73e9d9baf9" escape="true">Rent expense and sublease income were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><ix:continuation id="i4d76a6b26422464882e1fe73e9d9baf9"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.865%"><tr><td style="width:1.0%"></td><td style="width:51.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjk3ZTYwNmM4MDdkMjQ0MDc5OGVmZTA0ZmY2Nzc3Y2UzL3RhYmxlcmFuZ2U6OTdlNjA2YzgwN2QyNDQwNzk4ZWZlMDRmZjY3NzdjZTNfMi0yLTEtMS0xODc2_629be420-54c9-4e46-88a9-c23bff3cc15b">227,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjk3ZTYwNmM4MDdkMjQ0MDc5OGVmZTA0ZmY2Nzc3Y2UzL3RhYmxlcmFuZ2U6OTdlNjA2YzgwN2QyNDQwNzk4ZWZlMDRmZjY3NzdjZTNfMi00LTEtMS0xODc2_7417dd93-7709-4b51-b477-6aa81b834aba">221,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjk3ZTYwNmM4MDdkMjQ0MDc5OGVmZTA0ZmY2Nzc3Y2UzL3RhYmxlcmFuZ2U6OTdlNjA2YzgwN2QyNDQwNzk4ZWZlMDRmZjY3NzdjZTNfNC0yLTEtMS0xODc2_faa2206f-266f-488e-9e06-900760f7c27e">178,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjk3ZTYwNmM4MDdkMjQ0MDc5OGVmZTA0ZmY2Nzc3Y2UzL3RhYmxlcmFuZ2U6OTdlNjA2YzgwN2QyNDQwNzk4ZWZlMDRmZjY3NzdjZTNfNC00LTEtMS0xODc2_e1b6492d-b493-43d3-9ddc-2cfd7be2d683">169,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="ibed5a8c73c54452487f262c52ff9017c_49"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6) <ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfODc1OA_7d886101-b487-40a8-aeae-d3878c94361e" continuedAt="i6ff5cccc21e443188cf4117b3cecc3ab" escape="true">SHAREHOLDERS&#8217; EQUITY AND DEBT</ix:nonNumeric></span></div><ix:continuation id="i6ff5cccc21e443188cf4117b3cecc3ab" continuedAt="i51acc433fb4547ffa20a35b268c6d3c7"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland currently has a share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i61c481ad9f504703a94e6b9be6f518e2_I20100513" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMTI5_c065d962-6435-49dd-b733-391b75d55d14">10</ix:nonFraction> million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $<ix:nonFraction unitRef="usd" contextRef="i26d732474c194cee89c889d4f8a693f2_I20160131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMjkw_0609ea63-cc0d-40f2-b426-71973ef27594">10</ix:nonFraction> million repurchase program to replace the prior authorizations.  During the three months ended March 31, 2021 and March 31, 2020, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="i0b204f4dda214716a8d2597171f9411e_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMzk2_3121ab33-242d-4e89-9533-2a943cc49d36">91,724</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="if890c44461b6436496221a526f27e535_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfNDEw_4818f994-42e5-4323-b58a-b1344d6640ac">164,866</ix:nonFraction> shares, respectively, of common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="i0b204f4dda214716a8d2597171f9411e_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfNDYy_b9ab3b16-3f03-46f7-9b09-b75ec9fb1f94">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if890c44461b6436496221a526f27e535_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfNDY5_aaabfdb9-7ed0-4982-a138-956f692af312">0.4</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share purchases and sales</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Company's March 2021 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Sales</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $<ix:nonFraction unitRef="usd" contextRef="i08b1da814e684be58d651fa09524635d_D20171101-20171130" decimals="-6" format="ixt:numdotdecimal" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMTAyMA_ef72c331-40e2-496f-a5f0-7e550f120e71">100</ix:nonFraction> million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allows the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. The Company does not currently have an ATM feature in place.  Cumberland plans to continue to evaluate the market for its common shares, and if favorable, will further evaluate whether or not to enter into an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock.  The Company did not issue any shares under an ATM during the three months ended March 31, 2021 or March 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Grants and Incentive Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and March 31, 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="ib2eda2a4dac14ec3b727863dc09461ee_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMTM0Nw_979147cd-c164-405c-a64c-f85b27765e78">35,850</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i176b3b536b2f4266bb9351936fafc0a5_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMTM2MQ_1c152c8d-cb78-4018-8894-6c4217394e4c">229,141</ix:nonFraction> shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the <ix:nonNumeric contextRef="id97ac84efc164cb38bbe53650262439c_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfODc1OQ_f28f25aa-45bc-4aef-90f1-3cf89ad73a42">one-year</ix:nonNumeric> anniversary of the date of grant.  During the three months ended March 31, 2021, the Company also issued <ix:nonFraction unitRef="shares" contextRef="i8efd5212c2ea4438a3c6b998c82af06a_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMTA5OTUxMTY0MDY1OA_b4895bf2-86f5-4497-a965-d1953e897219">172,350</ix:nonFraction> incentive stock options to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in March 2031. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, the Company entered into a Third Amendment to the Revolving Credit Note and Fourth Amendment (&#8220;Fourth Amendment&#8221;) to the Revolving Credit Loan Agreement with Pinnacle Bank (the &#8220;Pinnacle Agreement&#8221;). The original Pinnacle Agreement was dated July 2017. The Fourth Amendment provides for a principal available for borrowing of up to $<ix:nonFraction unitRef="usd" contextRef="i2ddf705ec76d45ce90dcfd34b198b915_I20201007" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMzA1MA_371218c4-a9ec-4af5-b6eb-9243001541d4">15</ix:nonFraction>&#160;million and Cumberland has the ability to request an increase of up to an additional $<ix:nonFraction unitRef="usd" contextRef="i2ddf705ec76d45ce90dcfd34b198b915_I20201007" decimals="INF" format="ixt:numdotdecimal" name="cpix:LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMzEzMA_7eac9586-968b-4673-b2a0-2bb9a1009ac7">5</ix:nonFraction>&#160;million, upon the satisfaction of certain conditions and approval by Pinnacle Bank. If fully expanded, the Fourth Amendment would provide a maximum principal available for borrowing of up to $<ix:nonFraction unitRef="usd" contextRef="i2ddf705ec76d45ce90dcfd34b198b915_I20201007" decimals="INF" format="ixt:numdotdecimal" name="cpix:LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMzMxNg_cece4d77-73c3-4c85-b529-33d4e1354c29">20</ix:nonFraction>&#160;million.  The Fourth Amendment extended the maturity date of the Pinnacle Agreement through October 1, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Pinnacle Agreement, which extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of March 31, 2021.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="i49d1ed31c7894e6b987d5f1b88ea735e_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMTY0OTI2NzQ1NDE4NQ_d4cd0515-31b4-40cd-a7d1-67a4f7fd4e6f">15.0</ix:nonFraction> million in borrowings outstanding under its revolving credit facility.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The pricing under the Fourth Amendment provides for an interest rate spread of <ix:nonFraction unitRef="number" contextRef="ida4acda1a0824ddd98ba37f7456c0970_D20200814-20200814" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfNDcxNQ_94e809ef-5b13-4d2e-a723-e8c683af882f">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ic626a31ddbca438a89b05457be379d25_D20200814-20200814" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfNDcyMQ_55a56c22-9b60-4d3a-9ef8-2fe767659029">2.75</ix:nonFraction>% above LIBOR with a minimum LIBOR of <ix:nonFraction unitRef="number" contextRef="ic599c92ccd35431db3b06f4238341683_D20200814-20200814" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfNDc2MA_d8f1b1f8-ebdb-4b6a-917f-ec593ce45035">0.90</ix:nonFraction>%. The </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="i51acc433fb4547ffa20a35b268c6d3c7" continuedAt="i66795dee789f4149aebc5d9329fd233b"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable interest rate under the Pinnacle Agreement was <ix:nonFraction unitRef="number" contextRef="ib53bd71fe3994d2da24c5195efd6412c_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfNDgyNg_b101fae1-de75-4714-8fab-9481b667b575">3.65</ix:nonFraction>% at March 31, 2021.  In addition, a fee of <ix:nonFraction unitRef="number" contextRef="i6ccab55d30cd4f3595d41c3c3554b52a_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfNDkwNA_6570a942-19d7-4e20-b197-e2d460227dd2">0.25</ix:nonFraction>% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the line of credit are collateralized by substantially all of our assets. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the amount of $<ix:nonFraction unitRef="usd" contextRef="i830bb87cb40044cd957e698b46665fd6_D20200420-20200420" decimals="0" format="ixt:numdotdecimal" name="cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMjE5OTAyMzI3MDcxOA_080d6827-3cd9-4018-a485-0bd79a10ad60">2,187,140</ix:nonFraction> pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPP is administered by the U.S. Small Business Administration ("SBA").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan matures April 14, 2022, and bears interest at a rate of 1.0% per year, payable monthly. The loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the date of funding the Company used the loan amount for such qualifying expenses. Cumberland has elected to account for the proceeds of the loan as a government grant under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. As a result, the Company has recorded the $<ix:nonFraction unitRef="usd" contextRef="i830bb87cb40044cd957e698b46665fd6_D20200420-20200420" decimals="0" format="ixt:numdotdecimal" name="cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMjE5OTAyMzI3MDczMA_bab7b89a-074b-4e7e-aa67-eae443ddce05">2,187,140</ix:nonFraction> as a deferred income liability, which is included as a component of other current liabilities on the condensed consolidated balance sheet. The Company intends to apply IAS 20 to the PPP loan forgiveness and has presented the amounts expected to be forgiven as deferred income. The Company will account for the anticipated forgiveness of the PPP loan under IAS 20 when the Company believes that the forgiveness is reasonably assured.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland applied for this loan after carefully considering, with its bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. The Company evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, based on assistance from the PPP loan, the Company currently does not foresee doing so. In October 2020, the Company submitted a request for forgiveness of the PPP loan. The request was approved by the lender, Pinnacle Bank, who then submitted it to SBA for the SBA's review and approval. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i66795dee789f4149aebc5d9329fd233b" continuedAt="i3281599c942743a980f9563f9ae63fb2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WHC Biopharmaceuticals, Pte. Ltd</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3281599c942743a980f9563f9ae63fb2">. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $<ix:nonFraction unitRef="usd" contextRef="i59247f7dd59d4f28aee9f37d45d509aa_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfODQxMw_b9867a34-f31f-4153-a572-2243df76f2df">0.2</ix:nonFraction>&#160;million equity contribution and an initial investment from Cumberland in the form of a $<ix:nonFraction unitRef="usd" contextRef="icd3a639d6f35423aa3c2f6243856ec35_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfODQ5Mw_49c01eb0-8816-465c-90dc-a669f9bc68cd">0.2</ix:nonFraction>&#160;million convertible note, which was funded during the three months ended March 31, 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.</ix:continuation>   </span></div><div id="ibed5a8c73c54452487f262c52ff9017c_52"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7) <ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181Mi9mcmFnOmFiNjUxMzUzMDg4YzQzMGJiZGVjYjIxMWZhNTUwYzNlL3RleHRyZWdpb246YWI2NTEzNTMwODhjNDMwYmJkZWNiMjExZmE1NTBjM2VfNjM3_ed75dd45-bcd4-452e-aeb5-ac5a5cdc983c" continuedAt="i3190462c0aed411283d9cb0e64ecf316" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3190462c0aed411283d9cb0e64ecf316" continuedAt="ibe7f2d50190a4d12a428109c7ba64448">As of March 31, 2021, the Company has approximately $<ix:nonFraction unitRef="usd" contextRef="i6c5f356638654bbdaf6b452874ae5eaf_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181Mi9mcmFnOmFiNjUxMzUzMDg4YzQzMGJiZGVjYjIxMWZhNTUwYzNlL3RleHRyZWdpb246YWI2NTEzNTMwODhjNDMwYmJkZWNiMjExZmE1NTBjM2VfNjI_002b9e52-978e-487b-b385-95187ed79e72">56.3</ix:nonFraction> million in federal net operating loss carryforwards including approximately $<ix:nonFraction unitRef="usd" contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181Mi9mcmFnOmFiNjUxMzUzMDg4YzQzMGJiZGVjYjIxMWZhNTUwYzNlL3RleHRyZWdpb246YWI2NTEzNTMwODhjNDMwYmJkZWNiMjExZmE1NTBjM2VfMTMz_79481232-7084-4e8f-ba3c-b3c038e6a920">44.1</ix:nonFraction> million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2021 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. </ix:continuation></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibe7f2d50190a4d12a428109c7ba64448">The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.</ix:continuation> </span></div><div id="ibed5a8c73c54452487f262c52ff9017c_55"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8) <ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181NS9mcmFnOjIwMDMzYzU1NmQ2OTQ0MDI5NjQ5NWY2YmU4ZGY2ZTdhL3RleHRyZWdpb246MjAwMzNjNTU2ZDY5NDQwMjk2NDk1ZjZiZThkZjZlN2FfMTAxNw_5ae479a9-2d2a-4efa-aa7a-8e658499b256" continuedAt="i56d60a337452428fbc5ab797c5155fab" escape="true">COLLABORATIVE AGREEMENTS</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:continuation id="i56d60a337452428fbc5ab797c5155fab" continuedAt="ifd5433f2aca142389277a5ec12bdaae4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each </span></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifd5433f2aca142389277a5ec12bdaae4">other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</ix:continuation></span></div><div id="ibed5a8c73c54452487f262c52ff9017c_58"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9) <ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfNjcwMg_828df905-5a6b-466d-9b7b-26cade9a939e" continuedAt="i9a72f3f12fa14cb881f5889dd1c68267" escape="true">ADDITIONS AND RETURN OF PRODUCT RIGHTS</ix:nonNumeric></span></div><ix:continuation id="i9a72f3f12fa14cb881f5889dd1c68267" continuedAt="ie1f3b7603896493598008bee566a46fa"><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ic4690540184b48fa90ef75b783a03efb_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMTIxNw_18d0523f-a5a2-45d5-93f0-51ea64af8fed">20.0</ix:nonFraction>&#160;million at the closing of the transaction and a $<ix:nonFraction unitRef="usd" contextRef="ic4690540184b48fa90ef75b783a03efb_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMTI2MA_acf1025b-dc17-47da-828e-da879569a80a">5.0</ix:nonFraction>&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to <ix:nonFraction unitRef="number" contextRef="ic4690540184b48fa90ef75b783a03efb_D20181101-20181130" decimals="2" name="cpix:TieredRoyaltyPaymentsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMTM2Mw_15dc1128-6a55-44e2-b58c-806b29aaad9c">20</ix:nonFraction>% on future net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement. </span></div><div style="margin-top:6pt;text-align:justify"><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfNjcwMQ_b3610ea9-fee2-4a89-8a75-411a9042d3a3" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.977%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3f04630c9f547b5be864f1c66564cb8_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjNhMWZhZWJmM2QxNjRjNDdhZjkzMjI5MWFjMzRjZDc2L3RhYmxlcmFuZ2U6M2ExZmFlYmYzZDE2NGM0N2FmOTMyMjkxYWMzNGNkNzZfOS0xLTEtMS0w_ba5abfc6-dc34-4b14-b3da-521274a1dcd5">8,200,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied6025b276df445997781e0a3e02560b_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRoyalties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjNhMWZhZWJmM2QxNjRjNDdhZjkzMjI5MWFjMzRjZDc2L3RhYmxlcmFuZ2U6M2ExZmFlYmYzZDE2NGM0N2FmOTMyMjkxYWMzNGNkNzZfMTAtMS0xLTEtMA_23d06717-f7e9-4bd8-b51a-ed7f63faf19e">995,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied6025b276df445997781e0a3e02560b_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjNhMWZhZWJmM2QxNjRjNDdhZjkzMjI5MWFjMzRjZDc2L3RhYmxlcmFuZ2U6M2ExZmFlYmYzZDE2NGM0N2FmOTMyMjkxYWMzNGNkNzZfMTEtMS0xLTEtMA_f820b0a8-e0d0-4843-8aa8-9ea4bfc0b25a">280,020</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6025b276df445997781e0a3e02560b_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjNhMWZhZWJmM2QxNjRjNDdhZjkzMjI5MWFjMzRjZDc2L3RhYmxlcmFuZ2U6M2ExZmFlYmYzZDE2NGM0N2FmOTMyMjkxYWMzNGNkNzZfMTItMS0xLTEtMA_91280745-7a29-490a-b96b-eaacc41ab755">410,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b759ac132064b2787c2b5a4ad1e70f7_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjNhMWZhZWJmM2QxNjRjNDdhZjkzMjI5MWFjMzRjZDc2L3RhYmxlcmFuZ2U6M2ExZmFlYmYzZDE2NGM0N2FmOTMyMjkxYWMzNGNkNzZfMTMtMS0xLTEtMA_cae0e47c-269a-4727-8acc-5d6e224e3b95">7,336,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability of $<ix:nonFraction unitRef="usd" contextRef="i7b759ac132064b2787c2b5a4ad1e70f7_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMjQ0MQ_13fde4dc-a50f-4a41-a346-e5ab38c190c3">7.3</ix:nonFraction>&#160;million was classified as other current liabilities of $<ix:nonFraction unitRef="usd" contextRef="i3416c55598e64e2b95051149db842304_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMjQ5MQ_b6515f0a-aa26-443d-aa1d-7fc2a425b755">2.7</ix:nonFraction>&#160;million and other long-term liabilities of $<ix:nonFraction unitRef="usd" contextRef="id0ecdd80f5234983a18050bf8ecf1cda_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMjUyOQ_aaf03502-05b0-468b-98be-fdfc9801cb60">4.6</ix:nonFraction>&#160;million on the condensed consolidated balance sheet as of March 31, 2021.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license Cumberland paid a deposit of $<ix:nonFraction unitRef="usd" contextRef="ia0a8b608c7614df795f5ef973e97f9d9_D20161101-20161130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMjk4OA_2410009a-bea7-49c9-b578-beafbba6f92c">100,000</ix:nonFraction> at closing.  The Company provided $<ix:nonFraction unitRef="usd" contextRef="ia0a8b608c7614df795f5ef973e97f9d9_D20161101-20161130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMzAyNQ_28eaec7b-1eca-41c3-b13c-60a18ad49ed6">0.9</ix:nonFraction>&#160;million in consideration through a grant of <ix:nonFraction unitRef="shares" contextRef="i7582538d23084840b14af98041033df1_D20161101-20161130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMzA2NA_ca09e300-fbeb-4c3b-ad05-57e2742c3277">180,000</ix:nonFraction> restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name.  The <ix:nonFraction unitRef="shares" contextRef="i7582538d23084840b14af98041033df1_D20161101-20161130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMzY3NQ_4a27e200-6770-429a-80d9-b92de70cc25a">180,000</ix:nonFraction> shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $<ix:nonFraction unitRef="usd" contextRef="id8d1afac2fe04daeb9be14e2c01cb3cf_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMzg4MQ_188e9628-2d7f-4f20-8657-5ec68ea2e55a">0.9</ix:nonFraction>&#160;million on the vesting date. The FDA approval also resulted in a $<ix:nonFraction unitRef="usd" contextRef="ie0eada6a93ec412dbdce374da1fb4f0c_I20200731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMzk0MQ_d696541d-4433-48f4-a92e-de5b1f838e36">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic.  During December 2020, Cumberland launched RediTrex and the launch also resulted in a $<ix:nonFraction unitRef="usd" contextRef="id745598dd60b4f4088bc62c2d5c607b0_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMTY0OTI2NzQ0ODcwNw_2e49c163-5501-4644-bcf5-72b75b788f3d">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic.  This milestone payment will be paid during 2021 and was recorded as an other current liability at December 31, 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has approximately $<ix:nonFraction unitRef="usd" contextRef="i9a68ec61d27040248d7dd487e14454d4_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfNDEyMg_852d4e56-4887-4192-9b77-b595b3650b23">2.8</ix:nonFraction>&#160;million in net intangible assets related to RediTrex at March 31, 2021.  </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><ix:continuation id="ie1f3b7603896493598008bee566a46fa"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ethyol and Totect </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, Cumberland entered into an agreement with Clinigen for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to Clinigen. Under the final terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $<ix:nonFraction unitRef="usd" contextRef="i78e7ac2dbdbe4730beeb4a8d45f46205_D20191001-20210930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfNTIwNg_6251797d-7308-4a9a-856b-28fa7f2ae8d8">5</ix:nonFraction>&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first four quarterly installments totaling $<ix:nonFraction unitRef="usd" contextRef="i6a4c618331f148a9b3e193bc04d8c16e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMTA5OTUxMTY0NDg1MQ_685ca063-bbe2-443c-ba3c-d49719c16c77">3.0</ix:nonFraction> million during 2020 and the fifth installment of $<ix:nonFraction unitRef="usd" contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMjE5OTAyMzI3MzA3MA_13114e56-81a6-410b-a279-7c0e9a73a661">0.5</ix:nonFraction>&#160;million during the three months ended March 31, 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as discontinued operations.  The Company will record the remaining quarterly installments during the balance of 2021.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the products. Cumberland was responsible for the products through December 31, 2019 and beginning on January 1, 2020, the products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.</span></div><ix:nonNumeric contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMjE5OTAyMzI3MzA4Mw_62bef6f6-076e-429a-8b77-6825f9af8afb" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company does not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur expenses associated with these payments from Clinigen. </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6874375315de4805a4b9a90949e9e0a9_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjgyODY3YTA2N2Y4MDQ0MDk5NmE5YzZiZTE0MTY4MDJkL3RhYmxlcmFuZ2U6ODI4NjdhMDY3ZjgwNDQwOTk2YTljNmJlMTQxNjgwMmRfMi0yLTEtMS0xOTg5_9efd0625-d6dd-4e57-9daa-54326f591ab8">495,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d4b97906e974844a32b25017974062a_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjgyODY3YTA2N2Y4MDQ0MDk5NmE5YzZiZTE0MTY4MDJkL3RhYmxlcmFuZ2U6ODI4NjdhMDY3ZjgwNDQwOTk2YTljNmJlMTQxNjgwMmRfMi00LTEtMS0xOTg5_95a5840f-c429-42a1-95ae-f82dbcfbbf73">818,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of products sold</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6874375315de4805a4b9a90949e9e0a9_D20210101-20210331" decimals="0" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjgyODY3YTA2N2Y4MDQ0MDk5NmE5YzZiZTE0MTY4MDJkL3RhYmxlcmFuZ2U6ODI4NjdhMDY3ZjgwNDQwOTk2YTljNmJlMTQxNjgwMmRfMy0yLTEtMS0xOTg5_fcb8190a-45e5-460b-ba15-bc16194b8bbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d4b97906e974844a32b25017974062a_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjgyODY3YTA2N2Y4MDQ0MDk5NmE5YzZiZTE0MTY4MDJkL3RhYmxlcmFuZ2U6ODI4NjdhMDY3ZjgwNDQwOTk2YTljNmJlMTQxNjgwMmRfMy00LTEtMS0xOTg5_f8e71c45-9eae-4665-aaf3-99e645e5e4aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, Marketing and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6874375315de4805a4b9a90949e9e0a9_D20210101-20210331" decimals="0" format="ixt:zerodash" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjgyODY3YTA2N2Y4MDQ0MDk5NmE5YzZiZTE0MTY4MDJkL3RhYmxlcmFuZ2U6ODI4NjdhMDY3ZjgwNDQwOTk2YTljNmJlMTQxNjgwMmRfNC0yLTEtMS0xOTg5_f5ebbc85-fc26-45db-8537-8ac54f81dfae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d4b97906e974844a32b25017974062a_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjgyODY3YTA2N2Y4MDQ0MDk5NmE5YzZiZTE0MTY4MDJkL3RhYmxlcmFuZ2U6ODI4NjdhMDY3ZjgwNDQwOTk2YTljNmJlMTQxNjgwMmRfNC00LTEtMS0xOTg5_bf149f5b-10de-4b10-9024-24f458bc20c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6874375315de4805a4b9a90949e9e0a9_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjgyODY3YTA2N2Y4MDQ0MDk5NmE5YzZiZTE0MTY4MDJkL3RhYmxlcmFuZ2U6ODI4NjdhMDY3ZjgwNDQwOTk2YTljNmJlMTQxNjgwMmRfNS0yLTEtMS0xOTg5_85065061-6a79-4b42-b74e-d946c173f783">495,410</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d4b97906e974844a32b25017974062a_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjgyODY3YTA2N2Y4MDQ0MDk5NmE5YzZiZTE0MTY4MDJkL3RhYmxlcmFuZ2U6ODI4NjdhMDY3ZjgwNDQwOTk2YTljNmJlMTQxNjgwMmRfNS00LTEtMS0xOTg5_a9407771-d70a-4618-a456-ba041bbf0436">818,273</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="ibed5a8c73c54452487f262c52ff9017c_61"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure regarding forward-looking statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion contains certain forward-looking statements which reflect management&#8217;s current views of future events and operations. These statements involve certain risks and uncertainties, and actual results may differ materially from them. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ significantly from the results discussed in these forward-looking statements. Some important factors which may cause results to differ from expectations include: availability of additional debt and equity capital; market conditions at the time additional capital is required; our ability to continue to acquire branded products; product sales; management of our growth and integration of our acquisitions and impacts on our business as well as national and international markets and economies resulting from the COVID-19 pandemic. While forward-looking statements reflect our beliefs and best judgment based upon current information, they are not guarantees of future performance. Other important factors that may cause actual results to differ materially from forward-looking statements are discussed in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2020 and our other filings with the SEC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not undertake to publicly update or revise any of our forward-looking statements, even in the event that experience or future changes indicate that the anticipated results will not be realized. The following presentation of management&#8217;s discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this report on Form 10-Q.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div><span><br/></span></div><div id="ibed5a8c73c54452487f262c52ff9017c_64"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Our primary target markets are hospital acute care, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve the quality of care for patients and address poorly met medical needs.  We promote our approved products through our hospital and field sales forces in the United States and are establishing a network of international partners to register and provide our medicines to patients in their countries.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of FDA approved brands include:</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Acetadote</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">acetylcysteine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of acetaminophen poisoning; </span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Caldolor</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ibuprofen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of pain and fever;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Kristalose</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">lactulose</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Omeclamox</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-Pak</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">omeprazole, clarithromycin, and amoxicillin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of Helicobacter pylori (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">H. pylori</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) infection and related duodenal ulcer disease;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vaprisol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">conivaptan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vibativ</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">telavancin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and</span></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">RediTrex</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">methotrexate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Injection,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these commercial brands, we have Phase II clinical programs underway evaluating our ifetroban product candidates in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy (&#8220;DMD&#8221;), a degenerative disease, Systemic Sclerosis (&#8220;SSc&#8221;), a deadly autoimmune condition, and Aspirin-Exacerbated Respiratory Disease ("AERD"), a severe form of asthma. </span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has built core competencies in both product development and commercial capabilities.  We have established the capabilities needed to acquire, develop and commercialize branded pharmaceuticals in the U.S. and believe we can leverage this existing infrastructure to support our expected growth. Our management team consists of pharmaceutical industry veterans experienced in business development, product development, regulatory, manufacturing, sales, marketing and finance. Our business development team identifies, evaluates and negotiates product acquisition, licensing and co-promotion agreements. Our product development team creates proprietary product formulations, manages our clinical studies, prepares all regulatory submissions and staffs our medical call center. Our quality and manufacturing professionals oversee the manufacture, release and shipment of our products. Our marketing and sales team is responsible for our commercial activities, and we work closely with our distribution partners to ensure availability and delivery of our products.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth Strategy</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland's growth strategy involves maximizing the potential of our existing brands, while continuing to build a portfolio of differentiated products. We currently feature seven FDA products approved for sale in the United States.  Through our international partners, we are working to bring our medicines to patients in their countries. We also look for opportunities to expand our products into additional patient populations through clinical trials, new presentations, and our support for select, investigator-initiated studies. We actively pursue opportunities to acquire additional marketed products, as well as late-stage development product candidates in our target medical specialties. Our clinical team is developing a pipeline of new product candidates largely to address poorly met medical needs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are supplementing these activities with the earlier stage drug development at Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary. CET partners with academic research institutions to identify and progress promising, new product candidates, which Cumberland has the opportunity to further develop and commercialize.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, we are seeking long term sustainable growth by executing on the following:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Support and expand the use of our marketed products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continue to evaluate our products following their FDA approval to determine if additional clinical data could expand their market and use.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to explore opportunities for label expansion to bring our products to new patient populations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As examples, we have secured pediatric approvals, expanding the labeling for both our Acetadote and Caldolor brands. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selectively add complementary brands.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to our product development activities, we are also seeking to acquire products or late-stage development product candidates to continue to build a portfolio of complementary brands. We focus on under-promoted, FDA-approved drugs as well as late-stage development products that address poorly met medical needs. We will continue to target product acquisition candidates that are competitively differentiated, have valuable intellectual property or other protective features, and allow us to leverage our existing infrastructure.  Our acquisition of Vibativ represents the largest product acquisition we have completed.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Progress clinical pipeline and incubate future product opportunities at CET.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe it is important to build a pipeline of innovative new product opportunities. Our ifetroban Phase II development programs represent the implementation of this strategy. At CET, we are supplementing our acquisition and late-stage development activities with the early-stage drug development activities. CET partners with universities and other research organizations to develop promising, early-stage product candidates, which Cumberland has the opportunity to further develop and commercialize. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leverage our infrastructure through co-promotion partnerships.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe that our commercial infrastructure can help drive prescription volume and product sales. We look for strategic partners that can complement our capabilities and enhance the opportunity for our brands. Our co-promotion partnership with Poly Pharmaceuticals, Inc. and Foxland Pharmaceuticals, Inc. has allowed us to expand the support for Kristalose across the United States.     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Build an international contribution to our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have established our own commercial capabilities, including two sales divisions to cover the U.S. market for our products. We are also building a network of select international partners to register our products and make them available to patients in their countries. We will continue to develop and expand our network of international partners while supporting our partners&#8217; registration and commercialization efforts in their respective territories. The acquisition of Vibativ resulted in several new international partners and market opportunities.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manage our operations with financial discipline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continually work to manage our expenses in line with our revenues in order to deliver positive cash flow from operations. We remain in a strong financial position, with favorable gross margins, and a strong balance sheet. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in 1999 and have been headquartered in Nashville, Tennessee since inception. During 2009, we completed an initial public offering of our common shares and listing on the Nasdaq stock exchange. Our website address is www.cumberlandpharma.com. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all material press releases and other reports as soon as reasonably practicable after their filing with the U.S. Securities and Exchange Commission, (&#8220;SEC&#8221;). These filings are also available to the public at </span><span style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT DEVELOPMENTS</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness. The Company managed through the COVID-19 pandemic during 2020, continuing to operate our business - keeping facilities open and our organization intact. We also maintained our ongoing compliance with the many laws and regulations that apply to us as a publicly traded, pharmaceutical company.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, Cumberland faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue. Our business and our clinical studies were impacted as less patients sought elective surgeries and our access to medical facilities was substantially limited. During 2020, we carefully monitored our supply chain during the pandemic including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hyponatremia Publication</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recently published Health Outcome Predictive Evaluation (HOPE) COVID-19 Registry Analysis, an international study of over 4,000 patients, found that patients hospitalized with COVID-19 had a high risk of developing hyponatremia. These COVID-19 patients also had a higher incidence of mortality due to their hyponatremia. The study results support the use of an intravenous vaptan to treat hyponatremia in critically ill patients afflicted with COVID-19. </span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hyponatremia, an imbalance of serum sodium to body water, is the most common electrolyte disorder among hospitalized patients. Our Vaprisol product is one of two branded prescription products indicated for the treatment of hyponatremia, and the only intravenously administered branded treatment.  Vaprisol has a proven day-1 response rate to normalize serum sodium levels in hyponatremic patients and move them out of the ICU as efficiently as possible. </span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vibativ Case Studies</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s Vibativ product has been used to treat COVID-19 patients who developed secondary bacterial pneumonia and other Gram-positive infections while in the hospital. The Company subsequently compiled a dossier of patient case studies from across the country outlining several real-world instances where Vibativ effectively and safely treated the hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia resulting from MSSA and MRSA infections that developed in patients hospitalized with COVID-19.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Omeclamox-Pak Supply Update</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has partnered with a select group of FDA-approved facilities to manufacture its line of branded pharmaceutical products and has been carefully monitoring its supply chain during the pandemic. The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19, and their operations are currently suspended. We are awaiting resumption of those operations, while also exploring other alternatives to restart the product&#8217;s packaging.  Meanwhile, we informed the FDA of a shortage of the Omeclamox-Pak effective October 14, 2020 and have not provided a date for the availability of new inventory.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RediTrex Launch</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During late 2018, we completed the submission and filed with the FDA a New Drug Application for our methotrexate products. In December 2019, we received FDA approval for RediTrex and began planning for a launch of this product line. In November 2020, we provided initial shipments of RediTrex to select accounts and are currently planning a national launch of the product line in the second half of 2021, once additional product supplies are received and market conditions return to normal.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paycheck Protection Program</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPP is administered by the U.S. Small Business Administration.  The loan matures April 14, 2022 and bears interest at a rate of 1.0% per year, payable monthly. The loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities. From the date of funding, we used the loan amount for such qualifying expenses.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We applied for this loan after carefully considering, with our bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. We evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, due to assistance from our PPP loan, we currently do not foresee doing so. In October 2020, the Company submitted a request for the loan&#8217;s forgiveness. The request has been approved by the lender, Pinnacle Bank, and will require the approval of the U.S. Small Business Administration which we are awaiting.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ifetroban Phase II Clinical Programs</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been evaluating our ifetroban product candidate in a series of clinical studies. We are sponsoring Phase II clinical programs which are underway evaluating our ifetroban product candidates in 1) patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, a rare, fatal, genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles, 2) Systemic Sclerosis or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs and 3) Aspirin-Exacerbated Respiratory Disease, a severe form of asthma. </span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have completed two pilot Phase II studies involving 1) patients suffering from Hepatorenal Syndrome, a life-threatening condition involving liver and kidney failure and 2) patients with Portal Hypertension associated with chronic liver disease.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional pilot preclinical and clinical studies of ifetroban are underway, including several investigator-initiated trials. </span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enrollment in our clinical studies was interrupted due to the COVID-19 pandemic. While enrollment of new patients has been limited, many of our clinical study sites have reopened and resumed screening of patients for potential enrollment into our studies. We are awaiting results from the studies underway before deciding on the best development path for the registration of ifetroban, our first new chemical entity.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Hospital Product Candidate</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland was responsible for the formulation, development and FDA approval of both Acetadote and Caldolor. Our Medical Advisory Board has helped us identify additional opportunities that address unmet or poorly met medical needs. As a result, Cumberland has successfully designed, formulated and completed the preclinical studies for a cholesterol reducing agent for use in the hospital setting. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed a Phase I study which defined the pharmacokinetic properties and provided a favorable safety profile for this new product candidate. The study results and a proposed clinical development plan were discussed with the FDA.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also completed a Phase II study to further evaluate administration, dosing and pharmacokinetics of the product. We are now evaluating the next steps for this product development program. </span></div><div style="margin-top:8pt"><span><br/></span></div><div id="ibed5a8c73c54452487f262c52ff9017c_67"></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see a discussion of our critical accounting policies and significant judgments and estimates in Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report and the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2020 Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Estimates and Judgments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on past experience and on other factors we deem reasonable given the circumstances. Past results help form the basis of our judgments about the carrying value of assets and liabilities that cannot be determined from other sources. Actual results could differ from these estimates. These estimates, judgments and assumptions are most critical with respect to our accounting for revenue recognition, inventories, fair value of contingent consideration liability associated with a business combination, share-based compensation and intangible assets.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="ibed5a8c73c54452487f262c52ff9017c_70"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three months ended March 31, 2021 compared to the three months ended March 31, 2020 </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited interim statements of operations for continuing operations for the three months ended March 31, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,537,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,330,734&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,206,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,417,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,634,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787,340&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,707,676&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,664&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(465,188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,230,509&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,036,284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,225&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,861,459&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,176,735&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,724&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324,300)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,846,001)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,521,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,426&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,888&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,462)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,065)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343,291)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,849,178)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505,887&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,458)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350,749)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,883,418)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,669&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net revenues by product for the periods presented: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994,378&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,311,696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317,318)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,052,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,425,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539,496&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096,291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443,205&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(596,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450,263)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(565,033)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,252)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,252)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,458)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,537,159&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,330,734&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,206,425&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net revenues for the three months ended March 31, 2021, were $10.5 million compared to $8.3 million for the three months ended March 31, 2020.  As detailed in the table above, net revenue increased for three of our marketed products: Vibativ, Caldolor and Vaprisol during the quarter.  We returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen effective January 1, 2020.  In exchange for the return of these product license rights and associated non-compete provisions, Cumberland is receiving $5 million in financial consideration paid over the two-years following the return date. The installments of $0.5 million and $0.8 million due from Clinigen were recorded during the three months ended March 31, 2021 and March 31, 2020, as discontinued operations, respectively.  We do not incur expenses associated with these payments from Clinigen.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ revenue was $5.1 million for the three months ended March 31, 2021, an increase of $2.6 million over the same period last year.  The 108% increase was a result of increased net pricing and improved sales volumes during the period as a result of increased utilization in supporting patients impacted by COVID-19 infections.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose revenue decreased by $0.3 million during the first quarter of 2021, when compared to the prior year period.  The decrease was primarily the result of decreased sales volumes for the product.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor revenue was $1.5 million for the first quarter of 2021, an increase of $0.4 million compared to the same period last year. The 40.4% improvement in net revenue was the result of an increase in international shipments of Caldolor when compared to the prior year period and an improvement in net pricing.  These improvements were partially offset by lower domestic shipments of the product, impacted by COVID-19 and a reduction in elective surgeries.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol revenue was $1.1 million for the first quarter of 2021, an increase of $0.9 million. This increase of net sales compared to the first quarter of 2020 is primarily due to increased sales volumes during the period as a result of increased utilization in supporting patients impacted by COVID-19 infections.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak revenue decreased $0.6 million for the first quarter of 2021, compared to the first quarter of 2020.  The decrease was the result of no sales during the first quarter of 2021 as Cumberland is currently out of commercial inventory of this product. The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19, and their operations are currently suspended. We are awaiting resumption of their operations, while also exploring other alternatives to restart the product&#8217;s packaging.  Net revenue for the first quarter of 2021 was also negatively impacted by product returns during the period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. During the quarter, there was a decrease of $0.6 million in the product's revenue when compared to the prior year period as a result of lower sales volumes during the period, impacted by generic competition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">st of products sold for the first quarter of 2021 and 2020 were $2.4 million and $1.6 million, respectively. Cost of products sold, as a percentage of net revenues, were 22.9% during the three months ended March 31, 2021, compared to 19.6% during the three months ended March 31, 2020.  This change in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix, particularly the increase in sales of Vibativ and increased international sales.  The Vibativ inventory sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.  The increase in costs of product sold expense was also the result of a step up in the fair value of the inventory over the cost to Theravance, as required under purchase accounting rules.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling and marketing expense for the first quarter of 2021 increased $0.1 million compared to the prior year period.  This increase is primarily attributable to increases in royalty costs associated with growth in Vibativ sales during the current quarter.  Higher royalty costs were partially offset by decreases in direct promotional spending, meeting costs and travel expenses during the current quarter. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development costs were $1.3 million for the first quarter of 2021 and $1.7 million for the same period last year.  A portion of our research and development costs is variable based on the number of trials, study sites, number of patients and the cost per patient in each of our clinical programs. We continue to fund our ongoing clinical initiatives associated with our pipeline products.  The cost decreases were primarily the result of decreased study activity as well as a decrease in salaries expense associated with a reduction in personnel.     </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  General and administrative expense for the first quarter of 2021 increased to $2.2 million from  $2.0 million during the first quarter of 2020 as a result of increases in professional, legal and insurance costs.  These increases were partially offset by decreases in non-cash stock based compensation during the period.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Vibativ:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,052,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,425,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456,816&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,193,075&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968,224&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for the three months ended March 31, 2021, and three months ended March 31, 2020, totaled approximately $1.2 million and $1.1 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Income tax expense for the three months ended March 31, 2021, was comparable to the income tax expense for the three months ended March 31, 2020.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, we had approximately $44 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options that have historically been used to significantly offset income tax obligations.  We expect to continue to pay minimal income taxes during 2021 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. </span></div><div id="ibed5a8c73c54452487f262c52ff9017c_76"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Working Capital</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are cash flows provided by our operations, the proceeds from the Paycheck Protection Program loan, the amounts borrowed and available under our line of credit and the cash proceeds from our initial public offering of common stock that was completed in August 2009. We believe that our internally generated cash flows, existing working capital and our line of credit will be adequate to finance internal growth, finance business development initiatives, and fund capital expenditures for the foreseeable future. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our liquidity and working capital as of March 31, 2021 and December 31, 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,922,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,753,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (current assets less current liabilities)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,535,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,302,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current ratio (multiple of current assets to current liabilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit availability</span></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net changes in cash and cash equivalents for the three months ended March 31, 2021 and March 31, 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,785,549&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888,539&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(571,161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,298,079)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,503,279)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,185,901)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $0.2 million increase in cash and cash equivalents for the three months ended March 31, 2021, was primarily attributable to cash provided by operating activities, partially offset by cash used in investing and financing activities.  Cash provided by operating activities of $1.8 million was positively impacted by decreases in inventory of $1.9 million, as well as the add back of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $1.4 million.  Cash used by investing activities was the result of additions to intangibles of $0.1 million and the payment of $0.2 million to the WHC JV.  Our financing activities included the $0.3 million in cash used to repurchase shares of our common stock as well as the $1.0 million used for the payment of royalties to Theravance for sales of Vibativ. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $1.2 million decrease in cash and cash equivalents for the three months ended March 31, 2020 was primarily attributable to cash used in investing and financing activities.  Cash provided by operating activities of $0.9 million was positively impacted by decreases in accounts receivable of $2.0 million and inventory of $0.7 million, as well as the add back of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $1.4 million.  This was partially offset by a decrease in accounts payable of $2.4 million.  Cash used in investing activities was the result of additions to intangibles of $0.5 million.  Our financing activities reflected the $0.4 million in cash used to repurchase shares of our common stock as well as the $0.8 million used for the repurchase of subsidiary shares. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, we entered into a Fourth Amendment (&#8220;Fourth Amendment&#8221;) to the Revolving Credit Loan Agreement with Pinnacle Bank (the &#8220;Pinnacle Agreement&#8221;). The Fourth Amendment extends the maturity date of the Pinnacle Agreement through October 1, 2022 and provides for a principal available for borrowing of up to $15 million.  We also have the ability to request an increase of up to an additional $5 million, upon the satisfaction of certain conditions and approval by Pinnacle Bank. If fully expanded, the Fourth Amendment would provide a maximum principal available for borrowing of up to $20 million. On May 10, 2019, we entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#8220;Pinnacle Agreement&#8221;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021, as well as modified certain definitions and terms of the existing financial covenants.  For a summary of the material terms of the Pinnacle Agreement, as amended, see Note 6 to the accompanying unaudited condensed consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pinnacle Agreement, we were initially subject to one financial covenant, the maintenance of a Funded Debt Ratio. On August 14, 2018, we amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Third Amendment modified the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  We were in compliance with the Tangible Capital Ratio financial covenant as of March 31, 2021. We expect to maintain compliance with the Tangible Capital Ratio financial covenant in future periods. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. For a summary of the material terms of the Paycheck Protection Program loan, see Note 6 to the accompanying unaudited condensed consolidated financial statements.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the date of funding we used the loan amount for such qualifying expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, based on assistance from our PPP loan, we currently do not foresee doing so.  In October 2020, we submitted a request for forgiveness of the PPP loan. The request was approved by the lender, Pinnacle Bank, who then submitted it to the U.S. Small Business Administration ("SBA") for the SBA's review and approval. </span></div><div id="ibed5a8c73c54452487f262c52ff9017c_79"></div><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, we did not engage in any off-balance sheet arrangements.</span></div><div id="ibed5a8c73c54452487f262c52ff9017c_82"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates on our cash on deposit in highly-liquid money market accounts and our revolving credit facility. We do not utilize derivative financial instruments or other market risk-sensitive instruments to manage exposure to interest rate changes. The main objective of our cash investment activities is to preserve principal while maximizing interest income through low-risk investments. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our interest rate risk related to our cash and cash equivalents is not material. The risk related to interest rates for these accounts would produce less income than expected if market interest rates fall. Based on current interest rates, we do not believe we are exposed to significant downside risk related to a change in interest on our money market accounts at March 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate risk related to borrowings under our line of credit is based on LIBOR plus an interest rate spread.  The pricing under the Fourth Amendment of the Pinnacle Agreement provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The applicable interest rate under the Pinnacle Agreement was 3.65% at March 31, 2021.   As of March 31, 2021, we had $15.0 million in borrowings outstanding under our revolving credit facility. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Rate Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we operate primarily in the United States, we are exposed to foreign currency risk.  Currently, we do not utilize financial instruments to hedge exposure to foreign currency fluctuations.  We believe our exposure to foreign currency fluctuation is minimal as our purchases in foreign currency have a maximum exposure of 90 days based on invoice terms with a portion of the exposure being limited to 30 days based on the due date of the invoice.  Foreign currency exchange gains and losses were immaterial for the three months ended March 31, 2021 and 2020.  Neither a five percent increase nor decrease from current exchange rates would have a material effect on our operating results or financial condition.</span></div><div id="ibed5a8c73c54452487f262c52ff9017c_85"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management, with the participation of the Company&#8217;s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, the Company&#8217;s Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company&#8217;s disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and is accumulated and communicated to the Company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, there has not been any change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="ibed5a8c73c54452487f262c52ff9017c_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="ibed5a8c73c54452487f262c52ff9017c_91"></div><div style="-sec-extract:summary;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ibed5a8c73c54452487f262c52ff9017c_94"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the other information set forth in this quarterly report, an investor should consider the risk factors included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div id="ibed5a8c73c54452487f262c52ff9017c_97"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have a share repurchase program to purchase up to $10 million of our common stock pursuant to Rule 10b-18 of the Exchange Act. In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity, by month, during the three months ended March 31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares (or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price&#160;Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per&#160;Share</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(or Unit)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares (or Units)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased&#160;as&#160;Part</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Publicly</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Announced Plans</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">or Programs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(or Approximate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Value) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;(or&#160;Units)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">that May Yet Be</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased&#160;Under</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">the Plans or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Programs</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,349</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,349</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,108,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,325</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,325</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,994,725&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,050</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,050</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,887,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,724</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,724</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="ibed5a8c73c54452487f262c52ff9017c_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828021004654/a2020-10kxex1011ajkazimi.htm">Employment Agreement, dated March 8, 2021, effective as of January 1, 2021, by and between A.J. Kazimi and Cumberland Pharmaceuticals, Inc., incorporated herein by reference to Exhibit 10.11 of the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828021004654/a2020-xex1012martincearnal.htm">Employment Agreement, dated March 8, 2021, effective as of January 1, 2021, by and between Martian E. Cearnal and Cumberland Pharmaceuticals, Inc., incorporated herein by reference to Exhibit 10.12 of the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828021004654/a2020-10kxex1013leopavliv.htm">Employment Agreement, dated March 8, 2021, effective as of January 1, 2021, by and between Leo B. Pavliv and Cumberland Pharmaceuticals, Inc., incorporated herein by reference to Exhibit 10.13 of the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828021004654/a2020-xex1014michaelbonner.htm">Employment Agreement, dated March 8, 2021, effective as of January 1, 2021, by and between Michael P. Bonner and Cumberland Pharmaceuticals, Inc., incorporated herein by reference to Exhibit 10.14 of the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828021004654/a2020-10kxex1015jimherman.htm">Employment Agreement, dated March 8, 2021, effective as of January 1, 2021, by and between James L. Herman and Cumberland Pharmaceuticals, Inc., incorporated herein by reference to Exhibit 10.15 of the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2021q1-exhibit311.htm">Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2021q1-exhibit312.htm">Certification of Chief Financial Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2021q1-exhibit321.htm">Certification of Chief Executive and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVER PAGE INTERACTIVE DATA FILE (FORMATTED AS INLINE XBRL AND CONTAINED IN EXHIBIT 101)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="ibed5a8c73c54452487f262c52ff9017c_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:8.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.416%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 14, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael Bonner</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Bonner</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Duly Authorized Officer</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a2021q1-exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i447dc4a00c0b418e9542bee1c9d249ee_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, A.J. Kazimi, certify that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:50.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 14, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a2021q1-exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i17b3cc4ddf4d49669e2753f3eae9166e_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael Bonner, certify that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:50.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 14, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael Bonner</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Bonner</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a2021q1-exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i5261019b13e94e2dbbca787cb9fffed4_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE AND</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form&#160;10-Q for the fiscal quarter ended March 31, 2021 of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;), as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, A.J. Kazimi, Chief Executive Officer and Michael Bonner, Chief Financial Officer of the Company, certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:38.888%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A. J. Kazimi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 14, 2021</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael Bonner</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Bonner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 14, 2021</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:right"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cpix-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:04e28feb-0224-48c2-9aed-5419303ac6e2,g:7c5adb88-3a13-4fc9-bea7-995fc46bc2d7-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://www.cumberlandpharma.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cumberlandpharma.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cumberlandpharma.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquity" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statement of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationPolicies" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationOrganizationDetails" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails">
        <link:definition>2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShare" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare">
        <link:definition>2104102 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareTables" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables">
        <link:definition>2305301 - Disclosure - Earnings (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails">
        <link:definition>2406402 - Disclosure - Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual">
        <link:definition>2407403 - Disclosure - Earnings (Loss) Per Share (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.cumberlandpharma.com/role/Revenues">
        <link:definition>2108103 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.cumberlandpharma.com/role/RevenuesTables">
        <link:definition>2309302 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails">
        <link:definition>2410404 - Disclosure - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.cumberlandpharma.com/role/Inventories">
        <link:definition>2111104 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.cumberlandpharma.com/role/InventoriesTables">
        <link:definition>2312303 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails">
        <link:definition>2413405 - Disclosure - Inventories (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>2414406 - Disclosure - Inventories (Schedule of Inventories) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cumberlandpharma.com/role/Leases">
        <link:definition>2115105 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cumberlandpharma.com/role/LeasesTables">
        <link:definition>2316304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails">
        <link:definition>2417407 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasePositionDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails">
        <link:definition>2418408 - Disclosure - Leases (Lease Position) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails">
        <link:definition>2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1">
        <link:definition>2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesRentExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails">
        <link:definition>2420410 - Disclosure - Leases - Rent Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebt" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt">
        <link:definition>2121106 - Disclosure - Shareholders' Equity and Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtShareholdersEquityDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails">
        <link:definition>2422411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtDebtDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails">
        <link:definition>2423412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes">
        <link:definition>2124107 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2425413 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements">
        <link:definition>2126108 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRights" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights">
        <link:definition>2127109 - Disclosure - Additions and Returns of Product Rights</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsTables" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables">
        <link:definition>2328305 - Disclosure - Additions and Returns of Product Rights (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails">
        <link:definition>2429414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsChangeinConsiderationDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails">
        <link:definition>2430415 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails">
        <link:definition>2431416 - Disclosure - Additions and Returns of Product Rights - Dissolution Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cpix_MethotrexateMember" abstract="true" name="MethotrexateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_VIBATIVMember" abstract="true" name="VIBATIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ShareholdersEquityTextualAbstract" abstract="true" name="ShareholdersEquityTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_ClinigenHealthcareLimitedMember" abstract="true" name="ClinigenHealthcareLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_EquityAndDebtAbstract" abstract="true" name="EquityAndDebtAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_IncentiveStockOptionsMember" abstract="true" name="IncentiveStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" abstract="false" name="ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_RediTrexMember" abstract="true" name="RediTrexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_FourthAmendmentMember" abstract="true" name="FourthAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" abstract="false" name="TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" abstract="false" name="ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_PinnacleBankMember" abstract="true" name="PinnacleBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_OtherLongTermObligationsExcludingCurrentPortion" abstract="false" name="OtherLongTermObligationsExcludingCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" abstract="false" name="StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CaldolorMember" abstract="true" name="CaldolorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_WinHealthInvestmentSingaporeLtdDomain" abstract="true" name="WinHealthInvestmentSingaporeLtdDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCurrentOperatingLiabilities" abstract="false" name="IncreaseDecreaseInCurrentOperatingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" abstract="false" name="IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" abstract="false" name="BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_VaprisolMember" abstract="true" name="VaprisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_IfetrobanClinicalMember" abstract="true" name="IfetrobanClinicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ProductsAbstract" abstract="true" name="ProductsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_TieredRoyaltyPaymentsPercentage" abstract="false" name="TieredRoyaltyPaymentsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cpix_OmeclamoxPakMember" abstract="true" name="OmeclamoxPakMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_AcetadoteMember" abstract="true" name="AcetadoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_KristaloseMember" abstract="true" name="KristaloseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>cpix-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:04e28feb-0224-48c2-9aed-5419303ac6e2,g:7c5adb88-3a13-4fc9-bea7-995fc46bc2d7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20210331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e5c0fe74-8c60-40c5-945c-32c2b0627eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_b2620f39-86f4-47ff-a512-33fc574ddc6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e5c0fe74-8c60-40c5-945c-32c2b0627eb7" xlink:to="loc_us-gaap_LongTermLineOfCredit_b2620f39-86f4-47ff-a512-33fc574ddc6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b5228d23-5d9f-443a-9a93-993d7fab4a20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e5c0fe74-8c60-40c5-945c-32c2b0627eb7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b5228d23-5d9f-443a-9a93-993d7fab4a20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6f51d411-b87f-415a-b951-af1bafc2c8d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e5c0fe74-8c60-40c5-945c-32c2b0627eb7" xlink:to="loc_us-gaap_LiabilitiesCurrent_6f51d411-b87f-415a-b951-af1bafc2c8d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_16f6f72f-a6d1-4593-8d44-60632c25a03d" xlink:href="cpix-20210331.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e5c0fe74-8c60-40c5-945c-32c2b0627eb7" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_16f6f72f-a6d1-4593-8d44-60632c25a03d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e568a20c-8bcb-4841-8d52-ff86629ea167" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_71acf409-6094-4b9b-a26a-40317d465f53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e568a20c-8bcb-4841-8d52-ff86629ea167" xlink:to="loc_us-gaap_CommonStockValue_71acf409-6094-4b9b-a26a-40317d465f53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8d56a2ca-ca05-4687-95e1-2269d8f2327c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e568a20c-8bcb-4841-8d52-ff86629ea167" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8d56a2ca-ca05-4687-95e1-2269d8f2327c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_072b7720-1b81-4f08-8654-026723d12fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_90a5397c-448a-4383-baec-5d5e8cf90da9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_072b7720-1b81-4f08-8654-026723d12fc6" xlink:to="loc_us-gaap_Liabilities_90a5397c-448a-4383-baec-5d5e8cf90da9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2791682d-6993-4ca2-99ce-682e962e76ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_072b7720-1b81-4f08-8654-026723d12fc6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2791682d-6993-4ca2-99ce-682e962e76ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0520c956-f93e-4733-b530-55caf7852d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_072b7720-1b81-4f08-8654-026723d12fc6" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0520c956-f93e-4733-b530-55caf7852d05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7af7f7af-f71a-4b6a-b19d-a92d5a887cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_cb9f5434-3690-4560-8b0a-7c4b292e1cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7af7f7af-f71a-4b6a-b19d-a92d5a887cab" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_cb9f5434-3690-4560-8b0a-7c4b292e1cb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9a5c86dc-0093-45e7-b783-803d6299e51f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7af7f7af-f71a-4b6a-b19d-a92d5a887cab" xlink:to="loc_us-gaap_AccountsPayableCurrent_9a5c86dc-0093-45e7-b783-803d6299e51f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_33579ee1-dbb1-49d1-9c79-b0c251611e5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7af7f7af-f71a-4b6a-b19d-a92d5a887cab" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_33579ee1-dbb1-49d1-9c79-b0c251611e5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c1232ce5-53d0-4a9c-b220-6489e9cf830e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6bfb8b58-d50e-4c81-8198-95d7de9f584c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c1232ce5-53d0-4a9c-b220-6489e9cf830e" xlink:to="loc_us-gaap_StockholdersEquity_6bfb8b58-d50e-4c81-8198-95d7de9f584c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_62309ea2-d0c9-46b9-b027-21bf00f7d50c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c1232ce5-53d0-4a9c-b220-6489e9cf830e" xlink:to="loc_us-gaap_MinorityInterest_62309ea2-d0c9-46b9-b027-21bf00f7d50c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_491fab2c-e283-46d0-8340-8e3fb1c03081" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b48864e2-c074-40ff-b3d1-a13c66c9f758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_491fab2c-e283-46d0-8340-8e3fb1c03081" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b48864e2-c074-40ff-b3d1-a13c66c9f758" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_38c577b3-8d89-4a02-90d4-f24cd785b7cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_491fab2c-e283-46d0-8340-8e3fb1c03081" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_38c577b3-8d89-4a02-90d4-f24cd785b7cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_8b842e3b-4f3b-4af6-95cc-d474f14e63b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_491fab2c-e283-46d0-8340-8e3fb1c03081" xlink:to="loc_us-gaap_OtherAssetsCurrent_8b842e3b-4f3b-4af6-95cc-d474f14e63b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2bc73c40-da51-4d75-a6b4-4e97a1c63971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_491fab2c-e283-46d0-8340-8e3fb1c03081" xlink:to="loc_us-gaap_InventoryNet_2bc73c40-da51-4d75-a6b4-4e97a1c63971" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3370417d-5c4d-4917-b5e4-593e3ba95dd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_da8b5365-c2ae-4b2a-b9ef-c51a9f38179a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3370417d-5c4d-4917-b5e4-593e3ba95dd8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_da8b5365-c2ae-4b2a-b9ef-c51a9f38179a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fa47775f-e81c-4def-9e88-ee70b420933c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3370417d-5c4d-4917-b5e4-593e3ba95dd8" xlink:to="loc_us-gaap_Goodwill_fa47775f-e81c-4def-9e88-ee70b420933c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_35ede9dc-f661-4883-9db2-19b42c89ee29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3370417d-5c4d-4917-b5e4-593e3ba95dd8" xlink:to="loc_us-gaap_InventoryNoncurrent_35ede9dc-f661-4883-9db2-19b42c89ee29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_001eb5a8-6758-45fc-989d-1d3de2b48f1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3370417d-5c4d-4917-b5e4-593e3ba95dd8" xlink:to="loc_us-gaap_AssetsCurrent_001eb5a8-6758-45fc-989d-1d3de2b48f1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7c6701c4-1271-4c47-b18b-36306feb1f89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3370417d-5c4d-4917-b5e4-593e3ba95dd8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7c6701c4-1271-4c47-b18b-36306feb1f89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_90fd4d35-96a2-49bd-a7f6-0e4ab7ed62ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3370417d-5c4d-4917-b5e4-593e3ba95dd8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_90fd4d35-96a2-49bd-a7f6-0e4ab7ed62ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_21563db4-3206-4b05-9d40-5dc53e2803e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3370417d-5c4d-4917-b5e4-593e3ba95dd8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_21563db4-3206-4b05-9d40-5dc53e2803e0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_75803283-7b9c-441b-94b8-7a8062256ffa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0978bd50-2432-41d1-93b6-a4fa63249fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_75803283-7b9c-441b-94b8-7a8062256ffa" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0978bd50-2432-41d1-93b6-a4fa63249fca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_bb371247-d3c6-475c-8b08-ccf97ba4dd89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_75803283-7b9c-441b-94b8-7a8062256ffa" xlink:to="loc_us-gaap_SellingAndMarketingExpense_bb371247-d3c6-475c-8b08-ccf97ba4dd89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25ab9177-3db9-49b3-8df0-41cca5ed453f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_75803283-7b9c-441b-94b8-7a8062256ffa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25ab9177-3db9-49b3-8df0-41cca5ed453f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9023925a-d44a-4145-ad11-384d4f61a390" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_75803283-7b9c-441b-94b8-7a8062256ffa" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9023925a-d44a-4145-ad11-384d4f61a390" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5072e1f9-0c53-45f0-a002-e01b0e3071bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_75803283-7b9c-441b-94b8-7a8062256ffa" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5072e1f9-0c53-45f0-a002-e01b0e3071bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_60d56433-1384-4db4-8d76-0317c3ca3821" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9607b51f-0162-448a-b552-77b0aec6edcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_60d56433-1384-4db4-8d76-0317c3ca3821" xlink:to="loc_us-gaap_OperatingIncomeLoss_9607b51f-0162-448a-b552-77b0aec6edcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c90077d5-b8de-4416-a0cf-8124d657bb82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_60d56433-1384-4db4-8d76-0317c3ca3821" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c90077d5-b8de-4416-a0cf-8124d657bb82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5c4490db-76dd-4009-98a3-e0bc3bfa9415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_60d56433-1384-4db4-8d76-0317c3ca3821" xlink:to="loc_us-gaap_InterestExpense_5c4490db-76dd-4009-98a3-e0bc3bfa9415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_63aae7cd-315c-410e-b4be-8833d68bed66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4ad54bea-a183-43c4-af24-0516da92b952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_63aae7cd-315c-410e-b4be-8833d68bed66" xlink:to="loc_us-gaap_ProfitLoss_4ad54bea-a183-43c4-af24-0516da92b952" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a7902cf1-7c9b-4c3b-8183-18d7db3b0649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_63aae7cd-315c-410e-b4be-8833d68bed66" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a7902cf1-7c9b-4c3b-8183-18d7db3b0649" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5caa9ac4-db64-41ae-8517-5198af0aaf74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_91bdc017-983f-4ed8-95fb-49a7aae1fbf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5caa9ac4-db64-41ae-8517-5198af0aaf74" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_91bdc017-983f-4ed8-95fb-49a7aae1fbf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6d15ab0b-d8f8-4be4-91f4-6952846adaad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5caa9ac4-db64-41ae-8517-5198af0aaf74" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6d15ab0b-d8f8-4be4-91f4-6952846adaad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8a35d4b6-0317-4a6c-bfd1-9f5328c5f06d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0a281753-480f-41b7-9c84-c3aa33359ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8a35d4b6-0317-4a6c-bfd1-9f5328c5f06d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0a281753-480f-41b7-9c84-c3aa33359ed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_fae2351e-cafd-48ff-b351-25dee2140c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8a35d4b6-0317-4a6c-bfd1-9f5328c5f06d" xlink:to="loc_us-gaap_CostsAndExpenses_fae2351e-cafd-48ff-b351-25dee2140c34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9bd317bf-53a2-4c9c-a9b5-d8db2a74de0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b2903a23-81d1-416b-81d3-2f46c6f2e355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9bd317bf-53a2-4c9c-a9b5-d8db2a74de0e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b2903a23-81d1-416b-81d3-2f46c6f2e355" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_72ab65b1-fff1-44a4-bfd5-0008a16b76c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9bd317bf-53a2-4c9c-a9b5-d8db2a74de0e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_72ab65b1-fff1-44a4-bfd5-0008a16b76c0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f4e72b53-5ef2-424d-b906-15a1b00943be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e4c2e808-ee43-49d4-ab51-81683ba9f88d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f4e72b53-5ef2-424d-b906-15a1b00943be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e4c2e808-ee43-49d4-ab51-81683ba9f88d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_2c19fe6d-47ef-4b78-a69c-ec052084eb0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f4e72b53-5ef2-424d-b906-15a1b00943be" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_2c19fe6d-47ef-4b78-a69c-ec052084eb0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6dd5a862-e85c-4ab5-a72e-0bf1bbbe522f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a1752836-a40c-47c6-bac4-6ec91be796d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6dd5a862-e85c-4ab5-a72e-0bf1bbbe522f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a1752836-a40c-47c6-bac4-6ec91be796d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d51236d9-135c-4d3b-b586-d1882ae20a3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6dd5a862-e85c-4ab5-a72e-0bf1bbbe522f" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d51236d9-135c-4d3b-b586-d1882ae20a3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies_41f57645-f1e2-4f4a-81e4-c00c28d9e965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6dd5a862-e85c-4ab5-a72e-0bf1bbbe522f" xlink:to="loc_us-gaap_ProceedsFromLifeInsurancePolicies_41f57645-f1e2-4f4a-81e4-c00c28d9e965" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01fa248f-15bc-42c6-8ed3-3f6794091880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_c0cdbe4e-ce4f-4681-a6ae-5120c4bcdb76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01fa248f-15bc-42c6-8ed3-3f6794091880" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_c0cdbe4e-ce4f-4681-a6ae-5120c4bcdb76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_caaa0141-fd95-4da0-a20c-c6f79c1a1c85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01fa248f-15bc-42c6-8ed3-3f6794091880" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_caaa0141-fd95-4da0-a20c-c6f79c1a1c85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_bcf768ce-0bef-4cf2-9024-f6f88b0d6d5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01fa248f-15bc-42c6-8ed3-3f6794091880" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_bcf768ce-0bef-4cf2-9024-f6f88b0d6d5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_36e6462b-469d-4121-96a4-69da507b0c31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01fa248f-15bc-42c6-8ed3-3f6794091880" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_36e6462b-469d-4121-96a4-69da507b0c31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_38b4b9f9-7486-49bd-8215-e0af0bd06c99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01fa248f-15bc-42c6-8ed3-3f6794091880" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_38b4b9f9-7486-49bd-8215-e0af0bd06c99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_660088d3-58d5-4603-b473-c726dbc881ec" xlink:href="cpix-20210331.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_660088d3-58d5-4603-b473-c726dbc881ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_494ff29c-2dd9-42e7-8e87-32105bb10b7c" xlink:href="cpix-20210331.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_494ff29c-2dd9-42e7-8e87-32105bb10b7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8914839a-1c83-4af3-9b83-3c2e8c53d3b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8914839a-1c83-4af3-9b83-3c2e8c53d3b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_cace72e4-4fec-4495-9e04-36f4cee19b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_cace72e4-4fec-4495-9e04-36f4cee19b2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_81253525-61b8-45a1-bf39-5494aac4a1e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_81253525-61b8-45a1-bf39-5494aac4a1e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_70ff0a45-5dd9-423c-a309-e76d8ef0936a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_70ff0a45-5dd9-423c-a309-e76d8ef0936a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c0bb1cbb-039c-4351-8bbc-c370f961eb76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c0bb1cbb-039c-4351-8bbc-c370f961eb76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1f1ed2d1-db55-48bd-a0a8-7ea8614ecfc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1f1ed2d1-db55-48bd-a0a8-7ea8614ecfc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_4eb04311-5b5c-4b3b-b9f1-7fc12cc6cb58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_4eb04311-5b5c-4b3b-b9f1-7fc12cc6cb58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1f0331fa-eb6d-4178-8bd2-ceea67a81d56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1f0331fa-eb6d-4178-8bd2-ceea67a81d56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3c1ab56a-ce9c-4f9c-ae04-e8f2dae0cd58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_us-gaap_ShareBasedCompensation_3c1ab56a-ce9c-4f9c-ae04-e8f2dae0cd58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9f2b0dab-9a84-43c1-b0b8-e994e7a10f53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b0bdda33-bbeb-4f6c-9e18-5a03e0970824" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9f2b0dab-9a84-43c1-b0b8-e994e7a10f53" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b0bdda33-bbeb-4f6c-9e18-5a03e0970824" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1cd14462-8f67-44ce-a88f-7df44e87884a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9f2b0dab-9a84-43c1-b0b8-e994e7a10f53" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1cd14462-8f67-44ce-a88f-7df44e87884a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_60960018-fcf6-4f00-ad9d-96e61ea5113b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9f2b0dab-9a84-43c1-b0b8-e994e7a10f53" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_60960018-fcf6-4f00-ad9d-96e61ea5113b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20210331.xsd#OrganizationandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20210331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20210331.xsd#EarningsLossPerShare"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#EarningsLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#EarningsLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e09ffd23-9ef9-4276-8e83-1cb9b91b49ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_95893f01-1a5f-4477-89af-268fe7602219" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e09ffd23-9ef9-4276-8e83-1cb9b91b49ce" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_95893f01-1a5f-4477-89af-268fe7602219" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d110141b-e483-47f9-8d7a-00645efb16c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e09ffd23-9ef9-4276-8e83-1cb9b91b49ce" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d110141b-e483-47f9-8d7a-00645efb16c7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20210331.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20210331.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#RevenuesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20210331.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#InventoriesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_62303abe-46b0-435c-ba5a-5d3d8fa42be6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_670cc59f-7923-403a-aeca-603672878550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_62303abe-46b0-435c-ba5a-5d3d8fa42be6" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_670cc59f-7923-403a-aeca-603672878550" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_0a3ac672-7b58-4be4-ae87-40fba5d07dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_62303abe-46b0-435c-ba5a-5d3d8fa42be6" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_0a3ac672-7b58-4be4-ae87-40fba5d07dbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_97194357-4698-4cc0-9867-30e0633ea2d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_62303abe-46b0-435c-ba5a-5d3d8fa42be6" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_97194357-4698-4cc0-9867-30e0633ea2d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f5540d5a-efa8-4b10-a1be-36153e5a9339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_e9662682-b7f0-4d76-aa83-cca9e7760fad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f5540d5a-efa8-4b10-a1be-36153e5a9339" xlink:to="loc_us-gaap_InventoryNoncurrent_e9662682-b7f0-4d76-aa83-cca9e7760fad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_45c60da5-7316-491f-9dd4-f9d55ce487c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f5540d5a-efa8-4b10-a1be-36153e5a9339" xlink:to="loc_us-gaap_InventoryGross_45c60da5-7316-491f-9dd4-f9d55ce487c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20210331.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesLeasePositionDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e8b2c0e-c095-4719-a419-522224958e33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_87bb5f96-7dcf-4281-afbc-36f7bb5291c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e8b2c0e-c095-4719-a419-522224958e33" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_87bb5f96-7dcf-4281-afbc-36f7bb5291c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2d562397-c602-48db-b996-81cdd611c1a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e8b2c0e-c095-4719-a419-522224958e33" xlink:to="loc_us-gaap_OperatingLeaseLiability_2d562397-c602-48db-b996-81cdd611c1a6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f17ef5d-a6f3-4e75-9d42-d0fe1d281dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1d84f93d-263f-44da-83e2-ffae61a495a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f17ef5d-a6f3-4e75-9d42-d0fe1d281dd4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1d84f93d-263f-44da-83e2-ffae61a495a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_df69cf80-afda-422d-9fce-053eda3f6a62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f17ef5d-a6f3-4e75-9d42-d0fe1d281dd4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_df69cf80-afda-422d-9fce-053eda3f6a62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7c08c883-ff33-4208-b731-2785649a60b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f17ef5d-a6f3-4e75-9d42-d0fe1d281dd4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7c08c883-ff33-4208-b731-2785649a60b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_4105423b-bd12-434e-a790-57cc93801f23" xlink:href="cpix-20210331.xsd#cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f17ef5d-a6f3-4e75-9d42-d0fe1d281dd4" xlink:to="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_4105423b-bd12-434e-a790-57cc93801f23" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesRentExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20210331.xsd#ShareholdersEquityandDebt"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20210331.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20210331.xsd#IncomeTaxesDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20210331.xsd#CollaborativeAgreements"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRights"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRightsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRightsDissolutionPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>cpix-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:04e28feb-0224-48c2-9aed-5419303ac6e2,g:7c5adb88-3a13-4fc9-bea7-995fc46bc2d7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20210331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended" id="i8a1f0c468d244af7b1abb46ce477ad66_CoverPage"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="ia3d5f3fca6874fe9bf1b4fe6e461b3e0_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i8ab4b7bca14c433faf462abaeb6d505c_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="i2252e6464e7d4065ac2197e50e67e72b_CondensedConsolidatedStatementsofOperations"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="i874ccf66826e48a9989cf7c2f2b997db_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended" id="i5d9695d2be8240999f786bb3b9ce1ac3_CondensedConsolidatedStatementofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bffb47d7-4b39-4310-a4c9-6c23392b1db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bffb47d7-4b39-4310-a4c9-6c23392b1db9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fa2cd4e0-f00e-4305-b3db-845904e34b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fa2cd4e0-f00e-4305-b3db-845904e34b30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6f5eae8e-60b7-4afe-a4a2-bc909d1e0026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6f5eae8e-60b7-4afe-a4a2-bc909d1e0026" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_25709565-a4c8-4ee3-be2d-f14c4086cff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_25709565-a4c8-4ee3-be2d-f14c4086cff6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c98b10cf-71cf-4ed1-b53f-69ba7867a85d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c98b10cf-71cf-4ed1-b53f-69ba7867a85d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_2a1fdc8e-34e1-4cfd-838b-76ec0f372523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_2a1fdc8e-34e1-4cfd-838b-76ec0f372523" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_525a8c6f-41e7-481b-a534-855ec8c5188e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_525a8c6f-41e7-481b-a534-855ec8c5188e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_32316b37-d4c0-41f4-8e8d-a54dfd5454bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:to="loc_us-gaap_ProfitLoss_32316b37-d4c0-41f4-8e8d-a54dfd5454bf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_034806c0-e016-4008-a85e-8ddf2c041a17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e8146191-1313-4383-b239-a19189df4008" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b57b44b7-d275-48a8-af92-61faee925605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bffb47d7-4b39-4310-a4c9-6c23392b1db9" xlink:to="loc_us-gaap_StatementTable_b57b44b7-d275-48a8-af92-61faee925605" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_002ce15b-18a2-484b-98da-8b6c45aed706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b57b44b7-d275-48a8-af92-61faee925605" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_002ce15b-18a2-484b-98da-8b6c45aed706" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_002ce15b-18a2-484b-98da-8b6c45aed706_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_002ce15b-18a2-484b-98da-8b6c45aed706" xlink:to="loc_us-gaap_EquityComponentDomain_002ce15b-18a2-484b-98da-8b6c45aed706_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d885839c-e242-4a07-bb1a-d8062dc33f62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_002ce15b-18a2-484b-98da-8b6c45aed706" xlink:to="loc_us-gaap_EquityComponentDomain_d885839c-e242-4a07-bb1a-d8062dc33f62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e6871133-535a-4ac0-aa33-7e46a02bd62e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d885839c-e242-4a07-bb1a-d8062dc33f62" xlink:to="loc_us-gaap_CommonStockMember_e6871133-535a-4ac0-aa33-7e46a02bd62e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d0c2609a-b26e-4434-b134-6d99eb91e015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d885839c-e242-4a07-bb1a-d8062dc33f62" xlink:to="loc_us-gaap_RetainedEarningsMember_d0c2609a-b26e-4434-b134-6d99eb91e015" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_64607e1a-c59d-4d7d-9bce-e88cc98741e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d885839c-e242-4a07-bb1a-d8062dc33f62" xlink:to="loc_us-gaap_NoncontrollingInterestMember_64607e1a-c59d-4d7d-9bce-e88cc98741e9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20210331.xsd#OrganizationandBasisofPresentation"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended" id="ia37eb65722154491a014514212a92fb9_OrganizationandBasisofPresentation"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20210331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended" id="ia1489984c09140d9838f1f975bab56a3_OrganizationandBasisofPresentationPolicies"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended" id="ief28ca06102f44118284a1b7a9dc2d60_OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20210331.xsd#EarningsLossPerShare"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended" id="i4fbb9ec1b542481e8444aca5a9a977f1_EarningsLossPerShare"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#EarningsLossPerShareTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended" id="i22f8441cd9f8422da57795564fd28eb8_EarningsLossPerShareTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#EarningsLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended" id="iab3dcfe4ef01408d923ac259cadf556f_EarningsLossPerShareDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20210331.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended" id="iaf8b8dd59d494d81b86f5f6e56b2fe07_EarningsLossPerShareDetailsTextual"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20210331.xsd#Revenues"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended" id="ieaa542b5b4e94d3cb1623dbbda5093bd_Revenues"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#RevenuesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended" id="icb4f75b357144af688746b76b50e4516_RevenuesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#RevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended" id="i760a2ffdcc1847d78e132cbc9f9eedb2_RevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9b7f2c61-45aa-4682-bcf7-3b3556ad86de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7dd7f84e-9fe1-435f-9b69-9943921d2972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9b7f2c61-45aa-4682-bcf7-3b3556ad86de" xlink:to="loc_us-gaap_RevenuesAbstract_7dd7f84e-9fe1-435f-9b69-9943921d2972" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_bc5c370a-bcc3-49c5-a01f-5f32a0c1c335" xlink:href="cpix-20210331.xsd#cpix_ProductsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_7dd7f84e-9fe1-435f-9b69-9943921d2972" xlink:to="loc_cpix_ProductsAbstract_bc5c370a-bcc3-49c5-a01f-5f32a0c1c335" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f80cea69-7efb-4047-a275-84cf4e3cc84b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ProductsAbstract_bc5c370a-bcc3-49c5-a01f-5f32a0c1c335" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f80cea69-7efb-4047-a275-84cf4e3cc84b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c4063708-1b42-48c6-b721-9b4cd8632a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9b7f2c61-45aa-4682-bcf7-3b3556ad86de" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c4063708-1b42-48c6-b721-9b4cd8632a19" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2532944f-4728-46c5-ac04-a4c1ca41605a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c4063708-1b42-48c6-b721-9b4cd8632a19" xlink:to="loc_srt_ProductOrServiceAxis_2532944f-4728-46c5-ac04-a4c1ca41605a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2532944f-4728-46c5-ac04-a4c1ca41605a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2532944f-4728-46c5-ac04-a4c1ca41605a" xlink:to="loc_srt_ProductsAndServicesDomain_2532944f-4728-46c5-ac04-a4c1ca41605a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2532944f-4728-46c5-ac04-a4c1ca41605a" xlink:to="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_c597ee33-bc11-4280-83ab-7e1ca5628577" xlink:href="cpix-20210331.xsd#cpix_AcetadoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:to="loc_cpix_AcetadoteMember_c597ee33-bc11-4280-83ab-7e1ca5628577" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_5bee534f-f361-43e7-b7ba-ecd1bf39eb63" xlink:href="cpix-20210331.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:to="loc_cpix_OmeclamoxPakMember_5bee534f-f361-43e7-b7ba-ecd1bf39eb63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_0e9747d8-7424-4744-a63c-748621da5d3d" xlink:href="cpix-20210331.xsd#cpix_KristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:to="loc_cpix_KristaloseMember_0e9747d8-7424-4744-a63c-748621da5d3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_07a1c994-45f9-49f0-811e-d8d67f8222b6" xlink:href="cpix-20210331.xsd#cpix_VaprisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:to="loc_cpix_VaprisolMember_07a1c994-45f9-49f0-811e-d8d67f8222b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_12aaa9f2-2f64-4461-a738-5a624cb30de9" xlink:href="cpix-20210331.xsd#cpix_CaldolorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:to="loc_cpix_CaldolorMember_12aaa9f2-2f64-4461-a738-5a624cb30de9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_67aa69c0-0081-41a9-a911-17537672c1e8" xlink:href="cpix-20210331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:to="loc_cpix_VIBATIVMember_67aa69c0-0081-41a9-a911-17537672c1e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember_bc386de5-3305-4061-b976-305ce28d5ff2" xlink:href="cpix-20210331.xsd#cpix_RediTrexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:to="loc_cpix_RediTrexMember_bc386de5-3305-4061-b976-305ce28d5ff2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_6007e412-0f37-4aed-bdd7-0c4377572c2d" xlink:href="cpix-20210331.xsd#cpix_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:to="loc_cpix_OtherProductsMember_6007e412-0f37-4aed-bdd7-0c4377572c2d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_61fd03bc-1084-4326-ac2a-cd1d60f9abd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:to="loc_us-gaap_GrantMember_61fd03bc-1084-4326-ac2a-cd1d60f9abd0" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20210331.xsd#Inventories"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended" id="ibb3a363c1b524d71bd2b720ea1e48a80_Inventories"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#InventoriesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended" id="i6be02c306cb44befb2cfde028f02aa4b_InventoriesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="i7b9a0fedacaf447190266db3337a6b04_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_66b47a01-2f04-43d2-b1a8-f3544b026e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_16a79bee-0234-493e-ad63-8a827e7e84ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_66b47a01-2f04-43d2-b1a8-f3544b026e95" xlink:to="loc_us-gaap_InventoryValuationReserves_16a79bee-0234-493e-ad63-8a827e7e84ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_c3d6e888-2816-431f-a77c-3b88937691d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_66b47a01-2f04-43d2-b1a8-f3544b026e95" xlink:to="loc_us-gaap_InventoryNoncurrent_c3d6e888-2816-431f-a77c-3b88937691d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_f999aa47-8f5d-4af1-8d08-05c8e722e008" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_66b47a01-2f04-43d2-b1a8-f3544b026e95" xlink:to="loc_us-gaap_InventoryFinishedGoods_f999aa47-8f5d-4af1-8d08-05c8e722e008" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_70dd582b-dcc0-495e-9443-e39411b51040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_66b47a01-2f04-43d2-b1a8-f3544b026e95" xlink:to="loc_us-gaap_InventoryCurrentTable_70dd582b-dcc0-495e-9443-e39411b51040" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_540325ac-496a-433b-8c25-668c40ebda16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_70dd582b-dcc0-495e-9443-e39411b51040" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_540325ac-496a-433b-8c25-668c40ebda16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_540325ac-496a-433b-8c25-668c40ebda16_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_540325ac-496a-433b-8c25-668c40ebda16" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_540325ac-496a-433b-8c25-668c40ebda16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee8583ff-ad39-4284-99d3-f4cfafc2b669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_540325ac-496a-433b-8c25-668c40ebda16" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee8583ff-ad39-4284-99d3-f4cfafc2b669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_db161443-5a5a-4c46-8a3d-9ca8b7bb9520" xlink:href="cpix-20210331.xsd#cpix_IfetrobanClinicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee8583ff-ad39-4284-99d3-f4cfafc2b669" xlink:to="loc_cpix_IfetrobanClinicalMember_db161443-5a5a-4c46-8a3d-9ca8b7bb9520" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_32c7e97f-6069-447a-88d4-4896b88794fe" xlink:href="cpix-20210331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee8583ff-ad39-4284-99d3-f4cfafc2b669" xlink:to="loc_cpix_VIBATIVMember_32c7e97f-6069-447a-88d4-4896b88794fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_87d63448-d0c9-4e98-a632-1fe75491e5e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_70dd582b-dcc0-495e-9443-e39411b51040" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_87d63448-d0c9-4e98-a632-1fe75491e5e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_87d63448-d0c9-4e98-a632-1fe75491e5e7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_87d63448-d0c9-4e98-a632-1fe75491e5e7" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_87d63448-d0c9-4e98-a632-1fe75491e5e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_2a7ebf7c-6cae-4bea-ada1-6a35bc391295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_87d63448-d0c9-4e98-a632-1fe75491e5e7" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_2a7ebf7c-6cae-4bea-ada1-6a35bc391295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_052bd3bc-3ed4-4d4d-be60-c29fc24940f7" xlink:href="cpix-20210331.xsd#cpix_IfetrobanClinicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_2a7ebf7c-6cae-4bea-ada1-6a35bc391295" xlink:to="loc_cpix_IfetrobanClinicalMember_052bd3bc-3ed4-4d4d-be60-c29fc24940f7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended" id="i5a5d1160983843789ed9ee84d6eeef4e_InventoriesScheduleofInventoriesDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20210331.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended" id="i47299edc284d42b8b07a0bac69160dbb_Leases"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended" id="i50504116a95d4871b9db45d0d7c49cf8_LeasesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i99aab55e2cf74cb7897454b39b3bfc90_LeasesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesLeasePositionDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended" id="i0f1dc17482234bbebec912e48d4c21ea_LeasesLeasePositionDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended" id="i29d1bb1f1eee46999cb4307d21a21b89_LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesRentExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" xlink:type="extended" id="i51bde6ce1d654e7d96b13d51ca4c6bed_LeasesRentExpenseDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20210331.xsd#ShareholdersEquityandDebt"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended" id="ib6e3c05861514e31b9c7c8e4ecf60ed6_ShareholdersEquityandDebt"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended" id="i1ee7319e03574219a43917f33d39c4d6_ShareholdersEquityandDebtShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc01a531-5d9a-4594-a885-ac9167ffce27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_6997dc50-2c72-4614-96e4-fa938466b84c" xlink:href="cpix-20210331.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc01a531-5d9a-4594-a885-ac9167ffce27" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_6997dc50-2c72-4614-96e4-fa938466b84c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_67677d0f-c0d3-4b77-a035-504dad2dbfb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6997dc50-2c72-4614-96e4-fa938466b84c" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_67677d0f-c0d3-4b77-a035-504dad2dbfb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_8577e2ae-440c-4172-a221-2b65651c074b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6997dc50-2c72-4614-96e4-fa938466b84c" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_8577e2ae-440c-4172-a221-2b65651c074b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_a5f8c304-cea6-4862-b9cd-5f87aa8a020d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6997dc50-2c72-4614-96e4-fa938466b84c" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_a5f8c304-cea6-4862-b9cd-5f87aa8a020d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_f9b98d28-1041-49b5-9afd-93acf7f30b62" xlink:href="cpix-20210331.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6997dc50-2c72-4614-96e4-fa938466b84c" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_f9b98d28-1041-49b5-9afd-93acf7f30b62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2ea6145d-20eb-4531-b0f4-807fc33ee3db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6997dc50-2c72-4614-96e4-fa938466b84c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2ea6145d-20eb-4531-b0f4-807fc33ee3db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_859ca569-4966-4a6e-a6db-f5bb8ea4cb06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6997dc50-2c72-4614-96e4-fa938466b84c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_859ca569-4966-4a6e-a6db-f5bb8ea4cb06" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6876f181-a2ee-4198-9da1-fd177ae986b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc01a531-5d9a-4594-a885-ac9167ffce27" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6876f181-a2ee-4198-9da1-fd177ae986b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_dafd82a9-ec97-43f0-a642-16383dca8cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6876f181-a2ee-4198-9da1-fd177ae986b9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_dafd82a9-ec97-43f0-a642-16383dca8cfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dafd82a9-ec97-43f0-a642-16383dca8cfb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dafd82a9-ec97-43f0-a642-16383dca8cfb" xlink:to="loc_us-gaap_EquityComponentDomain_dafd82a9-ec97-43f0-a642-16383dca8cfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_44d9bb16-975f-4d3c-b626-b2a98688be48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dafd82a9-ec97-43f0-a642-16383dca8cfb" xlink:to="loc_us-gaap_EquityComponentDomain_44d9bb16-975f-4d3c-b626-b2a98688be48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_94f9b2d0-7c74-42fe-b7eb-51af3e80f846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_44d9bb16-975f-4d3c-b626-b2a98688be48" xlink:to="loc_us-gaap_CommonStockMember_94f9b2d0-7c74-42fe-b7eb-51af3e80f846" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_76f9d25f-310e-4bb4-850c-87a9508b8f7f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6876f181-a2ee-4198-9da1-fd177ae986b9" xlink:to="loc_srt_TitleOfIndividualAxis_76f9d25f-310e-4bb4-850c-87a9508b8f7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_76f9d25f-310e-4bb4-850c-87a9508b8f7f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_76f9d25f-310e-4bb4-850c-87a9508b8f7f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_76f9d25f-310e-4bb4-850c-87a9508b8f7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_917131b4-a1c5-4bfa-8f75-216f88a57058" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_76f9d25f-310e-4bb4-850c-87a9508b8f7f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_917131b4-a1c5-4bfa-8f75-216f88a57058" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_b4d9b31e-24ef-42c7-8cc3-1aa54fddb417" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_917131b4-a1c5-4bfa-8f75-216f88a57058" xlink:to="loc_srt_DirectorMember_b4d9b31e-24ef-42c7-8cc3-1aa54fddb417" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0bc3802e-9d97-4e0c-945c-96abb7992d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6876f181-a2ee-4198-9da1-fd177ae986b9" xlink:to="loc_us-gaap_AwardTypeAxis_0bc3802e-9d97-4e0c-945c-96abb7992d45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bc3802e-9d97-4e0c-945c-96abb7992d45_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0bc3802e-9d97-4e0c-945c-96abb7992d45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bc3802e-9d97-4e0c-945c-96abb7992d45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc9725b6-dffa-483b-afda-c1b70b8510f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0bc3802e-9d97-4e0c-945c-96abb7992d45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc9725b6-dffa-483b-afda-c1b70b8510f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b6113997-5623-4e1e-8024-cf70865d33fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc9725b6-dffa-483b-afda-c1b70b8510f9" xlink:to="loc_us-gaap_RestrictedStockMember_b6113997-5623-4e1e-8024-cf70865d33fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncentiveStockOptionsMember_208ba924-ed4e-4a84-b7e9-abc2b4bbf9ef" xlink:href="cpix-20210331.xsd#cpix_IncentiveStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc9725b6-dffa-483b-afda-c1b70b8510f9" xlink:to="loc_cpix_IncentiveStockOptionsMember_208ba924-ed4e-4a84-b7e9-abc2b4bbf9ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_52789baa-6999-40e6-9a03-da25613d0f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6876f181-a2ee-4198-9da1-fd177ae986b9" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_52789baa-6999-40e6-9a03-da25613d0f4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_52789baa-6999-40e6-9a03-da25613d0f4d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_52789baa-6999-40e6-9a03-da25613d0f4d" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_52789baa-6999-40e6-9a03-da25613d0f4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_13daa263-e826-400b-be90-9b42367ab5db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_52789baa-6999-40e6-9a03-da25613d0f4d" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_13daa263-e826-400b-be90-9b42367ab5db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_d2778428-3492-4515-9977-cd0e8a0451d7" xlink:href="cpix-20210331.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_13daa263-e826-400b-be90-9b42367ab5db" xlink:to="loc_cpix_PinnacleBankMember_d2778428-3492-4515-9977-cd0e8a0451d7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended" id="i3ea4cf49f8ec49de835e5b5415dfd198_ShareholdersEquityandDebtDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1a8a98af-e5fd-4a21-bafd-106e6e16b62d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1a8a98af-e5fd-4a21-bafd-106e6e16b62d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_2808eb0b-2b54-475c-b5c9-8e23ea9be939" xlink:href="cpix-20210331.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_2808eb0b-2b54-475c-b5c9-8e23ea9be939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_314d908d-6728-42c9-8528-cd4de1371a8e" xlink:href="cpix-20210331.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_314d908d-6728-42c9-8528-cd4de1371a8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d23ac6c7-8bfd-40d9-be4c-2efdab538e07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d23ac6c7-8bfd-40d9-be4c-2efdab538e07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c4dc3296-c8c8-4ef7-bb09-a838ef197970" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c4dc3296-c8c8-4ef7-bb09-a838ef197970" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_e060fd9e-14f9-44e0-bd5c-23a462807ed8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_e060fd9e-14f9-44e0-bd5c-23a462807ed8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_b8490e6e-4170-4078-944f-037291a5e6a9" xlink:href="cpix-20210331.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_b8490e6e-4170-4078-944f-037291a5e6a9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_416d09c3-ef94-4519-a8c2-2491d797da1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_us-gaap_LongTermLineOfCredit_416d09c3-ef94-4519-a8c2-2491d797da1f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_f39f9120-6a93-4b32-9630-8a2fab9d773d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_f39f9120-6a93-4b32-9630-8a2fab9d773d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_161f91e2-f6a6-4e2e-a3d1-8c99a1e03a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_161f91e2-f6a6-4e2e-a3d1-8c99a1e03a4a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_48b0c92c-bf66-408e-889f-67dfa4155789" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_48b0c92c-bf66-408e-889f-67dfa4155789" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_a077c40c-ae73-4394-b7ca-aee52462feac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_48b0c92c-bf66-408e-889f-67dfa4155789" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_a077c40c-ae73-4394-b7ca-aee52462feac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_a077c40c-ae73-4394-b7ca-aee52462feac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_a077c40c-ae73-4394-b7ca-aee52462feac" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_a077c40c-ae73-4394-b7ca-aee52462feac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_8c9d6df2-cbe2-4502-aa01-5e46a2f287ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_a077c40c-ae73-4394-b7ca-aee52462feac" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_8c9d6df2-cbe2-4502-aa01-5e46a2f287ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_3b420236-5822-4ca8-8db2-def2b7fe526b" xlink:href="cpix-20210331.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_8c9d6df2-cbe2-4502-aa01-5e46a2f287ef" xlink:to="loc_cpix_PinnacleBankMember_3b420236-5822-4ca8-8db2-def2b7fe526b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d4c9d5d9-8f52-4f46-b4db-fd812eae7c99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_48b0c92c-bf66-408e-889f-67dfa4155789" xlink:to="loc_us-gaap_DebtInstrumentAxis_d4c9d5d9-8f52-4f46-b4db-fd812eae7c99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d4c9d5d9-8f52-4f46-b4db-fd812eae7c99_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d4c9d5d9-8f52-4f46-b4db-fd812eae7c99" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d4c9d5d9-8f52-4f46-b4db-fd812eae7c99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c83007ea-7f4b-423e-8dbb-802723f8cada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d4c9d5d9-8f52-4f46-b4db-fd812eae7c99" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c83007ea-7f4b-423e-8dbb-802723f8cada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FourthAmendmentMember_91090cb0-c91f-4ab8-b301-aabc435e4334" xlink:href="cpix-20210331.xsd#cpix_FourthAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c83007ea-7f4b-423e-8dbb-802723f8cada" xlink:to="loc_cpix_FourthAmendmentMember_91090cb0-c91f-4ab8-b301-aabc435e4334" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_2beb14a3-6a44-4527-8c5d-c94ffbf1fdfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c83007ea-7f4b-423e-8dbb-802723f8cada" xlink:to="loc_us-gaap_LineOfCreditMember_2beb14a3-6a44-4527-8c5d-c94ffbf1fdfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_770cc267-3e4f-4ffe-bd76-5aefa37e5557" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_48b0c92c-bf66-408e-889f-67dfa4155789" xlink:to="loc_us-gaap_CreditFacilityAxis_770cc267-3e4f-4ffe-bd76-5aefa37e5557" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_770cc267-3e4f-4ffe-bd76-5aefa37e5557_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_770cc267-3e4f-4ffe-bd76-5aefa37e5557" xlink:to="loc_us-gaap_CreditFacilityDomain_770cc267-3e4f-4ffe-bd76-5aefa37e5557_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a28efcc3-50a0-4937-a75d-e6743ee58e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_770cc267-3e4f-4ffe-bd76-5aefa37e5557" xlink:to="loc_us-gaap_CreditFacilityDomain_a28efcc3-50a0-4937-a75d-e6743ee58e39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_8f15fe9e-6f82-436d-a845-51b09a475128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_a28efcc3-50a0-4937-a75d-e6743ee58e39" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_8f15fe9e-6f82-436d-a845-51b09a475128" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_df137318-903f-4bc1-86ea-25416cdf5109" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_48b0c92c-bf66-408e-889f-67dfa4155789" xlink:to="loc_srt_RangeAxis_df137318-903f-4bc1-86ea-25416cdf5109" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_df137318-903f-4bc1-86ea-25416cdf5109_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_df137318-903f-4bc1-86ea-25416cdf5109" xlink:to="loc_srt_RangeMember_df137318-903f-4bc1-86ea-25416cdf5109_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56f27e64-2e6a-47d5-abb7-d37a441b2b24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_df137318-903f-4bc1-86ea-25416cdf5109" xlink:to="loc_srt_RangeMember_56f27e64-2e6a-47d5-abb7-d37a441b2b24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c7664986-c887-4d99-ad03-b27393bd0071" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_56f27e64-2e6a-47d5-abb7-d37a441b2b24" xlink:to="loc_srt_MinimumMember_c7664986-c887-4d99-ad03-b27393bd0071" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b9b7051e-9e5e-48ba-addc-e322e366f68a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_56f27e64-2e6a-47d5-abb7-d37a441b2b24" xlink:to="loc_srt_MaximumMember_b9b7051e-9e5e-48ba-addc-e322e366f68a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_cc684317-7d0c-46d1-8991-9c3e3f9cf23a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_48b0c92c-bf66-408e-889f-67dfa4155789" xlink:to="loc_us-gaap_VariableRateAxis_cc684317-7d0c-46d1-8991-9c3e3f9cf23a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_cc684317-7d0c-46d1-8991-9c3e3f9cf23a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_cc684317-7d0c-46d1-8991-9c3e3f9cf23a" xlink:to="loc_us-gaap_VariableRateDomain_cc684317-7d0c-46d1-8991-9c3e3f9cf23a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_9c5b1832-2fce-4de7-bc5c-e8e3cf5a5cda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_cc684317-7d0c-46d1-8991-9c3e3f9cf23a" xlink:to="loc_us-gaap_VariableRateDomain_9c5b1832-2fce-4de7-bc5c-e8e3cf5a5cda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_605b38db-3052-4ff3-b42e-6e35c7e45ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_9c5b1832-2fce-4de7-bc5c-e8e3cf5a5cda" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_605b38db-3052-4ff3-b42e-6e35c7e45ab0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a756cfd9-7fe9-4049-981b-152383bde227" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_48b0c92c-bf66-408e-889f-67dfa4155789" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a756cfd9-7fe9-4049-981b-152383bde227" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a756cfd9-7fe9-4049-981b-152383bde227_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a756cfd9-7fe9-4049-981b-152383bde227" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a756cfd9-7fe9-4049-981b-152383bde227_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ba68ac51-08fe-4826-bf6d-040f77efa2f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a756cfd9-7fe9-4049-981b-152383bde227" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ba68ac51-08fe-4826-bf6d-040f77efa2f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_77c201c4-d989-4b35-9ce5-6fe57a291e3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ba68ac51-08fe-4826-bf6d-040f77efa2f6" xlink:to="loc_us-gaap_ConvertibleDebtMember_77c201c4-d989-4b35-9ce5-6fe57a291e3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_28999c23-52be-455f-89fd-c68d6a400b54" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_48b0c92c-bf66-408e-889f-67dfa4155789" xlink:to="loc_srt_CounterpartyNameAxis_28999c23-52be-455f-89fd-c68d6a400b54" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_28999c23-52be-455f-89fd-c68d6a400b54_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_28999c23-52be-455f-89fd-c68d6a400b54" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_28999c23-52be-455f-89fd-c68d6a400b54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6692345e-de0c-4b16-ab6d-03674ad90825" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_28999c23-52be-455f-89fd-c68d6a400b54" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6692345e-de0c-4b16-ab6d-03674ad90825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_f8a608b1-a4a7-4b88-8dc7-63f9f38687bb" xlink:href="cpix-20210331.xsd#cpix_WinHealthInvestmentSingaporeLtdDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6692345e-de0c-4b16-ab6d-03674ad90825" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_f8a608b1-a4a7-4b88-8dc7-63f9f38687bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20210331.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended" id="iba533a2e2fd44bd99cc407a37b9199fa_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20210331.xsd#IncomeTaxesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" id="i65b0ea0ff7f544f88dfd7c0081f48bf4_IncomeTaxesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_0ee50a66-1fc7-4ca5-989c-a61f369b6625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_fb47d8af-3982-4591-860c-9021a6428051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0ee50a66-1fc7-4ca5-989c-a61f369b6625" xlink:to="loc_us-gaap_OperatingLossCarryforwards_fb47d8af-3982-4591-860c-9021a6428051" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_9ca3611c-b646-48ed-a803-cb39da1ee307" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0ee50a66-1fc7-4ca5-989c-a61f369b6625" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_9ca3611c-b646-48ed-a803-cb39da1ee307" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d8390057-54c3-47f3-ba76-7f5ab507bb27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_9ca3611c-b646-48ed-a803-cb39da1ee307" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d8390057-54c3-47f3-ba76-7f5ab507bb27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d8390057-54c3-47f3-ba76-7f5ab507bb27_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d8390057-54c3-47f3-ba76-7f5ab507bb27" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d8390057-54c3-47f3-ba76-7f5ab507bb27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b9fd0288-d15e-4e04-9162-cf50e9803112" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d8390057-54c3-47f3-ba76-7f5ab507bb27" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b9fd0288-d15e-4e04-9162-cf50e9803112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_31b7b2aa-1c15-4672-a47b-b84ad13b6fe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b9fd0288-d15e-4e04-9162-cf50e9803112" xlink:to="loc_us-gaap_DomesticCountryMember_31b7b2aa-1c15-4672-a47b-b84ad13b6fe9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20210331.xsd#CollaborativeAgreements"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended" id="ide37f02f3dec495b951adbc9bc89d6e6_CollaborativeAgreements"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRights"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="extended" id="ia283a6647ab74ab2b8b20be08aea4a6b_AdditionsandReturnsofProductRights"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRightsTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="extended" id="i1503db1c8b844ceaad64775ae1021182_AdditionsandReturnsofProductRightsTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended" id="i6f2352ca92234a7caf91a49f4ee1d6d1_AdditionsandReturnsofProductRightsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_94e8868d-5bc8-4817-ac90-60c8442d961b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_94e8868d-5bc8-4817-ac90-60c8442d961b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_5b026b54-0a98-43c2-a5e6-18a4c6554dee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_5b026b54-0a98-43c2-a5e6-18a4c6554dee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_ab1bd4fc-ef33-43fe-bd07-5a299fa4d880" xlink:href="cpix-20210331.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_ab1bd4fc-ef33-43fe-bd07-5a299fa4d880" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8e6c45b3-08b6-436b-a34a-581e892c8735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8e6c45b3-08b6-436b-a34a-581e892c8735" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d3b001e4-9ee7-41d5-a23a-bcd989d75629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d3b001e4-9ee7-41d5-a23a-bcd989d75629" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1978df07-2737-4784-9de2-01bf328b4336" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1978df07-2737-4784-9de2-01bf328b4336" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fddd75dc-b566-4bb1-9d28-8f5883e3784c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fddd75dc-b566-4bb1-9d28-8f5883e3784c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b5241ea1-46a6-4404-89fe-cbc8b28efc4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b5241ea1-46a6-4404-89fe-cbc8b28efc4e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_b58b471c-d5b0-4ee3-a11f-ee052a9ab2b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_b58b471c-d5b0-4ee3-a11f-ee052a9ab2b6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_8a16a81e-3f06-493a-8e39-76cb4b7c7593" xlink:href="cpix-20210331.xsd#cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_8a16a81e-3f06-493a-8e39-76cb4b7c7593" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92b10567-f968-4998-9ca1-8f7689379617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92b10567-f968-4998-9ca1-8f7689379617" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7298b96d-c918-4712-8870-c3022498d6d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92b10567-f968-4998-9ca1-8f7689379617" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7298b96d-c918-4712-8870-c3022498d6d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7298b96d-c918-4712-8870-c3022498d6d7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7298b96d-c918-4712-8870-c3022498d6d7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7298b96d-c918-4712-8870-c3022498d6d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_211e500e-a488-4e52-97ef-3f74cf1f28b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7298b96d-c918-4712-8870-c3022498d6d7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_211e500e-a488-4e52-97ef-3f74cf1f28b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_11dc2c0d-6d41-424d-8753-5827f5916543" xlink:href="cpix-20210331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_211e500e-a488-4e52-97ef-3f74cf1f28b6" xlink:to="loc_cpix_VIBATIVMember_11dc2c0d-6d41-424d-8753-5827f5916543" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_70cf7c66-b6b8-4d4c-80f0-a75f2a04709c" xlink:href="cpix-20210331.xsd#cpix_MethotrexateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_211e500e-a488-4e52-97ef-3f74cf1f28b6" xlink:to="loc_cpix_MethotrexateMember_70cf7c66-b6b8-4d4c-80f0-a75f2a04709c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7e448f96-8270-4094-8602-8ff08c11cd52" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92b10567-f968-4998-9ca1-8f7689379617" xlink:to="loc_srt_CounterpartyNameAxis_7e448f96-8270-4094-8602-8ff08c11cd52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7e448f96-8270-4094-8602-8ff08c11cd52_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7e448f96-8270-4094-8602-8ff08c11cd52" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7e448f96-8270-4094-8602-8ff08c11cd52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_723a0317-4762-42fe-a118-e305e5be989f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7e448f96-8270-4094-8602-8ff08c11cd52" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_723a0317-4762-42fe-a118-e305e5be989f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_4fb6ce9c-29ed-4082-b8cb-b191ad89e1a3" xlink:href="cpix-20210331.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_723a0317-4762-42fe-a118-e305e5be989f" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_4fb6ce9c-29ed-4082-b8cb-b191ad89e1a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_66430851-6150-45e8-af4d-a5a0dc74d35b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92b10567-f968-4998-9ca1-8f7689379617" xlink:to="loc_srt_StatementScenarioAxis_66430851-6150-45e8-af4d-a5a0dc74d35b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_66430851-6150-45e8-af4d-a5a0dc74d35b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_66430851-6150-45e8-af4d-a5a0dc74d35b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_66430851-6150-45e8-af4d-a5a0dc74d35b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_cd71c5cd-229e-41fd-aaab-b08802345a05" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_66430851-6150-45e8-af4d-a5a0dc74d35b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_cd71c5cd-229e-41fd-aaab-b08802345a05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_800569de-98f4-4d56-90bb-4236d5bd1d16" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_cd71c5cd-229e-41fd-aaab-b08802345a05" xlink:to="loc_srt_ScenarioForecastMember_800569de-98f4-4d56-90bb-4236d5bd1d16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d7ed12a4-7a34-4193-870d-079f3cd49b1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92b10567-f968-4998-9ca1-8f7689379617" xlink:to="loc_us-gaap_AwardTypeAxis_d7ed12a4-7a34-4193-870d-079f3cd49b1f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7ed12a4-7a34-4193-870d-079f3cd49b1f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d7ed12a4-7a34-4193-870d-079f3cd49b1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7ed12a4-7a34-4193-870d-079f3cd49b1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54fbcf31-741c-456a-b4b5-858c7076e6ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d7ed12a4-7a34-4193-870d-079f3cd49b1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54fbcf31-741c-456a-b4b5-858c7076e6ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_442e2590-279e-45dd-8748-cd52e71c5f81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54fbcf31-741c-456a-b4b5-858c7076e6ae" xlink:to="loc_us-gaap_RestrictedStockMember_442e2590-279e-45dd-8748-cd52e71c5f81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_70a56af6-edaf-4976-a4af-6ebdea296e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92b10567-f968-4998-9ca1-8f7689379617" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_70a56af6-edaf-4976-a4af-6ebdea296e1e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_70a56af6-edaf-4976-a4af-6ebdea296e1e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_70a56af6-edaf-4976-a4af-6ebdea296e1e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_70a56af6-edaf-4976-a4af-6ebdea296e1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_19b61692-2e7a-41fa-b06c-b710cceb08e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_70a56af6-edaf-4976-a4af-6ebdea296e1e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_19b61692-2e7a-41fa-b06c-b710cceb08e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_0aee5e7a-29d6-41f8-8365-69adfae22736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_19b61692-2e7a-41fa-b06c-b710cceb08e5" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_0aee5e7a-29d6-41f8-8365-69adfae22736" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4e89e0f9-42ce-4e70-9722-19e04da1fdf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_19b61692-2e7a-41fa-b06c-b710cceb08e5" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4e89e0f9-42ce-4e70-9722-19e04da1fdf1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended" id="if18a79530bb24f1f893f2ebaf084735c_AdditionsandReturnsofProductRightsChangeinConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c51c216c-45d4-4b3a-9631-fd3db265c774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_65f88cd2-0956-4442-8f9b-f5765ad3ee22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c51c216c-45d4-4b3a-9631-fd3db265c774" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_65f88cd2-0956-4442-8f9b-f5765ad3ee22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d875a736-eadb-448a-964c-c6213531809f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_65f88cd2-0956-4442-8f9b-f5765ad3ee22" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d875a736-eadb-448a-964c-c6213531809f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_7a27f3a9-d5d6-4dd8-8444-dce480fed9f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_65f88cd2-0956-4442-8f9b-f5765ad3ee22" xlink:to="loc_us-gaap_PaymentsForRoyalties_7a27f3a9-d5d6-4dd8-8444-dce480fed9f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_008b0ab5-df21-4f82-a1ab-2baabdd75fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_65f88cd2-0956-4442-8f9b-f5765ad3ee22" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_008b0ab5-df21-4f82-a1ab-2baabdd75fb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_874fb218-dbc2-49a5-ac3d-f30552c35d70" xlink:href="cpix-20210331.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_65f88cd2-0956-4442-8f9b-f5765ad3ee22" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_874fb218-dbc2-49a5-ac3d-f30552c35d70" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_83deea32-2493-4366-a6e9-68ca15a199f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_068086ec-ed90-40fa-9a00-c8b23bb88bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c51c216c-45d4-4b3a-9631-fd3db265c774" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_068086ec-ed90-40fa-9a00-c8b23bb88bc2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7a582702-30dd-4e29-a3e7-e03e4b7b0cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_068086ec-ed90-40fa-9a00-c8b23bb88bc2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7a582702-30dd-4e29-a3e7-e03e4b7b0cf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a582702-30dd-4e29-a3e7-e03e4b7b0cf3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7a582702-30dd-4e29-a3e7-e03e4b7b0cf3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a582702-30dd-4e29-a3e7-e03e4b7b0cf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5f1c4a1-cb20-4aa3-8c05-0b32aad5a7a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7a582702-30dd-4e29-a3e7-e03e4b7b0cf3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5f1c4a1-cb20-4aa3-8c05-0b32aad5a7a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_efcb8821-b634-47af-aa44-ae05bbd6d060" xlink:href="cpix-20210331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5f1c4a1-cb20-4aa3-8c05-0b32aad5a7a7" xlink:to="loc_cpix_VIBATIVMember_efcb8821-b634-47af-aa44-ae05bbd6d060" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRightsDissolutionPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="extended" id="i1d877101cda94d5c92fd99ea1c6a00ca_AdditionsandReturnsofProductRightsDissolutionPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0655f401-28d1-4ead-b4e4-3bd5bdfcc0f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4583292a-46a3-4adf-927b-6a8772e1b225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0655f401-28d1-4ead-b4e4-3bd5bdfcc0f1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4583292a-46a3-4adf-927b-6a8772e1b225" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ac4d4fed-5589-4f3e-a85d-59b1695eecd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0655f401-28d1-4ead-b4e4-3bd5bdfcc0f1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ac4d4fed-5589-4f3e-a85d-59b1695eecd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_7ff987fb-adcb-4942-8d64-61628d27ceb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0655f401-28d1-4ead-b4e4-3bd5bdfcc0f1" xlink:to="loc_us-gaap_SellingAndMarketingExpense_7ff987fb-adcb-4942-8d64-61628d27ceb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_38dbb864-ec51-4054-821d-76c9b574d84b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0655f401-28d1-4ead-b4e4-3bd5bdfcc0f1" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_38dbb864-ec51-4054-821d-76c9b574d84b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a74a5b80-d474-4dcf-99bc-17b403efcfdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0655f401-28d1-4ead-b4e4-3bd5bdfcc0f1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a74a5b80-d474-4dcf-99bc-17b403efcfdc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_43189edc-2763-4796-98d5-abedd01fdb15" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a74a5b80-d474-4dcf-99bc-17b403efcfdc" xlink:to="loc_srt_CounterpartyNameAxis_43189edc-2763-4796-98d5-abedd01fdb15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_43189edc-2763-4796-98d5-abedd01fdb15_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_43189edc-2763-4796-98d5-abedd01fdb15" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_43189edc-2763-4796-98d5-abedd01fdb15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0c0570d-a9a4-47ba-9bcf-9ae52184f640" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_43189edc-2763-4796-98d5-abedd01fdb15" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0c0570d-a9a4-47ba-9bcf-9ae52184f640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_11bc6b8c-736e-4073-82f7-c816f7715464" xlink:href="cpix-20210331.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0c0570d-a9a4-47ba-9bcf-9ae52184f640" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_11bc6b8c-736e-4073-82f7-c816f7715464" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>cpix-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:04e28feb-0224-48c2-9aed-5419303ac6e2,g:7c5adb88-3a13-4fc9-bea7-995fc46bc2d7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3ff4fcaa-3723-4f15-8e48-a5b4f254b2ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock granted in period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_bc7f771f-5955-4b6b-ba26-f1155dd9c677_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_34051ac5-9c3d-470c-abcd-63b5716a5bdf_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IfetrobanClinicalMember_d1aa2be2-a2e1-48bf-a843-b5ddc40109aa_terseLabel_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_label_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical [Member]</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_documentation_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember" xlink:href="cpix-20210331.xsd#cpix_IfetrobanClinicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IfetrobanClinicalMember" xlink:to="lab_cpix_IfetrobanClinicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_02aec03a-e14d-4c56-a2ed-36ec8d265015_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After 2023</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Three</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:href="cpix-20210331.xsd#cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:to="lab_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_2e62a6ed-ad0f-47b1-8382-f7af7e4d6d0c_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_95802b81-560d-4e7f-b078-7042f4c39a30_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_f495883a-ca19-477a-a92b-f07886107d80_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_58ccf777-090b-4191-a697-3034fda87fe5_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_b93b251a-ae96-4b34-a668-40e4e051233b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_82af8dd8-92d1-4bf4-a983-1d28f12e5507_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_5883e57b-5870-4073-bb86-2e46a10748e8_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_ae3a3403-e879-402f-96ca-4c1f5ed3f29e_negatedTerseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_documentation_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:href="cpix-20210331.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:to="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_562c20d7-1318-451d-97e0-16302d21eec2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_59e75b55-8371-4d92-b2b4-a9357b2de77f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_22b7635c-7e8f-4ef5-bdd1-3973e26354f8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_adde947b-5f33-4c56-9b8c-cee3af1e322c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_6e251cb0-3840-4b45-85d9-cda8c8eebb8e_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_a5a93797-aed1-4825-bcb4-0819c4d58f99_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_b641e9ce-da11-4b38-8ea4-9be168d0ed7b_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_bca7376a-e927-49ca-a196-e04fef1fe7f9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments on line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_3a934339-df84-4e88-bb01-3b9fb324dadb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AcetadoteMember_c2160737-ede7-4c07-9bdd-40f93a3bdf88_terseLabel_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:label id="lab_cpix_AcetadoteMember_label_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote [Member]</link:label>
    <link:label id="lab_cpix_AcetadoteMember_documentation_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember" xlink:href="cpix-20210331.xsd#cpix_AcetadoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AcetadoteMember" xlink:to="lab_cpix_AcetadoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NumeratorAbstract_38182b1c-4959-4cf6-adbe-ce7f18d6ad15_verboseLabel_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_label_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_documentation_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract" xlink:href="cpix-20210331.xsd#cpix_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NumeratorAbstract" xlink:to="lab_cpix_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_ebb09c54-998f-42bf-9a43-a1b3bbfe9b60_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0d99b7aa-408e-4949-ba86-81f6d07d4491_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_8bbfae3e-250f-4bbd-9a9a-3f6d1941aad9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_a5283fb8-087d-4f47-a592-5525681b3e1c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_989b870e-be6b-4120-a92b-9139cfc69e88_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (income) loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6e978f02-af0e-4645-bce7-fc8c4f380f86_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_06bfcf47-df4c-4630-9ab6-b0abf06fae18_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8b1dc302-f308-4f00-b7e4-c99501a9355c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_e9954f90-b7d4-4b36-8f4c-658840d0789a_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f4f1a356-aa55-481f-be7f-037226b04c4b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33333ad0-a391-4ba7-9a70-6e10225e11b3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9343947a-6e3c-4d98-91ce-79db675de8ca_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS' EQUITY AND DEBT</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLifeInsurancePolicies_0aa8a776-4afb-4af9-b663-dd666c542916_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable investment funding</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLifeInsurancePolicies_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Life Insurance Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:to="lab_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_bb92ba32-ed77-4333-b4ba-11552bfac9ab_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9a37b810-dff4-4aca-bf32-b134d00746cc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9a9f6f3b-d945-4861-a6ca-1c4f00ece29b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_ea06fa6e-dc6c-4d49-9350-c3663280ee36_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_2876a94a-3df0-4c54-ba94-984f9eade206_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductsAbstract_a6850061-826b-4363-9af7-3c8bad11c212_verboseLabel_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products:</link:label>
    <link:label id="lab_cpix_ProductsAbstract_label_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products [Abstract]</link:label>
    <link:label id="lab_cpix_ProductsAbstract_documentation_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract" xlink:href="cpix-20210331.xsd#cpix_ProductsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductsAbstract" xlink:to="lab_cpix_ProductsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_95e84223-4340-45c8-a14f-64dae9dfea61_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of remaining lease payments, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_c5896a0a-b252-479a-b7be-10b5d60a7f44_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_5ec908f8-0a6e-4726-9e06-d08343e693eb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities from continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_08384fd8-09dd-4600-a5a0-249075f329b8_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cc5fc13a-a13f-497d-8ce8-75c84e3a1a68_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_47a0b387-0919-43e3-9028-4c2fc5c694e8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_ef4a1daa-a94f-4404-bc33-d5930797681f_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_cc296bde-9c60-413a-832d-fb13e4d53f2b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ea9b33fc-fe0a-4032-a33f-55706045195c_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_43ac7960-eaff-49b9-a87d-7c8ea5571108_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f269c3c3-16bc-4429-9f62-ed861accf322_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration included in operating expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_738b3ddd-a6ef-4a03-95eb-116f57fd3113_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e184a7bb-c772-45cb-8ec4-cb71f5807d51_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_cf59ea23-bb76-45ba-bf38-ba1e158977e7_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VIBATIVMember_e0f2d1a3-2ee3-4739-975a-39f5fc35a5cc_terseLabel_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:label id="lab_cpix_VIBATIVMember_label_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV [Member]</link:label>
    <link:label id="lab_cpix_VIBATIVMember_documentation_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember" xlink:href="cpix-20210331.xsd#cpix_VIBATIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VIBATIVMember" xlink:to="lab_cpix_VIBATIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_23187ddb-9032-44c8-a00a-00dc01b5a139_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_28a90bc1-8ec3-4155-bc7e-72717f6546ad_terseLabel_en-US" xlink:label="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration received in exchange for product license rights, installment payments</link:label>
    <link:label id="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_label_en-US" xlink:label="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets, Installment Payment</link:label>
    <link:label id="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_documentation_en-US" xlink:label="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets, Installment Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:href="cpix-20210331.xsd#cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:to="lab_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_d36cd67a-218d-45df-8d25-5dd61c449b7f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b01c5d12-57b1-4a13-991c-72da984427a7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c898089e-1f6c-49fb-9032-e005383d1de7_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_8c23cd05-ff43-434a-a58f-768efa270771_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_48d4c2de-0c6d-46f4-a86a-1eeaa8c7b015_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DenominatorAbstract_a207806a-e525-414a-bf70-1b9ee0504640_verboseLabel_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_label_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_documentation_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract" xlink:href="cpix-20210331.xsd#cpix_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DenominatorAbstract" xlink:to="lab_cpix_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_c82efbbc-0db1-4e90-af97-087ba2dc98a7_terseLabel_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen</link:label>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_label_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen Healthcare Limited [Member]</link:label>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_documentation_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen Healthcare Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember" xlink:href="cpix-20210331.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ClinigenHealthcareLimitedMember" xlink:to="lab_cpix_ClinigenHealthcareLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d988062d-ac42-4c64-bb46-845b23e1d28e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_6a2b3cd2-d45f-4cf4-a362-3a8383ee144a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward" xlink:to="lab_us-gaap_LossContingencyAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c0d20633-952b-42d5-a414-ca847bc746d5_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_91643a99-9b80-44e9-a9b3-5d5ba49e2325_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense, Sublease Rentals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5e9b80ff-f39a-4799-965a-1a528776b69a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_93fbfbbd-3229-4f9f-bf5f-062aa135ec41_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_187602dc-a6b5-42ab-8c12-d9d2bdd6da16_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_37717eb2-e537-4d1d-9f73-a9f335403682_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration received in exchange for product license rights</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_43cca6ef-c585-4bc1-aabc-01db787bab6a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_02d0e3a5-99ec-42e9-8242-0f7eda0325f5_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_38b05afc-c6d6-4ad7-bdfc-b0b4b04cce23_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_76e69dad-acdc-43e5-a4a6-f3a6b03107b8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LeaseLiability_e91bf47c-a95e-4d1e-8303-033122793df4_terseLabel_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_cpix_LeaseLiability_label_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_cpix_LeaseLiability_documentation_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability" xlink:href="cpix-20210331.xsd#cpix_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LeaseLiability" xlink:to="lab_cpix_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_bdc37451-5cac-4f12-9a8d-75ca3625e0be_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherProductsMember_5e7f8891-f4e8-43af-937b-cb1f9f251ed3_terseLabel_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_cpix_OtherProductsMember_label_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_cpix_OtherProductsMember_documentation_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember" xlink:href="cpix-20210331.xsd#cpix_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherProductsMember" xlink:to="lab_cpix_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_70a1d444-33b7-4148-b5ca-d1577a30e6cf_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_396f6962-04d3-48b7-a846-58acdbc65083_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_b9a3c5e1-08f3-42c5-873f-135512ef6462_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories classified as current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3cbc1e46-541e-4bc3-acad-f7e3eadd54c2_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_76b464da-defd-4f9a-93e8-7b7a5f9e4877_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_ed621299-1299-414c-ad18-6bf7d811ed7c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_753b41a9-0c79-4a42-8e0f-50f91894a5b4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_47bc728b-6307-4ae6-8c8c-cc50770fbf32_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6a05fefc-5233-4bd4-a171-6c658b22e91c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VaprisolMember_e5caf665-2790-4178-a77c-ed86c83ece63_terseLabel_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:label id="lab_cpix_VaprisolMember_label_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:label id="lab_cpix_VaprisolMember_documentation_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember" xlink:href="cpix-20210331.xsd#cpix_VaprisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VaprisolMember" xlink:to="lab_cpix_VaprisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_d18ed7b5-9bae-457f-9dc1-ccd99490764d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_63e86fd0-ade8-476a-be55-2b06b712445b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_7bded178-e395-4e9c-b93b-ce0384a21dc5_verboseLabel_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_label_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_documentation_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract" xlink:href="cpix-20210331.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract" xlink:to="lab_cpix_ShareholdersEquityTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_2d63da1e-dd2a-47ae-9501-125129baff98_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_60573388-0e2c-4f32-b46f-a926bc6ab8e0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_f9a573be-4c04-46dd-839f-9d816a4ee880_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_67873902-1adb-4988-aa56-9844a0b0c0d5_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0f649b0d-0ff4-44a6-8f96-eb5dc5fab56e_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_de3c2069-64f7-4916-a0d1-27581177fa24_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_9aef703b-3317-4129-8395-f3a627647a26_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_1657cb43-64cc-4590-8f48-8e5c7d708dac_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_684f8b01-f44d-4d20-af10-1aaed8e7a5b1_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_88f6e7c2-751b-42d3-98ed-cccf3527491d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_a2732d37-dbe8-4c2d-98aa-e48dd5d6cd05_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_057bfabe-8d2e-4f7e-bf56-2adcfaf29aad_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_290c7449-061f-4f08-8243-9c528f2ba1bb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_7e49e1a4-cc8e-4b63-b10e-648e672298ed_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_b7c3302a-ac5f-40a6-a2ae-31c0c736b9e7_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_b4a65e2f-7c49-45c4-892c-7a570d70fb0e_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, Marketing and other</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_b25a1151-1517-49cc-a0ef-ac3e32747c86_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total capacity</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:href="cpix-20210331.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:to="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_119c481e-5ccb-48fe-b656-61d96610388c_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncentiveStockOptionsMember_c80f4fff-63da-4b28-b4cc-84bacf06827f_terseLabel_en-US" xlink:label="lab_cpix_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:label id="lab_cpix_IncentiveStockOptionsMember_label_en-US" xlink:label="lab_cpix_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options [Member]</link:label>
    <link:label id="lab_cpix_IncentiveStockOptionsMember_documentation_en-US" xlink:label="lab_cpix_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncentiveStockOptionsMember" xlink:href="cpix-20210331.xsd#cpix_IncentiveStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncentiveStockOptionsMember" xlink:to="lab_cpix_IncentiveStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNoParValue_9ce3a1e3-243f-4ab7-b0c4-0c1eebf407d8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_e03b0fe0-8700-41e6-b6a5-59071ff7845b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_966ca416-539e-436e-a87c-362f3698c5a9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_e508004a-9b07-4e74-afce-a7c2d2266d0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Dissolution Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8e77dea3-0b45-45aa-92a7-f0400822ecf3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_6069111a-9d3f-4f23-a15c-894ac1cc15b6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obsolescence and discontinuance losses</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OmeclamoxPakMember_0cdf9b55-4f2d-4663-ac48-b6edd3040d22_terseLabel_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vibativ</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_label_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_documentation_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember" xlink:href="cpix-20210331.xsd#cpix_OmeclamoxPakMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OmeclamoxPakMember" xlink:to="lab_cpix_OmeclamoxPakMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_5acabefc-b9c7-4cb2-9aa2-a7e5250103b6_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_1c533226-da50-40b6-ae52-289dac1c07ee_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_da938eaa-08ca-4654-b229-a679649c153d_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_c5deca55-cbd0-4067-bed7-39d10f5e2575_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_85df2a62-3758-464b-bfdc-7cdfd17c921b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_9bafae3e-9a0a-4089-8459-744b7cc17db8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Lease Liabilities at March 31, 2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_99b43f21-bca6-4841-8911-e665eddd9b59_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_561f9b20-c109-4e10-af61-50db69a2c9d2_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b1ae43a3-a12e-4fd4-9ca4-50898fd5c490_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_32c47311-88f7-4a8e-8a89-6325ea74aa6c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of numerator and denominator</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_80872e8d-ff7f-48a0-b5d2-84b3b783274d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of royalty during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fd684aaf-cad1-4ab2-a243-ca88ae24b7e8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d5c931a1-73bc-4dae-a1e1-15a67a0ac9c4_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_00a39030-0431-4b98-ab7b-bacd145cf25e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_6f88d4c1-fd50-4598-ac50-cfd4b46cbc56_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_8e2a72f3-b726-4455-bceb-9d61a310d75d_terseLabel_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount</link:label>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_label_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_documentation_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:href="cpix-20210331.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:to="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_332d58f2-268e-4299-b2a6-919f5aa1fe88_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATIVE AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cd838d0f-c4ea-469b-b329-ef46ed9a1c65_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_99087140-28ed-429d-a45a-2fe412cc77ff_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2f186407-c007-451a-8a22-232be8c78829_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RediTrexMember_955924e7-0b28-43fe-98da-67c6123286c6_terseLabel_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex</link:label>
    <link:label id="lab_cpix_RediTrexMember_label_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex [Member]</link:label>
    <link:label id="lab_cpix_RediTrexMember_documentation_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember" xlink:href="cpix-20210331.xsd#cpix_RediTrexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RediTrexMember" xlink:to="lab_cpix_RediTrexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_9a49bf9f-b46a-4976-8336-c14cc9cf0a9f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c69c225a-8861-43e2-832a-f767f10dbaed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_e0ee76f6-19a3-49a1-9442-9a34617b60eb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_02f1d195-6739-44b8-8801-59b14cb6cbc1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_df58b7ee-e48a-4131-9bd4-ef8cc008e74f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_1fd144ca-b4f2-4538-9ba4-929f684bb170_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_1aad78c9-f4e2-4073-9d77-7b1b1681e03c_terseLabel_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of tiered royalty payments (up to)</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_label_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_documentation_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:href="cpix-20210331.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:to="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_6fc3ef98-1014-478c-bb93-2a60eeda950b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_5d2213fa-d952-47a9-be68-6760b2aa58a9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ab2db2de-7a9c-4a60-b841-5682b09f1506_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_33888e06-a44d-4a00-b345-58b753b7f6ac_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_060484a2-4ae5-42b1-b497-817e274aa1c7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_19f9cce5-1bb1-429c-b78b-ac154078e50a_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bd9ad90d-868d-477d-98c4-c8c3cc64e2a5_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for purchase through restricted stock awards and options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_04b578e3-97ec-49b5-8158-d2445030d23d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PinnacleBankMember_36cf60d2-d104-44fd-bc2c-5ae3f420ca0b_terseLabel_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_label_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_documentation_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember" xlink:href="cpix-20210331.xsd#cpix_PinnacleBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PinnacleBankMember" xlink:to="lab_cpix_PinnacleBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9a810a5d-02a8-418d-88c3-327382d5817a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of other securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_8563d3e5-d5e5-4fa8-add9-d3660ca4b643_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_36b3373c-bc73-4c43-bdfc-cfd4c3cd17e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of net revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_04dd7477-f753-4377-848a-b50d94011850_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested common stock, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_9c90c4de-8c0e-473c-b7b4-041ced812e8f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_973af53b-a938-48d6-a9ee-b3081c8f865f_verboseLabel_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_label_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_documentation_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:href="cpix-20210331.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:to="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d9652f73-7e67-4343-a717-2394c34e9cdf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KristaloseMember_fd2b3b19-ff4c-4b88-8627-8f5e7346944e_terseLabel_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:label id="lab_cpix_KristaloseMember_label_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose [Member]</link:label>
    <link:label id="lab_cpix_KristaloseMember_documentation_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember" xlink:href="cpix-20210331.xsd#cpix_KristaloseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KristaloseMember" xlink:to="lab_cpix_KristaloseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3c00d54a-274f-49ec-a1f6-e72ef667bd23_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7d3c73ef-fb52-4b87-80ca-5252b5222b08_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7a04bb24-e7d7-48d8-9a12-aeb33101983f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_79077f14-8c54-4726-8fbe-b8f7ec484006_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_156b9ae2-f4b5-48a5-9810-c04cb9b70734_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b4226246-7eea-4b8c-b968-6896d3114e24_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_edf78caf-b0d1-4556-b79d-5acd625c3b53_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d9c41cf0-23b0-4d17-aa67-0e59dbdc7e9c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities affecting operating activities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_9d5840f2-8358-48c0-a4b8-417e559b2d29_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_adf20e44-dc9e-4fab-9b84-10bda9d46a03_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_abf7e821-0e36-4ed7-9089-7628a4d2e04f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_73661c51-07e3-4335-9853-1f3874d9ddc0_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_ed04e17c-ba59-477d-83a3-d71c6b524eaf_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_ecc5321d-003f-458b-9589-a43d9e421c0b_terseLabel_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Position</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cpix-20210331.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_911e4e81-2c7a-436d-bb40-6cd9941248d1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_069ef888-fb07-443d-9c80-46660463ec41_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_69b9e1b8-a440-48d5-a72d-265e4f6fa4b2_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_d072e3e0-08f9-4481-9a9e-fa63f5f1d80b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_0acbfa05-4948-4d14-92e6-428ba1f769cf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consigned inventory</link:label>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_label_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_43ceb916-a0c6-4597-ae3f-1535e7aeda7f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_8194f9fc-ad80-4533-8e61-4afc7be1f4c5_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_86b3d993-3b47-4841-8962-fae21bcb220b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_07a11d98-e6ae-4b21-96d6-63d58a3e5d9d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_10365eaa-3a57-424f-a1e6-3c385a61fb22_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_4a2442af-b449-4b7e-a5a8-63523bfe0743_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_f8c76884-50da-49ee-ace3-c49c82c0b0b8_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7c414aa9-83ab-45ca-bda7-4b45804dd64b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_54fdb4cc-5c58-4f89-a172-aee823664da7_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_1b7b1a8f-5c8d-4ff6-b81d-82b53c32e687_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_abf3ee6e-3ad1-4afe-b829-c298afeeb05a_terseLabel_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:href="cpix-20210331.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:to="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_1da9d327-ce36-4594-9acb-581fb577e625_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c388c88d-7472-4c25-b903-fe667c2600eb_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_cb2fbcc8-d49a-4f5c-a569-3a405a1bc5d5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_838b6cfe-5bcb-4683-9520-00d840e790b4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_22279cbb-0802-4f89-8a3e-7c0f358f2e4e_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d88ce3d5-3c44-40a0-be28-63342079544a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9514fab3-e38e-4744-ae2a-c5677b712e2a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_69e8d377-5321-4399-93f3-eff9d2c08326_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_a219b7bd-c923-4842-8a78-4f963a00fe1a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of subsidiary shares from noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_e17a36e1-6c5d-4ab4-8292-b27484b27127_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_0622f3e1-6799-4bb7-bea7-d42332b2fde3_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_3b31b972-5e31-4903-bff9-9f08653fd6e8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_680d0b8d-1c19-4324-824c-30a551ec6820_negatedLabel_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in non-cash contingent consideration</link:label>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:to="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_dd31c04c-75fa-4892-9c31-d0bcdb525f16_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_8bec4364-a24b-447a-af9f-b675e33a416e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_69e08e0e-1c2c-4bb0-b41d-7d0c1e8af3d0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate spread</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_fe6f9730-b069-488d-8959-159a19d526f5_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross, Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FourthAmendmentMember_bf7d192a-0a50-4e92-9a86-4a318ec22df6_terseLabel_en-US" xlink:label="lab_cpix_FourthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fourth Amendment</link:label>
    <link:label id="lab_cpix_FourthAmendmentMember_label_en-US" xlink:label="lab_cpix_FourthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fourth Amendment [Member]</link:label>
    <link:label id="lab_cpix_FourthAmendmentMember_documentation_en-US" xlink:label="lab_cpix_FourthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fourth Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FourthAmendmentMember" xlink:href="cpix-20210331.xsd#cpix_FourthAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FourthAmendmentMember" xlink:to="lab_cpix_FourthAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_005d7925-5fca-4c21-8e4b-22321c3cf38c_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_677e3d26-cd7a-4df2-9acc-308516732d94_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_51c4a6c1-01a4-4d47-a01f-4c7dd2902d09_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_d188777e-6b5f-4810-ad97-bbe491d480f8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADDITIONS AND RETURN OF PRODUCT RIGHTS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_ea16ebeb-3f3f-4cf8-9ab8-57259549ec45_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum sublease income under noncancelable operating subleases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_86bbbeb9-6c25-46e3-b223-56f5f1da4059_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_524fd61f-d7bf-412c-bbcf-d897ab424716_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c5cf6c69-1d45-46c0-ad17-fa3ea0f6c73b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b2d1f9a4-6775-4b0d-b15c-a151e6072ddc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_81daa2b1-b73b-4d8d-a290-1f788d35496f_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a03507b9-14bb-4a7e-b75d-22b2e2a258e7_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6b374e49-145c-4723-8359-e52e72f25847_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0cc50825-7498-4abb-b5c3-93ef5cdcf7d1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_4e683066-be48-4a79-9113-0c786f711f75_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_af7cb552-b16b-4c15-be99-15875e4ad800_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial investment in joint ventures</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1ef85b36-19ac-455f-9c3f-521d73db0f1b_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_9c0f3c3a-c13a-4723-bc65-8dc8bf8ff6fa_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_526d0709-045a-4a14-8e0d-36f785ad60f2_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_11b549a3-630f-4f44-a76d-e89e38136ea5_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration earned and accrued in operating expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:href="cpix-20210331.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_MethotrexateMember_f9c4aa9a-a735-452c-82f1-fd68745921f8_terseLabel_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate</link:label>
    <link:label id="lab_cpix_MethotrexateMember_label_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:label id="lab_cpix_MethotrexateMember_documentation_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember" xlink:href="cpix-20210331.xsd#cpix_MethotrexateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_MethotrexateMember" xlink:to="lab_cpix_MethotrexateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_947d0b29-b044-4d51-b273-c4d0102e53ca_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6cefb56c-acdd-4099-90ba-ed9b275ffd78_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_340019cf-de97-49a8-9a07-c85d43352a15_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_f6c38cae-4aed-4fd0-9910-0caf5b7b37d1_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_42742880-5754-4b56-a8f2-f0b497d6da49_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability recorded</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5003c6a3-c9fb-4ec5-89d6-73124049b18e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8f73e22f-e459-4d7c-9cb8-2705810b3e9c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3c18441c-e57e-47c9-ae23-edb9f538f517_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_3c501ac9-a010-4b08-8023-11bdb35f7a2d_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4f40d500-782c-4d69-9b5c-3608b4a852d7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7a6ca042-582f-4d78-a670-2811548bcb07_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_cc6d6a52-2a09-4454-9652-d407618fda7b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_60e2ddaf-e66d-4f04-9c94-378091c13c7e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_5d526a53-fef4-49e7-92c5-1619bb27e74c_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_e3066eaa-a36e-4bce-91c1-27eec128687e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to acquire business upon closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_05c8f0bf-c55e-40d2-96b4-7782e6316770_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_faced6a7-5b99-4844-acf1-974cd4cdb1f0_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8aec1602-04b7-4659-8044-3e7d0889a34e_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_3cc5ba70-5199-44f8-8dd1-d77c5ba24723_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5b603e5e-5157-4a46-aed1-58374cd1be6d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3096f53e-e7d9-44ff-ad11-b0ed224e6a1f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_709554ed-47ff-4aa9-a4ca-496f16d62bb7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_90e7f656-9699-4b32-af39-d45971653ec8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f280d89d-ff8c-420f-b424-9f9517ae6ad0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EquityAndDebtAbstract_label_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:label id="lab_cpix_EquityAndDebtAbstract_documentation_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract" xlink:href="cpix-20210331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EquityAndDebtAbstract" xlink:to="lab_cpix_EquityAndDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_db00c9e5-d4ef-4eaa-b52f-2607621bdf90_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_bfabc549-0124-4652-8ccf-9a567fa52fd3_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_3fe507ae-b51c-49d3-ad14-8eadd36967ad_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase amount (up to)</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:href="cpix-20210331.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:to="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_cd8b9814-90f9-416b-9306-5e3d6dd638e5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_5d51c7ef-47a1-45d9-b3b0-31e88d67b677_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_0040eea7-462b-43b0-b998-f0cf551689de_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_d86f7af2-1f83-4889-ab27-ae7d5bcf870a_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e38f8afc-1ce6-4efd-9471-da741383003d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_0b577514-f5be-4702-aaa2-558baeb73e1c_verboseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncreaseDecreaseInCurrentOperatingLiabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:href="cpix-20210331.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:to="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a379a802-3097-40e8-b877-04ab5e3abee1_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_718cbbd8-2fb3-4b33-b600-85f3e33aaf74_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_9de22074-f505-4c2a-bf8e-75ea3057a919_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_82761585-a96e-4096-9732-7a3e1a130bb5_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_7e0b5136-fc15-47a3-b11d-0bafbaebc5ff_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_1205b2c3-026a-4445-abaf-c19e9cec9c28_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_d952238c-2fd1-48fc-8857-9df7dc2ab068_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7d4e5bd8-3f21-443d-a56f-06a46249b684_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_d51d1e34-726a-4019-a5a4-f95b4f77b507_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_1324adad-3d6e-4e72-9b9e-bfd3faf0d515_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_376e7ecc-4160-42e9-ad4e-0795893108b9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9dfe6307-9dc4-4aed-8eeb-940b13d9f11c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_6be7c4d6-9579-43d1-b67e-bd837e84d246_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_27f8b14e-4037-48bd-8c07-b305c9ce76c2_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase outstanding common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e26d7f5-dffd-456e-8298-ea510182f725_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_fec52cf5-0536-4f44-bab5-f92715591a34_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_e64b9c7f-3b52-4a72-b9a9-d2d7e8c1aa30_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_ed26105f-2f02-467f-9b0b-c793eba8a735_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12732a7c-5e6c-4bd7-81d9-e231bc86a7f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_84f8f6ee-4503-4bcb-9f40-855de7aa03c4_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_24959dfa-a7ce-4254-aa31-5bb1e942369d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5951a61e-469f-4c20-af53-a2ef5f4b37ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_d93ae63e-422a-4fe6-baa6-22cb4a89bdcb_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_1d7bd4ff-9d9a-415f-b42d-f916fcde20a7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_f55857ed-93bc-4cc1-ad79-ed8760b039c1_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_cb9bd545-a3be-44bf-95b8-7f744d19ee44_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_86b04fe5-86b3-4f2a-ad73-b2198a4c6d3b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CaldolorMember_f7c8872c-2dee-4c32-b15c-ce71762a67bb_terseLabel_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_CaldolorMember_label_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor [Member]</link:label>
    <link:label id="lab_cpix_CaldolorMember_documentation_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember" xlink:href="cpix-20210331.xsd#cpix_CaldolorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CaldolorMember" xlink:to="lab_cpix_CaldolorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_d0a1875e-2851-4bd0-81a5-73c3e914c9f8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_8c7bab4f-a397-46bf-a1fb-d6eb2d47ad51_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdDomain_45753ca3-c2fd-4a89-b7a6-d3ea308f11c0_terseLabel_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdDomain_label_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd [Domain]</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdDomain_documentation_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:href="cpix-20210331.xsd#cpix_WinHealthInvestmentSingaporeLtdDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:to="lab_cpix_WinHealthInvestmentSingaporeLtdDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_df47e57a-f6f1-497b-9eb1-27cd977e5423_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_f792c486-793d-44a2-a531-4228a7695525_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net, Items Net of Reserve Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:to="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1a7e9a61-eda1-4c81-b590-79378c97e48a_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d8694530-e8bc-4ebb-a88a-ef1986a76220_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_71f8e772-7b0e-4be4-b714-7a1b4a176413_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, sale of corporate securities (up to)</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:href="cpix-20210331.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:to="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_9f6f018b-83e1-4ccb-9ebc-674f4d50cdb9_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_fc8e054c-4d8d-4803-8c87-c135c61baee1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_90b07c5f-0586-4125-8e3e-075d5505f9de_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>cpix-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:04e28feb-0224-48c2-9aed-5419303ac6e2,g:7c5adb88-3a13-4fc9-bea7-995fc46bc2d7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20210331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9d09c023-ecb3-4cb4-8974-dba9abdd116e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_DocumentType_9d09c023-ecb3-4cb4-8974-dba9abdd116e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_45df8f10-e1dc-4eea-a382-fce560523a0f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_DocumentQuarterlyReport_45df8f10-e1dc-4eea-a382-fce560523a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_30011632-a64c-4e0a-9824-2dc1cb104e3f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_DocumentPeriodEndDate_30011632-a64c-4e0a-9824-2dc1cb104e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1a9fc0ef-9045-4e0d-85c1-629324e0483a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_DocumentTransitionReport_1a9fc0ef-9045-4e0d-85c1-629324e0483a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3cf4dd8c-bdc4-44ab-9bf1-cdda3aef8b8d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_EntityFileNumber_3cf4dd8c-bdc4-44ab-9bf1-cdda3aef8b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9f0ca36b-296b-48d9-b68c-517cc8fba4d9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_EntityRegistrantName_9f0ca36b-296b-48d9-b68c-517cc8fba4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f88a3dec-65be-431c-b8b1-513f607ba4aa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_EntityCentralIndexKey_f88a3dec-65be-431c-b8b1-513f607ba4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f2a3b215-0f29-4c6a-a359-e3f239cae6c3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_CurrentFiscalYearEndDate_f2a3b215-0f29-4c6a-a359-e3f239cae6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_8a121049-cdbe-4922-b044-0a1aecb9781f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_DocumentFiscalYearFocus_8a121049-cdbe-4922-b044-0a1aecb9781f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_46fb0f10-302b-4310-8ba4-08af54688170" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_DocumentFiscalPeriodFocus_46fb0f10-302b-4310-8ba4-08af54688170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_cc9b88c2-1863-43bf-aa0c-5e1de2624d9b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_AmendmentFlag_cc9b88c2-1863-43bf-aa0c-5e1de2624d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a958448d-d824-4c93-85b1-ceed8a931639" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a958448d-d824-4c93-85b1-ceed8a931639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_50468a9d-5426-42c2-9846-e3313ad1cb03" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_EntityTaxIdentificationNumber_50468a9d-5426-42c2-9846-e3313ad1cb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8a2cdbca-adf0-47a2-8633-47cceb7c4b79" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_EntityAddressAddressLine1_8a2cdbca-adf0-47a2-8633-47cceb7c4b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_4f164196-2c0c-4c36-bcdc-4c035850d09e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_EntityAddressAddressLine2_4f164196-2c0c-4c36-bcdc-4c035850d09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_dbccb77a-2576-4d09-9717-74b1107a304f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_EntityAddressCityOrTown_dbccb77a-2576-4d09-9717-74b1107a304f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_82acbad4-3002-44bf-8ff0-c68040380639" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_EntityAddressStateOrProvince_82acbad4-3002-44bf-8ff0-c68040380639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0808a824-ba0b-4de1-b92c-7b2c89092930" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_EntityAddressPostalZipCode_0808a824-ba0b-4de1-b92c-7b2c89092930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_67b00cdc-83a1-4ffa-a562-7f4634c86407" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_CityAreaCode_67b00cdc-83a1-4ffa-a562-7f4634c86407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bb108a53-af49-4fb1-a8e9-2292a7bdec54" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_LocalPhoneNumber_bb108a53-af49-4fb1-a8e9-2292a7bdec54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2ec484c1-46b4-49b3-840f-7db3f86dcbb7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_EntityCurrentReportingStatus_2ec484c1-46b4-49b3-840f-7db3f86dcbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_4356365b-6160-4926-8a27-0e8e24f72279" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_EntityInteractiveDataCurrent_4356365b-6160-4926-8a27-0e8e24f72279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_8a24d478-9cc1-4313-a7f1-bf70bc1f0e03" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_EntityFilerCategory_8a24d478-9cc1-4313-a7f1-bf70bc1f0e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_0a3511b5-12c7-491f-8f73-c42169290a5d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_EntitySmallBusiness_0a3511b5-12c7-491f-8f73-c42169290a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2cbd0423-aba2-4ab3-8ba1-f7a5e05dfc97" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_EntityEmergingGrowthCompany_2cbd0423-aba2-4ab3-8ba1-f7a5e05dfc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2bcb159b-ab18-4569-b4ac-c878733bcce4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_EntityShellCompany_2bcb159b-ab18-4569-b4ac-c878733bcce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3f95679f-3cbe-4e79-8612-4fe31a89a3e3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3f95679f-3cbe-4e79-8612-4fe31a89a3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7814e27b-ae4d-4f5d-815d-db27bacc77de" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_Security12bTitle_7814e27b-ae4d-4f5d-815d-db27bacc77de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_40c64aca-ffa7-4c38-9792-46abd73a360c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_TradingSymbol_40c64aca-ffa7-4c38-9792-46abd73a360c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5e4948d6-e94e-4b14-a681-90d42e3add60" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_dd1dfab7-7c05-49e1-8d63-a1de8428bc92" xlink:to="loc_dei_SecurityExchangeName_5e4948d6-e94e-4b14-a681-90d42e3add60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4c7ad5d5-d48e-48b7-a4af-c7232644bbcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3b5eb4ae-f350-45e4-ac56-f8ac4758dc74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4c7ad5d5-d48e-48b7-a4af-c7232644bbcc" xlink:to="loc_us-gaap_AssetsAbstract_3b5eb4ae-f350-45e4-ac56-f8ac4758dc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7a8c1b29-2260-4d80-b752-62662090ce88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b5eb4ae-f350-45e4-ac56-f8ac4758dc74" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7a8c1b29-2260-4d80-b752-62662090ce88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5811ca3-053e-406e-8174-5f1266d1fff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7a8c1b29-2260-4d80-b752-62662090ce88" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5811ca3-053e-406e-8174-5f1266d1fff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_256fa6bb-0a25-4872-9922-927f4dfcc528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7a8c1b29-2260-4d80-b752-62662090ce88" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_256fa6bb-0a25-4872-9922-927f4dfcc528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d834adbb-3a60-4ccf-9df5-c59ea64ecc20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7a8c1b29-2260-4d80-b752-62662090ce88" xlink:to="loc_us-gaap_InventoryNet_d834adbb-3a60-4ccf-9df5-c59ea64ecc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_cebb8050-868e-4ff2-9d23-7bddc2eb2cda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7a8c1b29-2260-4d80-b752-62662090ce88" xlink:to="loc_us-gaap_OtherAssetsCurrent_cebb8050-868e-4ff2-9d23-7bddc2eb2cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_743158b4-c052-4cea-ba45-f783069edcb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7a8c1b29-2260-4d80-b752-62662090ce88" xlink:to="loc_us-gaap_AssetsCurrent_743158b4-c052-4cea-ba45-f783069edcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_65499365-b1a8-4aac-8538-53ef5eedf20f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b5eb4ae-f350-45e4-ac56-f8ac4758dc74" xlink:to="loc_us-gaap_InventoryNoncurrent_65499365-b1a8-4aac-8538-53ef5eedf20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_39770ae1-d1cb-4e06-b7aa-3bef75124e59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b5eb4ae-f350-45e4-ac56-f8ac4758dc74" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_39770ae1-d1cb-4e06-b7aa-3bef75124e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f8787d23-86b4-456d-9db9-e00a4fadf385" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b5eb4ae-f350-45e4-ac56-f8ac4758dc74" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f8787d23-86b4-456d-9db9-e00a4fadf385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_92945aca-af32-4f0a-9474-2402304d0e6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b5eb4ae-f350-45e4-ac56-f8ac4758dc74" xlink:to="loc_us-gaap_Goodwill_92945aca-af32-4f0a-9474-2402304d0e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_881036d5-9650-4c52-ba21-d15af3691a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b5eb4ae-f350-45e4-ac56-f8ac4758dc74" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_881036d5-9650-4c52-ba21-d15af3691a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f24e480d-483f-4a2f-adc4-970929be4b98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b5eb4ae-f350-45e4-ac56-f8ac4758dc74" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f24e480d-483f-4a2f-adc4-970929be4b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_25940297-6cf5-44cc-a05a-006b3f93c559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3b5eb4ae-f350-45e4-ac56-f8ac4758dc74" xlink:to="loc_us-gaap_Assets_25940297-6cf5-44cc-a05a-006b3f93c559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_92911951-9f62-4946-bc6e-313371c126df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4c7ad5d5-d48e-48b7-a4af-c7232644bbcc" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_92911951-9f62-4946-bc6e-313371c126df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9a9d4e78-3cb9-428b-a576-21c49595ea4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_92911951-9f62-4946-bc6e-313371c126df" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9a9d4e78-3cb9-428b-a576-21c49595ea4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_00411fe4-938d-4169-80ad-020f6ef1fb5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9a9d4e78-3cb9-428b-a576-21c49595ea4d" xlink:to="loc_us-gaap_AccountsPayableCurrent_00411fe4-938d-4169-80ad-020f6ef1fb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c8bd83a6-b542-4430-a94e-79ebb44a30a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9a9d4e78-3cb9-428b-a576-21c49595ea4d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c8bd83a6-b542-4430-a94e-79ebb44a30a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b966ed64-e80e-429d-8fd5-8af4be73eb75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9a9d4e78-3cb9-428b-a576-21c49595ea4d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b966ed64-e80e-429d-8fd5-8af4be73eb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8e403118-66b6-453f-b3e4-1b9c45fcff1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9a9d4e78-3cb9-428b-a576-21c49595ea4d" xlink:to="loc_us-gaap_LiabilitiesCurrent_8e403118-66b6-453f-b3e4-1b9c45fcff1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_e29996ae-535c-4245-affc-a30ce3043c67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_92911951-9f62-4946-bc6e-313371c126df" xlink:to="loc_us-gaap_LongTermLineOfCredit_e29996ae-535c-4245-affc-a30ce3043c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0c1dabfa-1b9d-4e7d-a1b2-8375b44c90c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_92911951-9f62-4946-bc6e-313371c126df" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0c1dabfa-1b9d-4e7d-a1b2-8375b44c90c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_004b6248-0cc7-48c0-81ea-fbd5eea13bdb" xlink:href="cpix-20210331.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_92911951-9f62-4946-bc6e-313371c126df" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_004b6248-0cc7-48c0-81ea-fbd5eea13bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1aa703f2-92a1-497b-b1a7-c9caa8d7ac88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_92911951-9f62-4946-bc6e-313371c126df" xlink:to="loc_us-gaap_Liabilities_1aa703f2-92a1-497b-b1a7-c9caa8d7ac88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6924bf40-2293-4543-a6d7-422f102c985c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_92911951-9f62-4946-bc6e-313371c126df" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6924bf40-2293-4543-a6d7-422f102c985c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_817e7a44-7e3a-4127-a308-dd8a1864cd55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_92911951-9f62-4946-bc6e-313371c126df" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_817e7a44-7e3a-4127-a308-dd8a1864cd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_214a25a6-9596-47c8-931a-977668b829d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_817e7a44-7e3a-4127-a308-dd8a1864cd55" xlink:to="loc_us-gaap_StockholdersEquityAbstract_214a25a6-9596-47c8-931a-977668b829d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a7a7e6e2-6eb7-4be0-a5a0-0639adac8a93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_214a25a6-9596-47c8-931a-977668b829d1" xlink:to="loc_us-gaap_CommonStockValue_a7a7e6e2-6eb7-4be0-a5a0-0639adac8a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_492846ac-7306-4dc3-b519-54536ede8331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_214a25a6-9596-47c8-931a-977668b829d1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_492846ac-7306-4dc3-b519-54536ede8331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0b899e40-ba30-415b-b921-d383825c1d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_214a25a6-9596-47c8-931a-977668b829d1" xlink:to="loc_us-gaap_StockholdersEquity_0b899e40-ba30-415b-b921-d383825c1d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_db71987e-0091-45d8-91e5-883ddbb0f816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_817e7a44-7e3a-4127-a308-dd8a1864cd55" xlink:to="loc_us-gaap_MinorityInterest_db71987e-0091-45d8-91e5-883ddbb0f816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8e329e62-d5c7-49f5-95c7-e522c717f65e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_817e7a44-7e3a-4127-a308-dd8a1864cd55" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8e329e62-d5c7-49f5-95c7-e522c717f65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_382ca4c4-c27a-4094-b7ff-3f56ea3b9635" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_92911951-9f62-4946-bc6e-313371c126df" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_382ca4c4-c27a-4094-b7ff-3f56ea3b9635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6619093e-0af9-4ba0-8b1e-56c3973904c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue_14990543-7054-4035-9944-5647cfda983f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6619093e-0af9-4ba0-8b1e-56c3973904c4" xlink:to="loc_us-gaap_CommonStockNoParValue_14990543-7054-4035-9944-5647cfda983f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ec189566-8f81-47e5-b89c-f6987afd925f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6619093e-0af9-4ba0-8b1e-56c3973904c4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ec189566-8f81-47e5-b89c-f6987afd925f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4171e87d-2e65-48ca-9bca-4a66deaca595" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6619093e-0af9-4ba0-8b1e-56c3973904c4" xlink:to="loc_us-gaap_CommonStockSharesIssued_4171e87d-2e65-48ca-9bca-4a66deaca595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_edc95a70-14dc-4faf-a94f-770002a53363" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6619093e-0af9-4ba0-8b1e-56c3973904c4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_edc95a70-14dc-4faf-a94f-770002a53363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_556a1e50-57d3-4d60-9fac-5556a8824725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a1d110b-f9ae-4cff-8e31-beee0921c474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_556a1e50-57d3-4d60-9fac-5556a8824725" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a1d110b-f9ae-4cff-8e31-beee0921c474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_4f1d79d5-4931-4791-9690-6ce6cbef9c3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_556a1e50-57d3-4d60-9fac-5556a8824725" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_4f1d79d5-4931-4791-9690-6ce6cbef9c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2c08bdfe-265b-45f9-ab70-4ff0fda78229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4f1d79d5-4931-4791-9690-6ce6cbef9c3a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2c08bdfe-265b-45f9-ab70-4ff0fda78229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_a23a41c7-2a2f-42ae-9e9f-2e9b0f382dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4f1d79d5-4931-4791-9690-6ce6cbef9c3a" xlink:to="loc_us-gaap_SellingAndMarketingExpense_a23a41c7-2a2f-42ae-9e9f-2e9b0f382dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_67c271d4-8617-45c9-891b-8c5d58e8ffad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4f1d79d5-4931-4791-9690-6ce6cbef9c3a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_67c271d4-8617-45c9-891b-8c5d58e8ffad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d83b5a44-20f1-42e4-bc25-aeb1612b74fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4f1d79d5-4931-4791-9690-6ce6cbef9c3a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d83b5a44-20f1-42e4-bc25-aeb1612b74fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_a53064cc-0cab-469a-aaa9-0b43980a6318" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4f1d79d5-4931-4791-9690-6ce6cbef9c3a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_a53064cc-0cab-469a-aaa9-0b43980a6318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3f59eb53-69a3-4946-be17-07a0b50a3d65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4f1d79d5-4931-4791-9690-6ce6cbef9c3a" xlink:to="loc_us-gaap_CostsAndExpenses_3f59eb53-69a3-4946-be17-07a0b50a3d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_695de014-f2d6-4729-9a30-b6a2b67f5fa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4f1d79d5-4931-4791-9690-6ce6cbef9c3a" xlink:to="loc_us-gaap_OperatingIncomeLoss_695de014-f2d6-4729-9a30-b6a2b67f5fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_28891756-4c0b-4d76-a75f-9d2724132a9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_556a1e50-57d3-4d60-9fac-5556a8824725" xlink:to="loc_us-gaap_InvestmentIncomeInterest_28891756-4c0b-4d76-a75f-9d2724132a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_53e97b26-c4a5-44cd-b2a4-ba73f18c713f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_556a1e50-57d3-4d60-9fac-5556a8824725" xlink:to="loc_us-gaap_InterestExpense_53e97b26-c4a5-44cd-b2a4-ba73f18c713f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_73bbe269-803a-4030-9666-15e7b0f33c71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_556a1e50-57d3-4d60-9fac-5556a8824725" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_73bbe269-803a-4030-9666-15e7b0f33c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_09185b6a-c56d-45f0-987f-4a4f70c3488d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_556a1e50-57d3-4d60-9fac-5556a8824725" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_09185b6a-c56d-45f0-987f-4a4f70c3488d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_3f184242-85f3-45f0-935f-d876d2388250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_556a1e50-57d3-4d60-9fac-5556a8824725" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_3f184242-85f3-45f0-935f-d876d2388250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a438c8c6-41bb-4f58-9b86-3dafdd23825e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_556a1e50-57d3-4d60-9fac-5556a8824725" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a438c8c6-41bb-4f58-9b86-3dafdd23825e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_845112b6-eadb-4b2b-9f4c-ae62ca471d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_556a1e50-57d3-4d60-9fac-5556a8824725" xlink:to="loc_us-gaap_ProfitLoss_845112b6-eadb-4b2b-9f4c-ae62ca471d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fb103f9c-9acd-43e0-b84f-d69141e9142e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_556a1e50-57d3-4d60-9fac-5556a8824725" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fb103f9c-9acd-43e0-b84f-d69141e9142e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_96ce724d-b75f-4203-8d3b-284d7fe4dd35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_556a1e50-57d3-4d60-9fac-5556a8824725" xlink:to="loc_us-gaap_NetIncomeLoss_96ce724d-b75f-4203-8d3b-284d7fe4dd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_55714394-c1b9-4835-9cc8-35ebd4390266" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_556a1e50-57d3-4d60-9fac-5556a8824725" xlink:to="loc_us-gaap_EarningsPerShareAbstract_55714394-c1b9-4835-9cc8-35ebd4390266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0c254722-7854-4a8f-9f7e-e31c3f16bff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_55714394-c1b9-4835-9cc8-35ebd4390266" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0c254722-7854-4a8f-9f7e-e31c3f16bff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_be9980d2-755e-4ae2-9539-02fa76026df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_55714394-c1b9-4835-9cc8-35ebd4390266" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_be9980d2-755e-4ae2-9539-02fa76026df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_fe2e9353-5bcc-45c4-93b3-ee4b6f0e84fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_55714394-c1b9-4835-9cc8-35ebd4390266" xlink:to="loc_us-gaap_EarningsPerShareBasic_fe2e9353-5bcc-45c4-93b3-ee4b6f0e84fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_cb5b67e2-4167-43fe-b149-675685a9e935" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_55714394-c1b9-4835-9cc8-35ebd4390266" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_cb5b67e2-4167-43fe-b149-675685a9e935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_8f929d46-0124-4727-a151-941cadb25aca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_55714394-c1b9-4835-9cc8-35ebd4390266" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_8f929d46-0124-4727-a151-941cadb25aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f55f932f-cd84-4d46-a9d2-612fc82a0d4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_55714394-c1b9-4835-9cc8-35ebd4390266" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f55f932f-cd84-4d46-a9d2-612fc82a0d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_02b58a35-8ea4-41e7-adc6-6abeb08a434d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_556a1e50-57d3-4d60-9fac-5556a8824725" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_02b58a35-8ea4-41e7-adc6-6abeb08a434d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2b086ff9-466d-4c39-8000-27ee97dd3d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_02b58a35-8ea4-41e7-adc6-6abeb08a434d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2b086ff9-466d-4c39-8000-27ee97dd3d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e569c15a-0af7-4b70-a92d-eacd3a56216c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_02b58a35-8ea4-41e7-adc6-6abeb08a434d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e569c15a-0af7-4b70-a92d-eacd3a56216c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_dd01b8bd-bcb2-45a5-a14b-947bbddbfbfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a2d63dd0-a01e-47be-89f4-36f3a84da942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd01b8bd-bcb2-45a5-a14b-947bbddbfbfc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a2d63dd0-a01e-47be-89f4-36f3a84da942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0c091c30-9a85-478f-bd4d-2def1050f4da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a2d63dd0-a01e-47be-89f4-36f3a84da942" xlink:to="loc_us-gaap_ProfitLoss_0c091c30-9a85-478f-bd4d-2def1050f4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_34a74e5e-a351-4461-b8c4-8281e9980643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a2d63dd0-a01e-47be-89f4-36f3a84da942" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_34a74e5e-a351-4461-b8c4-8281e9980643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6d0486a4-28dd-4ef1-b80b-3ea8f3fb2a3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a2d63dd0-a01e-47be-89f4-36f3a84da942" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6d0486a4-28dd-4ef1-b80b-3ea8f3fb2a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb4b8f7c-22dd-4212-b777-a05359709c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a2d63dd0-a01e-47be-89f4-36f3a84da942" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb4b8f7c-22dd-4212-b777-a05359709c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_85b30a18-f761-48d0-a6d8-298d13fa6f91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb4b8f7c-22dd-4212-b777-a05359709c7d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_85b30a18-f761-48d0-a6d8-298d13fa6f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_308fc13e-fbf5-428d-94da-974808317048" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb4b8f7c-22dd-4212-b777-a05359709c7d" xlink:to="loc_us-gaap_ShareBasedCompensation_308fc13e-fbf5-428d-94da-974808317048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_12cf3c42-8165-4d24-9d10-254cb72a40de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb4b8f7c-22dd-4212-b777-a05359709c7d" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_12cf3c42-8165-4d24-9d10-254cb72a40de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_6c35af4e-02d1-444e-8045-f0f086987dcc" xlink:href="cpix-20210331.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb4b8f7c-22dd-4212-b777-a05359709c7d" xlink:to="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_6c35af4e-02d1-444e-8045-f0f086987dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_5ba4e524-2de1-4796-8bf5-25bd446b7a42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb4b8f7c-22dd-4212-b777-a05359709c7d" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_5ba4e524-2de1-4796-8bf5-25bd446b7a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cfd548bd-99d6-4eb1-b671-f4a8bbe54ecd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb4b8f7c-22dd-4212-b777-a05359709c7d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cfd548bd-99d6-4eb1-b671-f4a8bbe54ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2f8a4296-2cb6-45b4-9a34-a32778820251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cfd548bd-99d6-4eb1-b671-f4a8bbe54ecd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2f8a4296-2cb6-45b4-9a34-a32778820251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_37c25da2-9a50-4f68-97e0-c86bab1d5d18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cfd548bd-99d6-4eb1-b671-f4a8bbe54ecd" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_37c25da2-9a50-4f68-97e0-c86bab1d5d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_bf96a885-14e6-426c-a550-d40d53a8a06a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cfd548bd-99d6-4eb1-b671-f4a8bbe54ecd" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_bf96a885-14e6-426c-a550-d40d53a8a06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_61e9ba20-3e18-4a45-97b3-e0697402f65a" xlink:href="cpix-20210331.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cfd548bd-99d6-4eb1-b671-f4a8bbe54ecd" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_61e9ba20-3e18-4a45-97b3-e0697402f65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_534e68c1-563c-46f1-b71e-c80575c57907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cfd548bd-99d6-4eb1-b671-f4a8bbe54ecd" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_534e68c1-563c-46f1-b71e-c80575c57907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_bc128b78-4417-40fe-a6e7-6dafbcc214a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a2d63dd0-a01e-47be-89f4-36f3a84da942" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_bc128b78-4417-40fe-a6e7-6dafbcc214a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_33a10881-62a3-4aef-924b-1a929d442084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a2d63dd0-a01e-47be-89f4-36f3a84da942" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_33a10881-62a3-4aef-924b-1a929d442084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e422821c-ec1a-4240-8204-15850e233c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a2d63dd0-a01e-47be-89f4-36f3a84da942" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e422821c-ec1a-4240-8204-15850e233c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_422402c3-c438-4c02-ac77-23fd63111c3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd01b8bd-bcb2-45a5-a14b-947bbddbfbfc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_422402c3-c438-4c02-ac77-23fd63111c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_979ff6a4-e61e-48e5-8cbe-5def092b74a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_422402c3-c438-4c02-ac77-23fd63111c3b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_979ff6a4-e61e-48e5-8cbe-5def092b74a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies_8237ff93-e0ca-4458-a512-7aa15da1cf0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_422402c3-c438-4c02-ac77-23fd63111c3b" xlink:to="loc_us-gaap_ProceedsFromLifeInsurancePolicies_8237ff93-e0ca-4458-a512-7aa15da1cf0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_08a39551-b35b-4c24-8dd1-dd84d07a856e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_422402c3-c438-4c02-ac77-23fd63111c3b" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_08a39551-b35b-4c24-8dd1-dd84d07a856e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58b634da-128a-435f-b190-e1efabaa19ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_422402c3-c438-4c02-ac77-23fd63111c3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58b634da-128a-435f-b190-e1efabaa19ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97824a75-0bb7-4f80-ae94-ab37a9c467eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd01b8bd-bcb2-45a5-a14b-947bbddbfbfc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97824a75-0bb7-4f80-ae94-ab37a9c467eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_2ab57b91-b885-4d60-9335-3c5cb64ac69f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97824a75-0bb7-4f80-ae94-ab37a9c467eb" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_2ab57b91-b885-4d60-9335-3c5cb64ac69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_2f86ac73-bbaa-4f6f-9bd6-4b917d5bc7fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97824a75-0bb7-4f80-ae94-ab37a9c467eb" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_2f86ac73-bbaa-4f6f-9bd6-4b917d5bc7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_16d8b7fd-d899-49d2-849d-04581f87ce1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97824a75-0bb7-4f80-ae94-ab37a9c467eb" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_16d8b7fd-d899-49d2-849d-04581f87ce1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_bc1e057e-d58d-4fcf-9459-ec0cc7ff35c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97824a75-0bb7-4f80-ae94-ab37a9c467eb" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_bc1e057e-d58d-4fcf-9459-ec0cc7ff35c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b8330646-18ad-4bd6-b6e0-a1f68b760ee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97824a75-0bb7-4f80-ae94-ab37a9c467eb" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b8330646-18ad-4bd6-b6e0-a1f68b760ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22e5c0a1-e16e-45d7-8217-72397f10a970" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97824a75-0bb7-4f80-ae94-ab37a9c467eb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22e5c0a1-e16e-45d7-8217-72397f10a970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f5018b66-46d2-4a23-b25c-5ce78c95ae9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97824a75-0bb7-4f80-ae94-ab37a9c467eb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f5018b66-46d2-4a23-b25c-5ce78c95ae9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2ab4fd15-327a-4df0-88e7-603544de8994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97824a75-0bb7-4f80-ae94-ab37a9c467eb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2ab4fd15-327a-4df0-88e7-603544de8994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_af20bd83-170c-4f61-947c-f7c1c47a4984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97824a75-0bb7-4f80-ae94-ab37a9c467eb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_af20bd83-170c-4f61-947c-f7c1c47a4984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8001d982-74e2-4464-a462-9db90b9b88af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b57b44b7-d275-48a8-af92-61faee925605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8001d982-74e2-4464-a462-9db90b9b88af" xlink:to="loc_us-gaap_StatementTable_b57b44b7-d275-48a8-af92-61faee925605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_002ce15b-18a2-484b-98da-8b6c45aed706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b57b44b7-d275-48a8-af92-61faee925605" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_002ce15b-18a2-484b-98da-8b6c45aed706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d885839c-e242-4a07-bb1a-d8062dc33f62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_002ce15b-18a2-484b-98da-8b6c45aed706" xlink:to="loc_us-gaap_EquityComponentDomain_d885839c-e242-4a07-bb1a-d8062dc33f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e6871133-535a-4ac0-aa33-7e46a02bd62e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d885839c-e242-4a07-bb1a-d8062dc33f62" xlink:to="loc_us-gaap_CommonStockMember_e6871133-535a-4ac0-aa33-7e46a02bd62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d0c2609a-b26e-4434-b134-6d99eb91e015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d885839c-e242-4a07-bb1a-d8062dc33f62" xlink:to="loc_us-gaap_RetainedEarningsMember_d0c2609a-b26e-4434-b134-6d99eb91e015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_64607e1a-c59d-4d7d-9bce-e88cc98741e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d885839c-e242-4a07-bb1a-d8062dc33f62" xlink:to="loc_us-gaap_NoncontrollingInterestMember_64607e1a-c59d-4d7d-9bce-e88cc98741e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bffb47d7-4b39-4310-a4c9-6c23392b1db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b57b44b7-d275-48a8-af92-61faee925605" xlink:to="loc_us-gaap_StatementLineItems_bffb47d7-4b39-4310-a4c9-6c23392b1db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bffb47d7-4b39-4310-a4c9-6c23392b1db9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fa2cd4e0-f00e-4305-b3db-845904e34b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fa2cd4e0-f00e-4305-b3db-845904e34b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6f5eae8e-60b7-4afe-a4a2-bc909d1e0026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6f5eae8e-60b7-4afe-a4a2-bc909d1e0026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_25709565-a4c8-4ee3-be2d-f14c4086cff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_25709565-a4c8-4ee3-be2d-f14c4086cff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c98b10cf-71cf-4ed1-b53f-69ba7867a85d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c98b10cf-71cf-4ed1-b53f-69ba7867a85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_2a1fdc8e-34e1-4cfd-838b-76ec0f372523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_2a1fdc8e-34e1-4cfd-838b-76ec0f372523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_525a8c6f-41e7-481b-a534-855ec8c5188e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_525a8c6f-41e7-481b-a534-855ec8c5188e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_32316b37-d4c0-41f4-8e8d-a54dfd5454bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:to="loc_us-gaap_ProfitLoss_32316b37-d4c0-41f4-8e8d-a54dfd5454bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_034806c0-e016-4008-a85e-8ddf2c041a17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_034806c0-e016-4008-a85e-8ddf2c041a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e8146191-1313-4383-b239-a19189df4008" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8da9a368-9523-4486-9a56-ec35fd412ba0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e8146191-1313-4383-b239-a19189df4008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20210331.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f2b87f7a-5641-4b7d-b212-9d4d2fbdaa8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_299a6857-39da-49b4-b0e6-0d5ba6c2f285" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f2b87f7a-5641-4b7d-b212-9d4d2fbdaa8c" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_299a6857-39da-49b4-b0e6-0d5ba6c2f285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20210331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_504930d5-8b55-47ba-aad2-0b0bc25a509f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9a7cf929-8170-43ee-bfda-3cc348e915f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_504930d5-8b55-47ba-aad2-0b0bc25a509f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9a7cf929-8170-43ee-bfda-3cc348e915f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_4e8fb75f-5665-4903-88de-4cc4787406c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_504930d5-8b55-47ba-aad2-0b0bc25a509f" xlink:to="loc_us-gaap_UseOfEstimates_4e8fb75f-5665-4903-88de-4cc4787406c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6e03cd34-a835-48ec-b4fe-787a7aeb6a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_504930d5-8b55-47ba-aad2-0b0bc25a509f" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6e03cd34-a835-48ec-b4fe-787a7aeb6a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_699f7bc1-3da6-47e3-b220-0b18f116eb8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_58b270dd-2fab-4f62-b3de-ed9d7252ae88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_699f7bc1-3da6-47e3-b220-0b18f116eb8c" xlink:to="loc_us-gaap_NumberOfOperatingSegments_58b270dd-2fab-4f62-b3de-ed9d7252ae88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20210331.xsd#EarningsLossPerShare"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_35cc20d7-fcd5-4031-8f5f-a1eca5a4e7c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_ce92439a-fc54-4fc4-817e-d8d8c2a22e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_35cc20d7-fcd5-4031-8f5f-a1eca5a4e7c3" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_ce92439a-fc54-4fc4-817e-d8d8c2a22e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#EarningsLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_273afd63-51b3-4eb1-be8d-05fc6c1f50e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_43db81ba-d657-4c74-9760-6940cf26d651" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_273afd63-51b3-4eb1-be8d-05fc6c1f50e9" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_43db81ba-d657-4c74-9760-6940cf26d651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#EarningsLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_92a974e0-fae6-4cf1-9d2f-45063722416e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract_2a250deb-d08a-4722-9d9f-65d639b5fb89" xlink:href="cpix-20210331.xsd#cpix_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_92a974e0-fae6-4cf1-9d2f-45063722416e" xlink:to="loc_cpix_NumeratorAbstract_2a250deb-d08a-4722-9d9f-65d639b5fb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f9f245d0-830e-4061-9f54-54ded385341e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_2a250deb-d08a-4722-9d9f-65d639b5fb89" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f9f245d0-830e-4061-9f54-54ded385341e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_aea05c78-6b33-4cd3-8bd8-99ace80f10ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_2a250deb-d08a-4722-9d9f-65d639b5fb89" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_aea05c78-6b33-4cd3-8bd8-99ace80f10ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6050fd1b-60a6-407c-86cb-9c61f7a996c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_2a250deb-d08a-4722-9d9f-65d639b5fb89" xlink:to="loc_us-gaap_ProfitLoss_6050fd1b-60a6-407c-86cb-9c61f7a996c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0016a813-eb21-4bee-a432-efa3066a0866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_2a250deb-d08a-4722-9d9f-65d639b5fb89" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0016a813-eb21-4bee-a432-efa3066a0866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_37e971db-dc5d-43fc-ae6f-f51f1aeee660" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_2a250deb-d08a-4722-9d9f-65d639b5fb89" xlink:to="loc_us-gaap_NetIncomeLoss_37e971db-dc5d-43fc-ae6f-f51f1aeee660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract_3f3d2651-ce32-41f9-9a50-1877d732998a" xlink:href="cpix-20210331.xsd#cpix_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_92a974e0-fae6-4cf1-9d2f-45063722416e" xlink:to="loc_cpix_DenominatorAbstract_3f3d2651-ce32-41f9-9a50-1877d732998a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f5d0c43e-a52e-448e-a782-b14d5522d1ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_3f3d2651-ce32-41f9-9a50-1877d732998a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f5d0c43e-a52e-448e-a782-b14d5522d1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0589cdc8-f8e2-4747-8e28-23856d1881a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_3f3d2651-ce32-41f9-9a50-1877d732998a" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0589cdc8-f8e2-4747-8e28-23856d1881a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7096d22d-19c7-486e-bbec-68fb17642bbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_3f3d2651-ce32-41f9-9a50-1877d732998a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7096d22d-19c7-486e-bbec-68fb17642bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20210331.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e1e00ad9-9f87-44e3-91ed-0ec6f5e82c49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_63d769b6-3282-4bbf-afa6-c2c9450c9dab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e1e00ad9-9f87-44e3-91ed-0ec6f5e82c49" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_63d769b6-3282-4bbf-afa6-c2c9450c9dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20210331.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_98bf3bff-4926-484c-8915-256ee6082cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1014b277-f69c-4492-83a0-116cef438d44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_98bf3bff-4926-484c-8915-256ee6082cb4" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1014b277-f69c-4492-83a0-116cef438d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_cfaff1d1-beaf-4ac2-870a-8405207680b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_431ec3b6-e0cc-46d8-8d2a-3becfdeacb08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cfaff1d1-beaf-4ac2-870a-8405207680b7" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_431ec3b6-e0cc-46d8-8d2a-3becfdeacb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#RevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c7e4b8f9-9abe-419e-b541-cb5ed20c6b13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c4063708-1b42-48c6-b721-9b4cd8632a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c7e4b8f9-9abe-419e-b541-cb5ed20c6b13" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c4063708-1b42-48c6-b721-9b4cd8632a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2532944f-4728-46c5-ac04-a4c1ca41605a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c4063708-1b42-48c6-b721-9b4cd8632a19" xlink:to="loc_srt_ProductOrServiceAxis_2532944f-4728-46c5-ac04-a4c1ca41605a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2532944f-4728-46c5-ac04-a4c1ca41605a" xlink:to="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_c597ee33-bc11-4280-83ab-7e1ca5628577" xlink:href="cpix-20210331.xsd#cpix_AcetadoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:to="loc_cpix_AcetadoteMember_c597ee33-bc11-4280-83ab-7e1ca5628577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_5bee534f-f361-43e7-b7ba-ecd1bf39eb63" xlink:href="cpix-20210331.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:to="loc_cpix_OmeclamoxPakMember_5bee534f-f361-43e7-b7ba-ecd1bf39eb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_0e9747d8-7424-4744-a63c-748621da5d3d" xlink:href="cpix-20210331.xsd#cpix_KristaloseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:to="loc_cpix_KristaloseMember_0e9747d8-7424-4744-a63c-748621da5d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_07a1c994-45f9-49f0-811e-d8d67f8222b6" xlink:href="cpix-20210331.xsd#cpix_VaprisolMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:to="loc_cpix_VaprisolMember_07a1c994-45f9-49f0-811e-d8d67f8222b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_12aaa9f2-2f64-4461-a738-5a624cb30de9" xlink:href="cpix-20210331.xsd#cpix_CaldolorMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:to="loc_cpix_CaldolorMember_12aaa9f2-2f64-4461-a738-5a624cb30de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_67aa69c0-0081-41a9-a911-17537672c1e8" xlink:href="cpix-20210331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:to="loc_cpix_VIBATIVMember_67aa69c0-0081-41a9-a911-17537672c1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember_bc386de5-3305-4061-b976-305ce28d5ff2" xlink:href="cpix-20210331.xsd#cpix_RediTrexMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:to="loc_cpix_RediTrexMember_bc386de5-3305-4061-b976-305ce28d5ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_6007e412-0f37-4aed-bdd7-0c4377572c2d" xlink:href="cpix-20210331.xsd#cpix_OtherProductsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:to="loc_cpix_OtherProductsMember_6007e412-0f37-4aed-bdd7-0c4377572c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_61fd03bc-1084-4326-ac2a-cd1d60f9abd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a01e603-9bf9-4c01-b8bb-c5096dd45008" xlink:to="loc_us-gaap_GrantMember_61fd03bc-1084-4326-ac2a-cd1d60f9abd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9b7f2c61-45aa-4682-bcf7-3b3556ad86de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_c4063708-1b42-48c6-b721-9b4cd8632a19" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9b7f2c61-45aa-4682-bcf7-3b3556ad86de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7dd7f84e-9fe1-435f-9b69-9943921d2972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9b7f2c61-45aa-4682-bcf7-3b3556ad86de" xlink:to="loc_us-gaap_RevenuesAbstract_7dd7f84e-9fe1-435f-9b69-9943921d2972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_bc5c370a-bcc3-49c5-a01f-5f32a0c1c335" xlink:href="cpix-20210331.xsd#cpix_ProductsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_7dd7f84e-9fe1-435f-9b69-9943921d2972" xlink:to="loc_cpix_ProductsAbstract_bc5c370a-bcc3-49c5-a01f-5f32a0c1c335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f80cea69-7efb-4047-a275-84cf4e3cc84b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ProductsAbstract_bc5c370a-bcc3-49c5-a01f-5f32a0c1c335" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f80cea69-7efb-4047-a275-84cf4e3cc84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20210331.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_305aba65-6aed-400c-b038-a35ef5ac4af1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_a53b645e-f442-4177-afc9-843402dd533f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_305aba65-6aed-400c-b038-a35ef5ac4af1" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_a53b645e-f442-4177-afc9-843402dd533f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6011c3a3-a563-4b0e-b329-fe650f2015c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_abd1c2be-0b46-4088-bee0-c4581acb9d84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6011c3a3-a563-4b0e-b329-fe650f2015c3" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_abd1c2be-0b46-4088-bee0-c4581acb9d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b3f3369d-d78b-4e46-b590-66147ca28212" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_70dd582b-dcc0-495e-9443-e39411b51040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b3f3369d-d78b-4e46-b590-66147ca28212" xlink:to="loc_us-gaap_InventoryCurrentTable_70dd582b-dcc0-495e-9443-e39411b51040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_540325ac-496a-433b-8c25-668c40ebda16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_70dd582b-dcc0-495e-9443-e39411b51040" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_540325ac-496a-433b-8c25-668c40ebda16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee8583ff-ad39-4284-99d3-f4cfafc2b669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_540325ac-496a-433b-8c25-668c40ebda16" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee8583ff-ad39-4284-99d3-f4cfafc2b669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_db161443-5a5a-4c46-8a3d-9ca8b7bb9520" xlink:href="cpix-20210331.xsd#cpix_IfetrobanClinicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee8583ff-ad39-4284-99d3-f4cfafc2b669" xlink:to="loc_cpix_IfetrobanClinicalMember_db161443-5a5a-4c46-8a3d-9ca8b7bb9520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_32c7e97f-6069-447a-88d4-4896b88794fe" xlink:href="cpix-20210331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee8583ff-ad39-4284-99d3-f4cfafc2b669" xlink:to="loc_cpix_VIBATIVMember_32c7e97f-6069-447a-88d4-4896b88794fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_87d63448-d0c9-4e98-a632-1fe75491e5e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_70dd582b-dcc0-495e-9443-e39411b51040" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_87d63448-d0c9-4e98-a632-1fe75491e5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_2a7ebf7c-6cae-4bea-ada1-6a35bc391295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_87d63448-d0c9-4e98-a632-1fe75491e5e7" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_2a7ebf7c-6cae-4bea-ada1-6a35bc391295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_052bd3bc-3ed4-4d4d-be60-c29fc24940f7" xlink:href="cpix-20210331.xsd#cpix_IfetrobanClinicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_2a7ebf7c-6cae-4bea-ada1-6a35bc391295" xlink:to="loc_cpix_IfetrobanClinicalMember_052bd3bc-3ed4-4d4d-be60-c29fc24940f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_66b47a01-2f04-43d2-b1a8-f3544b026e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_70dd582b-dcc0-495e-9443-e39411b51040" xlink:to="loc_us-gaap_InventoryLineItems_66b47a01-2f04-43d2-b1a8-f3544b026e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_16a79bee-0234-493e-ad63-8a827e7e84ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_66b47a01-2f04-43d2-b1a8-f3544b026e95" xlink:to="loc_us-gaap_InventoryValuationReserves_16a79bee-0234-493e-ad63-8a827e7e84ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_c3d6e888-2816-431f-a77c-3b88937691d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_66b47a01-2f04-43d2-b1a8-f3544b026e95" xlink:to="loc_us-gaap_InventoryNoncurrent_c3d6e888-2816-431f-a77c-3b88937691d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_f999aa47-8f5d-4af1-8d08-05c8e722e008" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_66b47a01-2f04-43d2-b1a8-f3544b026e95" xlink:to="loc_us-gaap_InventoryFinishedGoods_f999aa47-8f5d-4af1-8d08-05c8e722e008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4399715f-6089-4148-b398-3d9881257efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_b273b9f5-f43f-4fb5-b13e-cf8afa30c72d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4399715f-6089-4148-b398-3d9881257efd" xlink:to="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_b273b9f5-f43f-4fb5-b13e-cf8afa30c72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_44491e60-1ceb-49b5-a1fa-d5f527f5fc56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_b273b9f5-f43f-4fb5-b13e-cf8afa30c72d" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_44491e60-1ceb-49b5-a1fa-d5f527f5fc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_d9164f69-d8a4-41ee-acb9-8df7a68cdddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_b273b9f5-f43f-4fb5-b13e-cf8afa30c72d" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_d9164f69-d8a4-41ee-acb9-8df7a68cdddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0244b70f-7aee-4e33-8a07-987186726f38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_b273b9f5-f43f-4fb5-b13e-cf8afa30c72d" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0244b70f-7aee-4e33-8a07-987186726f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_235851c5-b71c-476e-97fa-59896356eaa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_b273b9f5-f43f-4fb5-b13e-cf8afa30c72d" xlink:to="loc_us-gaap_InventoryGross_235851c5-b71c-476e-97fa-59896356eaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_0b1fe204-30ce-4047-b547-532c4295102c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_b273b9f5-f43f-4fb5-b13e-cf8afa30c72d" xlink:to="loc_us-gaap_InventoryNoncurrent_0b1fe204-30ce-4047-b547-532c4295102c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e7e9e985-da50-46e7-bb5b-9ae5376dd366" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_b273b9f5-f43f-4fb5-b13e-cf8afa30c72d" xlink:to="loc_us-gaap_InventoryNet_e7e9e985-da50-46e7-bb5b-9ae5376dd366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20210331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_49b07702-e1f2-4f44-9e11-7233147f65ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_7b4471b3-badd-42c8-a527-c9d39191e9ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_49b07702-e1f2-4f44-9e11-7233147f65ab" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_7b4471b3-badd-42c8-a527-c9d39191e9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9af7bba4-d7ff-44ca-8be2-b8a47f015449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_aaa38555-ea09-4a36-ba95-d39d8e40acc3" xlink:href="cpix-20210331.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9af7bba4-d7ff-44ca-8be2-b8a47f015449" xlink:to="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_aaa38555-ea09-4a36-ba95-d39d8e40acc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f6f170ca-b58c-42c4-93c8-e284287455b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9af7bba4-d7ff-44ca-8be2-b8a47f015449" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f6f170ca-b58c-42c4-93c8-e284287455b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_17d9155a-88a0-4c54-a360-b8bda19c0764" xlink:href="cpix-20210331.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9af7bba4-d7ff-44ca-8be2-b8a47f015449" xlink:to="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_17d9155a-88a0-4c54-a360-b8bda19c0764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c4031c80-2863-4740-b9c4-b782c2647594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b2ff4e40-fa52-4fbc-a8f9-15d780aaf6ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c4031c80-2863-4740-b9c4-b782c2647594" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b2ff4e40-fa52-4fbc-a8f9-15d780aaf6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ae8afc3e-19d1-4949-bb95-438a786de869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c4031c80-2863-4740-b9c4-b782c2647594" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ae8afc3e-19d1-4949-bb95-438a786de869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_0bd4e604-3eb5-4c16-9cd7-2ebbe987b315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c4031c80-2863-4740-b9c4-b782c2647594" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_0bd4e604-3eb5-4c16-9cd7-2ebbe987b315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesLeasePositionDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ebef3b0a-e311-4b35-bf74-d741b53caef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_09a2231a-b0d6-4581-a17d-54c74163e3ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ebef3b0a-e311-4b35-bf74-d741b53caef3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_09a2231a-b0d6-4581-a17d-54c74163e3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_54ec5857-38c6-448f-b9ff-22da57c765fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ebef3b0a-e311-4b35-bf74-d741b53caef3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_54ec5857-38c6-448f-b9ff-22da57c765fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_181b8249-c588-4ad5-9cc1-bfc6b8547df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ebef3b0a-e311-4b35-bf74-d741b53caef3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_181b8249-c588-4ad5-9cc1-bfc6b8547df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability_bfcf2940-038f-49c5-a75c-2fc97e040971" xlink:href="cpix-20210331.xsd#cpix_LeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ebef3b0a-e311-4b35-bf74-d741b53caef3" xlink:to="loc_cpix_LeaseLiability_bfcf2940-038f-49c5-a75c-2fc97e040971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b15303cd-79a7-4882-a043-43f53ef25eff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b2e4d0d6-54fa-4acd-b4ef-d4d9d53ffead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b15303cd-79a7-4882-a043-43f53ef25eff" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b2e4d0d6-54fa-4acd-b4ef-d4d9d53ffead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1c549307-ac0b-4435-927e-eabdcae1cdf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b2e4d0d6-54fa-4acd-b4ef-d4d9d53ffead" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1c549307-ac0b-4435-927e-eabdcae1cdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_905c1a4a-d6f8-4df7-b836-f67f0f553289" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b2e4d0d6-54fa-4acd-b4ef-d4d9d53ffead" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_905c1a4a-d6f8-4df7-b836-f67f0f553289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_92a2da71-10bc-4dda-ae0c-e89f832d5200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b2e4d0d6-54fa-4acd-b4ef-d4d9d53ffead" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_92a2da71-10bc-4dda-ae0c-e89f832d5200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_82bae7a6-2931-45df-bb8c-e4d293d3f0d9" xlink:href="cpix-20210331.xsd#cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b2e4d0d6-54fa-4acd-b4ef-d4d9d53ffead" xlink:to="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_82bae7a6-2931-45df-bb8c-e4d293d3f0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9317374c-5862-4173-b55b-8123e7bfaf1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b2e4d0d6-54fa-4acd-b4ef-d4d9d53ffead" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9317374c-5862-4173-b55b-8123e7bfaf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7b386020-dda5-46fe-a231-092fd8371584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b2e4d0d6-54fa-4acd-b4ef-d4d9d53ffead" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7b386020-dda5-46fe-a231-092fd8371584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_85636145-22dd-41db-b05b-1ad3d115ca28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b2e4d0d6-54fa-4acd-b4ef-d4d9d53ffead" xlink:to="loc_us-gaap_OperatingLeaseLiability_85636145-22dd-41db-b05b-1ad3d115ca28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesRentExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b60bde94-d22f-4306-9cac-868df8093430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_e27cc06f-8662-4ee5-951f-4651ec09d5c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b60bde94-d22f-4306-9cac-868df8093430" xlink:to="loc_us-gaap_LeaseAndRentalExpense_e27cc06f-8662-4ee5-951f-4651ec09d5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_ee77ccc0-a476-49a2-a241-74bbc77c1cd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b60bde94-d22f-4306-9cac-868df8093430" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_ee77ccc0-a476-49a2-a241-74bbc77c1cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20210331.xsd#ShareholdersEquityandDebt"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_a51209c2-98f0-46ca-9727-393e5fe55cc8" xlink:href="cpix-20210331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_39419a4f-45e8-4839-aa05-f48ea326b33d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_a51209c2-98f0-46ca-9727-393e5fe55cc8" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_39419a4f-45e8-4839-aa05-f48ea326b33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_2fc48062-3c3d-46e7-8b1b-e6535494a3b9" xlink:href="cpix-20210331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6876f181-a2ee-4198-9da1-fd177ae986b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_2fc48062-3c3d-46e7-8b1b-e6535494a3b9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6876f181-a2ee-4198-9da1-fd177ae986b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_dafd82a9-ec97-43f0-a642-16383dca8cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6876f181-a2ee-4198-9da1-fd177ae986b9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_dafd82a9-ec97-43f0-a642-16383dca8cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_44d9bb16-975f-4d3c-b626-b2a98688be48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dafd82a9-ec97-43f0-a642-16383dca8cfb" xlink:to="loc_us-gaap_EquityComponentDomain_44d9bb16-975f-4d3c-b626-b2a98688be48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_94f9b2d0-7c74-42fe-b7eb-51af3e80f846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_44d9bb16-975f-4d3c-b626-b2a98688be48" xlink:to="loc_us-gaap_CommonStockMember_94f9b2d0-7c74-42fe-b7eb-51af3e80f846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_76f9d25f-310e-4bb4-850c-87a9508b8f7f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6876f181-a2ee-4198-9da1-fd177ae986b9" xlink:to="loc_srt_TitleOfIndividualAxis_76f9d25f-310e-4bb4-850c-87a9508b8f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_917131b4-a1c5-4bfa-8f75-216f88a57058" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_76f9d25f-310e-4bb4-850c-87a9508b8f7f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_917131b4-a1c5-4bfa-8f75-216f88a57058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_b4d9b31e-24ef-42c7-8cc3-1aa54fddb417" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_917131b4-a1c5-4bfa-8f75-216f88a57058" xlink:to="loc_srt_DirectorMember_b4d9b31e-24ef-42c7-8cc3-1aa54fddb417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0bc3802e-9d97-4e0c-945c-96abb7992d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6876f181-a2ee-4198-9da1-fd177ae986b9" xlink:to="loc_us-gaap_AwardTypeAxis_0bc3802e-9d97-4e0c-945c-96abb7992d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc9725b6-dffa-483b-afda-c1b70b8510f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0bc3802e-9d97-4e0c-945c-96abb7992d45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc9725b6-dffa-483b-afda-c1b70b8510f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b6113997-5623-4e1e-8024-cf70865d33fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc9725b6-dffa-483b-afda-c1b70b8510f9" xlink:to="loc_us-gaap_RestrictedStockMember_b6113997-5623-4e1e-8024-cf70865d33fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncentiveStockOptionsMember_208ba924-ed4e-4a84-b7e9-abc2b4bbf9ef" xlink:href="cpix-20210331.xsd#cpix_IncentiveStockOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc9725b6-dffa-483b-afda-c1b70b8510f9" xlink:to="loc_cpix_IncentiveStockOptionsMember_208ba924-ed4e-4a84-b7e9-abc2b4bbf9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_52789baa-6999-40e6-9a03-da25613d0f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6876f181-a2ee-4198-9da1-fd177ae986b9" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_52789baa-6999-40e6-9a03-da25613d0f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_13daa263-e826-400b-be90-9b42367ab5db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_52789baa-6999-40e6-9a03-da25613d0f4d" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_13daa263-e826-400b-be90-9b42367ab5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_d2778428-3492-4515-9977-cd0e8a0451d7" xlink:href="cpix-20210331.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_13daa263-e826-400b-be90-9b42367ab5db" xlink:to="loc_cpix_PinnacleBankMember_d2778428-3492-4515-9977-cd0e8a0451d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc01a531-5d9a-4594-a885-ac9167ffce27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6876f181-a2ee-4198-9da1-fd177ae986b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc01a531-5d9a-4594-a885-ac9167ffce27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_6997dc50-2c72-4614-96e4-fa938466b84c" xlink:href="cpix-20210331.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc01a531-5d9a-4594-a885-ac9167ffce27" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_6997dc50-2c72-4614-96e4-fa938466b84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_67677d0f-c0d3-4b77-a035-504dad2dbfb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6997dc50-2c72-4614-96e4-fa938466b84c" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_67677d0f-c0d3-4b77-a035-504dad2dbfb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_8577e2ae-440c-4172-a221-2b65651c074b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6997dc50-2c72-4614-96e4-fa938466b84c" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_8577e2ae-440c-4172-a221-2b65651c074b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_a5f8c304-cea6-4862-b9cd-5f87aa8a020d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6997dc50-2c72-4614-96e4-fa938466b84c" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_a5f8c304-cea6-4862-b9cd-5f87aa8a020d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_f9b98d28-1041-49b5-9afd-93acf7f30b62" xlink:href="cpix-20210331.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6997dc50-2c72-4614-96e4-fa938466b84c" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_f9b98d28-1041-49b5-9afd-93acf7f30b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2ea6145d-20eb-4531-b0f4-807fc33ee3db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6997dc50-2c72-4614-96e4-fa938466b84c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2ea6145d-20eb-4531-b0f4-807fc33ee3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_859ca569-4966-4a6e-a6db-f5bb8ea4cb06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6997dc50-2c72-4614-96e4-fa938466b84c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_859ca569-4966-4a6e-a6db-f5bb8ea4cb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_85368fca-8164-4763-a8cf-c876f535cc9b" xlink:href="cpix-20210331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_48b0c92c-bf66-408e-889f-67dfa4155789" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_85368fca-8164-4763-a8cf-c876f535cc9b" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_48b0c92c-bf66-408e-889f-67dfa4155789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_a077c40c-ae73-4394-b7ca-aee52462feac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_48b0c92c-bf66-408e-889f-67dfa4155789" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_a077c40c-ae73-4394-b7ca-aee52462feac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_8c9d6df2-cbe2-4502-aa01-5e46a2f287ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_a077c40c-ae73-4394-b7ca-aee52462feac" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_8c9d6df2-cbe2-4502-aa01-5e46a2f287ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_3b420236-5822-4ca8-8db2-def2b7fe526b" xlink:href="cpix-20210331.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_8c9d6df2-cbe2-4502-aa01-5e46a2f287ef" xlink:to="loc_cpix_PinnacleBankMember_3b420236-5822-4ca8-8db2-def2b7fe526b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d4c9d5d9-8f52-4f46-b4db-fd812eae7c99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_48b0c92c-bf66-408e-889f-67dfa4155789" xlink:to="loc_us-gaap_DebtInstrumentAxis_d4c9d5d9-8f52-4f46-b4db-fd812eae7c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c83007ea-7f4b-423e-8dbb-802723f8cada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d4c9d5d9-8f52-4f46-b4db-fd812eae7c99" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c83007ea-7f4b-423e-8dbb-802723f8cada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FourthAmendmentMember_91090cb0-c91f-4ab8-b301-aabc435e4334" xlink:href="cpix-20210331.xsd#cpix_FourthAmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c83007ea-7f4b-423e-8dbb-802723f8cada" xlink:to="loc_cpix_FourthAmendmentMember_91090cb0-c91f-4ab8-b301-aabc435e4334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_2beb14a3-6a44-4527-8c5d-c94ffbf1fdfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c83007ea-7f4b-423e-8dbb-802723f8cada" xlink:to="loc_us-gaap_LineOfCreditMember_2beb14a3-6a44-4527-8c5d-c94ffbf1fdfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_770cc267-3e4f-4ffe-bd76-5aefa37e5557" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_48b0c92c-bf66-408e-889f-67dfa4155789" xlink:to="loc_us-gaap_CreditFacilityAxis_770cc267-3e4f-4ffe-bd76-5aefa37e5557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a28efcc3-50a0-4937-a75d-e6743ee58e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_770cc267-3e4f-4ffe-bd76-5aefa37e5557" xlink:to="loc_us-gaap_CreditFacilityDomain_a28efcc3-50a0-4937-a75d-e6743ee58e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_8f15fe9e-6f82-436d-a845-51b09a475128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_a28efcc3-50a0-4937-a75d-e6743ee58e39" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_8f15fe9e-6f82-436d-a845-51b09a475128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_df137318-903f-4bc1-86ea-25416cdf5109" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_48b0c92c-bf66-408e-889f-67dfa4155789" xlink:to="loc_srt_RangeAxis_df137318-903f-4bc1-86ea-25416cdf5109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56f27e64-2e6a-47d5-abb7-d37a441b2b24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_df137318-903f-4bc1-86ea-25416cdf5109" xlink:to="loc_srt_RangeMember_56f27e64-2e6a-47d5-abb7-d37a441b2b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c7664986-c887-4d99-ad03-b27393bd0071" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_56f27e64-2e6a-47d5-abb7-d37a441b2b24" xlink:to="loc_srt_MinimumMember_c7664986-c887-4d99-ad03-b27393bd0071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b9b7051e-9e5e-48ba-addc-e322e366f68a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_56f27e64-2e6a-47d5-abb7-d37a441b2b24" xlink:to="loc_srt_MaximumMember_b9b7051e-9e5e-48ba-addc-e322e366f68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_cc684317-7d0c-46d1-8991-9c3e3f9cf23a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_48b0c92c-bf66-408e-889f-67dfa4155789" xlink:to="loc_us-gaap_VariableRateAxis_cc684317-7d0c-46d1-8991-9c3e3f9cf23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_9c5b1832-2fce-4de7-bc5c-e8e3cf5a5cda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_cc684317-7d0c-46d1-8991-9c3e3f9cf23a" xlink:to="loc_us-gaap_VariableRateDomain_9c5b1832-2fce-4de7-bc5c-e8e3cf5a5cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_605b38db-3052-4ff3-b42e-6e35c7e45ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_9c5b1832-2fce-4de7-bc5c-e8e3cf5a5cda" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_605b38db-3052-4ff3-b42e-6e35c7e45ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a756cfd9-7fe9-4049-981b-152383bde227" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_48b0c92c-bf66-408e-889f-67dfa4155789" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a756cfd9-7fe9-4049-981b-152383bde227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ba68ac51-08fe-4826-bf6d-040f77efa2f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a756cfd9-7fe9-4049-981b-152383bde227" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ba68ac51-08fe-4826-bf6d-040f77efa2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_77c201c4-d989-4b35-9ce5-6fe57a291e3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ba68ac51-08fe-4826-bf6d-040f77efa2f6" xlink:to="loc_us-gaap_ConvertibleDebtMember_77c201c4-d989-4b35-9ce5-6fe57a291e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_28999c23-52be-455f-89fd-c68d6a400b54" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_48b0c92c-bf66-408e-889f-67dfa4155789" xlink:to="loc_srt_CounterpartyNameAxis_28999c23-52be-455f-89fd-c68d6a400b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6692345e-de0c-4b16-ab6d-03674ad90825" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_28999c23-52be-455f-89fd-c68d6a400b54" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6692345e-de0c-4b16-ab6d-03674ad90825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_f8a608b1-a4a7-4b88-8dc7-63f9f38687bb" xlink:href="cpix-20210331.xsd#cpix_WinHealthInvestmentSingaporeLtdDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6692345e-de0c-4b16-ab6d-03674ad90825" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdDomain_f8a608b1-a4a7-4b88-8dc7-63f9f38687bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_48b0c92c-bf66-408e-889f-67dfa4155789" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1a8a98af-e5fd-4a21-bafd-106e6e16b62d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1a8a98af-e5fd-4a21-bafd-106e6e16b62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_2808eb0b-2b54-475c-b5c9-8e23ea9be939" xlink:href="cpix-20210331.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount_2808eb0b-2b54-475c-b5c9-8e23ea9be939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_314d908d-6728-42c9-8528-cd4de1371a8e" xlink:href="cpix-20210331.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity_314d908d-6728-42c9-8528-cd4de1371a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d23ac6c7-8bfd-40d9-be4c-2efdab538e07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d23ac6c7-8bfd-40d9-be4c-2efdab538e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c4dc3296-c8c8-4ef7-bb09-a838ef197970" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c4dc3296-c8c8-4ef7-bb09-a838ef197970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_e060fd9e-14f9-44e0-bd5c-23a462807ed8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_e060fd9e-14f9-44e0-bd5c-23a462807ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_b8490e6e-4170-4078-944f-037291a5e6a9" xlink:href="cpix-20210331.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_b8490e6e-4170-4078-944f-037291a5e6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_416d09c3-ef94-4519-a8c2-2491d797da1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_us-gaap_LongTermLineOfCredit_416d09c3-ef94-4519-a8c2-2491d797da1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_f39f9120-6a93-4b32-9630-8a2fab9d773d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_f39f9120-6a93-4b32-9630-8a2fab9d773d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_161f91e2-f6a6-4e2e-a3d1-8c99a1e03a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_89f89735-8ea1-45d4-9fa6-e2baa7c26ca7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_161f91e2-f6a6-4e2e-a3d1-8c99a1e03a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20210331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_df80f30b-9013-4038-8342-42685183e3cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_74980d3c-e5a3-4eef-b4ad-0bb1d0a61422" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_df80f30b-9013-4038-8342-42685183e3cf" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_74980d3c-e5a3-4eef-b4ad-0bb1d0a61422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20210331.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_daf53567-e3ea-427d-889c-c6b266bc6e07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_9ca3611c-b646-48ed-a803-cb39da1ee307" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_daf53567-e3ea-427d-889c-c6b266bc6e07" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_9ca3611c-b646-48ed-a803-cb39da1ee307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d8390057-54c3-47f3-ba76-7f5ab507bb27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_9ca3611c-b646-48ed-a803-cb39da1ee307" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d8390057-54c3-47f3-ba76-7f5ab507bb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b9fd0288-d15e-4e04-9162-cf50e9803112" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d8390057-54c3-47f3-ba76-7f5ab507bb27" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b9fd0288-d15e-4e04-9162-cf50e9803112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_31b7b2aa-1c15-4672-a47b-b84ad13b6fe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b9fd0288-d15e-4e04-9162-cf50e9803112" xlink:to="loc_us-gaap_DomesticCountryMember_31b7b2aa-1c15-4672-a47b-b84ad13b6fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_0ee50a66-1fc7-4ca5-989c-a61f369b6625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_9ca3611c-b646-48ed-a803-cb39da1ee307" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_0ee50a66-1fc7-4ca5-989c-a61f369b6625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_fb47d8af-3982-4591-860c-9021a6428051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0ee50a66-1fc7-4ca5-989c-a61f369b6625" xlink:to="loc_us-gaap_OperatingLossCarryforwards_fb47d8af-3982-4591-860c-9021a6428051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20210331.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e48d4bef-01d5-4052-a1e0-f62cd5a5c848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_92d14c66-2071-4f70-9b0b-5d517ad3b5cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e48d4bef-01d5-4052-a1e0-f62cd5a5c848" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_92d14c66-2071-4f70-9b0b-5d517ad3b5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRights"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_40b0d58b-f5dc-4ab9-8668-f1214a76512d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_c48525f7-8c8a-4eab-b604-a20a863b7cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_40b0d58b-f5dc-4ab9-8668-f1214a76512d" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_c48525f7-8c8a-4eab-b604-a20a863b7cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRightsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_09d63213-1f01-42ba-ab27-dbb4ae8fe56f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_f0f8886c-7737-4adc-ae1f-ca563742a9c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_09d63213-1f01-42ba-ab27-dbb4ae8fe56f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_f0f8886c-7737-4adc-ae1f-ca563742a9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_75f56753-d0c5-4e07-a9c2-575b677b0f5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_09d63213-1f01-42ba-ab27-dbb4ae8fe56f" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_75f56753-d0c5-4e07-a9c2-575b677b0f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_06efd051-b3c1-44d9-9cfa-7a2f2a825bbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92b10567-f968-4998-9ca1-8f7689379617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_06efd051-b3c1-44d9-9cfa-7a2f2a825bbf" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92b10567-f968-4998-9ca1-8f7689379617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7298b96d-c918-4712-8870-c3022498d6d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92b10567-f968-4998-9ca1-8f7689379617" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7298b96d-c918-4712-8870-c3022498d6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_211e500e-a488-4e52-97ef-3f74cf1f28b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7298b96d-c918-4712-8870-c3022498d6d7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_211e500e-a488-4e52-97ef-3f74cf1f28b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_11dc2c0d-6d41-424d-8753-5827f5916543" xlink:href="cpix-20210331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_211e500e-a488-4e52-97ef-3f74cf1f28b6" xlink:to="loc_cpix_VIBATIVMember_11dc2c0d-6d41-424d-8753-5827f5916543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_70cf7c66-b6b8-4d4c-80f0-a75f2a04709c" xlink:href="cpix-20210331.xsd#cpix_MethotrexateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_211e500e-a488-4e52-97ef-3f74cf1f28b6" xlink:to="loc_cpix_MethotrexateMember_70cf7c66-b6b8-4d4c-80f0-a75f2a04709c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7e448f96-8270-4094-8602-8ff08c11cd52" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92b10567-f968-4998-9ca1-8f7689379617" xlink:to="loc_srt_CounterpartyNameAxis_7e448f96-8270-4094-8602-8ff08c11cd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_723a0317-4762-42fe-a118-e305e5be989f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7e448f96-8270-4094-8602-8ff08c11cd52" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_723a0317-4762-42fe-a118-e305e5be989f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_4fb6ce9c-29ed-4082-b8cb-b191ad89e1a3" xlink:href="cpix-20210331.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_723a0317-4762-42fe-a118-e305e5be989f" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_4fb6ce9c-29ed-4082-b8cb-b191ad89e1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_66430851-6150-45e8-af4d-a5a0dc74d35b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92b10567-f968-4998-9ca1-8f7689379617" xlink:to="loc_srt_StatementScenarioAxis_66430851-6150-45e8-af4d-a5a0dc74d35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_cd71c5cd-229e-41fd-aaab-b08802345a05" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_66430851-6150-45e8-af4d-a5a0dc74d35b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_cd71c5cd-229e-41fd-aaab-b08802345a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_800569de-98f4-4d56-90bb-4236d5bd1d16" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_cd71c5cd-229e-41fd-aaab-b08802345a05" xlink:to="loc_srt_ScenarioForecastMember_800569de-98f4-4d56-90bb-4236d5bd1d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d7ed12a4-7a34-4193-870d-079f3cd49b1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92b10567-f968-4998-9ca1-8f7689379617" xlink:to="loc_us-gaap_AwardTypeAxis_d7ed12a4-7a34-4193-870d-079f3cd49b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54fbcf31-741c-456a-b4b5-858c7076e6ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d7ed12a4-7a34-4193-870d-079f3cd49b1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54fbcf31-741c-456a-b4b5-858c7076e6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_442e2590-279e-45dd-8748-cd52e71c5f81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54fbcf31-741c-456a-b4b5-858c7076e6ae" xlink:to="loc_us-gaap_RestrictedStockMember_442e2590-279e-45dd-8748-cd52e71c5f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_70a56af6-edaf-4976-a4af-6ebdea296e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92b10567-f968-4998-9ca1-8f7689379617" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_70a56af6-edaf-4976-a4af-6ebdea296e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_19b61692-2e7a-41fa-b06c-b710cceb08e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_70a56af6-edaf-4976-a4af-6ebdea296e1e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_19b61692-2e7a-41fa-b06c-b710cceb08e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_0aee5e7a-29d6-41f8-8365-69adfae22736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_19b61692-2e7a-41fa-b06c-b710cceb08e5" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_0aee5e7a-29d6-41f8-8365-69adfae22736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4e89e0f9-42ce-4e70-9722-19e04da1fdf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_19b61692-2e7a-41fa-b06c-b710cceb08e5" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4e89e0f9-42ce-4e70-9722-19e04da1fdf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_92b10567-f968-4998-9ca1-8f7689379617" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_94e8868d-5bc8-4817-ac90-60c8442d961b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_94e8868d-5bc8-4817-ac90-60c8442d961b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_5b026b54-0a98-43c2-a5e6-18a4c6554dee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_5b026b54-0a98-43c2-a5e6-18a4c6554dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_ab1bd4fc-ef33-43fe-bd07-5a299fa4d880" xlink:href="cpix-20210331.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_ab1bd4fc-ef33-43fe-bd07-5a299fa4d880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8e6c45b3-08b6-436b-a34a-581e892c8735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8e6c45b3-08b6-436b-a34a-581e892c8735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d3b001e4-9ee7-41d5-a23a-bcd989d75629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d3b001e4-9ee7-41d5-a23a-bcd989d75629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1978df07-2737-4784-9de2-01bf328b4336" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1978df07-2737-4784-9de2-01bf328b4336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fddd75dc-b566-4bb1-9d28-8f5883e3784c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fddd75dc-b566-4bb1-9d28-8f5883e3784c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b5241ea1-46a6-4404-89fe-cbc8b28efc4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b5241ea1-46a6-4404-89fe-cbc8b28efc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_b58b471c-d5b0-4ee3-a11f-ee052a9ab2b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_b58b471c-d5b0-4ee3-a11f-ee052a9ab2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_8a16a81e-3f06-493a-8e39-76cb4b7c7593" xlink:href="cpix-20210331.xsd#cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_898c1c51-da39-4c4b-8dda-85d96c29a7af" xlink:to="loc_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment_8a16a81e-3f06-493a-8e39-76cb4b7c7593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_e644984d-2c6c-4348-a4fa-bf65110859df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_068086ec-ed90-40fa-9a00-c8b23bb88bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_e644984d-2c6c-4348-a4fa-bf65110859df" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_068086ec-ed90-40fa-9a00-c8b23bb88bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7a582702-30dd-4e29-a3e7-e03e4b7b0cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_068086ec-ed90-40fa-9a00-c8b23bb88bc2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7a582702-30dd-4e29-a3e7-e03e4b7b0cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5f1c4a1-cb20-4aa3-8c05-0b32aad5a7a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7a582702-30dd-4e29-a3e7-e03e4b7b0cf3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5f1c4a1-cb20-4aa3-8c05-0b32aad5a7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_efcb8821-b634-47af-aa44-ae05bbd6d060" xlink:href="cpix-20210331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5f1c4a1-cb20-4aa3-8c05-0b32aad5a7a7" xlink:to="loc_cpix_VIBATIVMember_efcb8821-b634-47af-aa44-ae05bbd6d060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c51c216c-45d4-4b3a-9631-fd3db265c774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_068086ec-ed90-40fa-9a00-c8b23bb88bc2" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_c51c216c-45d4-4b3a-9631-fd3db265c774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_65f88cd2-0956-4442-8f9b-f5765ad3ee22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c51c216c-45d4-4b3a-9631-fd3db265c774" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_65f88cd2-0956-4442-8f9b-f5765ad3ee22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d875a736-eadb-448a-964c-c6213531809f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_65f88cd2-0956-4442-8f9b-f5765ad3ee22" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d875a736-eadb-448a-964c-c6213531809f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_7a27f3a9-d5d6-4dd8-8444-dce480fed9f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_65f88cd2-0956-4442-8f9b-f5765ad3ee22" xlink:to="loc_us-gaap_PaymentsForRoyalties_7a27f3a9-d5d6-4dd8-8444-dce480fed9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_008b0ab5-df21-4f82-a1ab-2baabdd75fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_65f88cd2-0956-4442-8f9b-f5765ad3ee22" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_008b0ab5-df21-4f82-a1ab-2baabdd75fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_874fb218-dbc2-49a5-ac3d-f30552c35d70" xlink:href="cpix-20210331.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_65f88cd2-0956-4442-8f9b-f5765ad3ee22" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_874fb218-dbc2-49a5-ac3d-f30552c35d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_83deea32-2493-4366-a6e9-68ca15a199f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_65f88cd2-0956-4442-8f9b-f5765ad3ee22" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_83deea32-2493-4366-a6e9-68ca15a199f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRightsDissolutionPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_9cb045b7-b609-4957-88a2-0c020262ecf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a74a5b80-d474-4dcf-99bc-17b403efcfdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_9cb045b7-b609-4957-88a2-0c020262ecf6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a74a5b80-d474-4dcf-99bc-17b403efcfdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_43189edc-2763-4796-98d5-abedd01fdb15" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a74a5b80-d474-4dcf-99bc-17b403efcfdc" xlink:to="loc_srt_CounterpartyNameAxis_43189edc-2763-4796-98d5-abedd01fdb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0c0570d-a9a4-47ba-9bcf-9ae52184f640" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_43189edc-2763-4796-98d5-abedd01fdb15" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0c0570d-a9a4-47ba-9bcf-9ae52184f640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_11bc6b8c-736e-4073-82f7-c816f7715464" xlink:href="cpix-20210331.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0c0570d-a9a4-47ba-9bcf-9ae52184f640" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_11bc6b8c-736e-4073-82f7-c816f7715464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0655f401-28d1-4ead-b4e4-3bd5bdfcc0f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a74a5b80-d474-4dcf-99bc-17b403efcfdc" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_0655f401-28d1-4ead-b4e4-3bd5bdfcc0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4583292a-46a3-4adf-927b-6a8772e1b225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0655f401-28d1-4ead-b4e4-3bd5bdfcc0f1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4583292a-46a3-4adf-927b-6a8772e1b225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ac4d4fed-5589-4f3e-a85d-59b1695eecd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0655f401-28d1-4ead-b4e4-3bd5bdfcc0f1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ac4d4fed-5589-4f3e-a85d-59b1695eecd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_7ff987fb-adcb-4942-8d64-61628d27ceb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0655f401-28d1-4ead-b4e4-3bd5bdfcc0f1" xlink:to="loc_us-gaap_SellingAndMarketingExpense_7ff987fb-adcb-4942-8d64-61628d27ceb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_38dbb864-ec51-4054-821d-76c9b574d84b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0655f401-28d1-4ead-b4e4-3bd5bdfcc0f1" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_38dbb864-ec51-4054-821d-76c9b574d84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>cpix-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cpix="http://www.cumberlandpharma.com/20210331"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cpix-20210331.xsd" xlink:type="simple"/>
    <context id="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i38218dfd921040d7b3b26c174a646322_I20210510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-05-10</instant>
        </period>
    </context>
    <context id="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i32068be194474f9cb55326666a7fbec0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ida5da6da6f1940a89e2ca94214d39333_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie233d42748ec407f95f541fbd71d46ac_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id2ffeb106dc64405a2176740c3911624_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib06687c2aa5440aa9603d320be455732_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic61089dc435b40fba685b7b8a3119d6a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if890c44461b6436496221a526f27e535_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iadc27382cf1543aeab148380997ffd49_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i932d3a3642fe4eea9f64a3315bad0bf3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic03d7f9f76264ef5b4cb398729aed58c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i42ffa52e2ca34a65970a04537b3b4818_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6cbedf5761f7490b8032ca938d802c9f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic2641b7e1d4f4e36a6431338fd938d84_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i32683bdb8c0e4ba1bd2ad06feb02693a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02023e16463a45f891a3eca1a68aa423_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b204f4dda214716a8d2597171f9411e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie6a93a5acaec4b8598b2aebbfadd4119_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i832ffbf2902c4a768fc2b9b3becc3924_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idd6f054d04374954ad9f0a6ad2ea298c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i745ba0295e724b4bbd4b33a5ee76d597_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icce24f39974b4ed98da8bfbe93943fbf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i529667d136134653822f8cd1f52ea7d0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9c72789317264e7cac1350e71f0ab560_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2cea9b0a3e2640afb98e17b1e3a6f819_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i590eaf4520974d29b6b01a687d2d13fc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id94b2cb8e46b43f8ba1807feeb2a3fe7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i586cba84dc4847daab9569a2b1c1b879_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib469a00b1c1e41ebaf007975ede59684_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifcc02cc49f4b429aa9f1c74f9bc16e6b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7f27ae48034942de95317f99306eea46_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i645b158fe75341daa01ca68e5cf1c2b6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i613693e28d6e4692be7579f7e5ab1d49_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i823406d319024699bfab22321dde04e3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i39d646b80ea44ec583582f1c79953d87_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0edefe7ed797492eae26ff926abd627a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i763bd43cce884a5780a96bbcfb7e0253_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i541a71eb9df04c92806ebdb9f1ae4771_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2e10e772bb294442900e5d9b697e71e3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4068d158ecb7413b92d283e5bce21c80_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic3f04630c9f547b5be864f1c66564cb8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b759ac132064b2787c2b5a4ad1e70f7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idd43aeaa2b4b4955aef55acce99cd31d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a40e1cbac204fb18cf00c3b1f6c81c6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i61c481ad9f504703a94e6b9be6f518e2_I20100513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2010-05-13</instant>
        </period>
    </context>
    <context id="i26d732474c194cee89c889d4f8a693f2_I20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="i08b1da814e684be58d651fa09524635d_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="ib2eda2a4dac14ec3b727863dc09461ee_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i176b3b536b2f4266bb9351936fafc0a5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id97ac84efc164cb38bbe53650262439c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8efd5212c2ea4438a3c6b998c82af06a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:IncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2ddf705ec76d45ce90dcfd34b198b915_I20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:FourthAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-07</instant>
        </period>
    </context>
    <context id="i49d1ed31c7894e6b987d5f1b88ea735e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ida4acda1a0824ddd98ba37f7456c0970_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="ic626a31ddbca438a89b05457be379d25_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="ic599c92ccd35431db3b06f4238341683_D20200814-20200814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="ib53bd71fe3994d2da24c5195efd6412c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6ccab55d30cd4f3595d41c3c3554b52a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i830bb87cb40044cd957e698b46665fd6_D20200420-20200420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-20</startDate>
            <endDate>2020-04-20</endDate>
        </period>
    </context>
    <context id="i59247f7dd59d4f28aee9f37d45d509aa_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdDomain</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="icd3a639d6f35423aa3c2f6243856ec35_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i6c5f356638654bbdaf6b452874ae5eaf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic4690540184b48fa90ef75b783a03efb_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="ied6025b276df445997781e0a3e02560b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3416c55598e64e2b95051149db842304_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id0ecdd80f5234983a18050bf8ecf1cda_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia0a8b608c7614df795f5ef973e97f9d9_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i7582538d23084840b14af98041033df1_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="id8d1afac2fe04daeb9be14e2c01cb3cf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie0eada6a93ec412dbdce374da1fb4f0c_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="id745598dd60b4f4088bc62c2d5c607b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9a68ec61d27040248d7dd487e14454d4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i78e7ac2dbdbe4730beeb4a8d45f46205_D20191001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6a4c618331f148a9b3e193bc04d8c16e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6874375315de4805a4b9a90949e9e0a9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8d4b97906e974844a32b25017974062a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>cpix:Segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180L2ZyYWc6OWExZjA3ZTllZmI2NGNjMmFiZmZhOGRjYzI5ZDY0NWUvdGFibGU6ZjEwOGY4YTQyYWM2NGRhNTlhMjA2ZGM2MjdlZGY1YTgvdGFibGVyYW5nZTpmMTA4ZjhhNDJhYzY0ZGE1OWEyMDZkYzYyN2VkZjVhOF81LTEtMS0xLTA_f7862fdf-139e-453e-89ed-7e9448a68bc0">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180L2ZyYWc6OWExZjA3ZTllZmI2NGNjMmFiZmZhOGRjYzI5ZDY0NWUvdGFibGU6ZjEwOGY4YTQyYWM2NGRhNTlhMjA2ZGM2MjdlZGY1YTgvdGFibGVyYW5nZTpmMTA4ZjhhNDJhYzY0ZGE1OWEyMDZkYzYyN2VkZjVhOF82LTEtMS0xLTA_99926dee-1365-47f0-9335-eb40651dec7c">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180L2ZyYWc6OWExZjA3ZTllZmI2NGNjMmFiZmZhOGRjYzI5ZDY0NWUvdGFibGU6ZjEwOGY4YTQyYWM2NGRhNTlhMjA2ZGM2MjdlZGY1YTgvdGFibGVyYW5nZTpmMTA4ZjhhNDJhYzY0ZGE1OWEyMDZkYzYyN2VkZjVhOF83LTEtMS0xLTA_f3e2e0b2-fba2-4a22-95a1-e02a4f858100">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180L2ZyYWc6OWExZjA3ZTllZmI2NGNjMmFiZmZhOGRjYzI5ZDY0NWUvdGV4dHJlZ2lvbjo5YTFmMDdlOWVmYjY0Y2MyYWJmZmE4ZGNjMjlkNjQ1ZV83OQ_be221f3d-a6d1-4c5d-8e19-bd1577ef422d">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180L2ZyYWc6OWExZjA3ZTllZmI2NGNjMmFiZmZhOGRjYzI5ZDY0NWUvdGV4dHJlZ2lvbjo5YTFmMDdlOWVmYjY0Y2MyYWJmZmE4ZGNjMjlkNjQ1ZV84MA_63b724cd-9e1a-45c1-9d96-d7eb5d3f0dbf">0001087294</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18yMDEy_ff6a6f6e-cd70-42a3-895e-0e87f75ada01">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6NjY1NDZlYmI3MDMwNGU4MDk1YjJhMTE2ZTM4MjczZjEvdGFibGVyYW5nZTo2NjU0NmViYjcwMzA0ZTgwOTViMmExMTZlMzgyNzNmMV8wLTAtMS0xLTA_c8d05ffd-1b67-4738-9809-64849bd7369d">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18xMzE_94939131-3d30-4b7c-af17-f8aee63cb279">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6OGYyNDQwMDE3YTQyNDcyYThiNGU2NDIwM2UyNDIzNmYvdGFibGVyYW5nZTo4ZjI0NDAwMTdhNDI0NzJhOGI0ZTY0MjAzZTI0MjM2Zl8wLTAtMS0xLTA_512a1272-0084-4db8-8e66-1d3ce05a3c33">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18yMDE1_d022d4d1-cf98-4200-8d49-a48db962c4c1">001-33637</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18yMDA2_161a0e35-e34c-4fad-b523-410ca98b0eda">Cumberland Pharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6MjgwMDMwZDg3OGY5NDY3YTkwNWI2NTQ0NGU5MjdhZDkvdGFibGVyYW5nZToyODAwMzBkODc4Zjk0NjdhOTA1YjY1NDQ0ZTkyN2FkOV8wLTAtMS0xLTA_daed7df7-6f34-4678-b61b-ec6b1132301d">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6MjgwMDMwZDg3OGY5NDY3YTkwNWI2NTQ0NGU5MjdhZDkvdGFibGVyYW5nZToyODAwMzBkODc4Zjk0NjdhOTA1YjY1NDQ0ZTkyN2FkOV8wLTItMS0xLTA_53e0ff7c-59f8-4ed7-9e6d-6fa381e3355c">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6MjgwMDMwZDg3OGY5NDY3YTkwNWI2NTQ0NGU5MjdhZDkvdGFibGVyYW5nZToyODAwMzBkODc4Zjk0NjdhOTA1YjY1NDQ0ZTkyN2FkOV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphMTYzZDg4Njk1ZWU0NGYwOTM1ZTM5YTc5MTU5YTExYV81_b1f8d365-90e2-4bbe-9446-a6f598fa05a1">2525 West End Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6MjgwMDMwZDg3OGY5NDY3YTkwNWI2NTQ0NGU5MjdhZDkvdGFibGVyYW5nZToyODAwMzBkODc4Zjk0NjdhOTA1YjY1NDQ0ZTkyN2FkOV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphMTYzZDg4Njk1ZWU0NGYwOTM1ZTM5YTc5MTU5YTExYV85_d1475538-1afe-4550-89c3-0d3632cb5ab9">Suite 950</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6MjgwMDMwZDg3OGY5NDY3YTkwNWI2NTQ0NGU5MjdhZDkvdGFibGVyYW5nZToyODAwMzBkODc4Zjk0NjdhOTA1YjY1NDQ0ZTkyN2FkOV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphMTYzZDg4Njk1ZWU0NGYwOTM1ZTM5YTc5MTU5YTExYV8xMw_52ecac74-0e07-4427-ba66-6774e76cc534">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6MjgwMDMwZDg3OGY5NDY3YTkwNWI2NTQ0NGU5MjdhZDkvdGFibGVyYW5nZToyODAwMzBkODc4Zjk0NjdhOTA1YjY1NDQ0ZTkyN2FkOV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphMTYzZDg4Njk1ZWU0NGYwOTM1ZTM5YTc5MTU5YTExYV8xNw_62e87303-23c6-48a1-a4bc-cdb89fa43c68">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6MjgwMDMwZDg3OGY5NDY3YTkwNWI2NTQ0NGU5MjdhZDkvdGFibGVyYW5nZToyODAwMzBkODc4Zjk0NjdhOTA1YjY1NDQ0ZTkyN2FkOV8zLTItMS0xLTA_14cc438b-5116-465f-ad5b-ed0b49cec3e4">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18yMDA4_ab3907ed-78d9-4a51-86cb-a193fef27409">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18yMDA5_af818f16-f07f-44d6-8878-ea09edadd910">255-0068</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18yMDEw_5116375a-427b-4674-8faf-554a0a44b9d1">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18yMDA3_3ced5073-0912-4fec-9507-b46c1b5be0f9">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6M2JlMmEwMTJiMTU2NDNhMDk4ZDc1N2E2NjQ3OWVkYmYvdGFibGVyYW5nZTozYmUyYTAxMmIxNTY0M2EwOThkNzU3YTY2NDc5ZWRiZl8xLTAtMS0xLTA_aff32518-15c4-4dee-88b8-653ae0b8cd4b">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6M2JlMmEwMTJiMTU2NDNhMDk4ZDc1N2E2NjQ3OWVkYmYvdGFibGVyYW5nZTozYmUyYTAxMmIxNTY0M2EwOThkNzU3YTY2NDc5ZWRiZl8xLTUtMS0xLTA_785b8669-8ce9-4a55-bdad-0b3069a38dd9">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6M2JlMmEwMTJiMTU2NDNhMDk4ZDc1N2E2NjQ3OWVkYmYvdGFibGVyYW5nZTozYmUyYTAxMmIxNTY0M2EwOThkNzU3YTY2NDc5ZWRiZl8yLTItMS0xLTA_1dd6ff34-5101-4af8-b191-cfb9bcb4a5d9">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18yMDEx_b5b1e754-a11d-41d7-b7fa-cd74961acc65">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i38218dfd921040d7b3b26c174a646322_I20210510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGV4dHJlZ2lvbjphMTRhNmVhOWEwN2M0MjA5OGNkZGEwYzEzMmI0MGFlM18xMDk5NTExNjI5ODMy_c0023b3f-7fd0-4603-9374-b60e4d21c7c6"
      unitRef="shares">15050025</dei:EntityCommonStockSharesOutstanding>
    <dei:Security12bTitle
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6NGMxM2Y5NWJiMTNlNDU4MWI2ZTY5NmRlODJkZTZhNTQvdGFibGVyYW5nZTo0YzEzZjk1YmIxM2U0NTgxYjZlNjk2ZGU4MmRlNmE1NF8xLTAtMS0xLTA_4db93bd3-51c6-45b0-972e-e254e18891fb">Common stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6NGMxM2Y5NWJiMTNlNDU4MWI2ZTY5NmRlODJkZTZhNTQvdGFibGVyYW5nZTo0YzEzZjk1YmIxM2U0NTgxYjZlNjk2ZGU4MmRlNmE1NF8xLTItMS0xLTA_a128c659-e87a-410b-af00-a5b9159cb3cc">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xL2ZyYWc6YTE0YTZlYTlhMDdjNDIwOThjZGRhMGMxMzJiNDBhZTMvdGFibGU6NGMxM2Y5NWJiMTNlNDU4MWI2ZTY5NmRlODJkZTZhNTQvdGFibGVyYW5nZTo0YzEzZjk1YmIxM2U0NTgxYjZlNjk2ZGU4MmRlNmE1NF8xLTQtMS0xLTA_47eb58ae-5f24-4352-bb46-5e3f06fdbae0">NASDAQ</dei:SecurityExchangeName>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMy0xLTEtMS0w_d33521a3-b4cd-427a-9856-711dee5fa502"
      unitRef="usd">24922925</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMy0zLTEtMS0w_fe1c004c-6244-43f1-966b-fede490650b0"
      unitRef="usd">24753796</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfNS0xLTEtMS0w_29839a91-62fe-4f02-9134-dd58203d5088"
      unitRef="usd">12549297</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfNS0zLTEtMS0w_af242aa1-5d35-4891-8938-a663a877b5e6"
      unitRef="usd">12377713</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfNi0xLTEtMS0w_0292b84e-9564-4c3f-8b67-25ee9943f2e1"
      unitRef="usd">10010763</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfNi0zLTEtMS0w_5fab1f31-8dc6-4297-87a6-0c817a17b06c"
      unitRef="usd">10638157</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfOC0xLTEtMS0w_8f658f14-e20e-499f-8703-c94d9170b88b"
      unitRef="usd">1900032</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfOC0zLTEtMS0w_d1e36c81-23d5-451a-89ec-eae869ac31ba"
      unitRef="usd">2199926</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfOS0xLTEtMS0w_aac82d83-eda7-4ae8-8aee-94483a8b5ca9"
      unitRef="usd">49383017</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfOS0zLTEtMS0w_ef682c62-abff-4c73-94cf-efac23a8b68f"
      unitRef="usd">49969592</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTAtMS0xLTEtMA_e08e8a0f-31a3-4e29-bcc1-1aa0069caa8d"
      unitRef="usd">10415786</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTAtMy0xLTEtMA_f042b44a-8008-40ae-a3a4-fb073beacd91"
      unitRef="usd">11656742</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTEtMS0xLTEtMA_aa83e25e-73fb-4582-b096-50a09db6256b"
      unitRef="usd">534933</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTEtMy0xLTEtMA_cd08681a-f8dd-4b18-8742-cca21acdf631"
      unitRef="usd">574169</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTItMS0xLTEtMA_76fb9a83-5ec1-40ed-90cb-3df39a883608"
      unitRef="usd">27024544</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTItMy0xLTEtMA_ab8903a5-dc52-414c-9c5c-7ed1074ade11"
      unitRef="usd">28118316</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTMtMS0xLTEtMA_54a0ac28-45c0-4f0b-8993-8e8be71432d8"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTMtMy0xLTEtMA_841d9fe2-690e-4354-8902-1191a2f2def4"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTUtMS0xLTEtMA_e6f68ee6-031b-45cd-af89-12fb7eb56130"
      unitRef="usd">1784142</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTUtMy0xLTEtMA_8a2d7a39-c421-4f89-9abd-0202e1a6c662"
      unitRef="usd">2028148</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTYtMS0xLTEtMA_52a1e1ed-af2b-49cb-a05d-22f8ce38d44b"
      unitRef="usd">3323603</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTYtMy0xLTEtMA_24e0c4d7-96dd-4ed5-8572-839c3ffa7555"
      unitRef="usd">3234338</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTctMS0xLTEtMA_06cd07a6-20fd-4a57-9661-41fd0c2bcd36"
      unitRef="usd">93348025</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMTctMy0xLTEtMA_cc4803e7-bf6e-4fc1-b0a0-8062958465dc"
      unitRef="usd">96463305</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjAtMS0xLTEtMA_89c424ee-fe3d-43ce-bfcc-80ed383caee7"
      unitRef="usd">10466281</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjAtMy0xLTEtMA_116515bb-9e93-43f2-8d3b-9d5b84435c19"
      unitRef="usd">13396286</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjItMS0xLTEtMA_7796e2c6-0558-49f6-995c-98d965dcdafe"
      unitRef="usd">1042074</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjItMy0xLTEtMA_dc94fbbf-3c81-49db-abe0-1fb72ccc9b00"
      unitRef="usd">1016779</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjQtMS0xLTEtMA_9e0f663f-4808-477e-bad1-b51ac216d73d"
      unitRef="usd">11339215</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjQtMy0xLTEtMA_324c97e6-4ca2-413a-b8ed-4e7beae9bf31"
      unitRef="usd">11254381</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjUtMS0xLTEtMA_744eacf5-00f8-49ed-91f2-8886148f46ce"
      unitRef="usd">22847570</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjUtMy0xLTEtMA_6c20335d-5c80-4416-955d-9fcaea94d70e"
      unitRef="usd">25667446</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLineOfCredit
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjYtMS0xLTEtMA_e72ee778-5567-4e11-8863-440f6384af43"
      unitRef="usd">15000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjYtMy0xLTEtMA_80787f93-52ed-462f-a02a-96c1c18f6620"
      unitRef="usd">15000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjctMS0xLTEtMA_cb40b9a6-bb5e-42c8-86cd-e07142a6e99b"
      unitRef="usd">789200</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjctMy0xLTEtMA_c9d0c727-a838-40f7-a4f0-60c637a599de"
      unitRef="usd">1059693</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjgtMS0xLTEtMA_3cf53b17-f013-4d4e-85be-d2e06e81f63a"
      unitRef="usd">7833328</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjgtMy0xLTEtMA_f4a58ad9-68f9-4efc-a306-9b2e02ad46fb"
      unitRef="usd">7862772</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <us-gaap:Liabilities
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjktMS0xLTEtMA_6cd25af9-6d1d-44dc-8726-56d5c69922d8"
      unitRef="usd">46470098</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMjktMy0xLTEtMA_82f00a52-f8eb-48d1-85d6-8478c42f5f84"
      unitRef="usd">49589911</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzAtMS0xLTEtMA_24861e21-64a8-4f6d-b12e-a2340c5fc4c4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzAtMy0xLTEtMA_6081c930-102a-4cea-9a2e-4f6e408d842f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI5MDU4Mzk1MDE1ZTRiNWM4ZGU1MTcwNGMyMjFhYWQzXzE3_4a90d0a5-e8b6-46d3-a393-81809ef3b4d3"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI5MDU4Mzk1MDE1ZTRiNWM4ZGU1MTcwNGMyMjFhYWQzXzE3_b618b274-8d48-4d53-8410-cecdd2764c56"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI5MDU4Mzk1MDE1ZTRiNWM4ZGU1MTcwNGMyMjFhYWQzXzMx_3a1b34fb-db9f-491e-8035-5d383a1baee8"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI5MDU4Mzk1MDE1ZTRiNWM4ZGU1MTcwNGMyMjFhYWQzXzMx_f12e2eeb-1599-4ceb-b23f-9cad955f0321"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI5MDU4Mzk1MDE1ZTRiNWM4ZGU1MTcwNGMyMjFhYWQzXzUz_15a76be6-cdb6-4ad8-99b9-713e4836e965"
      unitRef="shares">15084464</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI5MDU4Mzk1MDE1ZTRiNWM4ZGU1MTcwNGMyMjFhYWQzXzUz_eeadc2e3-1b8a-43a6-84a4-a159d7563a5f"
      unitRef="shares">15084464</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI5MDU4Mzk1MDE1ZTRiNWM4ZGU1MTcwNGMyMjFhYWQzXzYw_55264ba8-416e-4543-a917-95f9a693f62a"
      unitRef="shares">14988429</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmI5MDU4Mzk1MDE1ZTRiNWM4ZGU1MTcwNGMyMjFhYWQzXzYw_8bfc0231-3bf1-4c57-9e45-8c33713e6eb6"
      unitRef="shares">14988429</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMS0xLTEtMA_281bc740-d703-41f5-8e51-613064f94b53"
      unitRef="usd">48981395</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzMtMy0xLTEtMA_64c2bfd4-79bc-4017-b20b-b5817e8b7a49"
      unitRef="usd">49121523</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzQtMS0xLTEtMA_a4771095-bb7f-4edb-8ccb-67c4e0af2513"
      unitRef="usd">-1964185</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzQtMy0xLTEtMA_5ae1f4d7-7dc9-4ead-83fe-f3a8f0dd34cd"
      unitRef="usd">-2131013</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzUtMS0xLTEtMA_e60561c1-d8bf-470f-b636-d978833b2129"
      unitRef="usd">47017210</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzUtMy0xLTEtMA_ba3c2eeb-23c4-492c-9fe1-ad5b64ecabaf"
      unitRef="usd">46990510</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzYtMS0xLTEtMA_69db001e-5651-40d9-bd6f-86e60d54e48c"
      unitRef="usd">-139283</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzYtMy0xLTEtMA_8b2402a7-3810-48df-9ba3-1e5ad24917a0"
      unitRef="usd">-117116</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzctMS0xLTEtMA_3a4d177b-a63d-4aac-be48-9b064b18e104"
      unitRef="usd">46877927</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzctMy0xLTEtMA_85ab35a6-eac1-4551-a28e-cf483a79f0bd"
      unitRef="usd">46873394</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzgtMS0xLTEtMA_acc8603e-6fb6-490d-9a4c-75cb818295d1"
      unitRef="usd">93348025</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xNi9mcmFnOjgzOTg0NWZmOTc3NjQ2N2VhZjBlOGJkNDQ4YTNmMGFkL3RhYmxlOjdkZTI1NDJjMjZiNTQ0NGFhOGYxMmQ1NGVmY2RkNWQ1L3RhYmxlcmFuZ2U6N2RlMjU0MmMyNmI1NDQ0YWE4ZjEyZDU0ZWZjZGQ1ZDVfMzgtMy0xLTEtMA_6852c40a-30a2-4a4f-86d0-26f691f6dc09"
      unitRef="usd">96463305</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMi0xLTEtMS0w_e841fe40-cca9-43f6-a292-bcf416010925"
      unitRef="usd">10537159</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMi0zLTEtMS0w_9f7d72ad-210a-414d-85a5-9116d33da034"
      unitRef="usd">8330734</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfNC0xLTEtMS0w_90586fae-1ad3-454e-99ac-c9ee6840d334"
      unitRef="usd">2417329</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfNC0zLTEtMS0w_a092a26e-ab23-4fb5-b101-1a51232f719e"
      unitRef="usd">1634181</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfNS0xLTEtMS0w_301c2017-453d-4354-879a-61bfde8f7c7d"
      unitRef="usd">3787340</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfNS0zLTEtMS0w_a92df567-9d5d-433e-aa73-f20d64eda4f6"
      unitRef="usd">3707676</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfNi0xLTEtMS0w_55c50c9f-7e61-46cd-9146-abf97a1b4017"
      unitRef="usd">1257367</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfNi0zLTEtMS0w_b2f2c74b-3697-4402-8ae4-b8480d4da8d3"
      unitRef="usd">1722555</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfNy0xLTEtMS0w_1e9a1dd4-4281-4b74-a6ef-58514ee9ca56"
      unitRef="usd">2230509</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfNy0zLTEtMS0w_0ca2a97d-9aea-40d9-a2ad-45c543d2f2e3"
      unitRef="usd">2036284</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfOC0xLTEtMS0w_6ec40728-295d-409c-b5f2-1882e606c562"
      unitRef="usd">1168914</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfOC0zLTEtMS0w_b734b62b-6a84-4c19-b8bf-76b62bfa1b3d"
      unitRef="usd">1076039</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfOS0xLTEtMS0w_e350de00-52ca-4f1b-a66c-4752e6ab21c5"
      unitRef="usd">10861459</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfOS0zLTEtMS0w_3cbdb0b4-1419-4370-80c3-a8dbc9e22f53"
      unitRef="usd">10176735</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTAtMS0xLTEtMA_8b8d139a-a7fd-4b99-bb49-14f59b07ed77"
      unitRef="usd">-324300</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTAtMy0xLTEtMA_046da1cd-ce3e-40be-b04b-6b006041f03e"
      unitRef="usd">-1846001</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTEtMS0xLTEtMA_1e4443db-9cc9-442d-bf8b-49d0b503656a"
      unitRef="usd">5426</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTEtMy0xLTEtMA_2fc3870a-a699-4faa-ac63-67d082111d5f"
      unitRef="usd">29888</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTItMS0xLTEtMA_a4c7379f-5d83-4d33-92fe-bb34760c705a"
      unitRef="usd">24417</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTItMy0xLTEtMA_4b36212d-72b3-452b-a931-ad19a62178a1"
      unitRef="usd">33065</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTMtMS0xLTEtMA_4d5dc03d-f595-4682-b525-cdf2cb3e0777"
      unitRef="usd">-343291</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTMtMy0xLTEtMA_e114a97d-92dc-4115-9234-f7ebd2bf7cf8"
      unitRef="usd">-1849178</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTQtMS0xLTEtMA_dab3f8a4-d725-4a99-a76f-2b0028570f95"
      unitRef="usd">7458</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTQtMy0xLTEtMA_cc770ad9-0e65-4eea-8e70-488e02beb7ba"
      unitRef="usd">34240</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTUtMS0xLTEtMA_f70f9fd6-6381-435a-8bf4-30043e54eac3"
      unitRef="usd">-350749</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTUtMy0xLTEtMA_f5f0e4ac-d631-4ca7-9f9b-aa2516b5b4a1"
      unitRef="usd">-1883418</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTYtMS0xLTEtMA_5baed91d-594a-4426-a50b-c6ba3234eb82"
      unitRef="usd">495410</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTYtMy0xLTEtMA_1049c477-057b-4f74-b478-8dc4cc4f75de"
      unitRef="usd">818273</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTctMS0xLTEtMA_704e1c94-abc0-40d6-af33-754c88910bc0"
      unitRef="usd">144661</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTctMy0xLTEtMA_8ca5ee37-e8e2-4271-8f31-0b410c3b892b"
      unitRef="usd">-1065145</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTgtMS0xLTEtMA_c953f20e-2dcc-426e-902a-9cbb34db97e5"
      unitRef="usd">-22167</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTgtMy0xLTEtMA_38c11bb2-890c-477f-b418-e8268b19696b"
      unitRef="usd">-9525</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTktMS0xLTEtMA_6d3d5965-f6be-4ce1-89a9-20450e17c16e"
      unitRef="usd">166828</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMTktMy0xLTEtMA_640be224-2250-4e6a-9bfa-cd9636bc3f3b"
      unitRef="usd">-1055620</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjEtMS0xLTEtMA_2fe4bed7-d61f-4bf2-913a-75bdc25930fd"
      unitRef="usdPerShare">-0.02</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjEtMy0xLTEtMA_06f1ac42-42ce-4159-9f55-8f44256a0795"
      unitRef="usdPerShare">-0.12</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjItMS0xLTEtMA_23719c4b-c48e-4431-9de0-e1b6c2b77eca"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjItMy0xLTEtMA_c55102c0-8d74-4721-9c9b-525a70dd7c94"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjMtMS0xLTEtMA_5fc32c6c-0243-4383-98ac-1575270faefd"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjMtMy0xLTEtMA_92083032-3aa3-4990-9890-b4d152c4eb62"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjUtMS0xLTEtMA_b5120b41-4b96-497c-88ca-c74461e1a32b"
      unitRef="usdPerShare">-0.02</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjUtMy0xLTEtMA_e05168eb-ff78-487c-81b7-e5f69876af5d"
      unitRef="usdPerShare">-0.12</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjYtMS0xLTEtMA_82c87cc6-7636-4e3c-8eef-2ee18ea5c0d9"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjYtMy0xLTEtMA_5e954a03-4809-402e-afaa-152c5874e8a8"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjctMS0xLTEtMA_471b74cc-5f1f-4bb9-8103-dfd541b64264"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjctMy0xLTEtMA_3b38c04c-5940-4926-8e81-c570de37e4fa"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjktMS0xLTEtMA_3f443b5e-ab6e-4d21-ba42-06ae5407afc6"
      unitRef="shares">14974663</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMjktMy0xLTEtMA_e275d1b9-295a-472e-8e87-c97786815ebd"
      unitRef="shares">15240614</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMzAtMS0xLTEtMA_ee53aef5-becf-4d4f-b0c3-f2e6dadf5002"
      unitRef="shares">15244146</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18xOS9mcmFnOjgwMzJhYWY1ZjY1MjQ2MmE5NzYyNTZjZjZiZGM2MDM2L3RhYmxlOjhkZjlhMGQ0NzhlMzRjZTQ4MTJkODkzNjMyMTYzZTBkL3RhYmxlcmFuZ2U6OGRmOWEwZDQ3OGUzNGNlNDgxMmQ4OTM2MzIxNjNlMGRfMzAtMy0xLTEtMA_5fe8f37d-1e79-4a11-8666-533b5b9701a8"
      unitRef="shares">15578309</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMy0xLTEtMS0w_a8098da5-5a8b-4dd3-807c-b612652d4f37"
      unitRef="usd">144661</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMy0zLTEtMS0w_d1b89506-f4e5-457f-ae24-a9a5960f1c94"
      unitRef="usd">-1065145</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNC0xLTEtMS0w_977daff6-1329-4239-bb5e-f539f3d4f188"
      unitRef="usd">495410</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNC0zLTEtMS0w_4db65a1e-d7a5-4b53-8765-d86405af3fde"
      unitRef="usd">818273</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNS0xLTEtMS0w_d852595b-fd5d-414a-a7d5-8f7ffe220d1d"
      unitRef="usd">-350749</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNS0zLTEtMS0w_087bc6a1-13f3-4749-aed3-2b515571f115"
      unitRef="usd">-1883418</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNy0xLTEtMS0w_97b27229-dc34-44f0-990a-9fde269d614b"
      unitRef="usd">1227607</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNy0zLTEtMS0w_391cfd0c-283e-4058-a501-ab62d8461e60"
      unitRef="usd">1152062</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfOS0xLTEtMS0w_f3c296d5-de0b-48ee-adb6-de0a31f68f55"
      unitRef="usd">162960</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfOS0zLTEtMS0w_019c0741-d45f-4f37-ab7a-9d1bfa22ba44"
      unitRef="usd">264574</us-gaap:ShareBasedCompensation>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTAtMS0xLTEtMA_33996a0e-72ba-4d8e-bced-935031d31b2b"
      unitRef="usd">280020</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTAtMy0xLTEtMA_73de50ff-2b0d-4f2e-8dfb-b0d408963182"
      unitRef="usd">543006</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTAtMS0xLTEtMTE1Nw_ca90fe73-4bef-4d7b-801e-44d072ba9e91"
      unitRef="usd">76300</cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy>
    <cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTAtMy0xLTEtMTE1Nw_be55e431-09c7-48f0-8a3e-c9ec60684514"
      unitRef="usd">-548261</cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTEtMS0xLTEtMA_8c22a6e7-7e3f-4e98-97d3-72af3a52d79b"
      unitRef="usd">13833</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTEtMy0xLTEtMA_505260f2-1ba7-472c-8d81-72e54b6c2c91"
      unitRef="usd">11333</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTQtMS0xLTEtMA_e56b51c4-83cf-43eb-88c3-d5682d328adb"
      unitRef="usd">171584</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTQtMy0xLTEtMA_9a41cd78-e787-4eab-85fd-b769df65fd6f"
      unitRef="usd">-2014438</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTUtMS0xLTEtMA_bd1d62c9-734d-4d62-8784-93b42d68d454"
      unitRef="usd">-1868350</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTUtMy0xLTEtMA_0b7de498-367f-4ce8-a3d5-416ad68a3426"
      unitRef="usd">-706102</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTYtMS0xLTEtMA_7c26d9bf-2154-421d-85db-197be2dcfce4"
      unitRef="usd">-507102</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTYtMy0xLTEtMA_2b059168-d0de-4039-b93a-c0b031ed4c06"
      unitRef="usd">-545256</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTctMS0xLTEtMA_ecfdf822-336a-4c6f-819a-1696fab9393f"
      unitRef="usd">-1311123</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTctMy0xLTEtMA_fa9dccda-9af6-4124-b451-d054872905e9"
      unitRef="usd">-2394824</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTgtMS0xLTEtMA_65a323e3-b9f3-4e7a-a8a4-0a028e780d62"
      unitRef="usd">-299937</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTgtMy0xLTEtMA_4b3f3c82-40aa-4842-b6f8-42e402fc53b4"
      unitRef="usd">-865109</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTktMS0xLTEtMA_4d6de2aa-9386-40a4-b002-486a94df09ee"
      unitRef="usd">1290139</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMTktMy0xLTEtMA_87d788fc-1b74-4e1d-ae43-f2a3b1e0e67b"
      unitRef="usd">-444331</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjAtMS0xLTEtMA_75af0df2-9df4-4ce1-8a8b-aa7196652d28"
      unitRef="usd">495410</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjAtMy0xLTEtMA_6053790d-0916-4080-a7eb-73081e6ecdb0"
      unitRef="usd">1332870</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjEtMS0xLTEtMA_45bfa7fa-b178-4a58-8d62-7379cc600294"
      unitRef="usd">1785549</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjEtMy0xLTEtMA_b7b3203a-30a0-43c9-ba47-3178eea1df35"
      unitRef="usd">888539</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjMtMS0xLTEtMA_2f9d4eca-757b-40ac-adf5-cbb8831eb342"
      unitRef="usd">19458</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjMtMy0xLTEtMA_7f29ea41-f4de-4048-8cc9-dae1ce8722c4"
      unitRef="usd">22726</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromLifeInsurancePolicies
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjYtMS0xLTEtMA_6f527164-737f-4121-b025-934d52839698"
      unitRef="usd">-200000</us-gaap:ProceedsFromLifeInsurancePolicies>
    <us-gaap:ProceedsFromLifeInsurancePolicies
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjYtMy0xLTEtMA_2c31d0fe-a568-4ef2-b400-7a0b14ed26e7"
      unitRef="usd">0</us-gaap:ProceedsFromLifeInsurancePolicies>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjgtMS0xLTEtMA_2449fc14-77a6-4a08-9faa-0a4d19677d39"
      unitRef="usd">98883</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjgtMy0xLTEtMA_115b6b43-4970-4ed6-943a-c8bff538159e"
      unitRef="usd">548435</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjktMS0xLTEtMA_ef396d20-fc0b-45db-b129-8bddacf33292"
      unitRef="usd">-318341</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMjktMy0xLTEtMA_2d5e23fd-29a3-48a4-9be1-6e8133033355"
      unitRef="usd">-571161</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzItMS0xLTEtMA_d49c8c49-8a89-4573-a9ad-ee26bf311e73"
      unitRef="usd">15000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzItMy0xLTEtMA_1fc9bd9f-a5a8-4c8d-9006-4f132ceea3a5"
      unitRef="usd">18500000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzMtMS0xLTEtMA_d5a77f4c-dd25-4dff-93af-acd36b01b58d"
      unitRef="usd">15000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzMtMy0xLTEtMA_8360529b-da6b-4a23-9ba5-37239fc10dbf"
      unitRef="usd">18500000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzUtMS0xLTEtMA_ad7de5a4-9ad3-4d6c-92cf-a984bc0e286f"
      unitRef="usd">995277</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzUtMy0xLTEtMA_3325443d-b2b0-47fb-815d-2db6ca25daf6"
      unitRef="usd">260735</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzAtMS0xLTEtNDI4_d2784439-047b-4a41-97cc-72c01005e7a8"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest>
    <us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzAtMy0xLTEtNDI4_b65a482b-b337-4ce9-a79e-6cfd3a7b9cf7"
      unitRef="usd">800000</us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzctMS0xLTEtMA_492cefbb-24a6-4530-9af7-5c21e7d7d20f"
      unitRef="usd">302802</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzctMy0xLTEtMA_ee9ac09d-6d48-448f-8d2f-10846d231047"
      unitRef="usd">442544</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzgtMS0xLTEtMA_0cbc351f-cab8-4292-a436-206fc5c9ed91"
      unitRef="usd">-1298079</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzgtMy0xLTEtMA_2bdbd0fb-0663-42ed-b25f-362a9042cde0"
      unitRef="usd">-1503279</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzktMS0xLTEtMA_0f91d6dd-e8ae-4395-b654-13511ab3c7b8"
      unitRef="usd">169129</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfMzktMy0xLTEtMA_8c0a8c15-29a3-4a02-935d-268274bf1cc7"
      unitRef="usd">-1185901</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNDAtMS0xLTEtMA_dc60aede-ca52-4038-bba2-e0f400ee2984"
      unitRef="usd">24753796</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ida5da6da6f1940a89e2ca94214d39333_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNDAtMy0xLTEtMA_e29111e4-76fd-4711-b164-40fa5c0233ce"
      unitRef="usd">28212635</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNDEtMS0xLTEtMA_d342e7b7-4740-4d09-8907-d8595c7f4a81"
      unitRef="usd">24922925</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie233d42748ec407f95f541fbd71d46ac_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yMi9mcmFnOjEzMjJkYmZlYmIwODQ2YTFhM2ZmYTIwZTZiOGFhMjA3L3RhYmxlOjc0ZTA1MDU4ZGM0YzRkODNhYTRlMTUxZWVlMDhjODYwL3RhYmxlcmFuZ2U6NzRlMDUwNThkYzRjNGQ4M2FhNGUxNTFlZWUwOGM4NjBfNDEtMy0xLTEtMA_63888486-fa78-4fb8-b684-108203907049"
      unitRef="usd">27026734</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id2ffeb106dc64405a2176740c3911624_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfMi0xLTEtMS0w_1e14be1d-c13a-46ae-9024-7e193a17b6eb"
      unitRef="shares">15263555</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id2ffeb106dc64405a2176740c3911624_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfMi0zLTEtMS0w_067a296a-9382-40d4-b110-3074cb793c43"
      unitRef="usd">49914478</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib06687c2aa5440aa9603d320be455732_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfMi01LTEtMS0w_0d54dc08-2851-498c-9b15-63472af9d41c"
      unitRef="usd">1208395</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic61089dc435b40fba685b7b8a3119d6a_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfMi03LTEtMS0w_a6cfc10c-3e13-4e6a-8ed0-beb71221a747"
      unitRef="usd">-37620</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ida5da6da6f1940a89e2ca94214d39333_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfMi05LTEtMS0w_84a4de80-407c-4120-99ba-141ac6392bc4"
      unitRef="usd">51085253</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if890c44461b6436496221a526f27e535_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfMy0xLTEtMS0w_8e4f8de7-9a16-4c11-ae33-33e1094fd07b"
      unitRef="shares">219850</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if890c44461b6436496221a526f27e535_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfMy0zLTEtMS0w_85479f12-6052-4d8c-99be-7f24225e0fb4"
      unitRef="usd">264574</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfMy05LTEtMS0w_e321a44f-8ff7-4068-8359-f306243dec02"
      unitRef="usd">264574</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="if890c44461b6436496221a526f27e535_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNC0xLTEtMS0w_5797046c-5cd1-451b-94de-b83ace6c718a"
      unitRef="shares">164866</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="if890c44461b6436496221a526f27e535_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNC0zLTEtMS0w_e771120b-1e43-459e-9b15-d9a1d0d1fe62"
      unitRef="usd">441624</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNC05LTEtMS0w_1e931085-b9e5-4db2-a392-7bd14f47e0a0"
      unitRef="usd">441624</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="iadc27382cf1543aeab148380997ffd49_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNS01LTEtMS0w_a93f83f8-1249-4d94-864f-055d9fa8febd"
      unitRef="usd">-1055620</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i932d3a3642fe4eea9f64a3315bad0bf3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNS03LTEtMS0w_ed0a48b3-0c5b-433e-a1f0-14c69b4de50c"
      unitRef="usd">-9525</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNS05LTEtMS0w_8432aa26-13cd-4e66-9a60-5c51388eb506"
      unitRef="usd">-1065145</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic03d7f9f76264ef5b4cb398729aed58c_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNi0xLTEtMS0w_9446a4c1-ddfe-472e-b436-07fd773dae46"
      unitRef="shares">15318539</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic03d7f9f76264ef5b4cb398729aed58c_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNi0zLTEtMS0w_98a75a51-942e-4fc9-8a94-c2bd9dcbcb8e"
      unitRef="usd">49737428</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i42ffa52e2ca34a65970a04537b3b4818_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNi01LTEtMS0w_77aa352c-b109-4a8c-a66e-bd875c1bc715"
      unitRef="usd">152775</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6cbedf5761f7490b8032ca938d802c9f_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNi03LTEtMS0w_ba9d34e1-58d0-4279-ab67-4c4efb2813d1"
      unitRef="usd">-47145</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie233d42748ec407f95f541fbd71d46ac_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJiODI2YjA0MzJiMDRjNTE5YTg3NWM0NmZjZmQzYmNmL3RhYmxlcmFuZ2U6YmI4MjZiMDQzMmIwNGM1MTlhODc1YzQ2ZmNmZDNiY2ZfNi05LTEtMS0w_a06b689d-d2d7-4ab6-88b4-ca48035b8122"
      unitRef="usd">49843058</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic2641b7e1d4f4e36a6431338fd938d84_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfMi0xLTEtMS0w_f41b8b47-179b-49f7-a763-2f3e05117a16"
      unitRef="shares">14988429</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic2641b7e1d4f4e36a6431338fd938d84_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfMi0zLTEtMS0w_73507129-8916-4bd0-9f18-58f13f2194f3"
      unitRef="usd">49121523</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32683bdb8c0e4ba1bd2ad06feb02693a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfMi01LTEtMS0w_5e3a7a69-114c-4648-85a5-a2160e2d76e8"
      unitRef="usd">-2131013</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i02023e16463a45f891a3eca1a68aa423_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfMi03LTEtMS0w_e3b7dd69-7318-40ee-aca6-946e87104aed"
      unitRef="usd">-117116</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfMi05LTEtMS0w_f28d4529-4a6a-42b7-b4e7-48f1e4c4b113"
      unitRef="usd">46873394</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0b204f4dda214716a8d2597171f9411e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfMy0xLTEtMS0w_d59869e4-115a-42ca-bba0-447f0ea2f11d"
      unitRef="shares">187759</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0b204f4dda214716a8d2597171f9411e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfMy0zLTEtMS0w_93ad612f-61d1-489b-b6bb-f42aa26cb1c0"
      unitRef="usd">162960</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfMy05LTEtMS0w_5d44cbd0-1232-4325-bc15-684074fa8385"
      unitRef="usd">162960</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i0b204f4dda214716a8d2597171f9411e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNC0xLTEtMS0w_18d86210-d815-4678-aa61-228b90347dcc"
      unitRef="shares">91724</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i0b204f4dda214716a8d2597171f9411e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNC0zLTEtMS0w_861478ef-82fe-487f-a81e-3a462ce85c5b"
      unitRef="usd">303088</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNC05LTEtMS0w_fb4a3c68-fa18-4928-90ca-d3385ab8eee5"
      unitRef="usd">303088</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="ie6a93a5acaec4b8598b2aebbfadd4119_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNS01LTEtMS0w_602a2215-b12b-48eb-8072-18ba969e181f"
      unitRef="usd">166828</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i832ffbf2902c4a768fc2b9b3becc3924_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNS03LTEtMS0w_52594f89-da13-4557-8ce8-514296b4b2bd"
      unitRef="usd">-22167</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNS05LTEtMS0w_292430f1-5c38-46c7-9105-7e77e9c518fc"
      unitRef="usd">144661</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idd6f054d04374954ad9f0a6ad2ea298c_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNi0xLTEtMS0w_5eb96418-6f3f-40a7-b038-94859a3c2777"
      unitRef="shares">15084464</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd6f054d04374954ad9f0a6ad2ea298c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNi0zLTEtMS0w_f5de3545-fd84-441e-8ce5-24ee4ee39998"
      unitRef="usd">48981395</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i745ba0295e724b4bbd4b33a5ee76d597_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNi01LTEtMS0w_dfbe3db3-c7a7-42c0-8b82-f3e338e4c73e"
      unitRef="usd">-1964185</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icce24f39974b4ed98da8bfbe93943fbf_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNi03LTEtMS0w_9519dd5c-22b9-463e-a315-e30181a0e2dc"
      unitRef="usd">-139283</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18yNS9mcmFnOjA4OTdkNWEzY2Y0YzRmODM5MjQ5ZWI2OTNkYmFmOWVkL3RhYmxlOmJhYjk5MmQwMmVhNTQ5ZTM5OTkzNmY2ZTE0MmQ0NjQ0L3RhYmxlcmFuZ2U6YmFiOTkyZDAyZWE1NDllMzk5OTM2ZjZlMTQyZDQ2NDRfNi05LTEtMS0w_643fa925-65de-4a20-bbfd-c8a764c34a3d"
      unitRef="usd">46877927</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zMS9mcmFnOjg2MzQzNjEwY2Y1ZDQ0Njk5OGQ2MWU2ZTE1NjE2ODQyL3RleHRyZWdpb246ODYzNDM2MTBjZjVkNDQ2OTk4ZDYxZTZlMTU2MTY4NDJfMTEzNTU_4aef16a5-4f1b-4cfc-8c19-38e0e5ea8a9e">ORGANIZATION AND BASIS OF PRESENTATION&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland Pharmaceuticals Inc. (&#x201c;Cumberland,&#x201d; the &#x201c;Company,&#x201d; or as used in the context of &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital and field sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#x2019;s products are manufactured by third parties, which are overseen by Cumberland&#x2019;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2020, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2020 (the &#x201c;2020 Annual Report on Form 10-K&#x201d;). The results of operations for the three months ended March 31, 2021, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Discontinued Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed further in Note 9, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Totect&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been presented in the financial statements and footnotes to reflect the discontinued status of Ethyol and Totect. Refer to Note 9, for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revision of prior period condensed consolidated statement of cash flows presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has made a revision to prior period amounts to conform to the current year presentation of the cash surrender value of life insurance policies over premiums paid on the condensed consolidated statement of cash flows.  The revised amounts were previously included as net changes in assets affecting operating activities.  These revisions have no net effect on the reported net cash provided by operating activities nor any impact on the reported operating results or balance sheet for the 2020 period presented.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID-19 Pandemic &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the U.S. declared a health care emergency following the outbreak of the SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect its employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Throughout the pandemic, Cumberland has faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue.  Our business and our clinical studies were impacted as less patients sought elective surgeries and our access to medical facilities was substantially limited.  During 2020, we carefully monitored our supply chain during the pandemic including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain its employees&#x2019; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Policies:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of a contingent consideration liability associated with a business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Operating Segments&lt;/span&gt;&lt;/div&gt;The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zMS9mcmFnOjg2MzQzNjEwY2Y1ZDQ0Njk5OGQ2MWU2ZTE1NjE2ODQyL3RleHRyZWdpb246ODYzNDM2MTBjZjVkNDQ2OTk4ZDYxZTZlMTU2MTY4NDJfMTEzNDg_3cf21652-02d0-452b-8c45-2289d712c660">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zMS9mcmFnOjg2MzQzNjEwY2Y1ZDQ0Njk5OGQ2MWU2ZTE1NjE2ODQyL3RleHRyZWdpb246ODYzNDM2MTBjZjVkNDQ2OTk4ZDYxZTZlMTU2MTY4NDJfMTEzNTE_42405416-9360-45bd-a543-4ffa367ff585">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of a contingent consideration liability associated with a business combination.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zMS9mcmFnOjg2MzQzNjEwY2Y1ZDQ0Njk5OGQ2MWU2ZTE1NjE2ODQyL3RleHRyZWdpb246ODYzNDM2MTBjZjVkNDQ2OTk4ZDYxZTZlMTU2MTY4NDJfMTEzNTI_328123b6-d2ac-4c53-86de-adb7f799b7ff">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zMS9mcmFnOjg2MzQzNjEwY2Y1ZDQ0Njk5OGQ2MWU2ZTE1NjE2ODQyL3RleHRyZWdpb246ODYzNDM2MTBjZjVkNDQ2OTk4ZDYxZTZlMTU2MTY4NDJfMTA1NDU_4ef1d08c-4f08-4e7e-bf66-026ab176416a"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RleHRyZWdpb246ODYyMGYxYTc2NzdjNDgwMDlmMjUxNTFkMWQ2Yjc3ZjdfNDI5_e7cd8ff3-1c8d-47d3-9416-45033d87912b">EARNINGS (LOSS) PER SHARE&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(350,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,883,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,065,145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (income) loss at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,055,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,974,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,240,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,244,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,578,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021 and 2020, restricted stock awards and options to purchase 215,600 and 431,226 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RleHRyZWdpb246ODYyMGYxYTc2NzdjNDgwMDlmMjUxNTFkMWQ2Yjc3ZjdfNDMx_721c8e87-f8f7-478e-ba64-cf67a9484b64">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2021 and 2020:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(350,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,883,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,065,145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (income) loss at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,055,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,974,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,240,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,244,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,578,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfMy0xLTEtMS0w_f70f9fd6-6381-435a-8bf4-30043e54eac3"
      unitRef="usd">-350749</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfMy0zLTEtMS0w_f5f0e4ac-d631-4ca7-9f9b-aa2516b5b4a1"
      unitRef="usd">-1883418</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfNC0xLTEtMS0w_5baed91d-594a-4426-a50b-c6ba3234eb82"
      unitRef="usd">495410</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfNC0zLTEtMS0w_1049c477-057b-4f74-b478-8dc4cc4f75de"
      unitRef="usd">818273</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfNS0xLTEtMS0xOTUx_66e368ca-3de1-41f8-90c4-8d0aa6c44aff"
      unitRef="usd">144661</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfNS0zLTEtMS0xOTUx_be41b949-3f19-496e-a724-046fd0e1dc11"
      unitRef="usd">-1065145</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfNS0xLTEtMS0w_c953f20e-2dcc-426e-902a-9cbb34db97e5"
      unitRef="usd">-22167</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfNS0zLTEtMS0w_38c11bb2-890c-477f-b418-e8268b19696b"
      unitRef="usd">-9525</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfNi0xLTEtMS0w_6d3d5965-f6be-4ce1-89a9-20450e17c16e"
      unitRef="usd">166828</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfNi0zLTEtMS0w_640be224-2250-4e6a-9bfa-cd9636bc3f3b"
      unitRef="usd">-1055620</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfOC0xLTEtMS0w_3f443b5e-ab6e-4d21-ba42-06ae5407afc6"
      unitRef="shares">14974663</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfOC0zLTEtMS0w_e275d1b9-295a-472e-8e87-c97786815ebd"
      unitRef="shares">15240614</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfMTAtMS0xLTEtMTk1MQ_dbf829bb-3f65-40c2-844d-8bd917f46e6d"
      unitRef="shares">269483</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfMTAtMy0xLTEtMTk1MQ_5eeb6546-82ba-4fa2-833b-7f078a666e53"
      unitRef="shares">337695</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfMTAtMS0xLTEtMA_ee53aef5-becf-4d4f-b0c3-f2e6dadf5002"
      unitRef="shares">15244146</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RhYmxlOjNlNjYwMzFhN2ZmMjQ1ZjY5NWUwNjY3ZGJjMDFjMzZjL3RhYmxlcmFuZ2U6M2U2NjAzMWE3ZmYyNDVmNjk1ZTA2NjdkYmMwMWMzNmNfMTAtMy0xLTEtMA_5fe8f37d-1e79-4a11-8666-533b5b9701a8"
      unitRef="shares">15578309</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RleHRyZWdpb246ODYyMGYxYTc2NzdjNDgwMDlmMjUxNTFkMWQ2Yjc3ZjdfMjUz_a1cdeaba-2962-430a-ad61-f1939d53453e"
      unitRef="shares">215600</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y18zNy9mcmFnOjg2MjBmMWE3Njc3YzQ4MDA5ZjI1MTUxZDFkNmI3N2Y3L3RleHRyZWdpb246ODYyMGYxYTc2NzdjNDgwMDlmMjUxNTFkMWQ2Yjc3ZjdfMjYw_c1e43dbb-afc7-4a27-8c78-d341f227f30c"
      unitRef="shares">431226</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RleHRyZWdpb246MzViZjAyYzAxYWQ4NDI0ZTlmMTg5MDE1ZjIxMDcxNTJfMjMxNQ_531ca765-c12f-44d3-bfee-cf0433401b85">REVENUES&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net revenues consisted of the following for the three months ended March 31, 2021 and 2020:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,994,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,311,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,052,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,425,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,096,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(450,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RediTrex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,537,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,330,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Omeclamox-Pak revenue for the first quarter of 2021 was the result of Cumberland currently being out of commercial inventory of this product. The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19, and their operations are currently suspended. The Company is awaiting resumption of their operations.  Net revenue for the first quarter of 2021 was also negatively impacted by product returns during the period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#x2019;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual payments associated with the partner&#x2019;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.&lt;/span&gt;Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#x2019;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.1&#160;million and $0.2 million for the three months ended March 31, 2021 and 2020</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RleHRyZWdpb246MzViZjAyYzAxYWQ4NDI0ZTlmMTg5MDE1ZjIxMDcxNTJfMjMxOQ_ddb24f23-153b-43b8-a79b-ec2b14985092">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net revenues consisted of the following for the three months ended March 31, 2021 and 2020:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,994,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,311,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,052,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,425,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,096,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(450,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RediTrex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,537,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,330,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i529667d136134653822f8cd1f52ea7d0_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfMy0xLTEtMS0w_4f9e22d7-7790-4d72-9f92-891910ea1689"
      unitRef="usd">2994378</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c72789317264e7cac1350e71f0ab560_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfMy0zLTEtMS0w_283aca1c-4bcb-46b7-b233-62ad1f976f4d"
      unitRef="usd">3311696</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2cea9b0a3e2640afb98e17b1e3a6f819_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfNC0xLTEtMS0w_2a06980c-11e7-4c25-807e-a646ec4f5147"
      unitRef="usd">5052243</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i590eaf4520974d29b6b01a687d2d13fc_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfNC0zLTEtMS0w_137b905e-a31b-4a8c-aaff-b7a36394894b"
      unitRef="usd">2425755</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id94b2cb8e46b43f8ba1807feeb2a3fe7_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfNS0xLTEtMS0w_1489e0bc-c1fa-4596-a8b4-5aa45f48c15a"
      unitRef="usd">1539496</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i586cba84dc4847daab9569a2b1c1b879_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfNS0zLTEtMS0w_09bec910-2884-48df-9dee-1f102fd6b281"
      unitRef="usd">1096291</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib469a00b1c1e41ebaf007975ede59684_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfNi0xLTEtMS0w_1ccfc71b-01a0-4958-b5be-e5e156816a90"
      unitRef="usd">117191</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcc02cc49f4b429aa9f1c74f9bc16e6b_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfNi0zLTEtMS0w_14260d12-2681-4842-be7a-1a43afaaa7ec"
      unitRef="usd">713899</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f27ae48034942de95317f99306eea46_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfNy0xLTEtMS0w_35643522-0185-40e4-ac23-6c555f801d22"
      unitRef="usd">-450263</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i645b158fe75341daa01ca68e5cf1c2b6_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfNy0zLTEtMS0w_ad546a39-1120-45ba-b9b3-c900e540ef08"
      unitRef="usd">114770</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i613693e28d6e4692be7579f7e5ab1d49_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfOC0xLTEtMS0w_f38768bf-9429-40a0-9399-ef544dc186ec"
      unitRef="usd">1134264</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i823406d319024699bfab22321dde04e3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfOC0zLTEtMS0w_d1d9d1a0-b0ad-401d-b9c2-71860744fd22"
      unitRef="usd">208763</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39d646b80ea44ec583582f1c79953d87_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfOS0xLTEtMS0yMzc_1c43feba-d345-4931-a1d5-434e09a8a3ad"
      unitRef="usd">-32252</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0edefe7ed797492eae26ff926abd627a_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfOS0zLTEtMS0yNDM_33c0349e-4d77-496f-a9e7-611ef03ab763"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i763bd43cce884a5780a96bbcfb7e0253_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfOS0xLTEtMS0w_196d93e6-6483-4403-a4dd-021e5d240a85"
      unitRef="usd">182102</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i541a71eb9df04c92806ebdb9f1ae4771_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfOS0zLTEtMS0w_053464f4-6eb1-4135-9a95-1c6bb0a88011"
      unitRef="usd">459560</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfMTAtMS0xLTEtMA_2587ed58-584c-4341-b840-199867a6916b"
      unitRef="usd">10537159</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RhYmxlOjIzNDkyY2ExZmI2MDQ4M2I5ZGRjM2M2YjM3M2ZjOGRmL3RhYmxlcmFuZ2U6MjM0OTJjYTFmYjYwNDgzYjlkZGMzYzZiMzczZmM4ZGZfMTAtMy0xLTEtMA_f0ccd5ce-bf17-434a-a19d-12819b3f6ff1"
      unitRef="usd">8330734</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e10e772bb294442900e5d9b697e71e3_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RleHRyZWdpb246MzViZjAyYzAxYWQ4NDI0ZTlmMTg5MDE1ZjIxMDcxNTJfMjIxNw_67c261ae-5b53-46b4-a4c4-e43c765d611f"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4068d158ecb7413b92d283e5bce21c80_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180MC9mcmFnOjM1YmYwMmMwMWFkODQyNGU5ZjE4OTAxNWYyMTA3MTUyL3RleHRyZWdpb246MzViZjAyYzAxYWQ4NDI0ZTlmMTg5MDE1ZjIxMDcxNTJfMjIyNA_32b4c045-ee2d-4d33-a29c-bfe494928edb"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMjA2NA_06691972-4218-449e-ab8d-ed0ba94754fb">INVENTORIES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company works closely with third parties to manufacture and package finished goods for sale.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#x2019;s warehouses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At March 31, 2021 and December 31, 2020, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.1 million and $0.2 million, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient (&#x201c;API&#x201d;) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory at March 31, 2021 and December 31, 2020.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consigned inventory represents Authorized Generic inventory stored with Perrigo until shipment.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition.  At March 31, 2021 and December 31, 2020, total non-current inventory, including Vibativ and ifetroban, was $10.4&#160;million and $11.7&#160;million, respectively. The Company had $0.8 million and $2.1 million of Vibativ finished goods included in non-current inventory at March 31, 2021 and December 31, 2020.  The Company also has obtained $0.4&#160;million of finished goods in non-current inventory for API related to its ifetroban clinical initiatives at March 31, 2021 and December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2021 and December 31, 2020 the Company's net inventories consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,763,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,223,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,497,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,943,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,426,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,294,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,415,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,656,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,010,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,638,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryValuationReserves
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMTA5OTUxMTYzMDQxMA_677e2d5e-685b-44d5-bb32-96ab30e48ee2"
      unitRef="usd">100000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMTA5OTUxMTYzMDM3OA_40930b6c-f808-4dad-a527-f76159c587d2"
      unitRef="usd">200000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNoncurrent
      contextRef="ic3f04630c9f547b5be864f1c66564cb8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMTA5OTUxMTYzMTU2Mw_2c09cb6a-00ca-4ba7-9de6-3b7464ac7b2a"
      unitRef="usd">15600000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMTgwOQ_51231c4e-0217-4478-b1b0-13e464c1647f"
      unitRef="usd">10400000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMTgxNg_8821c5f4-f4b2-4164-9e50-de84bd0c461d"
      unitRef="usd">11700000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryFinishedGoods
      contextRef="i7b759ac132064b2787c2b5a4ad1e70f7_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMTg1MA_4c89d1af-2180-4cd7-a0b5-a7199a4c702e"
      unitRef="usd">800000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="ic3f04630c9f547b5be864f1c66564cb8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMTA5OTUxMTYzMTkzMA_c6e0d23d-8fa6-4cb9-b87f-38ea70df9426"
      unitRef="usd">2100000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNoncurrent
      contextRef="idd43aeaa2b4b4955aef55acce99cd31d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMTA5OTUxMTYzMTY5OA_1ec454d7-ff27-4c45-9b9d-88bf4954c256"
      unitRef="usd">400000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i2a40e1cbac204fb18cf00c3b1f6c81c6_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMTA5OTUxMTYzMTY5OA_c9e8c95f-6bd4-4d75-aecd-5df002058046"
      unitRef="usd">400000</us-gaap:InventoryNoncurrent>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RleHRyZWdpb246MGE0ZTlkYTYwNzM2NGM3MDg4NTJjOThhMjcyZGI5N2JfMjA2NQ_ee443190-2ea3-49fe-bdc0-d7b4f92036d3">he Company's net inventories consisted of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,763,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,223,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,497,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,943,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,426,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,294,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,415,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,656,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,010,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,638,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfMi0yLTEtMS0w_bc1d9888-067d-4a18-b25a-9ea028ac4252"
      unitRef="usd">14763418</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfMi00LTEtMS0w_85c4d800-7f65-43a1-80d0-b934b6c57493"
      unitRef="usd">16223162</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfMi00LTEtMS0w_a87595c0-4f9a-49b2-84b8-a42980a4c8ca"
      unitRef="usd">16223162</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfMy0yLTEtMS0w_23a307a0-e150-4c44-ba23-ebeb0e64b9d7"
      unitRef="usd">166052</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfMy00LTEtMS0w_8aa43aca-d9fb-47cc-8b59-cccbe7b389a1"
      unitRef="usd">128005</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfMy00LTEtMS0w_967e84c7-bb22-469d-bab6-b11559378ac2"
      unitRef="usd">128005</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfNC0yLTEtMS0w_939c49d1-5b92-4fa0-9119-9bf3907d85be"
      unitRef="usd">5497079</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfNC00LTEtMS0w_a59fe63e-109a-404f-9734-a219d4f801f6"
      unitRef="usd">5943732</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfNC00LTEtMS0w_f7fc6513-7e0d-4e6c-8152-1d7516c5491b"
      unitRef="usd">5943732</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryGross
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfNS0yLTEtMS0w_ccee4921-d5da-4291-b27a-e888e092b07c"
      unitRef="usd">20426549</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfNS00LTEtMS0w_fad0ec44-7b44-4599-ab6c-6d5be1a9770c"
      unitRef="usd">22294899</us-gaap:InventoryGross>
    <us-gaap:InventoryNoncurrent
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfNi0yLTEtMS0w_2095f614-e0d1-452d-94dd-bbb7754a376c"
      unitRef="usd">10415786</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfNi00LTEtMS0w_f72e202e-8091-4656-8800-9e954337d43b"
      unitRef="usd">11656742</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfNy0yLTEtMS0w_df926762-746d-40ec-8d89-12ac3fe76efa"
      unitRef="usd">10010763</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180My9mcmFnOjBhNGU5ZGE2MDczNjRjNzA4ODUyYzk4YTI3MmRiOTdiL3RhYmxlOjc4Njc3ZjEwMjQ4MTRmOGQ4MTlmMDIyZGI0ZjJkNWZmL3RhYmxlcmFuZ2U6Nzg2NzdmMTAyNDgxNGY4ZDgxOWYwMjJkYjRmMmQ1ZmZfNy00LTEtMS0w_c83b058d-6dd9-4816-8fe4-d48e1034fc06"
      unitRef="usd">10638157</us-gaap:InventoryNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RleHRyZWdpb246ODQ1MWFmZTA3ZWE0NDVlNzkyYmU4YWI3MDkwNTVmMThfMTc5NQ_d09f9ed8-1806-4483-9564-99742d56c4dd">LEASES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland&#x2019;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#x2019;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#x2019;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%. The weighted-average remaining lease term at March 31, 2021 is 1.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Position&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2021 and December 31, 2020 , the Company's lease assets and liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,784,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,028,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,831,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.3 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Lease Liabilities at March 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(143,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,831,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.865%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RleHRyZWdpb246ODQ1MWFmZTA3ZWE0NDVlNzkyYmU4YWI3MDkwNTVmMThfMTYzNw_e915ab4e-5f32-4f5a-ac40-e9345a21d4bc"
      unitRef="number">0.0742</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RleHRyZWdpb246ODQ1MWFmZTA3ZWE0NDVlNzkyYmU4YWI3MDkwNTVmMThfMTY5Mg_d672bae0-b99e-4670-acdc-005803a5c8e9">P1Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <cpix:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RleHRyZWdpb246ODQ1MWFmZTA3ZWE0NDVlNzkyYmU4YWI3MDkwNTVmMThfMTc5Mw_dc9c2930-f229-45ee-9a8e-f97744a63ee0">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2021 and December 31, 2020 , the Company's lease assets and liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,784,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,028,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,831,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.3 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:&lt;/span&gt;&lt;/div&gt;</cpix:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjZmNDBiYTgwYTEzYzQ2YzU4NWIwNzI0NjE1YzhhYjkwL3RhYmxlcmFuZ2U6NmY0MGJhODBhMTNjNDZjNTg1YjA3MjQ2MTVjOGFiOTBfMS0yLTEtMS0w_e6f68ee6-031b-45cd-af89-12fb7eb56130"
      unitRef="usd">1784142</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjZmNDBiYTgwYTEzYzQ2YzU4NWIwNzI0NjE1YzhhYjkwL3RhYmxlcmFuZ2U6NmY0MGJhODBhMTNjNDZjNTg1YjA3MjQ2MTVjOGFiOTBfMS00LTEtMS0w_346306d0-56b8-4495-8348-fea13322983d"
      unitRef="usd">2028148</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjVhN2YyOTEyZjYxNTRiMTE4NzhhYzc2ZjcyMTc4YzZhL3RhYmxlcmFuZ2U6NWE3ZjI5MTJmNjE1NGIxMTg3OGFjNzZmNzIxNzhjNmFfMS0yLTEtMS0w_7796e2c6-0558-49f6-995c-98d965dcdafe"
      unitRef="usd">1042074</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjVhN2YyOTEyZjYxNTRiMTE4NzhhYzc2ZjcyMTc4YzZhL3RhYmxlcmFuZ2U6NWE3ZjI5MTJmNjE1NGIxMTg3OGFjNzZmNzIxNzhjNmFfMS00LTEtMS0w_e6e03b8c-00a9-465e-a8cc-7636f7c1e225"
      unitRef="usd">1016779</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjVhN2YyOTEyZjYxNTRiMTE4NzhhYzc2ZjcyMTc4YzZhL3RhYmxlcmFuZ2U6NWE3ZjI5MTJmNjE1NGIxMTg3OGFjNzZmNzIxNzhjNmFfMy0yLTEtMS0w_cb40b9a6-bb5e-42c8-86cd-e07142a6e99b"
      unitRef="usd">789200</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjVhN2YyOTEyZjYxNTRiMTE4NzhhYzc2ZjcyMTc4YzZhL3RhYmxlcmFuZ2U6NWE3ZjI5MTJmNjE1NGIxMTg3OGFjNzZmNzIxNzhjNmFfMy00LTEtMS0w_d873dae5-ad4b-4d11-81a2-3767e5c9cf95"
      unitRef="usd">1059693</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:LeaseLiability
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjVhN2YyOTEyZjYxNTRiMTE4NzhhYzc2ZjcyMTc4YzZhL3RhYmxlcmFuZ2U6NWE3ZjI5MTJmNjE1NGIxMTg3OGFjNzZmNzIxNzhjNmFfNC0yLTEtMS0w_1e794a74-5be4-455d-b3ea-234d806b10a5"
      unitRef="usd">1831274</cpix:LeaseLiability>
    <cpix:LeaseLiability
      contextRef="i32068be194474f9cb55326666a7fbec0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjVhN2YyOTEyZjYxNTRiMTE4NzhhYzc2ZjcyMTc4YzZhL3RhYmxlcmFuZ2U6NWE3ZjI5MTJmNjE1NGIxMTg3OGFjNzZmNzIxNzhjNmFfNC00LTEtMS0w_a0526f03-1e5d-4f95-b195-eb343d99d1bc"
      unitRef="usd">2076472</cpix:LeaseLiability>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RleHRyZWdpb246ODQ1MWFmZTA3ZWE0NDVlNzkyYmU4YWI3MDkwNTVmMThfMTA5OTUxMTYzMzc1MQ_bf4a69fe-adc0-472d-a99b-d1346935014e"
      unitRef="usd">300000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RleHRyZWdpb246ODQ1MWFmZTA3ZWE0NDVlNzkyYmU4YWI3MDkwNTVmMThfMTc5NA_a3a9443f-2902-467d-bf1f-15cbaba4cbff">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Lease Liabilities at March 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(143,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,831,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOmJkNGM5ZTRkZTJmMzQyNmU4NzBhYmIxZjEzMjhkZWU0L3RhYmxlcmFuZ2U6YmQ0YzllNGRlMmYzNDI2ZTg3MGFiYjFmMTMyOGRlZTRfMi0yLTEtMS0w_6112cac3-5152-4b8b-971d-963e6487e264"
      unitRef="usd">862682</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOmJkNGM5ZTRkZTJmMzQyNmU4NzBhYmIxZjEzMjhkZWU0L3RhYmxlcmFuZ2U6YmQ0YzllNGRlMmYzNDI2ZTg3MGFiYjFmMTMyOGRlZTRfMy0yLTEtMS0w_654fe661-2ba2-4bcb-ae13-5183fba137a2"
      unitRef="usd">1019313</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOmJkNGM5ZTRkZTJmMzQyNmU4NzBhYmIxZjEzMjhkZWU0L3RhYmxlcmFuZ2U6YmQ0YzllNGRlMmYzNDI2ZTg3MGFiYjFmMTMyOGRlZTRfNC0yLTEtMS0w_6067b3e2-5871-4f1d-b4e5-6c48f93033b7"
      unitRef="usd">92478</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <cpix:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOmJkNGM5ZTRkZTJmMzQyNmU4NzBhYmIxZjEzMjhkZWU0L3RhYmxlcmFuZ2U6YmQ0YzllNGRlMmYzNDI2ZTg3MGFiYjFmMTMyOGRlZTRfNS0yLTEtMS0w_e8a7d313-5647-4c30-a90e-4e72978e42df"
      unitRef="usd">0</cpix:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOmJkNGM5ZTRkZTJmMzQyNmU4NzBhYmIxZjEzMjhkZWU0L3RhYmxlcmFuZ2U6YmQ0YzllNGRlMmYzNDI2ZTg3MGFiYjFmMTMyOGRlZTRfNi0yLTEtMS0w_609590d1-760c-4d8a-b40d-f4c977538481"
      unitRef="usd">1974473</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOmJkNGM5ZTRkZTJmMzQyNmU4NzBhYmIxZjEzMjhkZWU0L3RhYmxlcmFuZ2U6YmQ0YzllNGRlMmYzNDI2ZTg3MGFiYjFmMTMyOGRlZTRfNy0yLTEtMS0w_7ca8c2c4-c39a-4615-86bb-3d5efc421387"
      unitRef="usd">143199</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOmJkNGM5ZTRkZTJmMzQyNmU4NzBhYmIxZjEzMjhkZWU0L3RhYmxlcmFuZ2U6YmQ0YzllNGRlMmYzNDI2ZTg3MGFiYjFmMTMyOGRlZTRfOC0yLTEtMS0w_e0b22d5e-f84b-4b28-ad82-2e1fd117f288"
      unitRef="usd">1831274</us-gaap:OperatingLeaseLiability>
    <cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RleHRyZWdpb246ODQ1MWFmZTA3ZWE0NDVlNzkyYmU4YWI3MDkwNTVmMThfMjE5OTAyMzI2MzI5Ng_ad879b04-7d11-4bba-8c5b-912b5061015a">Rent expense and sublease income were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.865%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjk3ZTYwNmM4MDdkMjQ0MDc5OGVmZTA0ZmY2Nzc3Y2UzL3RhYmxlcmFuZ2U6OTdlNjA2YzgwN2QyNDQwNzk4ZWZlMDRmZjY3NzdjZTNfMi0yLTEtMS0xODc2_629be420-54c9-4e46-88a9-c23bff3cc15b"
      unitRef="usd">227395</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjk3ZTYwNmM4MDdkMjQ0MDc5OGVmZTA0ZmY2Nzc3Y2UzL3RhYmxlcmFuZ2U6OTdlNjA2YzgwN2QyNDQwNzk4ZWZlMDRmZjY3NzdjZTNfMi00LTEtMS0xODc2_7417dd93-7709-4b51-b477-6aa81b834aba"
      unitRef="usd">221201</us-gaap:LeaseAndRentalExpense>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjk3ZTYwNmM4MDdkMjQ0MDc5OGVmZTA0ZmY2Nzc3Y2UzL3RhYmxlcmFuZ2U6OTdlNjA2YzgwN2QyNDQwNzk4ZWZlMDRmZjY3NzdjZTNfNC0yLTEtMS0xODc2_faa2206f-266f-488e-9e06-900760f7c27e"
      unitRef="usd">178029</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="iab034ee5f7a24d37956b0daf2324f335_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180Ni9mcmFnOjg0NTFhZmUwN2VhNDQ1ZTc5MmJlOGFiNzA5MDU1ZjE4L3RhYmxlOjk3ZTYwNmM4MDdkMjQ0MDc5OGVmZTA0ZmY2Nzc3Y2UzL3RhYmxlcmFuZ2U6OTdlNjA2YzgwN2QyNDQwNzk4ZWZlMDRmZjY3NzdjZTNfNC00LTEtMS0xODc2_e1b6492d-b493-43d3-9ddc-2cfd7be2d683"
      unitRef="usd">169631</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfODc1OA_7d886101-b487-40a8-aeae-d3878c94361e">SHAREHOLDERS&#x2019; EQUITY AND DEBT&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the three months ended March 31, 2021 and March 31, 2020, the Company repurchased 91,724 shares and 164,866 shares, respectively, of common stock for approximately $0.3 million and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share purchases and sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the Company's March 2021 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allows the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. The Company does not currently have an ATM feature in place.  Cumberland plans to continue to evaluate the market for its common shares, and if favorable, will further evaluate whether or not to enter into an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock.  The Company did not issue any shares under an ATM during the three months ended March 31, 2021 or March 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Share Grants and Incentive Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021 and March 31, 2020, the Company issued 35,850 shares and 229,141 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant.  During the three months ended March 31, 2021, the Company also issued 172,350 incentive stock options to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in March 2031. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 7, 2020, the Company entered into a Third Amendment to the Revolving Credit Note and Fourth Amendment (&#x201c;Fourth Amendment&#x201d;) to the Revolving Credit Loan Agreement with Pinnacle Bank (the &#x201c;Pinnacle Agreement&#x201d;). The original Pinnacle Agreement was dated July 2017. The Fourth Amendment provides for a principal available for borrowing of up to $15&#160;million and Cumberland has the ability to request an increase of up to an additional $5&#160;million, upon the satisfaction of certain conditions and approval by Pinnacle Bank. If fully expanded, the Fourth Amendment would provide a maximum principal available for borrowing of up to $20&#160;million.  The Fourth Amendment extended the maturity date of the Pinnacle Agreement through October 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Pinnacle Agreement, which extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of March 31, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021 and December 31, 2020, the Company had $15.0 million in borrowings outstanding under its revolving credit facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The pricing under the Fourth Amendment provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;applicable interest rate under the Pinnacle Agreement was 3.65% at March 31, 2021.  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the line of credit are collateralized by substantially all of our assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Paycheck Protection Program Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The PPP is administered by the U.S. Small Business Administration ("SBA").&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The loan matures April 14, 2022, and bears interest at a rate of 1.0% per year, payable monthly. The loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From the date of funding the Company used the loan amount for such qualifying expenses. Cumberland has elected to account for the proceeds of the loan as a government grant under &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. As a result, the Company has recorded the $2,187,140 as a deferred income liability, which is included as a component of other current liabilities on the condensed consolidated balance sheet. The Company intends to apply IAS 20 to the PPP loan forgiveness and has presented the amounts expected to be forgiven as deferred income. The Company will account for the anticipated forgiveness of the PPP loan under IAS 20 when the Company believes that the forgiveness is reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland applied for this loan after carefully considering, with its bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. The Company evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, based on assistance from the PPP loan, the Company currently does not foresee doing so. In October 2020, the Company submitted a request for forgiveness of the PPP loan. The request was approved by the lender, Pinnacle Bank, who then submitted it to SBA for the SBA's review and approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;WHC Biopharmaceuticals, Pte. Ltd&lt;/span&gt;. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of a $0.2&#160;million convertible note, which was funded during the three months ended March 31, 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i61c481ad9f504703a94e6b9be6f518e2_I20100513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMTI5_c065d962-6435-49dd-b733-391b75d55d14"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i26d732474c194cee89c889d4f8a693f2_I20160131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMjkw_0609ea63-cc0d-40f2-b426-71973ef27594"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i0b204f4dda214716a8d2597171f9411e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMzk2_3121ab33-242d-4e89-9533-2a943cc49d36"
      unitRef="shares">91724</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="if890c44461b6436496221a526f27e535_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfNDEw_4818f994-42e5-4323-b58a-b1344d6640ac"
      unitRef="shares">164866</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i0b204f4dda214716a8d2597171f9411e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfNDYy_b9ab3b16-3f03-46f7-9b09-b75ec9fb1f94"
      unitRef="usd">300000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="if890c44461b6436496221a526f27e535_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfNDY5_aaabfdb9-7ed0-4982-a138-956f692af312"
      unitRef="usd">400000</us-gaap:StockRepurchasedDuringPeriodValue>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities
      contextRef="i08b1da814e684be58d651fa09524635d_D20171101-20171130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMTAyMA_ef72c331-40e2-496f-a5f0-7e550f120e71"
      unitRef="usd">100000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib2eda2a4dac14ec3b727863dc09461ee_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMTM0Nw_979147cd-c164-405c-a64c-f85b27765e78"
      unitRef="shares">35850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i176b3b536b2f4266bb9351936fafc0a5_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMTM2MQ_1c152c8d-cb78-4018-8894-6c4217394e4c"
      unitRef="shares">229141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id97ac84efc164cb38bbe53650262439c_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfODc1OQ_f28f25aa-45bc-4aef-90f1-3cf89ad73a42">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8efd5212c2ea4438a3c6b998c82af06a_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMTA5OTUxMTY0MDY1OA_b4895bf2-86f5-4497-a965-d1953e897219"
      unitRef="shares">172350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2ddf705ec76d45ce90dcfd34b198b915_I20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMzA1MA_371218c4-a9ec-4af5-b6eb-9243001541d4"
      unitRef="usd">15000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <cpix:LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount
      contextRef="i2ddf705ec76d45ce90dcfd34b198b915_I20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMzEzMA_7eac9586-968b-4673-b2a0-2bb9a1009ac7"
      unitRef="usd">5000000</cpix:LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount>
    <cpix:LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity
      contextRef="i2ddf705ec76d45ce90dcfd34b198b915_I20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMzMxNg_cece4d77-73c3-4c85-b529-33d4e1354c29"
      unitRef="usd">20000000</cpix:LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity>
    <us-gaap:LongTermLineOfCredit
      contextRef="i49d1ed31c7894e6b987d5f1b88ea735e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMTY0OTI2NzQ1NDE4NQ_d4cd0515-31b4-40cd-a7d1-67a4f7fd4e6f"
      unitRef="usd">15000000.0</us-gaap:LongTermLineOfCredit>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ida4acda1a0824ddd98ba37f7456c0970_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfNDcxNQ_94e809ef-5b13-4d2e-a723-e8c683af882f"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic626a31ddbca438a89b05457be379d25_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfNDcyMQ_55a56c22-9b60-4d3a-9ef8-2fe767659029"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic599c92ccd35431db3b06f4238341683_D20200814-20200814"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfNDc2MA_d8f1b1f8-ebdb-4b6a-917f-ec593ce45035"
      unitRef="number">0.0090</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib53bd71fe3994d2da24c5195efd6412c_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfNDgyNg_b101fae1-de75-4714-8fab-9481b667b575"
      unitRef="number">0.0365</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i6ccab55d30cd4f3595d41c3c3554b52a_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfNDkwNA_6570a942-19d7-4e20-b197-e2d460227dd2"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived
      contextRef="i830bb87cb40044cd957e698b46665fd6_D20200420-20200420"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMjE5OTAyMzI3MDcxOA_080d6827-3cd9-4018-a485-0bd79a10ad60"
      unitRef="usd">2187140</cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived>
    <cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived
      contextRef="i830bb87cb40044cd957e698b46665fd6_D20200420-20200420"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfMjE5OTAyMzI3MDczMA_bab7b89a-074b-4e7e-aa67-eae443ddce05"
      unitRef="usd">2187140</cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i59247f7dd59d4f28aee9f37d45d509aa_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfODQxMw_b9867a34-f31f-4153-a572-2243df76f2df"
      unitRef="usd">200000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icd3a639d6f35423aa3c2f6243856ec35_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y180OS9mcmFnOjFiZjM3NmZlNDZiYjQ0YWU5MWYyOTE1NTdmMjJkN2ZlL3RleHRyZWdpb246MWJmMzc2ZmU0NmJiNDRhZTkxZjI5MTU1N2YyMmQ3ZmVfODQ5Mw_49c01eb0-8816-465c-90dc-a669f9bc68cd"
      unitRef="usd">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181Mi9mcmFnOmFiNjUxMzUzMDg4YzQzMGJiZGVjYjIxMWZhNTUwYzNlL3RleHRyZWdpb246YWI2NTEzNTMwODhjNDMwYmJkZWNiMjExZmE1NTBjM2VfNjM3_ed75dd45-bcd4-452e-aeb5-ac5a5cdc983c">INCOME TAXESAs of March 31, 2021, the Company has approximately $56.3 million in federal net operating loss carryforwards including approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2021 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i6c5f356638654bbdaf6b452874ae5eaf_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181Mi9mcmFnOmFiNjUxMzUzMDg4YzQzMGJiZGVjYjIxMWZhNTUwYzNlL3RleHRyZWdpb246YWI2NTEzNTMwODhjNDMwYmJkZWNiMjExZmE1NTBjM2VfNjI_002b9e52-978e-487b-b385-95187ed79e72"
      unitRef="usd">56300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181Mi9mcmFnOmFiNjUxMzUzMDg4YzQzMGJiZGVjYjIxMWZhNTUwYzNlL3RleHRyZWdpb246YWI2NTEzNTMwODhjNDMwYmJkZWNiMjExZmE1NTBjM2VfMTMz_79481232-7084-4e8f-ba3c-b3c038e6a920"
      unitRef="usd">44100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181NS9mcmFnOjIwMDMzYzU1NmQ2OTQ0MDI5NjQ5NWY2YmU4ZGY2ZTdhL3RleHRyZWdpb246MjAwMzNjNTU2ZDY5NDQwMjk2NDk1ZjZiZThkZjZlN2FfMTAxNw_5ae479a9-2d2a-4efa-aa7a-8e658499b256">COLLABORATIVE AGREEMENTS&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The agreements do not specifically designate each party&#x2019;s rights and obligations to each &lt;/span&gt;other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfNjcwMg_828df905-5a6b-466d-9b7b-26cade9a939e">ADDITIONS AND RETURN OF PRODUCT RIGHTS&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vibativ&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0&#160;million at the closing of the transaction and a $5.0&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% on future net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,200,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(995,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,336,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liability of $7.3&#160;million was classified as other current liabilities of $2.7&#160;million and other long-term liabilities of $4.6&#160;million on the condensed consolidated balance sheet as of March 31, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RediTrex&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#x2019;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As consideration for the license Cumberland paid a deposit of $100,000 at closing.  The Company provided $0.9&#160;million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#x2019; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name.  The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9&#160;million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic.  During December 2020, Cumberland launched RediTrex and the launch also resulted in a $1.0&#160;million milestone payment due to Nordic.  This milestone payment will be paid during 2021 and was recorded as an other current liability at December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has approximately $2.8&#160;million in net intangible assets related to RediTrex at March 31, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ethyol and Totect &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, Cumberland entered into an agreement with Clinigen for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the United States to Clinigen. Under the final terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $5&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first four quarterly installments totaling $3.0 million during 2020 and the fifth installment of $0.5&#160;million during the three months ended March 31, 2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as discontinued operations.  The Company will record the remaining quarterly installments during the balance of 2021.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the products. Cumberland was responsible for the products through December 31, 2019 and beginning on January 1, 2020, the products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company does not &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incur expenses associated with these payments from Clinigen. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, Marketing and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ic4690540184b48fa90ef75b783a03efb_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMTIxNw_18d0523f-a5a2-45d5-93f0-51ea64af8fed"
      unitRef="usd">20000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="ic4690540184b48fa90ef75b783a03efb_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMTI2MA_acf1025b-dc17-47da-828e-da879569a80a"
      unitRef="usd">5000000.0</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:TieredRoyaltyPaymentsPercentage
      contextRef="ic4690540184b48fa90ef75b783a03efb_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMTM2Mw_15dc1128-6a55-44e2-b58c-806b29aaad9c"
      unitRef="number">0.20</cpix:TieredRoyaltyPaymentsPercentage>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfNjcwMQ_b3610ea9-fee2-4a89-8a75-411a9042d3a3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,200,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(995,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,336,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic3f04630c9f547b5be864f1c66564cb8_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjNhMWZhZWJmM2QxNjRjNDdhZjkzMjI5MWFjMzRjZDc2L3RhYmxlcmFuZ2U6M2ExZmFlYmYzZDE2NGM0N2FmOTMyMjkxYWMzNGNkNzZfOS0xLTEtMS0w_ba5abfc6-dc34-4b14-b3da-521274a1dcd5"
      unitRef="usd">8200552</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsForRoyalties
      contextRef="ied6025b276df445997781e0a3e02560b_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjNhMWZhZWJmM2QxNjRjNDdhZjkzMjI5MWFjMzRjZDc2L3RhYmxlcmFuZ2U6M2ExZmFlYmYzZDE2NGM0N2FmOTMyMjkxYWMzNGNkNzZfMTAtMS0xLTEtMA_23d06717-f7e9-4bd8-b51a-ed7f63faf19e"
      unitRef="usd">995277</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ied6025b276df445997781e0a3e02560b_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjNhMWZhZWJmM2QxNjRjNDdhZjkzMjI5MWFjMzRjZDc2L3RhYmxlcmFuZ2U6M2ExZmFlYmYzZDE2NGM0N2FmOTMyMjkxYWMzNGNkNzZfMTEtMS0xLTEtMA_f820b0a8-e0d0-4843-8aa8-9ea4bfc0b25a"
      unitRef="usd">-280020</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="ied6025b276df445997781e0a3e02560b_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjNhMWZhZWJmM2QxNjRjNDdhZjkzMjI5MWFjMzRjZDc2L3RhYmxlcmFuZ2U6M2ExZmFlYmYzZDE2NGM0N2FmOTMyMjkxYWMzNGNkNzZfMTItMS0xLTEtMA_91280745-7a29-490a-b96b-eaacc41ab755"
      unitRef="usd">410790</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7b759ac132064b2787c2b5a4ad1e70f7_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjNhMWZhZWJmM2QxNjRjNDdhZjkzMjI5MWFjMzRjZDc2L3RhYmxlcmFuZ2U6M2ExZmFlYmYzZDE2NGM0N2FmOTMyMjkxYWMzNGNkNzZfMTMtMS0xLTEtMA_cae0e47c-269a-4727-8acc-5d6e224e3b95"
      unitRef="usd">7336045</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7b759ac132064b2787c2b5a4ad1e70f7_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMjQ0MQ_13fde4dc-a50f-4a41-a346-e5ab38c190c3"
      unitRef="usd">7300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3416c55598e64e2b95051149db842304_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMjQ5MQ_b6515f0a-aa26-443d-aa1d-7fc2a425b755"
      unitRef="usd">2700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id0ecdd80f5234983a18050bf8ecf1cda_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMjUyOQ_aaf03502-05b0-468b-98be-fdfc9801cb60"
      unitRef="usd">4600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ia0a8b608c7614df795f5ef973e97f9d9_D20161101-20161130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMjk4OA_2410009a-bea7-49c9-b578-beafbba6f92c"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="ia0a8b608c7614df795f5ef973e97f9d9_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMzAyNQ_28eaec7b-1eca-41c3-b13c-60a18ad49ed6"
      unitRef="usd">900000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i7582538d23084840b14af98041033df1_D20161101-20161130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMzA2NA_ca09e300-fbeb-4c3b-ad05-57e2742c3277"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i7582538d23084840b14af98041033df1_D20161101-20161130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMzY3NQ_4a27e200-6770-429a-80d9-b92de70cc25a"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="id8d1afac2fe04daeb9be14e2c01cb3cf_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMzg4MQ_188e9628-2d7f-4f20-8657-5ec68ea2e55a"
      unitRef="usd">900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie0eada6a93ec412dbdce374da1fb4f0c_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMzk0MQ_d696541d-4433-48f4-a92e-de5b1f838e36"
      unitRef="usd">1000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id745598dd60b4f4088bc62c2d5c607b0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMTY0OTI2NzQ0ODcwNw_2e49c163-5501-4644-bcf5-72b75b788f3d"
      unitRef="usd">1000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i9a68ec61d27040248d7dd487e14454d4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfNDEyMg_852d4e56-4887-4192-9b77-b595b3650b23"
      unitRef="usd">2800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="i78e7ac2dbdbe4730beeb4a8d45f46205_D20191001-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfNTIwNg_6251797d-7308-4a9a-856b-28fa7f2ae8d8"
      unitRef="usd">5000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment
      contextRef="i6a4c618331f148a9b3e193bc04d8c16e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMTA5OTUxMTY0NDg1MQ_685ca063-bbe2-443c-ba3c-d49719c16c77"
      unitRef="usd">3000000.0</cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment>
    <cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMjE5OTAyMzI3MzA3MA_13114e56-81a6-410b-a279-7c0e9a73a661"
      unitRef="usd">500000</cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RleHRyZWdpb246YTE3ODU5OGI2M2I0NDA3NzlkYzhmNjcxOWMyNGZmMjdfMjE5OTAyMzI3MzA4Mw_62bef6f6-076e-429a-8b77-6825f9af8afb">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company does not &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incur expenses associated with these payments from Clinigen. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, Marketing and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6874375315de4805a4b9a90949e9e0a9_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjgyODY3YTA2N2Y4MDQ0MDk5NmE5YzZiZTE0MTY4MDJkL3RhYmxlcmFuZ2U6ODI4NjdhMDY3ZjgwNDQwOTk2YTljNmJlMTQxNjgwMmRfMi0yLTEtMS0xOTg5_9efd0625-d6dd-4e57-9daa-54326f591ab8"
      unitRef="usd">495410</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d4b97906e974844a32b25017974062a_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjgyODY3YTA2N2Y4MDQ0MDk5NmE5YzZiZTE0MTY4MDJkL3RhYmxlcmFuZ2U6ODI4NjdhMDY3ZjgwNDQwOTk2YTljNmJlMTQxNjgwMmRfMi00LTEtMS0xOTg5_95a5840f-c429-42a1-95ae-f82dbcfbbf73"
      unitRef="usd">818273</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6874375315de4805a4b9a90949e9e0a9_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjgyODY3YTA2N2Y4MDQ0MDk5NmE5YzZiZTE0MTY4MDJkL3RhYmxlcmFuZ2U6ODI4NjdhMDY3ZjgwNDQwOTk2YTljNmJlMTQxNjgwMmRfMy0yLTEtMS0xOTg5_fcb8190a-45e5-460b-ba15-bc16194b8bbc"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8d4b97906e974844a32b25017974062a_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjgyODY3YTA2N2Y4MDQ0MDk5NmE5YzZiZTE0MTY4MDJkL3RhYmxlcmFuZ2U6ODI4NjdhMDY3ZjgwNDQwOTk2YTljNmJlMTQxNjgwMmRfMy00LTEtMS0xOTg5_f8e71c45-9eae-4665-aaf3-99e645e5e4aa"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i6874375315de4805a4b9a90949e9e0a9_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjgyODY3YTA2N2Y4MDQ0MDk5NmE5YzZiZTE0MTY4MDJkL3RhYmxlcmFuZ2U6ODI4NjdhMDY3ZjgwNDQwOTk2YTljNmJlMTQxNjgwMmRfNC0yLTEtMS0xOTg5_f5ebbc85-fc26-45db-8537-8ac54f81dfae"
      unitRef="usd">0</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i8d4b97906e974844a32b25017974062a_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjgyODY3YTA2N2Y4MDQ0MDk5NmE5YzZiZTE0MTY4MDJkL3RhYmxlcmFuZ2U6ODI4NjdhMDY3ZjgwNDQwOTk2YTljNmJlMTQxNjgwMmRfNC00LTEtMS0xOTg5_bf149f5b-10de-4b10-9024-24f458bc20c8"
      unitRef="usd">0</us-gaap:SellingAndMarketingExpense>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i6874375315de4805a4b9a90949e9e0a9_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjgyODY3YTA2N2Y4MDQ0MDk5NmE5YzZiZTE0MTY4MDJkL3RhYmxlcmFuZ2U6ODI4NjdhMDY3ZjgwNDQwOTk2YTljNmJlMTQxNjgwMmRfNS0yLTEtMS0xOTg5_85065061-6a79-4b42-b74e-d946c173f783"
      unitRef="usd">495410</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i8d4b97906e974844a32b25017974062a_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJlZDVhOGM3M2M1NDQ1MjQ4N2YyNjJjNTJmZjkwMTdjL3NlYzpiZWQ1YThjNzNjNTQ0NTI0ODdmMjYyYzUyZmY5MDE3Y181OC9mcmFnOmExNzg1OThiNjNiNDQwNzc5ZGM4ZjY3MTljMjRmZjI3L3RhYmxlOjgyODY3YTA2N2Y4MDQ0MDk5NmE5YzZiZTE0MTY4MDJkL3RhYmxlcmFuZ2U6ODI4NjdhMDY3ZjgwNDQwOTk2YTljNmJlMTQxNjgwMmRfNS00LTEtMS0xOTg5_a9407771-d70a-4618-a456-ba041bbf0436"
      unitRef="usd">818273</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294767065192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cumberland Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 West End Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,050,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294767976168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 24,922,925<span></span>
</td>
<td class="nump">$ 24,753,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">12,549,297<span></span>
</td>
<td class="nump">12,377,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">10,010,763<span></span>
</td>
<td class="nump">10,638,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">1,900,032<span></span>
</td>
<td class="nump">2,199,926<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">49,383,017<span></span>
</td>
<td class="nump">49,969,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">10,415,786<span></span>
</td>
<td class="nump">11,656,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">534,933<span></span>
</td>
<td class="nump">574,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">27,024,544<span></span>
</td>
<td class="nump">28,118,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">882,000<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,784,142<span></span>
</td>
<td class="nump">2,028,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3,323,603<span></span>
</td>
<td class="nump">3,234,338<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">93,348,025<span></span>
</td>
<td class="nump">96,463,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,466,281<span></span>
</td>
<td class="nump">13,396,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">1,042,074<span></span>
</td>
<td class="nump">1,016,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">11,339,215<span></span>
</td>
<td class="nump">11,254,381<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,847,570<span></span>
</td>
<td class="nump">25,667,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease noncurrent liabilities</a></td>
<td class="nump">789,200<span></span>
</td>
<td class="nump">1,059,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_OtherLongTermObligationsExcludingCurrentPortion', window );">Other long-term liabilities</a></td>
<td class="nump">7,833,328<span></span>
</td>
<td class="nump">7,862,772<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">46,470,098<span></span>
</td>
<td class="nump">49,589,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">48,981,395<span></span>
</td>
<td class="nump">49,121,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (deficit)</a></td>
<td class="num">(1,964,185)<span></span>
</td>
<td class="num">(2,131,013)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">47,017,210<span></span>
</td>
<td class="nump">46,990,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(139,283)<span></span>
</td>
<td class="num">(117,116)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">46,877,927<span></span>
</td>
<td class="nump">46,873,394<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 93,348,025<span></span>
</td>
<td class="nump">$ 96,463,305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_OtherLongTermObligationsExcludingCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Long Term Obligations, Excluding Current Portion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_OtherLongTermObligationsExcludingCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294765360696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">15,084,464<span></span>
</td>
<td class="nump">14,988,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">15,084,464<span></span>
</td>
<td class="nump">14,988,429<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294765010760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 10,537,159<span></span>
</td>
<td class="nump">$ 8,330,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">2,417,329<span></span>
</td>
<td class="nump">1,634,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">3,787,340<span></span>
</td>
<td class="nump">3,707,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,257,367<span></span>
</td>
<td class="nump">1,722,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,230,509<span></span>
</td>
<td class="nump">2,036,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">1,168,914<span></span>
</td>
<td class="nump">1,076,039<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">10,861,459<span></span>
</td>
<td class="nump">10,176,735<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(324,300)<span></span>
</td>
<td class="num">(1,846,001)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">5,426<span></span>
</td>
<td class="nump">29,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(24,417)<span></span>
</td>
<td class="num">(33,065)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) from continuing operations before income taxes</a></td>
<td class="num">(343,291)<span></span>
</td>
<td class="num">(1,849,178)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(7,458)<span></span>
</td>
<td class="num">(34,240)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total</a></td>
<td class="num">(350,749)<span></span>
</td>
<td class="num">(1,883,418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">495,410<span></span>
</td>
<td class="nump">818,273<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">144,661<span></span>
</td>
<td class="num">(1,065,145)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (income) loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">22,167<span></span>
</td>
<td class="nump">9,525<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="nump">$ 166,828<span></span>
</td>
<td class="num">$ (1,055,620)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to common shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)</a></td>
<td class="nump">0.03<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="num">(0.07)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)</a></td>
<td class="num">(0.02)<span></span>
</td>
<td class="num">(0.12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)</a></td>
<td class="nump">0.03<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">- basic (in shares)</a></td>
<td class="nump">14,974,663<span></span>
</td>
<td class="nump">15,240,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">- diluted (in shares)</a></td>
<td class="nump">15,244,146<span></span>
</td>
<td class="nump">15,578,309<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294767981288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 144,661<span></span>
</td>
<td class="num">$ (1,065,145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">495,410<span></span>
</td>
<td class="nump">818,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(350,749)<span></span>
</td>
<td class="num">(1,883,418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,227,607<span></span>
</td>
<td class="nump">1,152,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">162,960<span></span>
</td>
<td class="nump">264,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities', window );">Decrease in non-cash contingent consideration</a></td>
<td class="num">(280,020)<span></span>
</td>
<td class="num">(543,006)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy', window );">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</a></td>
<td class="num">(76,300)<span></span>
</td>
<td class="nump">548,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Noncash interest expense</a></td>
<td class="nump">13,833<span></span>
</td>
<td class="nump">11,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities affecting operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(171,584)<span></span>
</td>
<td class="nump">2,014,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">1,868,350<span></span>
</td>
<td class="nump">706,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and other assets</a></td>
<td class="nump">507,102<span></span>
</td>
<td class="nump">545,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="num">(1,311,123)<span></span>
</td>
<td class="num">(2,394,824)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(299,937)<span></span>
</td>
<td class="num">(865,109)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by (used in) operating activities from continuing operations</a></td>
<td class="nump">1,290,139<span></span>
</td>
<td class="num">(444,331)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Discontinued operations</a></td>
<td class="nump">495,410<span></span>
</td>
<td class="nump">1,332,870<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">1,785,549<span></span>
</td>
<td class="nump">888,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(19,458)<span></span>
</td>
<td class="num">(22,726)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLifeInsurancePolicies', window );">Note receivable investment funding</a></td>
<td class="num">(200,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="num">(98,883)<span></span>
</td>
<td class="num">(548,435)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(318,341)<span></span>
</td>
<td class="num">(571,161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">18,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments on line of credit</a></td>
<td class="num">(15,000,000)<span></span>
</td>
<td class="num">(18,500,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Cash payment of contingent consideration</a></td>
<td class="num">(995,277)<span></span>
</td>
<td class="num">(260,735)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest', window );">Repurchase of subsidiary shares from noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(800,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common shares</a></td>
<td class="num">(302,802)<span></span>
</td>
<td class="num">(442,544)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(1,298,079)<span></span>
</td>
<td class="num">(1,503,279)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">169,129<span></span>
</td>
<td class="num">(1,185,901)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">24,753,796<span></span>
</td>
<td class="nump">28,212,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 24,922,925<span></span>
</td>
<td class="nump">$ 27,026,734<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCurrentOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period for redemption of redeemable noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLifeInsurancePolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of corporate-owned life insurance policy, classified as investing activities. Includes, but is not limited to, bank-owned life insurance policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21C<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080552-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLifeInsurancePolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294767994872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Noncontrolling interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2019</a></td>
<td class="nump">$ 51,085,253<span></span>
</td>
<td class="nump">$ 49,914,478<span></span>
</td>
<td class="nump">$ 1,208,395<span></span>
</td>
<td class="num">$ (37,620)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,263,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">264,574<span></span>
</td>
<td class="nump">$ 264,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(441,624)<span></span>
</td>
<td class="num">$ (441,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(164,866)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,065,145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,055,620)<span></span>
</td>
<td class="num">(9,525)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2020</a></td>
<td class="nump">49,843,058<span></span>
</td>
<td class="nump">$ 49,737,428<span></span>
</td>
<td class="nump">152,775<span></span>
</td>
<td class="num">(47,145)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,318,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2020</a></td>
<td class="nump">$ 46,873,394<span></span>
</td>
<td class="nump">$ 49,121,523<span></span>
</td>
<td class="num">(2,131,013)<span></span>
</td>
<td class="num">(117,116)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2020</a></td>
<td class="nump">14,988,429<span></span>
</td>
<td class="nump">14,988,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 162,960<span></span>
</td>
<td class="nump">$ 162,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(303,088)<span></span>
</td>
<td class="num">$ (303,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">144,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,828<span></span>
</td>
<td class="num">(22,167)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2021</a></td>
<td class="nump">$ 46,877,927<span></span>
</td>
<td class="nump">$ 48,981,395<span></span>
</td>
<td class="num">$ (1,964,185)<span></span>
</td>
<td class="num">$ (139,283)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2021</a></td>
<td class="nump">15,084,464<span></span>
</td>
<td class="nump">15,084,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294762959176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BASIS OF PRESENTATION</a></td>
<td class="text">ORGANIZATION AND BASIS OF PRESENTATION<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital and field sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2020, audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2020 (the &#8220;2020 Annual Report on Form 10-K&#8221;). The results of operations for the three months ended March 31, 2021, are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in Note 9, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Totect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been presented in the financial statements and footnotes to reflect the discontinued status of Ethyol and Totect. Refer to Note 9, for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revision of prior period condensed consolidated statement of cash flows presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has made a revision to prior period amounts to conform to the current year presentation of the cash surrender value of life insurance policies over premiums paid on the condensed consolidated statement of cash flows.  The revised amounts were previously included as net changes in assets affecting operating activities.  These revisions have no net effect on the reported net cash provided by operating activities nor any impact on the reported operating results or balance sheet for the 2020 period presented.  </span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. declared a health care emergency following the outbreak of the SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect its employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, Cumberland has faced the same headwinds affecting other companies that rely on hospital admissions and patient visits to drive revenue.  Our business and our clinical studies were impacted as less patients sought elective surgeries and our access to medical facilities was substantially limited.  During 2020, we carefully monitored our supply chain during the pandemic including the flow of raw materials into the plants that manufacture our products as well as the batches of finished product emerging from those facilities. Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio, with other brands delivering a strong performance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.   The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain its employees&#8217; safety and well-being, while also keeping its business operating.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of a contingent consideration liability associated with a business combination.</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Segments</span></div>The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294763134904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2021 and 2020:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350,749)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,883,418)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,065,145)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,828&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,055,620)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,974,663&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,240,614&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,244,146&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,578,309&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:58.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.518%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and 2020, restricted stock awards and options to purchase 215,600 and 431,226 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294848311960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three months ended March 31, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.082%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994,378&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,311,696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,052,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,425,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539,496&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096,291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450,263)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,252)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459,560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,537,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,330,734&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Omeclamox-Pak revenue for the first quarter of 2021 was the result of Cumberland currently being out of commercial inventory of this product. The packager for our Omeclamox-Pak product encountered financial difficulties due to the impact of COVID-19, and their operations are currently suspended. The Company is awaiting resumption of their operations.  Net revenue for the first quarter of 2021 was also negatively impacted by product returns during the period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span>Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.1&#160;million and $0.2 million for the three months ended March 31, 2021 and 2020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294763055816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company works closely with third parties to manufacture and package finished goods for sale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#8217;s warehouses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At March 31, 2021 and December 31, 2020, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.1 million and $0.2 million, respectively.  </span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at third-party packagers. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory at March 31, 2021 and December 31, 2020.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consigned inventory represents Authorized Generic inventory stored with Perrigo until shipment.   </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.6 million that were all initially classified as non-current inventories at the date of acquisition.  At March 31, 2021 and December 31, 2020, total non-current inventory, including Vibativ and ifetroban, was $10.4&#160;million and $11.7&#160;million, respectively. The Company had $0.8 million and $2.1 million of Vibativ finished goods included in non-current inventory at March 31, 2021 and December 31, 2020.  The Company also has obtained $0.4&#160;million of finished goods in non-current inventory for API related to its ifetroban clinical initiatives at March 31, 2021 and December 31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2021 and December 31, 2020 the Company's net inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,763,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,223,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,497,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,943,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,426,549&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,294,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,415,786)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,656,742)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,010,763&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,638,157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294763102136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%. The weighted-average remaining lease term at March 31, 2021 is 1.7 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2021 and December 31, 2020 , the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,784,142&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,028,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831,274&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,472&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.3 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at March 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143,199)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831,274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income were as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.865%"><tr><td style="width:1.0%"/><td style="width:51.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.157%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,029&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,631&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294763063272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_EquityAndDebtAbstract', window );"><strong>Equity and Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY AND DEBT</a></td>
<td class="text">SHAREHOLDERS&#8217; EQUITY AND DEBT<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the three months ended March 31, 2021 and March 31, 2020, the Company repurchased 91,724 shares and 164,866 shares, respectively, of common stock for approximately $0.3 million and $0.4 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share purchases and sales</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Company's March 2021 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Sales</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allows the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. The Company does not currently have an ATM feature in place.  Cumberland plans to continue to evaluate the market for its common shares, and if favorable, will further evaluate whether or not to enter into an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock.  The Company did not issue any shares under an ATM during the three months ended March 31, 2021 or March 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Grants and Incentive Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and March 31, 2020, the Company issued 35,850 shares and 229,141 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant.  During the three months ended March 31, 2021, the Company also issued 172,350 incentive stock options to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in March 2031. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, the Company entered into a Third Amendment to the Revolving Credit Note and Fourth Amendment (&#8220;Fourth Amendment&#8221;) to the Revolving Credit Loan Agreement with Pinnacle Bank (the &#8220;Pinnacle Agreement&#8221;). The original Pinnacle Agreement was dated July 2017. The Fourth Amendment provides for a principal available for borrowing of up to $15&#160;million and Cumberland has the ability to request an increase of up to an additional $5&#160;million, upon the satisfaction of certain conditions and approval by Pinnacle Bank. If fully expanded, the Fourth Amendment would provide a maximum principal available for borrowing of up to $20&#160;million.  The Fourth Amendment extended the maturity date of the Pinnacle Agreement through October 1, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Pinnacle Agreement, which extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of March 31, 2021.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the Company had $15.0 million in borrowings outstanding under its revolving credit facility.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The pricing under the Fourth Amendment provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90%. The </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable interest rate under the Pinnacle Agreement was 3.65% at March 31, 2021.  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the line of credit are collateralized by substantially all of our assets. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPP is administered by the U.S. Small Business Administration ("SBA").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan matures April 14, 2022, and bears interest at a rate of 1.0% per year, payable monthly. The loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the date of funding the Company used the loan amount for such qualifying expenses. Cumberland has elected to account for the proceeds of the loan as a government grant under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. As a result, the Company has recorded the $2,187,140 as a deferred income liability, which is included as a component of other current liabilities on the condensed consolidated balance sheet. The Company intends to apply IAS 20 to the PPP loan forgiveness and has presented the amounts expected to be forgiven as deferred income. The Company will account for the anticipated forgiveness of the PPP loan under IAS 20 when the Company believes that the forgiveness is reasonably assured.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland applied for this loan after carefully considering, with its bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. The Company evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, based on assistance from the PPP loan, the Company currently does not foresee doing so. In October 2020, the Company submitted a request for forgiveness of the PPP loan. The request was approved by the lender, Pinnacle Bank, who then submitted it to SBA for the SBA's review and approval. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WHC Biopharmaceuticals, Pte. Ltd</span>. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of a $0.2&#160;million convertible note, which was funded during the three months ended March 31, 2021. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EquityAndDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity and Debt [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EquityAndDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294849501192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXESAs of March 31, 2021, the Company has approximately $56.3 million in federal net operating loss carryforwards including approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2021 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294763087064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATIVE AGREEMENTS</a></td>
<td class="text">COLLABORATIVE AGREEMENTS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each </span>other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294763102136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ADDITIONS AND RETURN OF PRODUCT RIGHTS</a></td>
<td class="text">ADDITIONS AND RETURN OF PRODUCT RIGHTS<div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0&#160;million at the closing of the transaction and a $5.0&#160;million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% on future net sales of the product.  The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland prepared the valuations of the contingent consideration liability utilizing significant unobservable inputs.  As a result, the valuation is classified as Level 3 fair value measurement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.977%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,200,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(995,277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280,020)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,336,045&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability of $7.3&#160;million was classified as other current liabilities of $2.7&#160;million and other long-term liabilities of $4.6&#160;million on the condensed consolidated balance sheet as of March 31, 2021.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license Cumberland paid a deposit of $100,000 at closing.  The Company provided $0.9&#160;million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name.  The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9&#160;million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic.  During December 2020, Cumberland launched RediTrex and the launch also resulted in a $1.0&#160;million milestone payment due to Nordic.  This milestone payment will be paid during 2021 and was recorded as an other current liability at December 31, 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has approximately $2.8&#160;million in net intangible assets related to RediTrex at March 31, 2021.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ethyol and Totect </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, Cumberland entered into an agreement with Clinigen for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to Clinigen. Under the final terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $5&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first four quarterly installments totaling $3.0 million during 2020 and the fifth installment of $0.5&#160;million during the three months ended March 31, 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as discontinued operations.  The Company will record the remaining quarterly installments during the balance of 2021.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exit from Ethyol and Totect meets the accounting criteria to be reported as discontinued operations. December 31, 2019, as the transition date, was the final day Cumberland was responsible for the products. Cumberland was responsible for the products through December 31, 2019 and beginning on January 1, 2020, the products' rights transitioned back to Clinigen. As a result, January 1, 2020, was the first day of discontinued operations for the Ethyol and Totect products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company does not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur expenses associated with these payments from Clinigen. </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of products sold</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, Marketing and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,410&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818,273&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294764670008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Guidance</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of a contingent consideration liability associated with a business combination.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294765500072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of numerator and denominator</a></td>
<td class="text">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2021 and 2020:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350,749)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,883,418)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,065,145)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,828&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,055,620)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,974,663&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,240,614&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,244,146&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,578,309&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294764739048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of net revenue</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net revenues consisted of the following for the three months ended March 31, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.082%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994,378&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,311,696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,052,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,425,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539,496&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096,291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450,263)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,252)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459,560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,537,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,330,734&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294849962184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text">he Company's net inventories consisted of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:57.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,763,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,223,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,497,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,943,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,426,549&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,294,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,415,786)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,656,742)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,010,763&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,638,157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294843321048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Lease Position</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2021 and December 31, 2020 , the Company's lease assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,784,142&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,028,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831,274&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,472&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.3 million and will be paid through the leases ending in October 2022 and April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Lease Liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Lease Liabilities at March 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143,199)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831,274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock', window );">Schedule of Rent Expense and Sublease Income</a></td>
<td class="text">Rent expense and sublease income were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.865%"><tr><td style="width:1.0%"/><td style="width:51.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.157%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,029&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,631&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Rent Expense and Sublease Income [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294762982856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.977%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,200,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(995,277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280,020)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,336,045&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Dissolution Payments</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dissolution payments from Clinigen are reflected as revenue from discontinued operations.  The Company does not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur expenses associated with these payments from Clinigen. </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of products sold</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, Marketing and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,410&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818,273&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294763007320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation Organization (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294843338632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">$ (350,749)<span></span>
</td>
<td class="num">$ (1,883,418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">495,410<span></span>
</td>
<td class="nump">818,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">144,661<span></span>
</td>
<td class="num">(1,065,145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (income) loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">22,167<span></span>
</td>
<td class="nump">9,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="nump">$ 166,828<span></span>
</td>
<td class="num">$ (1,055,620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; basic (in shares)</a></td>
<td class="nump">14,974,663<span></span>
</td>
<td class="nump">15,240,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of other securities (in shares)</a></td>
<td class="nump">269,483<span></span>
</td>
<td class="nump">337,695<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">15,244,146<span></span>
</td>
<td class="nump">15,578,309<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294843648040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock available for purchase through restricted stock awards and options (in shares)</a></td>
<td class="nump">215,600<span></span>
</td>
<td class="nump">431,226<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294760694600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 10,537,159<span></span>
</td>
<td class="nump">$ 8,330,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember', window );">Kristalose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,994,378<span></span>
</td>
<td class="nump">3,311,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">5,052,243<span></span>
</td>
<td class="nump">2,425,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_KristaloseMember', window );">Caldolor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,539,496<span></span>
</td>
<td class="nump">1,096,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VaprisolMember', window );">Acetadote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">117,191<span></span>
</td>
<td class="nump">713,899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_CaldolorMember', window );">Omeclamox-Pak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(450,263)<span></span>
</td>
<td class="nump">114,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,134,264<span></span>
</td>
<td class="nump">208,763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_RediTrexMember', window );">RediTrex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(32,252)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">182,102<span></span>
</td>
<td class="nump">459,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProductsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_AcetadoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_KristaloseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_KristaloseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VaprisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VaprisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_CaldolorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_CaldolorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_RediTrexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_RediTrexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294843820680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Obsolescence and discontinuance losses</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">10,415,786<span></span>
</td>
<td class="nump">11,656,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember', window );">Ifetroban Clinical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294847323752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Schedule of Inventories) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">$ 14,763,418<span></span>
</td>
<td class="nump">$ 16,223,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Consigned inventory</a></td>
<td class="nump">166,052<span></span>
</td>
<td class="nump">128,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">5,497,079<span></span>
</td>
<td class="nump">5,943,732<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, Gross, Total</a></td>
<td class="nump">20,426,549<span></span>
</td>
<td class="nump">22,294,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent</a></td>
<td class="num">(10,415,786)<span></span>
</td>
<td class="num">(11,656,742)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories classified as current</a></td>
<td class="nump">$ 10,010,763<span></span>
</td>
<td class="nump">$ 10,638,157<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294764701576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Present value of remaining lease payments, percent</a></td>
<td class="nump">7.42%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals', window );">Future minimum sublease income under noncancelable operating subleases</a></td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractually required future rental payments receivable on noncancelable subleasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294843173144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Lease Position) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 1,784,142<span></span>
</td>
<td class="nump">$ 2,028,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">1,042,074<span></span>
</td>
<td class="nump">1,016,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease noncurrent liabilities</a></td>
<td class="nump">789,200<span></span>
</td>
<td class="nump">1,059,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LeaseLiability', window );">Total</a></td>
<td class="nump">$ 1,831,274<span></span>
</td>
<td class="nump">$ 2,076,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294763187208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of Lease Liabilities at March 31, 2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 862,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">1,019,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">92,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree', window );">After 2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,974,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(143,199)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 1,831,274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, after Year Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294764787832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Rent Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="nump">$ 227,395<span></span>
</td>
<td class="nump">$ 221,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1', window );">Sublease income</a></td>
<td class="nump">$ 178,029<span></span>
</td>
<td class="nump">$ 169,631<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseSubleaseRentals1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294760789112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt (Shareholders' Equity) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>May 13, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Repurchase outstanding common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (303,088)<span></span>
</td>
<td class="num">$ (441,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities', window );">Shelf Registration, sale of corporate securities (up to)</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted in period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,850<span></span>
</td>
<td class="nump">229,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cpix_IncentiveStockOptionsMember', window );">Incentive Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted in period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock awards, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,724<span></span>
</td>
<td class="nump">164,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (303,088)<span></span>
</td>
<td class="num">$ (441,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareholdersEquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shareholders Equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareholdersEquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cpix_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cpix_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294760670360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt (Debt) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 14, 2020</div></th>
<th class="th"><div>Apr. 20, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 07, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdDomain', window );">WinHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Initial investment in joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | WinHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,187,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Fourth Amendment | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount', window );">Increase amount (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity', window );">Total capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit, unused capacity, commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Minimum | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Maximum | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_FourthAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_FourthAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294768046168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 44,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 56,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294761682520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment', window );">Financial consideration received in exchange for product license rights, installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember', window );">Clinigen | Scenario, Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Financial consideration received in exchange for product license rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Other Payments to Acquire Businesses</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TieredRoyaltyPaymentsPercentage', window );">Percentage of tiered royalty payments (up to)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,336,045<span></span>
</td>
<td class="nump">8,200,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vaprisol | Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vaprisol | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Liability recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Vested common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Net intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Unvested restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Intangible Assets, Installment Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TieredRoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tiered Royalty Payments, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TieredRoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294843258136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Change in Consideration (Details) - Vaprisol<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 8,200,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Cash payment of royalty during the period</a></td>
<td class="num">(995,277)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration included in operating expenses</a></td>
<td class="num">(280,020)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses', window );">Contingent consideration earned and accrued in operating expenses</a></td>
<td class="nump">410,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 7,336,045<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140294843004440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Dissolution Payments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 10,537,159<span></span>
</td>
<td class="nump">$ 8,330,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of products sold</a></td>
<td class="nump">2,417,329<span></span>
</td>
<td class="nump">1,634,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling, Marketing and other</a></td>
<td class="nump">3,787,340<span></span>
</td>
<td class="nump">3,707,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember', window );">Clinigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">495,410<span></span>
</td>
<td class="nump">818,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of products sold</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling, Marketing and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from discontinued operations</a></td>
<td class="nump">$ 495,410<span></span>
</td>
<td class="nump">$ 818,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>48
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MO!: [U><J\.-WJ#[P63V/U!+ P04    " #.B:Y2E<QQLO4&  "O&P  &
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M65.B>T2\.D+KY-N9>HXG((UU'=Y^.P@\CQQ-723/+CNDI*' 4&]@;?4C.)K
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MPM(&?%\:G-SU"P78WIQ/_@502P,$%     @ SHFN4AZ+<]02!@  I@X  !D
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M4?=,X2&(PLE/GK<$L5I'8!/Z7";#>$R\4UDOF4J486,H*,P^T2:(#O5<"WZ
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MX/>%05+$+W1 ^Z+VS7\!4$L#!!0    ( ,Z)KE*F9IFY0P@  "D4   9
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M+RMZ["[."1O1&O2%2O^>@=&7CM8D?>M(J!31M(J!28B: 6CA=8VS'-.P95>
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ML8R,B *B?1 ^]F>03@S_-VE:#+(B32(GR=:0T.?V2Z@@.]-+.:(>)865$+G
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M=CC0P5E*Z0#[19JYU(8G@3T])<B(GS-86=R8$ZR[A185)_RULVT3QYI\HUO
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M=O011.T,Z+Y5RIXV+L#T6=W\"U!+ P04    " #.B:Y2*URFF0<#   /!@
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MOG9W^O 7'NM)/%ZN:]O_PF'P%5D ^=XZW1R#B4%3M<-7/1_[<!(PC5X)$,<
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M-+I,DP#,L'X&Q>FN'_F-=K1 >K&DC8W&.]#Y5E-3CXI/,/X'+/\'4$L#!!0
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M+X;6>/H]%A#''@ZC$V9#.XP1"N)@G%G4A1890WO*GHEJ288DXTXIG@P,N;K
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MK;[;09@ O;_F7+U,S.W1_%M(_P)02P,$%     @ SHFN4@OOE5;$ @  P0<
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MAAE:4TU?:Q9&UJXUK*3!1N.F._P4@+(%>+Z1TCPM;+?I/B[%?U!+ P04
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MU0VH&BB>ER?V)5?Z_%\^)OK6",(LT.]7G*O=P 1H[J'3_P%02P,$%     @
MSHFN4@.#BXI?!   /!0  !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
MM5A;C]HX&/TK5K35SDBS)'8(EPJ0!B@M4D<=S?3RL-H'$PQX)[&IXT K]<>O
M[:0Q0X/)SBX\$#OQ^>XY^>S!GHNG;$.(!-_2A&5#;R/E]K7O9_&&I#AK\2UA
MZLF*BQ1+-15K/]L*@I<&E"8^"H*.GV+*O-' W+L7HP'/94(9N1<@R],4B^]C
MDO#]T(/>SQL/=+V1^H8_&FSQFCP2^6E[+]3,KZ0L:4I81CD#@JR&WBU\_38,
M-<"L^$S)/CL8 ^W*@O,G/9DOAUZ@+2()B:46@=5E1R8D2;0D9<?74JA7Z=3
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M^M]R4'+O^1R$ED;#RVX2#W:);JH\GP,W'IW*@7]P+*+/U>ZP6%.6@82LE*!
MP3P@BJ.J8B+YUIR4++B4/#7#C:(4(O0"]7S%U8Z@G.C#E^K </0/4$L#!!0
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M9"H'$D!2!)(>$/('#2 S!#([".2BPO$_#2 '".3@@)"=2 X1R.$A(;, <H1
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M=?_ 9U]02P$"% ,4    " #.B:Y2!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,Z)KE(QNK?4[P
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( ,Z)KE*97)PC$ 8  )PG   3              "  <T!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ SHFN4IK#"8M&!0   !8  !@
M             ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( ,Z)KE)^BA*<(@8  *<7   8              " @8H-  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #.B:Y2,Q:22H("  #0
M!@  &               @('B$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ SHFN4O^"@(P4!@  /!D  !@              ("!FA8
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( ,Z)KE*5S'&R
M]08  *\;   8              " @>0<  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " #.B:Y2=[*L%IP$  #]$@  &
M@($/)   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ SHFN
M4BE4)Z$Z$   ,RD  !@              ("!X2@  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( ,Z)KE)MV'#7W@,  %8(   8
M      " @5$Y  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" #.B:Y22Q1=Y!,&  #'#0  &               @(%E/0  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ SHFN4@ CA8E:!@  10\  !D
M             ("!KD,  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " #.B:Y2'HMSU!(&  "F#@  &0              @($_2@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( ,Z)KE+&"8 \3 T
M  <C   9              " @8A0  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ SHFN4IY",D(7 P  S@8  !D              ("!
M"UX  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #.B:Y2
M;;-3$F@#   5!P  &0              @(%980  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( ,Z)KE)&LD8\!@L  +0=   9
M      " @?AD  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ SHFN4J9FF;E#"   *10  !D              ("!-7   'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #.B:Y2P:U*470#  !B!P
M&0              @(&O>   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( ,Z)KE(K7*:9!P,   \&   9              " @5I\  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ SHFN4G1VL&7-
M @  T 4  !D              ("!F'\  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " #.B:Y23"I2ZAD$   )"@  &0
M@(&<@@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( ,Z)
MKE*2>L#=P0,  -D(   9              " @>R&  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ SHFN4NF%&G$F @  H 0  !D
M         ("!Y(H  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " #.B:Y2-FX. 9 #  "W"@  &0              @(%!C0  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( ,Z)KE(%DEZ96P(  %$%
M   9              " @0B1  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ SHFN4L8'9 ^] P  S@\  !D              ("!FI,
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #.B:Y2@LUX
M*Z4"   Y"   &0              @(&.EP  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( ,Z)KE(+[Y56Q (  ,$'   9
M  " @6J:  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
MSHFN4KC'2215 @  3 4  !D              ("!99T  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " #.B:Y2\>1_EFD"  !H!@  &0
M            @('QGP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( ,Z)KE+6SXJPC0(  -(&   9              " @9&B  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ SHFN4ARV+G-$ @
MBP4  !D              ("!5:4  'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " #.B:Y2],R*B-D#  "3#@  &0              @('0
MIP  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( ,Z)KE(#
M@XN*7P0  #P4   9              " @>"K  !X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ SHFN4A7!HS43 @  $ 4  !D
M     ("!=K   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M   L$0  #0              @ % O@  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( ,Z)KE*7BKL<P    !,"   +              "  7S!  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( ,Z)KE+W1P"': ,  /,8   /              "
M 67"  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #.B:Y2F3ZBA'P!  "6
M%@  &@              @ 'ZQ0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " #.B:Y2JF<489@!   +%P  $P              @ &N
LQP  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     +0 M #(,  !WR0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>79</ContextCount>
  <ElementCount>251</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>32</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statement of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity</Role>
      <ShortName>Condensed Consolidated Statement of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Shareholders' Equity and Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</Role>
      <ShortName>Shareholders' Equity and Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2127109 - Disclosure - Additions and Returns of Product Rights</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights</Role>
      <ShortName>Additions and Returns of Product Rights</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Earnings (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShare</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Revenues</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Inventories</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2316304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Leases</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2328305 - Disclosure - Additions and Returns of Product Rights (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables</Role>
      <ShortName>Additions and Returns of Product Rights (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails</Role>
      <ShortName>Organization and Basis of Presentation Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Earnings (Loss) Per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual</Role>
      <ShortName>Earnings (Loss) Per Share (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesDetails</Role>
      <ShortName>Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RevenuesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Inventories (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Inventories (Schedule of Inventories) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories (Schedule of Inventories) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Leases (Lease Position) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails</Role>
      <ShortName>Leases (Lease Position) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails</Role>
      <ShortName>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Leases - Rent Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails</Role>
      <ShortName>Leases - Rent Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity and Debt (Shareholders' Equity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails</Role>
      <ShortName>Shareholders' Equity and Debt (Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Change in Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cpix-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Additions and Returns of Product Rights - Dissolution Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Dissolution Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cpix-20210331.htm">cpix-20210331.htm</File>
    <File>a2021q1-exhibit311.htm</File>
    <File>a2021q1-exhibit312.htm</File>
    <File>a2021q1-exhibit321.htm</File>
    <File>cpix-20210331.xsd</File>
    <File>cpix-20210331_cal.xml</File>
    <File>cpix-20210331_def.xml</File>
    <File>cpix-20210331_lab.xml</File>
    <File>cpix-20210331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>54
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cpix-20210331.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 79,
   "dts": {
    "calculationLink": {
     "local": [
      "cpix-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cpix-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "cpix-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20210331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cpix-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 297,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 14,
   "keyStandard": 237,
   "memberCustom": 15,
   "memberStandard": 16,
   "nsprefix": "cpix",
   "nsuri": "http://www.cumberlandpharma.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cumberlandpharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Inventories",
     "role": "http://www.cumberlandpharma.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Leases",
     "role": "http://www.cumberlandpharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Shareholders' Equity and Debt",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt",
     "shortName": "Shareholders' Equity and Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Income Taxes",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Collaborative Agreements",
     "role": "http://www.cumberlandpharma.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127109 - Disclosure - Additions and Returns of Product Rights",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights",
     "shortName": "Additions and Returns of Product Rights",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Basis of Presentation (Policies)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies",
     "shortName": "Organization and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Earnings (Loss) Per Share (Tables)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables",
     "shortName": "Earnings (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Revenues (Tables)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Inventories (Tables)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316304 - Disclosure - Leases (Tables)",
     "role": "http://www.cumberlandpharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328305 - Disclosure - Additions and Returns of Product Rights (Tables)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables",
     "shortName": "Additions and Returns of Product Rights (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails",
     "shortName": "Organization and Basis of Presentation Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Earnings (Loss) Per Share (Details)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails",
     "shortName": "Earnings (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Earnings (Loss) Per Share (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual",
     "shortName": "Earnings (Loss) Per Share (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Revenues (Details)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesDetails",
     "shortName": "Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i529667d136134653822f8cd1f52ea7d0_D20210101-20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Inventories (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Inventories (Schedule of Inventories) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories (Schedule of Inventories) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Leases (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
     "shortName": "Leases (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Leases (Lease Position) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
     "shortName": "Leases (Lease Position) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:LeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails",
     "shortName": "Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Leases - Rent Expense (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails",
     "shortName": "Leases - Rent Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i26d732474c194cee89c889d4f8a693f2_I20160131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails",
     "shortName": "Shareholders' Equity and Debt (Shareholders' Equity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i26d732474c194cee89c889d4f8a693f2_I20160131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermLineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
     "shortName": "Shareholders' Equity and Debt (Debt) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i59247f7dd59d4f28aee9f37d45d509aa_I20200831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i9bbc43ed7e524a6ca314bad9dab13ba6_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
     "shortName": "Additions and Returns of Product Rights - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ProceedsFromSaleOfIntangibleAssetsInstallmentPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "ic3f04630c9f547b5be864f1c66564cb8_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
     "shortName": "Additions and Returns of Product Rights - Change in Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "ied6025b276df445997781e0a3e02560b_D20210101-20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Additions and Returns of Product Rights - Dissolution Payments (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
     "shortName": "Additions and Returns of Product Rights - Dissolution Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i6874375315de4805a4b9a90949e9e0a9_D20210101-20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "ida5da6da6f1940a89e2ca94214d39333_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statement of Equity",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
     "shortName": "Condensed Consolidated Statement of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "ida5da6da6f1940a89e2ca94214d39333_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Earnings (Loss) Per Share",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Revenues",
     "role": "http://www.cumberlandpharma.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20210331.htm",
      "contextRef": "i0109e65bd9644b7b853db5f9a5a36dc5_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 32,
   "tag": {
    "cpix_AcetadoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acetadote",
        "label": "Acetadote [Member]",
        "terseLabel": "Kristalose"
       }
      }
     },
     "localname": "AcetadoteMember",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Lease Position"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "label": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "terseLabel": "Contingent consideration earned and accrued in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CaldolorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Caldolor",
        "label": "Caldolor [Member]",
        "terseLabel": "Omeclamox-Pak"
       }
      }
     },
     "localname": "CaldolorMember",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ClinigenHealthcareLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinigen Healthcare Limited",
        "label": "Clinigen Healthcare Limited [Member]",
        "terseLabel": "Clinigen"
       }
      }
     },
     "localname": "ClinigenHealthcareLimitedMember",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denominator.",
        "label": "Denominator [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_EquityAndDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity and Debt [Abstract]",
        "label": "Equity and Debt [Abstract]"
       }
      }
     },
     "localname": "EquityAndDebtAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "xbrltype": "stringItemType"
    },
    "cpix_FourthAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fourth Amendment",
        "label": "Fourth Amendment [Member]",
        "terseLabel": "Fourth Amendment"
       }
      }
     },
     "localname": "FourthAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IfetrobanClinicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ifetroban Clinical",
        "label": "Ifetroban Clinical [Member]",
        "terseLabel": "Ifetroban Clinical"
       }
      }
     },
     "localname": "IfetrobanClinicalMember",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncentiveStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Stock Options",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "Incentive Stock Options"
       }
      }
     },
     "localname": "IncentiveStockOptionsMember",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy",
        "label": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy",
        "negatedTerseLabel": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_IncreaseDecreaseInCurrentOperatingLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IncreaseDecreaseInCurrentOperatingLiabilities",
        "verboseLabel": "Accounts payable and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInCurrentOperatingLiabilities",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_KristaloseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kristalose",
        "label": "Kristalose [Member]",
        "terseLabel": "Caldolor"
       }
      }
     },
     "localname": "KristaloseMember",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_LeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Three",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Three",
        "terseLabel": "After 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearThree",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity, Increase Amount",
        "terseLabel": "Increase amount (up to)"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityIncreaseAmount",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity, Total Capacity",
        "terseLabel": "Total capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityTotalCapacity",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_MethotrexateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Methotrexate [Member]",
        "label": "Methotrexate [Member]",
        "terseLabel": "Methotrexate"
       }
      }
     },
     "localname": "MethotrexateMember",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Numerator.",
        "label": "Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_OmeclamoxPakMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omeclamox-Pak",
        "label": "Omeclamox-Pak [Member]",
        "terseLabel": "Vibativ"
       }
      }
     },
     "localname": "OmeclamoxPakMember",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_OtherLongTermObligationsExcludingCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long Term Obligations, Excluding Current Portion",
        "label": "Other Long Term Obligations, Excluding Current Portion",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLongTermObligationsExcludingCurrentPortion",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products",
        "label": "Other Products [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PinnacleBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pinnacle Bank",
        "label": "Pinnacle Bank [Member]",
        "terseLabel": "Pinnacle Bank"
       }
      }
     },
     "localname": "PinnacleBankMember",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ProceedsFromSaleOfIntangibleAssetsInstallmentPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Sale of Intangible Assets, Installment Payment",
        "label": "Proceeds from Sale of Intangible Assets, Installment Payment",
        "terseLabel": "Financial consideration received in exchange for product license rights, installment payments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssetsInstallmentPayment",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_ProductsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products.",
        "label": "Products [Abstract]",
        "verboseLabel": "Products:"
       }
      }
     },
     "localname": "ProductsAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_RediTrexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RediTrex",
        "label": "RediTrex [Member]",
        "terseLabel": "RediTrex"
       }
      }
     },
     "localname": "RediTrexMember",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Rent Expense and Sublease Income [Table Text Block]",
        "label": "Schedule of Rent Expense and Sublease Income [Table Text Block]",
        "terseLabel": "Schedule of Rent Expense and Sublease Income"
       }
      }
     },
     "localname": "ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ShareholdersEquityTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholders Equity.",
        "label": "Shareholders Equity (Textual) [Abstract]",
        "verboseLabel": "Shareholders' Equity (Textual) [Abstract]"
       }
      }
     },
     "localname": "ShareholdersEquityTextualAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
        "terseLabel": "Shelf Registration, sale of corporate securities (up to)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "label": "The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "terseLabel": "Aggregate amount"
       }
      }
     },
     "localname": "TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TieredRoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tiered Royalty Payments, Percentage",
        "label": "Tiered Royalty Payments, Percentage",
        "terseLabel": "Percentage of tiered royalty payments (up to)"
       }
      }
     },
     "localname": "TieredRoyaltyPaymentsPercentage",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_VIBATIVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VIBATIV",
        "label": "VIBATIV [Member]",
        "terseLabel": "Vaprisol"
       }
      }
     },
     "localname": "VIBATIVMember",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_VaprisolMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaprisol",
        "label": "Vaprisol [Member]",
        "terseLabel": "Acetadote"
       }
      }
     },
     "localname": "VaprisolMember",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_WinHealthInvestmentSingaporeLtdDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WinHealth Investment (Singapore) Ltd",
        "label": "WinHealth Investment (Singapore) Ltd [Domain]",
        "terseLabel": "WinHealth"
       }
      }
     },
     "localname": "WinHealthInvestmentSingaporeLtdDomain",
     "nsuri": "http://www.cumberlandpharma.com/20210331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r63",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r203",
      "r206",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r334",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r203",
      "r206",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r334",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r167",
      "r199",
      "r200",
      "r305",
      "r333",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r167",
      "r199",
      "r200",
      "r305",
      "r333",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r201",
      "r203",
      "r206",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r334",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r201",
      "r203",
      "r206",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r334",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario, Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r190",
      "r204",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r172",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r22",
      "r35",
      "r173",
      "r174"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r71",
      "r89",
      "r285"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "verboseLabel": "Noncash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r89",
      "r183",
      "r185"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Common stock available for purchase through restricted stock awards and options (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r95",
      "r147",
      "r157",
      "r163",
      "r176",
      "r261",
      "r266",
      "r275",
      "r308",
      "r321"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r23",
      "r24",
      "r62",
      "r95",
      "r176",
      "r261",
      "r266",
      "r275"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r209",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r202",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r202",
      "r205",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]",
        "verboseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r245",
      "r247",
      "r248",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Liability recorded"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r88",
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration included in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r246",
      "r249",
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Additional liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ADDITIONS AND RETURN OF PRODUCT RIGHTS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Net intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r20",
      "r45",
      "r91"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r85",
      "r91",
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r85",
      "r276"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r13",
      "r85"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r255",
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATIVE AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r55",
      "r189",
      "r313",
      "r326"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r102",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r34",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, End of Period (in shares)",
        "periodStartLabel": "Balance, Beginning of Period (in shares)",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock\u2014no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r73",
      "r305"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Costs of products sold",
        "verboseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r309",
      "r310",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r284",
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Convertible note"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate spread"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r89",
      "r145"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r70",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r115",
      "r117",
      "r120",
      "r121",
      "r122",
      "r126",
      "r127",
      "r317",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r70",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r117",
      "r120",
      "r121",
      "r122",
      "r126",
      "r127",
      "r317",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r114",
      "r129",
      "r177",
      "r195",
      "r196",
      "r215",
      "r216",
      "r217",
      "r231",
      "r232",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": {
     "auth_ref": [
      "r219"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.",
        "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities",
        "negatedLabel": "Decrease in non-cash contingent consideration"
       }
      }
     },
     "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r184",
      "r306"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r181",
      "r182",
      "r307"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r99",
      "r147",
      "r156",
      "r159",
      "r162",
      "r165"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r95",
      "r105",
      "r147",
      "r156",
      "r159",
      "r162",
      "r165",
      "r176",
      "r260",
      "r275"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) from continuing operations",
        "totalLabel": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r66",
      "r70",
      "r105",
      "r107",
      "r108",
      "r109",
      "r110",
      "r117",
      "r120",
      "r121",
      "r314",
      "r315",
      "r317",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r66",
      "r70",
      "r105",
      "r107",
      "r108",
      "r109",
      "r110",
      "r117",
      "r120",
      "r121",
      "r122",
      "r317",
      "r327",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r15",
      "r18",
      "r237",
      "r328"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r12",
      "r15",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r68",
      "r70",
      "r118",
      "r120",
      "r121",
      "r317",
      "r328",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r118",
      "r120",
      "r121",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r224",
      "r225",
      "r227",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r222",
      "r226",
      "r228",
      "r233",
      "r235",
      "r238",
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r113",
      "r114",
      "r146",
      "r221",
      "r234",
      "r236",
      "r332"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Net changes in assets and liabilities affecting operating activities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other current assets and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r67",
      "r144",
      "r283",
      "r285",
      "r318"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r40",
      "r179"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Inventory, Gross, Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r21",
      "r59"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories classified as current",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net, Items Net of Reserve Alternative [Abstract]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetItemsNetOfReserveAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "negatedLabel": "Inventory, Noncurrent",
        "terseLabel": "Non-current inventories"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r41",
      "r179"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r59",
      "r101",
      "r178"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Obsolescence and discontinuance losses"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r75",
      "r143"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Initial investment in joint ventures"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r50",
      "r95",
      "r158",
      "r176",
      "r262",
      "r266",
      "r267",
      "r275"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r39",
      "r95",
      "r176",
      "r275",
      "r312",
      "r324"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r52",
      "r95",
      "r176",
      "r262",
      "r266",
      "r267",
      "r275"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r49",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r49",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Line of credit, unused capacity, commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermLineOfCredit": {
     "auth_ref": [
      "r54",
      "r191",
      "r192"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit, Noncurrent",
        "verboseLabel": "Revolving line of credit"
       }
      }
     },
     "localname": "LongTermLineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r54",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Loss Contingency Accrual [Roll Forward]",
        "terseLabel": "Loss Contingency Accrual [Roll Forward]"
       }
      }
     },
     "localname": "LossContingencyAccrualRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r57",
      "r95",
      "r176",
      "r275",
      "r311",
      "r323"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r85",
      "r87",
      "r90"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r85",
      "r87",
      "r90"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash provided by (used in) operating activities from continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r18",
      "r64",
      "r65",
      "r69",
      "r90",
      "r95",
      "r105",
      "r107",
      "r108",
      "r109",
      "r110",
      "r113",
      "r114",
      "r119",
      "r147",
      "r156",
      "r159",
      "r162",
      "r165",
      "r176",
      "r275",
      "r316",
      "r329"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) attributable to common shareholders",
        "totalLabel": "Net income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r64",
      "r65",
      "r113",
      "r114",
      "r264",
      "r269"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net (income) loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Guidance"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r196",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r147",
      "r156",
      "r159",
      "r162",
      "r165"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Maturity of Lease Liabilities at March 31, 2021"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease noncurrent liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r292",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Present value of remaining lease payments, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r291",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractually required future rental payments receivable on noncancelable subleasing arrangements.",
        "label": "Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals",
        "terseLabel": "Future minimum sublease income under noncancelable operating subleases"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseSubleaseRentals1": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.",
        "label": "Operating Leases, Rent Expense, Sublease Rentals",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseSubleaseRentals1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r19",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.",
        "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross",
        "terseLabel": "Consigned inventory"
       }
      }
     },
     "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r25",
      "r26",
      "r51"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Other Payments to Acquire Businesses"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Cash payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period for redemption of redeemable noncontrolling interests.",
        "label": "Payments for Repurchase of Redeemable Noncontrolling Interest",
        "negatedLabel": "Repurchase of subsidiary shares from noncontrolling interest"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfRedeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "negatedLabel": "Cash payment of royalty during the period"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r78",
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payment to acquire business upon closing"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Additions to intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLifeInsurancePolicies": {
     "auth_ref": [
      "r77",
      "r84"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow for proceeds from settlement of corporate-owned life insurance policy, classified as investing activities. Includes, but is not limited to, bank-owned life insurance policy.",
        "label": "Proceeds from Life Insurance Policy",
        "terseLabel": "Note receivable investment funding"
       }
      }
     },
     "localname": "ProceedsFromLifeInsurancePolicies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from (Repayments of) Lines of Credit",
        "terseLabel": "Borrowings on line of credit"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Financial consideration received in exchange for product license rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r18",
      "r64",
      "r65",
      "r83",
      "r95",
      "r105",
      "r113",
      "r114",
      "r147",
      "r156",
      "r159",
      "r162",
      "r165",
      "r176",
      "r260",
      "r263",
      "r265",
      "r269",
      "r270",
      "r275",
      "r319"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r28",
      "r29",
      "r186",
      "r325"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Repayments on line of credit"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r220",
      "r342"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r36",
      "r196",
      "r218",
      "r322",
      "r340",
      "r341"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings (deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r114",
      "r177",
      "r215",
      "r216",
      "r217",
      "r231",
      "r232",
      "r337",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r141",
      "r142",
      "r155",
      "r160",
      "r161",
      "r167",
      "r168",
      "r170",
      "r198",
      "r199",
      "r305"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Net revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Net Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r0",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r14",
      "r16",
      "r17",
      "r18",
      "r187",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of Dissolution Payments"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Reconciliation of numerator and denominator"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Summary of net revenue"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r27",
      "r42",
      "r43",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r209",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r137",
      "r139",
      "r140",
      "r147",
      "r148",
      "r159",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r93",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Operating Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Selling, Marketing and other",
        "verboseLabel": "Selling and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Restricted stock awards, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock granted in period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r207",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r56",
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r114",
      "r129",
      "r177",
      "r195",
      "r196",
      "r215",
      "r216",
      "r217",
      "r231",
      "r232",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r129",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r33",
      "r34",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Unvested restricted shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r33",
      "r34",
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r56",
      "r195",
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Vested common stock, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r33",
      "r34",
      "r196",
      "r208",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "verboseLabel": "Repurchase outstanding common shares"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r33",
      "r34",
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of shares (in shares)",
        "terseLabel": "Repurchase of shares (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r33",
      "r34",
      "r195",
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of common shares",
        "negatedTerseLabel": "Repurchase of shares, value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r34",
      "r37",
      "r38",
      "r95",
      "r175",
      "r176",
      "r275"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r95",
      "r102",
      "r103",
      "r104",
      "r106",
      "r112",
      "r176",
      "r177",
      "r196",
      "r215",
      "r216",
      "r217",
      "r231",
      "r232",
      "r258",
      "r259",
      "r268",
      "r275",
      "r277",
      "r278",
      "r282",
      "r338",
      "r339"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, End of Period",
        "periodStartLabel": "Balance, Beginning of Period",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r94",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' EQUITY AND DEBT"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive effect of other securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r116",
      "r122"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)",
        "verboseLabel": "- diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r115",
      "r122"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)",
        "verboseLabel": "- basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11374-113907"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r343": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r344": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r345": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r346": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r347": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r348": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21C",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080552-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>55
<FILENAME>0001628280-21-010387-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-010387-xbrl.zip
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ML@H= X1SO5GEEG?OBT_[,P#S@X2C_P-02P,$%     @ SHFN4E)I,LA\"
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MRGFTQ$(.D0ULT5+PP)XIZVRL><"IXC@![H2RC=$)]I1I%*_6/;55NC:"2<W
M( ,1$QNE%!DF$Q0#+TS+&K$4P=#"2>K53 "^C1E6A-@([5FP)18^"=R.'P]N
MZ]7V)FQWYJD-].[.<#N#&( _Y0%BDVJ96#5#-> :TR\$+%5! 1Z ,Z=C+KB9
MH]K:-BRZDL69A9#S@K6J*^F;C1A7^8323*4 86W5H>^#D+(&V$1NPA(0?0*0
M#"4L11?!*I"D.K2"*_$42/NIXM5_/'@M>'8PI2*S9(2[R<(0!#J?PC[H+4)[
M(1EV(%=WN5U[6WQ"0R!&[13^6&;F9@MVH7^ZJ,TP?0GO/@H@XR(QLB['W$J
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M--K G*9<2,#!(R[B,L),[14$7.13 Y9Y)(+WQ0J@B8^5Y80(+X2F52^*" _
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MJ"]H1%1-NG5><D7FO)DTKY:0)3)Z)6\O^<012_E;G/;DYTZ'_P)02P,$%
M  @ SHFN4H <8:2_* $ 5,L+ !$   !C<&EX+3(P,C$P,S,Q+FAT;>R]:5=;
M2;(N_/W\"KV<\]Y;M982YSQ05=Q% ::I:PD;A-WPQ2M'M$$#+8G)O_YF;DD@
M)AN!0 /;U6U+VE/NC(@GGXB,C/SS_UPV&Z5SW^EF[=9?2V@9+I7^S^J?_Q\
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M'['(W2PV?T+9SNEV^HCG.P8[G)9$Y),$DL)-3ZF7.D[EZ/?2<?#5-78*5K
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M;3"R_;6$DJ,R'7LMX716RHQ#9]ZOO;YQ)F]AK\^WUQL20ZQQ!AH*$$5I[:^
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M BHP!F2@%#.NH4@K_^$RF@7@F#NNMT#[98/2(VM5'J.![WC^\M6(UO.3V O
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M'/?@Q7<MH9).,Q!=90.H<P1(*"PP'&'.L*.!B.=N)3\.G+W6O,*=1SZ6/UW
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MU*KRD1\85"F&O$*N%K!N"EB'\XQ$@ P)#12,J93V-4B#C#(,%:8@*DA5>$$
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M#_"=O[[M'N^<[OVQBW</>D?[VPZ___87^0#?^;"]5[XG'^)N6>]VO2U./^*
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M?T=I@N<4)7EBSQM7H?-J?'0VZ#72>QA!B$U^C:EVB:L^32)$-R\)5$R65'I
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M"7%Z-*AWB/HA-J1J8<\")DSR]"WZ/?][[K5S%.@0^'[CA$WO2@E:LW,Q[Y:
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MS';JE=-#1.>B^JL=^=S(U)"%&\?G'%?AFN'S5S6H=G76WNW&9SF_#U!%D'?
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M#K@(4A)KB6:,D7S$T"=Z(H/$X4<Q.8@_D(=0K*>'\!8%$'>^[IU^%-(1@4U
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M\:3 G^HF7"B"QYMANV[JKU$]M]"PL1AP0*!<EC=VOU#,1-*FX#K#!F1G5Q+
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MI9R&(V_#3]2MLC&6&A>_C;L*)MCV5MU=L=QFR7LLX+BGA.D@A?";G*%VA/0
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M[6@@]BR/V2;G4<PPP!*$D>$ZKA\)VP^YY>YHX*%I8-%[?^JZ#,Z@9>EAY!E
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MF3SF[HN_@HYE&!W7W50*]R-' \Z]=LLC<C?.JQ*%[\1Y'^-0OF+%L.F9+MT
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M+)77-BK3"J7.M,;0T48,M*FA"G4.L:O9"C@ E;E519.@5&SHK5II8ZUR22I
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M5)>K3^9%\P'J0V"[ZL/?.ZC?,JV0J@AHM=/6B EH#R5;DL7T:M7LH:&3=EI
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M2AF_Q=.YUB Y9ZM8QA+^KH)W[FC+@.*MR!1&MA'^:3WTD\SNZJETY2[_CNK
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M0F.%CA7!G>P+^/9@* 5Q* $O?'>F<&4BSD]*O%9?ED1A*/5\$QM8DAV'!.$
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MZP9SFP;AC$D[<16W^C@@6.GO8+9"FB3&AWG*B C*\0=!3.VL[$S$8[O#H3N
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M'$7:3GT\\5P:^!1XRDDPGXM'J$B? IAS\><'O!DRK3&YC,RWG68PK,'=@QB
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M?WVR1RE@WL,D3<MQ4(;6@'+AE+3@?@MK28'YG-!]8"R6QD&N#\Y 3,*)'E9
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M7^3T,5+>(HP3P7[^WJ4GO_VTM[=DQWPV@4^0]\K/WS^]N=0E2C/ ?.*GZ>C
MSP_]SW%V^+0\^/3%#-7BH]\OL/MF%C^.X-<GW?CP:'+VWL$<\J]/XM'X.RGR
MI6+9^=_.O_ST'$?TDW@\Z<E^BW^?-%$ZVPX2?%_ -$&ZV->F-&,[TPX2_M+-
M)N-45/RYGQ3I?3X 6'2;,>/.5NMRZ7Y$G+&O8#A%,9G%2P]-BK[.YJ??G/@
MD_[=T7%']KT_&KT=^S">C!=CZ$:@(LU@)+%14R)I5,1)%8G@D0>JN8%@+G/M
MA+)>O[/O0J_D)TVCLG/Z%":+[O2=PE]**#O1];^MP+!DZ1;DS*;[7V!^B#*
M#QFM71HO1H%K3K-PQ.J,ULKD3+PJ0T[DJ(Q,*>K<A*X58"X3>$%KGLWCWFR>
M8([V_,G>-RC6]\2T+Y'Y>;RF3I<-R\D33[OCP\.^33)>P.'I]XN=KR/[Q:PR
MTY?21?C;BO_#$<R1\NG^6T#;>DK?C_>S:3R>S]$!CH+BW"8NB$HN$RF%1\_E
M!+HDD4SV07I.6^C"G<C640S^R!2CKCBJ:<D%\EZ<X-!9L209(\$:Q,&4)\$I
M1GQFP>?(HTVZL>E[L;X>B$>F!ULR?&O!%^<^^K X@/FIJ?H0)N/]G@7=J^]Q
M<EPBYQ-H'V?S\OZ(Z:RSX6BV=&)$*M1*FZ0DFNI"L_)4I+MBB$TZ7D<!Y"-1
M@.:,KV83/B]F\<^#V039V[WZGV.T4DBPMFA^(K$A!DQR)$,<BI.<K=;<@6>Z
M23AT'<JVQ+V8'1[.IGV[_^DGQS RS,<LJ4.>.G3.P07BN?8H5<%,DEIE)5J0
M=A7(D**A+37@JLW;BN?5U/H3+#Q&9>F5GT]QI'7/(F8@A<>07D(>1PS4D"+M
M>?0D>JJ(U!;S<P6,<*Y=LID+;F(+7;@;VI!"HLK:45DN+4*C9].T@FAJ># &
M!<J"1>.<J<4 7TE"N39<),9S;!THK016D?"1HUX)9R+&HQ;'I[""! \18U0%
M-F9'DW<[S8,'DR9NKQ.WA(;WXGM#Q_]F>A*7G 0DSQ:+^3@<+WR8P)=925YF
MTP5R$%O<?S-=P!RZQ8@;Q[3EB6A,78B,GF,.$X'@>^ T!Z,]["98V 3^D"QM
M4W5[ &E7T]0248P791J_,.8%PD)(,(UEZ%"%CL@I3;(30*01.'24H$2IZ+.Q
MBB>J6@5T-V ::");7Z=JR:7E_(;!WC*^D(QA* :?&'<&YA+QCB?EK371AX>8
MW]A@BJ_/)J]3&(/+2@I)A':8GBK,46V@GI@H W<<6 Q-1L -> ;JP#?1AVNS
M>A4D4$W7,7">'>/(^^A_%(M]BL5Y%:U.D5!:#+0"0X+!>,)2D3 V=Z!8DRG_
MU7 &ZEYK*$,%_K>>_3_%)(0R#C"#2B&@C7>)$1>-(X%&KIAF#%03G;@=UD#=
M9!5#44\>0POW(\/\.X(B2B2T==Y%$CA*7TOKP,5L!7TTX7Z5R5(=<K!!69(4
MQ4 G8A1EF;/$J602H&.PLLDLTETS 4.;4VRN;7=G//>25;6!]VX\G<U[!IP0
MI;F@#C!S2A@A$ZE#&?G<$,Y"IC0;!-=$8ZX"&9)S'H"^;"6G>F%=U\'BS E)
MQ[(//!+@&$-(C419(?$%1 XL4D$M:Q+-742Q=?KNNX.2'^*/(MJO?M)GC(L7
M?C[_@=);KA($::V6P$FD1A))<R8!\T_BF8A:1Y>-LDT2^770#<FT;JXAU_+W
MZH*IGMU\@@@(#,?\>UB<Q4\V*F-"61VU.# ]Y<31)$GF,B9C53 Q-1D5MX :
MDC&MIR'5Q% OU2DY^&4";;"2@PA$YO+BLT:''B-)TLC,)&@1FJQ:7(<RI)2F
MGA)LR?)JHG\S_8I]S^8_4 ='/$0C(E*0O,(<*AE%O YHG\ 9SZ(6SC3QC!=!
M#&G#2CUQ;\SFRC$0ILF&2F8245$F3).9(4&!),H)5#V/07MJ$A$LN]^6B(_S
MV1',%S\^3OQT@5ZV>-BC,E=>V)H\IB%"*Q*YQT0D\+()##*)BGF7A67&^1:D
MW09J>#'.O33@JAI7XW\UM?[';):^C2>34?;2&*,R <LB#BKLV(&U!,#0(#EU
M0C1) $\!#"]6V4K2&_&U@5<ZW]PK%"1P*9*L-5I-BS;8I< )<P@C8BH*O$E$
ML@++\$*2K62]+;<;Y>F4,@C*6Z(Q&2)2Y4B<=8FP)!)PS* R:S*B[QU][C8<
MV4K4FW.X1;)Q0=],U(:R* GC!O4M2B2*V4"$%E1G""S;UOG&_<:W>CQ"WY[C
MU83_>CQ%<M^.OT)Z,UWXZ?X8T]\3:!A".)J33$(1ISU'*D,BWF >1$'Z8"!I
M#DT6U6Z'M8XZZ,>C#A5ET&BQ]5-AY(?\>[>$->),:9$P0Q*<:HPL*8)+F#^I
M%)7 ;(P*V,$QJRNHUM$*\WBTHIX$KBC%WY]>9=!;_+O]*=V/OIBY UB,L>O+
MV&H=V;W<Q6[/[]Y"7N.ST)\7^-IO4)OE$ZW!3ZMQ^(;FFW-W';(J'9-^,>OZ
MW7VOOA\5&-T(PR\JRJR2":YL6&:!.!DL,=Y2S;G2.3>9NK@*9/M-I1U:C9([
M]CLC8?YU'*'[/)ND$77&AJ0HX5*@6V%E?X8(FGB9O19<NAR;D;@:TI#F9K;2
MB.M;2*M(H=XN&>@7E!'+.S__$XJ3.:%S%((PC&/HF41$OV)4.?]"+8DQ.Q.\
M1(?5).R_&=*0YG&J:D4E*50\3-8!-E,62U_"5YC,^HG$4TA<^8#QBR$8=;@2
MA985L4Q196/T"I)4HDDF<"NJ(<W[5-6->K*H-[$+4_3!$T3T+!UBQM(MBD?^
M"J>@'.7"(3*2I/0(12KB$T-Y6IEDULP+UR0GN /7D.:+JJI(37G4FS \+/N8
M_K=GQH=\-9L=*6HXL.P(Q2RES&]1XBGE!"@+% 0U++39TW KK"'-+E55D8K2
MJ+B2@%$_O)UUW6LD?GF<YAA=WWF$_QSR; [+Y[[X[]!=W;.&[+G<RG(OW3M8
M',Q2F3OOEL=U1IHFI:40A*'2$UG299N,)N5(=A31"\L;+9_OC,9J\SSGO8V<
MIB8HEI$RS9>G-8-2G!@3J(>H(;79>;0"RY!2@J%J[HT31QN*M.JBX9*@)9+S
M#:R.4F.2(L$F*#8-\QT:,[$8\R:M3 B6MUHY7 5H2"G&8]&R*L*MJ&K+WD^#
M'Q6E=#0%8G1*1%+JB+->H&L+483LG61-C@M>P7'/_(3\OV9M*<MJ"O4>%A?,
MIQ;>@XD)Q8VIN&042) !B+5")&T#)-VD+,8E%!7V:N7QHJ='^J00OR>>E9US
M(DKB,Y>$*J:3=SPXU<0 GT,8DF/?7-8KMF-MPN(V6KO661)O,$^,F1$372 2
M!Q0::@3,<+BF( +5LLE\W[V1WM-'MS6E]32FK<2J*=8%Q5;1>^=1G5/0:-J9
M1T(5,T0QM,J9>I^-W*7MV#8%?3GNXM(70CIWA2B7#QE]X,AA$APITN>LR$1"
M*@?I,C+>>8-B9SGD)N3>!^20C.F&FG(]"&@DHQU.9&QTN$\GIGR@@22;+4$S
M(HEC61*-_L)*[9/W39+O-N0,*;-JHID/(O?ZNWPN>#,,K56281FK$^EU)"&7
M9<FL!+=19:H?9O9GDQ6MKX FXU1.<Q\7?XP7!R^.NP7V,#^K4%KF0_%?*K:$
M>FZ9*?.AEI;*M0&M2L0<)J*3%T(H!ZE)YK@!UB&9_6TUZ?H"6%O152S;=67"
M/GO@0C$@T6=,5VU_DE0QPE4"X$S2*)H$#+=O'7G@@+FV>FS%]:&' "XDY$C(
M1(FRX3.Z2+P+"CU#"MP;F:!-]9%=A ##7C *W%'DN<",JM2F9KKD5DD0GJ6.
M.G,0JM&TX0,M& U]1:7Y^+E_=/<PVE;99B'P$]/Y'*: 8?'(<!^T"HSDG!&,
M]+)88T4HI=8C-*-CD^T;-^ 9E/<:K)YN)\:'VQ=^<6MO*<SQ>C+[UF;#\GGK
M.]VO? -1E;8KE_(4V $FM%_'V-KS'[]WY>C(69#U+"[&7Y=%E[,$PP/&Q HR
MZAB7B01'-<%DDP5*G12A22RQ/L0*<]YK]K1JX(Y 1@Z6EO.S4I0R=9+XH$K)
M+&W+$8UL;9-T=SO80_+BC;1QQ4SYKN1<+SE<#_#JZ<T1C\QET)C.&,!\-AA+
MO$8G ;'4';82 FVBFENA'M*,WXXT<W=2KKE0N KU,CJ]S!F=2B50S0G8LKJ%
M@X9XPX'0D%D( 13G339^KP]QZ\4M_Z-WVU]FSR*&ZG.XL:K&R#.CN!7E? 9%
M9IBH22CSR!JB8P&,TZG)S3KK0[RG9VB^3MI"S:XMN[<18+W5TZOXKFW%38IQ
MH9,C3!3JDP@D**M)8M9R#YQZT:2 ^YW(!I6'/90Z;26NFFOP$2#U.>C;<494
MW?&\G#_]B!E(?QV!9%D9+17)#-")9>DQO %)(J61V^3 Z2;35W<B&](YG5TI
M455IM7;\K\=3Q':9>LJRY])FC($"4L_15%I(@HBLC9/4H:XWF1%:'^+VZX-'
M)T/]0WX_6\!IF?M1I#$%D$ BR%PNYV(8DWD@..QIE $_-$WV^]T$Z#$X]6U5
MZ/H*8 7AU';AKV?SLQM@%F7R!SDP/YE(.JE_OXH/T7M/F60D)Z?07WA*^JOE
MHL[&1>99M&T,\S:H'X/KKZUTNQ-SD[#@XIAY.YY"=WY?=\Q&VUA\5\DR8RYE
M;+DD66=K,</4236IW;46ND<0'E17M.I2JYZMX"! 9,?S>."[<O'[^8VG(Z%!
M2\T#6E^7B&2<E>)$9;-2\HJ:0*-H<K#N;FCW/.[[5S):M0366I$^00(X[,ML
MKUX7$S;(X+(C1F).U1>\LIPI M1G&A+5T379D[XAWGL>'_XKJUQ5T;;.>=9=
M.=#*.Q%I2<RLQ0$D, NT7).0,.6/Y?2D:G7XI]H*T?I,Z^]T?S.-\U)U["4L
M?[Z9GE2H/"]*=N%B5ZTI<@8U1]E4KC*F@@1I!(F&ZQ2BQ:SV2FQQ?2'W_MT^
MSB6PK37L="0VEM/6@^\F?,BFSSU&%%!_]4:)>:Y.C_P822=SYBX2GI)#XP0&
MC9,U1*#.J! 8#5>O+5]?I]:#\!C2GX=0L 8"K+FYZ0K<TU+*1?^M8](*YPGF
M8:+<YR"("_B;*"O#48DD0I-2^[>B&M01X0=0L_JB&_KVWN@C& Z2R REHHM3
MQ $M]ZIFB3DA<X'_Q4[X[*J^TL.J[T/K2D,KVA>L/B]5?3&HL(PKH;@BFH52
MLMPS$K)P1*$#\#Y*SZ#)BOA]0 ZIP-.@3&PEN38J'W:6M/:G/4:&YDR]5$0M
M(PH1B1?4$3 Z6<C4"=VD8.EMH(94B?P!-:N:W%K;L'-F+!?R(\50-(9 J"C5
MU<J)(1M")%$@:J<9-%KH6P_>/2N:_PO%AEL+LZ&B7;].<,0R@\13N0M;8>9M
M2PE_ZBTQX*UF$F)N=KCB3G#K*)G]EU2R+0593<5>?8_0=5_\]Y-#'B7"_'S@
MY_#<]T<0#LL)D*7M7;&SM6P@E8(QHD+9Q!+*7B57RH?DR'B,.H8V5\YNA7H=
MI73_ DJY.]%7T]:7<#2'..Y!X>\3Z,4V31=C!!Q'998N>P*A['QFQJ*I3IQ@
M3N.U\9:E-G/JZX!;:V*9_O6#NNJ"K%>_?N4(&(G(?%#:8^?%_^=RGJXDRV S
M3_A;3&TLW6HX:ZG17WB!HJ*PJI['N7(1^"?H%O-Q7$ ZN2C\\AL7GOP(\W$Y
MP'LU3#B9UD%3?>"G^_#)+^!5SA 7(Y=YH,D'XGRI@H@DDT QFP;G)!C/:%9-
MYD9V2^;NEF='R+V4O! D!"C7,NM('#!+E"_W'3E#+6]26V/3TXP/?(?)<+5]
M\\-]]]*!A]@VS6)B4FI.;-:&2!D!;:7-Q*0L)5ACK6PR3;7IMND'OE'ET>OH
MMCKP(&?ZJ-.4XJ#),6L<0Y02GUPB3H-FX!5C;8X;;7JF[X%O=GGT.KJM#@R@
M4L0L+\NH7(94HTK$6<N[JQ"QFIAZUP1^F._[Z4F*AA]C]#WN9OGC'#KL?)F=
M;,#&-5JMR<+[$K%+]IT=;&O"QLO'YG;&SM5$[9*M%Y]X"0L_GC3B\*J.=LOL
M.TFMQ_=7?CY%V]^5W0GHCOJ$?!.VKFRG)M?N!MJ6*5_*'/]&&G=+:ZT9M IT
M6S9M,3)O:ZXUHVX?9=O%WG_T<2BD9U\Q8=V']SVP#_GE>')<_'[IOOMPO.@6
MB!5QC3!1S3EQ@:EK+FOBINR]+T7<8W#!L2!=;%*6Z9XXMTU);NCN6C_%/L:1
M4]:)C*"95QFS)F.(=3X3KFT&HRGGK,FYCWNA'-($3TNMNYI9M!-EM01X)<2;
MF/$L_??QLA#C*#%63FT& K)L+C7(&YN,)Y1JJ2 'IJ/9F=[=C7=(TS</KH&5
MQ;N31/<6Y_0%_='QU>OCMW:MIZWNR,.N)*)>2')2&GRC^./LNS59L1I0?8(W
M#T^OM-""^+9AZ&DO6X2>5YMHP83&B=S%8R,;<.#:J9-*U-\(JPGEFX^"ZXTT
MXD+;L7"AH_=^OKST>8MQ<5MSC?AS.^PFG/H<#R =3V"6+[Q9AVNW-MV(@^N3
M4RG!/>WFQS_F_95G7%"!3Q&I RU;;2,)7GFBDD@V>\D#--HW?1%&C0MJ^]8^
M^6_O_ +F8S]9WBKU"3J8?RVK)(;&J%PFQF'4*I%HXB%ZHJG0AEMCE6JT<_<N
M:$-*1+?0CE7WRE:42;VKDLJ.\S-P9\@^'Q\=37#L/9NF=U#*(&#VT<'OY7!L
M7S=H?]KG(-0+'Q$<,4&=W.[DRVE823-R)E&30I,BJENA'E*B65'#=B?)JC=I
M]VA?CZ?C#DW_/V:S=&54.,,<,L*4$B\(+$9*G-6&" I4"P&>IT87%=Z);4B+
M^2U,526IU%<7Q#+*2DF:D"3(OB@LH\0S)%AHI@24C9VBR:SJ11#U"#H[JS@"
MIS77EI-@,DJNW"[MO14D1N_ &$USJXL2KV$9I"N^K^QOU.X->5Y?FY<C5JJH
M:?**&,%*"2&6B4M)DNR24A&D-;')W=6WA9X#\8W51'Y_3N]DXO1MV3JU4;IV
M\LV:V=@J,/52UV7KF\]U7/I^?;+;SG L^Z@QN7%#2_49LJLIC65O_>O'63?>
M<J/,+:W59]'=H&NSZ7R6I/_[0GD#C/J/RYUM^-77Q_@KO,,0[O#XL'^N%$X<
M+^]HVYJW]2#4%T@C]E2:<7I;[G6%\T)F%R'^.*T_^/(81AILX)$"B;14W<6
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M/'_3S&8CP07301B29*0()R,(L GAR)23DDJ&7,-(OD-XVL9PH*IODVX>R.8
M%=)2C0( 99I(2BW!11*(32GS2"7SS#R6S8&! U>P3&KF&&&BY+<(B\XK%XYX
M_)EU*1=EG39P[;'M^K&H=124"5)B')BX43AQ>60_.TXTRQ[ <:6IJKKENH0Q
MX)1Q+>FE^FYB#UUNVX-Y=IG"\)<X:7"5^>'YO%W ]Q^B[</7^4^3Y0-_>#Z#
M3^6+P<SA\A4LOG0S+0<P9U_'LQ&E/ )3@3#K.4HD W$X>1(;=)3*0S*T4N!]
M!ZH!C>6.;*0[C.< MG<93F^M5]C+V\#TXW(-[@1JM)$?-:1);$4UI*NQ*\GK
M#D/HSUY32_5'LXMDK;+"10)<(CA/#0F!>9+0J> I"I$U?^3V<".)[O3FL(_&
MZV[U_[+TRT>@K6%,"**$\@@(?4GO\5L#4GO*0]*\2EQZ"\GQ(X\!&-J]=7^
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M.>RAOH&+Z5V'HW3F!K0D'+0GTB1%2G4;DH3!,((%'KA\-"S>43EQ6!+WT=K
MY*VZ.Z^ 1*.U=+;D8%M#9'*.^$0%"=P()T+" ),-1=^-)Q^W#N+!NF^&4-S
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M6A_P['N_R]E=0/[1BU[L1>1!I0P.8>%D12\,%YZ6,I+2:([K5(:R%6<)"*I
M!7#6=4DN? RFLF_1BR-8RA[*']J_>X4_'7^"55&&Z%MX,[X8SR&MECV9@X[@
M(N$.4BD9Q$FP,9# '//).F"^F\=WSX,>:J&+O;AI*BEVX&I9'^;HUBPK;T28
M^G;<+.U<:RFH58QHIM#.%5CB,_JK7GF:HI%)J"ZIMIVF@*T(GKQ'T5_O V8\
M+0&M</QC.OL,<9S'L"[ T@74T"[$3C3'=QD&8*JII>:!?83=X&(R+*J8",<I
MBDB6$9?W.$-1:VFI_N/I8(6PCLS]'3[ L:C?1[N5*/^Y:2'ZV;I^HZ4XJ;D$
MQ-DL,<)5FC@:ENTR=5(AL<2Z;/7MQ?=-",=U @;B9@O;/11;X0+%6:G2<E7U
M-1E(C'M)C!<(ACE!K*&)4..RB$FZP*I<([J!XDDO]?WU7B.UM&0KOD2'-[UJ
M+CZCGOREOMO2+&:9X?_RV_?/K([=EQ)\%V.:WDW\]'I3\PXRU3Q2JB'4:4ZA
M>MC*YH'X0R&ZPG%5%=D41F(Q"T:,9!&7=NU)D$$1JVPTU&C0ODJ&XN,QWGL.
MQ1ZX[>[#;P6;?0^S>3N.&/@O4X'7T;_DP)6CA)OB8:A4SH6D)64S"8KSD6V5
M6G5;T1S_Z.;T1-]J[MJ7I0J.VTN/ D;X< XP?U,^?77<3#U*ES6!Y#-Z)4:7
M0JF9: @)/'<:6)VDZAV _A#NW"!L5+CUL0W7>O.R [*J*3\[H9THUV<0"CO8
M10_]U\CRV8V0N:"9=IS@?.9+I(MS)M61!,-HC( !+]2Y&'MDR[@OK^?(AK&/
MVBL8Q/(Z_ZMRY7$ZOW:98[7J40^@"B[NDB[@++%"*Z*=3]F7KC!U[A;>B>H$
MZ24#T;>ME,(@NJ]5:^/OS>5UV&WX)%@'-#LB>6DL!X829S@G#'\JDV<YY3HU
MEN\!]K3,8R@&=DX=5<K@W5\NZ=5Y\>_'-Z]D5RU'=><3CUJ:JKOL&V6J,K/>
M."5H"%QFG!&<R!R"S]1*(U3L4*;JSF=7+%D5%8N<Z1*,)5DZ0GGB- 9H.8D4
MN%;1F"X=F(9('KX"U;_)7+DR>540^2S&=N$G[YO)Y.?+>N@CC6&AC8D3ZE2Y
M "E+KH@+)"NCE4\"<!JO(?6]R!Y$BN9AUG&[_]R0+-2(W0^H?9*L41X7> (^
M!81LBT)D)%%S)I1@EG9*PAJH>L@#JU(S,.,#E*K9AZX*3ORZ,A.*?UFK"7V$
MD?'<9.$=2:KXCRFA_XB:("F"M#1#<G7\LVU@GIJ-]%;X28MA7=]<O?0'7D_/
M+DK2V]M\GZFS$:4V4!\429DS(K/EQ#,?" _>AU*X(H<C%C8:7+ZG9JH/T2P&
MS%U;)EAVE_$GWTZ7A2N66B[5*JZ:V?STM9P^X'MLC<R!,TM2B)Q(YQ7Q4222
M!56*1Z&2Z58D<%!83\4N3TQ8A7R*@VK;B03@!2=<NE(X46OB-3BB;?1,^=*!
MC3Y(_^Z D_I]3V:HMM1JB 17S))EG]&9\I224C-&A& MLESE%/XQ%DSH$SE5
M9>;!%TSPY>(EY430E(@$[H@78 A0 3*80&,6-=_ QUHP82\;Z%HP80\N3E,P
MH0/ ?Q=,.(S/_0LF'$#&2:PFJ<RB](S$@*Q*[P6QD2I"@^#>)^6-/UI-E@=<
M,*&JL>S#0=V""9 CSHX8&P5=LN&,S\1[*8D'JD)(.E'=+:QX\ 43]M+Y[H()
M^RCLN%V>[C]F^7$\FS631?G0>J^HZN'6'<\[ZM%65[DWN^<D:PRC+";O9%+1
M\9R< \^B1M\B^@X'6W<\N>*Q%M5*98E3,+>)X>3E$PD2)!&AW.;(,=(ZFZPU
MC[7>PQ>8+J 4Y2NQ8>OC_)_C^?FKQ6S>7$#[T]<X622,&$N%/OQ?^NB_CJ2R
M@CON2Z5/C&=]RL1Q$XCV2"P'%GB=!M,'8'T0,^9A%G0[5;4N4Q4.PUXUL_G;
M_+>F2;.S:?H [9=QA-F'9I)&/LHD,R2BE'5$9@'$6X7?NL"T4P Q54DVV@WI
M"9G*0'JO<9,#)I-BH]/TBV]_@VL[>R.3L[,F!^)3#$2ZLK^8M"2::50!-Q%"
MG=*9.R$](8L82.\53K(N.XF6[><RL^'"'I=;E M(J[U?] /^#FC.I=GH?-Z.
MPV)>]B8^-N_A<],N)<$_F'\;"9M"L(@<2DU1294DZ%"F4BO6!65DLK)*S[#!
M)'A"]G8:5BLTAME[R\P;Z56PE"1IRJ7?B$NN"Y$P$R0&N3GF5*?'PF/<T.XU
MI=5DYM0;VCNK$DG!K(,4"3>Z=-AVFCA;VM4$2(FRG (;K#C#HR[_MA?;]Y5_
MVT?K)ZOEU07D'[W\VUY$'E34ZQ 63F8RD4:JRBU=[WS9=0N>X#N";XH'Q9F5
M6<LN)]./P53V+?]6WU+V4?ZQR[\Q%J(.-A(C-*#7901Z7=F0:)G.QC E]48&
M]],J_[87-_N4?]M'L?ON<Z]^7/X)*.-?__3_ 5!+ P04    " #.B:Y2B@]"
MI-:"  !/9P4 %0   &-P:7@M,C R,3 S,S%?;&%B+GAM;-2]:Y/<.'8M^MV_
M@G<<<=P=49@F09  9FR?*+W&.E9+.J7J'OMVW,C LY2GLS++S$RUZOSZ"Y#)
M?)),@*^B'9Y6E40">R\2BQO QMK__#^_/RZ";RI;SU?+?_E3].?P3X%:BI6<
M+Q_^Y4^_W+\#Y$__\U__X1_^^?\!X#]>W7T(WJS$]E$M-\'K3+&-DL$?\\W7
MX.]2K7\/=+9Z#/Z^RGZ??V, _&M^T^O5TW,V?_BZ"6 (H_-_S?X2(@6)5AR$
M$"* B(" ,B5!@B(:AS$3J8(W#W_!(F&2$P)B%L4 :4$!5PP#2A,M4,H%E#AO
M=#%?_OX7^Q_.UBHPSBW7^:__\J>OF\W37W[ZZ8\__OCS=YXM_KS*'GZ"81C_
M5%[]I]WEWR^N_R/.KXXHI3_E_[J_=#VONM T&_WT'S]_^"*^JD<&YLOUABV%
M[6 ]_\LZ_\L/*\$V.>97[0IJK["_@?(R8/\*1!#$T9^_K^6?_O4?@J" (ULM
MU)W2@?WSE[OWM5W2G^P5/RW5@WVRGU4V7\DO&Y9M/C"N%L;ZO+7-\Y/ZES^M
MYX]/"U7^W==,Z>IF%UEVTJJUDEHKH]1:^8]UG?W4P?R>[-U<VMJ#<;F['_NR
ML0G3C[V9>V_X00UO\%$WG4TN7JBW2SG6N[OOJK/IPUO<UVNQVK#%"*_%H9LC
MDQ?V+SZ8GW;=V(8:R#3O9T?=1Z:J[QNUE*I@RY.F@[G\ES^9GV;;-7A@[&GV
MY2O+U"M#M/+UZO%)+=<Y?]]F&5L^*/M)?/5\N.0S>[9_=?L'R^3;_]K.-\_O
MS4<@RS^=ZT^;KRJ[_\J6GYYL$^N_F28VZ_?+XD6:Q5J;#QQC(,;0?NNB!!"%
M"& )1QHFB$.E9YO]6)FI)?CE2^E6;OO+&/XGCR>QJ6&43*U7VTP<OL6/BZH/
MK/FVVJ\Q^6G)'M7ZB>UN,-[;L*4 Y%_OE#%\+FR0LMZLQ._!@S77_#9?!D^Y
MQ3?!VCJ^_N>?#MA-Z$58_+=]O(MAGVSN#[!!CPR.G0Z.O [X<W!\W<[S('?]
M)BB<#XZ\#W+W@XWQ/]@!<!,4$-@WI@"A]DU9B1-O%S:\6V7GCVTE7NRQG=!P
M_L@T6_,<\YU)YOG!\">UV*S+OP'V;T 8[4+*?QS=]I\N1N-M5@+-,G'E5=Q=
M\9-8F>#[:0-.WDH[67G9)[)9O>Q +MY4 ]*?@E4F56:F?Q6 7]#?![5>*_7)
M,*BQ;_GP01ESUO?F0_K*@/G[C NL,8XT2&B2 ,13;@8@3(&.HB21DHH48Y^O
M5W-W4_OF?'A[^^7M%[_OR15 W;X"_<$T,'<7AMX$>U.#PM;@-VMMD)O[__5'
MLVZX]$F.5WH<E=+<O#\G(L>[_.A#JOFL7#RZ-[?.8A0F$1,)H"*6 .%0 ,:%
M!&G,$QRE)MJ53F'N><-3HX3]BIDUSHT9+K!JYH N" P\VMV<=Q[5=9X>QN^Z
M',!K)?[\L/KVD[FE&+OFA_,A>]'<*(.SSHER&-;^N]^ $T_S[[/W6FVR%6?+
MU^:*N6"+G]4C5]E,1HQ!KB!@4$4 $:X!(R@&W'RB!0JCD#+F,OB:.IG:0-R;
M&91VNHW&1B";1V9?\ P\2B^1"7XKC*S_$GN\:[MW.0]G!X?JI+=)O$S.[.8"
M0<%T]DI+9E$8[ZBL\=Y1:,W%^I+BG*YM07=5D<N'.>/SA9D@W:]>J<]L+F^U
M89O_5,S,D#*E9B%D2H0Q RI")@X126I)48(X58)(F"9AE#A380L#ID:3N75V
MMR[V&/MM@'>@SH'A?)FISDVP=^$FV*P"K@+KQDW <N2M)T'NRL#X>_#RP,]A
M),X>['GX,7P',!O9OTV[XWT9.GA]\M7HTDZ[!:_7J_7FD_[;:B77MTOY167?
MYD*MOZP6<@95"EEJ/A9,AMK,87D$2$P@T)AIK)!,92AFWU3&5Z[+7?6=^0RH
MXRZ'&T_6UF"E@Z=L);=BLP[6QDR_M:\&;&E"0LA)!)(T--]EA37@(28 APAJ
M)&+*XM!G(;$?9,?X EM+U\,!Z[:@V ]< W]ARS<P-S-@2QF4A@9?FB#S7D:\
MCD:?2X@-O8VZ?'C=Z_.E0X<[VI'P^Z58/:H/J_7ZG3'SS7QM7##\OU5R]RE8
M+=<?E>G[GGV_W6RR.=]N&%^H^]6=>EIE]E/QUMRP>9YI9)B%F'A?L(@:SL8,
M, HYT(9<2!J%6!(O7NG-LJG14.%8D=4GC]P*5GN__#BIOV?H1F$O\F2&7JHI
M'LH/UJL?BV=S[%AP\.PF,+Y9<C3>W03'_MD@]S/+3,#='T'VCG6??-J?<:/2
M;^^8GK-U_QVTC[#M]^+M=[OMK=:SA BA,<8@I"$'**(18"G%( YCI"4C6*MD
MMMGGA3D%,\<=>%%M399;GZ,Z3W$+1![WV2A&[>STC_E.8'2/]-J",T)\5R#R
M]AHBK4*Z*K?[#N1.^A@]?*ORL"IHJ[RNW6C^LF&;/%^ER$NQR2RKI4U+N?T^
M7\\XC3E,(A-T*9H"Q&-DAG9*  H54F$2P3CF7MF-3;U-+:3:99T=C Q^LV8Z
M[K*X >PVZ'N#;6 &\$;,/Q'/!8E>L^<:.QPWY<W%]XL\-:>;VG''(6?WBTW9
MW>T@$L@TD9( "F5D.$,;SJ D!I&$1$=0)4GHE5-6V<O4N.(H?3FWTH\CJH%T
MXX;.\ S,">?(7-^L]B:%1@CZ)(/JCD8E@49?SP=_\\5MUW:^&?I89<_OYLOY
M^JN2^?I1/O$PW:GL6SXC(+%*, <)P:$)%G ,."<I@ JE+ HQ(HKXK;0[]#J]
M)??2UN#!&NN[_'(=9M>%E5ZA&WS)9&?M3;"'+S=XOT)2&MWG<H@S0OTN=%SO
M=N0E#&<<+A<GW&]MDQFW%)G=.WRCBC_?+U^S]=<OVRRS!\*R7]EBJS[I#W-M
M_F6]S>SYW<^KQ5P\SYB*68S"&"B"J:$BJ %-!0-(1#I1,M:0JMG%D<8KB4]M
MK7$:9VZG.7M>ILS]"'XH/?HQ>+\,K%/!WJL@=ROXI /K6+#W+"A<\TD]:_TP
MFPEOA&<SVK+Q?X_GX9,L.,9S&2N=<,CGXYF V!76YA3%UJV/F,38%8'3-,?.
MK;6+JM\HOCF<"?MH7KXWJT<V7\Z2% H82@RB."( )9$$%*L01&D<0@DCI03T
MF4W7=32U";6U\^C IXG^S,7!;X6QGDMPM>"Z!=!]0#;P%Z,E6MZ1\C4H^@R/
M:_L:-2:^YO%Y('SU^G;\\#E;":5DOO5WIYZ*\Z1KRT1+9?YXG2DYW\P2JG#"
MDP20&$< 20H!A]RNO\5F-@ZEPMA+C,"IUZDQQZM5EJW^F"\?UL%J&9A.E)TU
MBMQ6/]YP ]V-1'J'<F!&*>TMLA9^.)ALP/PQR*VVL+YNAM6;8+Q@ZI-MW#H>
ME7J\L#CG(;^;_4AIG6UF/YMY_N/V<;=4#2'':9P(@!71 "F= "ZE 9GB6$'S
M+T@3%^*Y:'EJY+(SSHU'+G%JYHI.W@_,!SN[>ER]K_6V85B;>XZ&M/GM?#A?
M-CK*D*WUI1R6]1>TBP=>L86=>WSYJM2F5*?;!;5,2D6177S7<5P<D:*<"&#H
M(&8Z4C&$PB<(J.]J:H-S9VF0FQJ4MK:<-#0@[/;%[P>W@8=U6\B\/^S7T>CS
M:][0VZB?\.M>GW^W'>YHF^BS$K^;2,"\.5^M)LV;;69BY)V48RZL-4L53"+!
M0Q 3% +$D9E())("(1D11"G.R7ZMW(T[KG?:8DE\8!8YF&L#W$)S+/AAOMS]
M^*-O^L]5V%EBYF>88L"439@@T 1/PLS:0A)1@61"-*5^25:]@#YJ]L3(D+LQ
M>+] #LSD17+%D;5!8>Y."^VFT%?K<=?4'9U^\[&N]CIR4I8K"I>96<YWMF/\
M(MO[[W.IWB_U*GO,OR5WZIM:;I6=%K[];L;VDBU>;]>;U:/*[-3P_48]KF<\
M19&B0@')(IO"%1- %$,FCE112F2H)/9*^VQMR?2(*K>Y6!0IK0Y*LX/?K.%!
M;KEGM-G^6;E1V2A/8&"&ZP-\;Y;K#%R?Y-?>F%$YL3-FYU39O<&V":Z'A;./
MJXU:?V;/]DC-C N&8YPRH"C$ %'! (MH"E2(M-*15EA3CZR2:_U--&_D>%&X
MVTI[+=!N[-8)M['(ZV@!/<B-#'96]ID(VXQ#O[FP-7V-G [;[/%E1NR5Z]L1
M18W"Q>L\;V SB\T$#\4Q!5(3!) B!'!N(>54\Q@BR:17/-7<W=2"IH."RR+/
MFA&%F88P"KOGOD?GKJ#MQAG]83@P<S0)X.RL[8]!W%#IDT>N]#@JF[AY?\XI
MCG>U2'N]%6K#I*&IW?:1@%$:FL #**E,V"%";*9D4@(4:AJSF!MZ<=IFJVI\
M:JSQ[]E\O6&+U=I'6>L<L&8JZ K#P -_;UD;?<=S)#Q2-3L@,E("YM["GK(H
M:SQNS(T\OV>\C,<::T_R&.NN:4%"'\T3S2QZMWR]R9@PX0R)".21,!.?A!H:
MTBDP 8P"PDQ[(B)3)J/$[7A/=0<^;]PX)WGV)O[%8PA> N= 1YW &)B0]K8%
MOY76^5#2)1X>I-0)EY%H:6_CGWOBI5JG&YGI\J[QN*G6XA-VJK_*/Q'ISA;<
MV'WDE)E549$@8)Z4!@AR#2A#,6 1CSG7BO+422WJK-VIA4:Y:9YI#>=0-5-1
M!P &W^8R@WB]R66O?S;Q]C8K"@CUE[%0XWO7K*3C)D?+2:KPXS@CJ>J?6]:9
M.<SEK92<W=KZNEJ8^]>%[L">\D-)*<>,F3D+42: 0!1P1E) (IW*$$N$:.1W
M--BUZ^E%%1_>W[YZ_^']_?NW7X+;CV^"M__[E_?W_^E9C\85>+=5D2' ')@1
MCDPNQ(<*$1*'$,6_/HTG.KU6JG'M>]R:-9Z(7%2O\;V_9?*3^*KD=J$^Z5?;
MM<V 7M\*T_YZGJNFO7H^^NUUKJKV8+XIYJ?U7.ZDU0XEGHB)))B*%8")E1'F
M7)H@@S(0&P*+*(H8DW[I.OW9-K5 I73-;GF4S@7'WMFZ?T>_WP0'#X,3%STS
M@'I\W&Z\^4(/<>A@J[?G%_QVGXM9#E(V; #P>TU9ZM&\<7.;^L?U(@EJ@"[:
M1K!+59Z+V<V16 ))K#D!(<$2((TP8 F%($E@DA(SIU215R;]91=3(^P/NSW\
M*\>Z7 %TC3F[P#)X='F,R #B5?7>]QL]7O0R<IQ8Y^5E1%A[9;N!_5%M#M*Y
MI\*X'XWQAE6,(^;^A_=+,\34>C.CA'*"0P6X2JV@K4$T%QVG44R%%BE5A/CE
MP7O;X#0"1DV+M^I+/\QS)WX,%L:-@&V"]98;)IZS[-G\=JI9O3SQ*YCO'//<
MZO=_>&Z<,\P#&6D97MFS_L?*XN=ZX:<N!*4/_9%6:_CZY#1_(T:EO-88G3-B
M^X9:3I;;EK;^L$]*3A7%1(<0,&UH%*7('FE1&&A!!-(Q"35)O>;(G4V:6J1U
M7.W^V*?@R"D[NSJ^;N=8D'O6(=F\AP?L."L>];$-/1D>YXGYSWY[ [G726]W
MJ\:=Z_:&XL44M[^66U?C.=.T^K3YJC+[[2A2U(X686=ARK6P,UVID3#,'8>
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ML]JPA1O%5/3A12K[G@;<A-[//>:[G#^;?.DIB5N%I1MW=$1H8+8X@'.2$#F
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M8P6X3E( F12::4@9\SK!ZFO U,AFOUY?;I9DI<W!PAH=&",>/8G']YDX<M&
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MRF$(4$AU2A#G$0Y])O.774QMTGYO^RCRZ79VYA5,\5_SM)F&A2Q72!U#DDY
M#1V,N)R:_\RL>'K/0FF5B/2N@W;:R_@R9Y5>5JJ855_9YECQ7&5*%KJ0SZ52
MY&=E7ICEACVH6<28Q$10H)$R1!#B&%"),< \XE%*(A7&3AK8+IU-;:9\L,QN
M 6QRX_<BKT^EEND/VR?SVCNFX#IAWLP4?2,Y,&<4EN[47I]+E<7U37"PMD?H
M?([G]@?A6(=O.T#I>:+6#9OF\[)7VACQ-*R;-Z=G71WO:;G=NOFJ,BLO4U0:
M.:K.MDL)2[6(E:8$1&&$ #(,##BG,8 L#962C":A4SU8UPZG1KVYO<%BM7P
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M;ES6&:>!F<H?(F\6:H2@3XZI[FA4!FGT]9P?FB^>B/KPH71?RN,8QP)P@6.
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M>'XAX>-R3]MMU'OV_;TT;<WU7.01=)&X/,,L1)Q#9.(FB>WV!@&411 PQ4U
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MGYX65L]H*7]6F3TW(>=K]<O2-/QZM5S/'Y9Y%="0":Y9F !$$;%'3!"@4*4
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MBJLU9#K5XJYAY54Q[FIC_GF!;TV,MWE^-U^H[+7AC8=5]CR3A @5RP3$ B&
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M%4G,,DEXCT[;0WB:9E!G/Q?L]3RXB&[UU[(1Z'GN$2\8MH@93PH($PXDPA)
MS F@,LV %(PHE!4*)=BY9_>X2Q@^K-.Y@+(*]8R_=';?E]$6(_!7R-/\O8G,
MT OQ71O&T'^="7?GOI%^'NKV)=VLM[-O\^U"WJN/2S'_,1<O=/'W^?;[5[FH
M!L9^GS]_6]TMM_/MS_>K)SI?:I6+XH0:11LGL>GT7( BUBHW29A@&5*8IL+F
MS*T'[:D=L#4Y-5'8BM?HSXI;RQRV/FO0K3L#(QM84Y:<FT_2@??+B%JKOP'8
M="@[_=2&HM-_>ZWD^I =1:4-P&.GP(8\PL<@NOTQMXECFY.RY78&%8P%BF.
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M&T5RGGGAY1"9D,<IV \D':=0!Q+NV GVRL,2PX9N8R-C=3MT,G!0I9 ?I8T
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M6GI@H@1K6+U4W^3>TM$4CUOW> 9PMM)>!S"]+[T-)Y." KW4$G1,J9;AU;E
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M*0UBGWI<*P/U--UG,%51%BF-SY"M(Y\7"111>P;&<&53$$[P)MF/<_A$MU?
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MT\[R1U?2]=.[9>!]ZSC==)$4V\P_NIFN]"REY468O5G,9K]>#D2:&%V<2UD
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M\9O1GM^@)RS9V,</OP%02P$"% ,4    " #.B:Y2PV8CMX (  #K,   %@
M            @ $     83(P,C%Q,2UE>&AI8FET,S$Q+FAT;5!+ 0(4 Q0
M   ( ,Z)KE)2:3+(? @  /0P   6              "  ;0(  !A,C R,7$Q
M+65X:&EB:70S,3(N:'1M4$L! A0#%     @ SHFN4M1+#Y([!0  TAH  !8
M             ( !9!$  &$R,#(Q<3$M97AH:6)I=#,R,2YH=&U02P$"% ,4
M    " #.B:Y2@!QAI+\H 0!4RPL $0              @ '3%@  8W!I>"TR
M,#(Q,#,S,2YH=&U02P$"% ,4    " #.B:Y2Y;%%H_X*  !H:@  $0
M        @ '!/P$ 8W!I>"TR,#(Q,#,S,2YX<V102P$"% ,4    " #.B:Y2
M7,E\S=X8  "0^@  %0              @ 'N2@$ 8W!I>"TR,#(Q,#,S,5]C
M86PN>&UL4$L! A0#%     @ SHFN4OMM"'A**P  <:\! !4
M ( !_V,! &-P:7@M,C R,3 S,S%?9&5F+GAM;%!+ 0(4 Q0    ( ,Z)KE**
M#T*DUH(  $]G!0 5              "  7R/ 0!C<&EX+3(P,C$P,S,Q7VQA
M8BYX;6Q02P$"% ,4    " #.B:Y2(],,:VA1   (A@, %0
M@ &%$@( 8W!I>"TR,#(Q,#,S,5]P<F4N>&UL4$L%!@     )  D 5@(  "!D
$ @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
